Data analysis methods for copy number discovery and interpretation by Fitzgerald, Tomas W.
	   I	  
Data	  Analysis	  Methods	  for	  Copy	  Number	  
Discovery	  and	  Interpretation	  	  	  	  	  
	  
	  	  	  
Tomas	  William	  Fitzgerald	  









This dissertation is submitted for the degree of 
Doctor of Philosophy 
October 2014 	   	  
	   II	  
Declaration	  
 
I hereby declare that this dissertation describes my own work and does 
not include work that has been done in collaboration, except where 
explicitly stated in the text. The thesis contains material that has not been 




Tomas William Fitzgerald 
23 October 2014	  	   	  
	   III	  
Abstract	  	  Copy	  number	  variation	  (CNV)	  is	  an	  important	  type	  of	  genetic	  variation	  that	  can	  give	  rise	  to	  a	  wide	  variety	  of	  phenotypic	  traits.	  Differences	   in	  copy	  number	  are	  thought	   to	   play	   major	   roles	   in	   processes	   that	   involve	   dosage	   sensitive	   genes,	  providing	   beneficial,	   deleterious	   or	   neutral	   modifications	   to	   individual	  phenotypes.	   Copy	   number	   analysis	   has	   long	   been	   a	   standard	   in	   clinical	  cytogenetic	   laboratories.	   Gene	   deletions	   and	   duplications	   can	   often	   be	   linked	  with	   genetic	   Syndromes	   such	   as:	   the	   7q11.23	   deletion	   of	   Williams-­‐Bueren	  Syndrome,	   the	   22q11	   deletion	   of	   DiGeorge	   syndrome	   and	   the	   17q11.2	  duplication	   of	   Potocki-­‐Lupski	   syndrome.	   Interestingly,	   copy	   number	   based	  genomic	   disorders	   often	   display	   reciprocal	   deletion	   /	   duplication	   syndromes,	  with	   the	   latter	   frequently	   exhibiting	  milder	   symptoms.	  Moreover,	   the	   study	   of	  chromosomal	  imbalances	  plays	  a	  key	  role	  in	  cancer	  research.	  The	  datasets	  used	   for	   the	  development	  of	  analysis	  methods	  during	   this	  project	  are	   generated	   as	   part	   of	   the	   cutting-­‐edge	   translational	   project,	   Deciphering	  Developmental	  Disorders	  (DDD).	  This	  project,	  the	  DDD,	  is	  the	  first	  of	  its	  kind	  and	  will	   directly	   apply	   state	   of	   the	   art	   technologies,	   in	   the	   form	   of	   ultra-­‐high	  resolution	   microarray	   and	   next	   generation	   sequencing	   (NGS),	   to	   real-­‐time	  genetic	  clinical	  practice.	   It	   is	  collaboration	  between	  the	  Wellcome	  Trust	  Sanger	  Institute	  (WTSI)	  and	  the	  National	  Health	  Service	  (NHS)	  involving	  the	  24	  regional	  genetic	   services	   across	   the	   UK	   and	   Ireland.	   	   Although	   the	   application	   of	   DNA	  microarrays	   for	   the	   detection	   of	   CNVs	   is	   well	   established,	   individual	   change	  point	  detection	  algorithms	  often	  display	  variable	  performances.	  The	  definition	  of	  an	   optimal	   set	   of	   parameters	   for	   achieving	   a	   certain	   level	   of	   performance	   is	  rarely	  straightforward,	  especially	  where	  data	  qualities	  vary.	  	  A	  combined	  change	  point	  detection	  package,	  CNsolidate,	  is	  developed	  as	  part	  of	  this	   research,	   which	   makes	   use	   of	   multiple	   weighted	   algorithms.	   Using	   this	  approach	   it	   is	   possible	   to	   rank	   detections	   based	   on	   differential	   weighting	  functions	   between	   component	   algorithms,	   which	   substantially	   improves	   the	  Type	  I	  and	  Type	  II	  error	  rates	  relative	  to	  other	  approaches.	  	  The	  DDD	  project	  has	  a	  responsibility	  to	  ensure	  accuracy	  and	  consistency	  in	  all	  data	  sets	  reported	  back	  to	   the	   UK	   clinical	   teams.	   A	   novel	   method	   is	   developed	   to	   allow	   the	   accurate	  tracking	   of	   array-­‐CGH	   data	   generated	   as	   part	   of	   the	   DDD	   project	   using	   copy	  number	  tagging	  SNPs.	  Additionally,	  the	  DDD	  makes	  use	  of	  a	  number	  of	  advanced	  variant	  prediction	  approaches,	   including	  the	  accurate	  assignment	  of	  population	  based	  frequency	  estimates	  and	  the	  ranking	  of	  variants	  based	  on	  their	  relevance	  to	   health.	   In	   addition	   to	   microarray	   data	   on	   approximately	   1,000	   control	  individuals	  generated	  specifically	   for	   the	  DDD	  project,	  a	  consensus	  approach	   is	  used	   to	   generate	   common	   CNV	   reference	   sets,	   calculating	   frequency	   estimates	  across	   studies	   displaying	   differential	   sensitivities	   across	   the	   genomic	   range.	  Finally	  a	  rule-­‐based	  approach	  for	  ranking	  CNVs	  in	  terms	  of	  their	  potential	  clinical	  significance	  is	  implemented	  to	  facilitate	  the	  feedback	  of	  clinically	  relevant	  CNVs	  to	  patients	  via	  the	  NHS	  regional	  genetic	  services.	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1 |	  Introduction	  and	  Literature	  Review	  	  
1.1	   INTRODUCTION	  Comparative	   Genomic	   Hybridisation	   (CGH)	   was	   developed	   around	   the	   early	  1990s	   and	   has	   been	   applied	   for	   over	   a	   decade	   to	   screen	   for	   chromosomal	  aberrations	  in	  tumour	  samples	  [1].	  Originally,	  this	  type	  of	  CGH	  would	  have	  been	  carried	   out	   using	   metaphase	   chromosomes	   spread	   on	   glass	   slides	   and	   co-­‐hybridising	  labelled	  DNA	  from	  both	  test	  and	  reference	  samples.	  	  This	  allowed	  for	  a	   direct	   comparison	   between	   the	   two	   samples	   using	   a	   confocal	  microscope	   to	  check	  for	  large-­‐scale	  rearrangements	  of	  genetic	  material	  within	  each	  sample.	  By	  using	   specific	   probes,	   complementary	   to	   important	   sequences	   of	  DNA	   (e.g.	   the	  b52	  gene),	   labelled	  with	  one	  of	  a	  variety	  of	   fluorophores	   it	  became	  possible	   to	  check	   for	  both	  gene	  deletion	  and	  amplification	   in	   a	   range	  of	  different	   samples.	  However,	   the	   functional	   resolution	  remained	  relatively	   low	  (5-­‐15Mb)	  and	  both	  the	  experimental	  processing	  and	  data	  interpretation	  were	  challenging,	  requiring	  a	  high	  degree	  of	  skill	  and	  expertise	  [2].	  As	  the	  technology	  progressed,	  and	  new	  resources	  from	  large	  scale	  sequencing	  projects	  became	  available	  (BAC	  clones),	  in	  the	  mid	  1990s,	   the	   field	   of	   array-­‐CGH	   (first	   called	  matrix-­‐CGH)	  was	  born.	  This	  methodology	  was	  first	  described	  in	  1997	  where	  the	  production	  of	  the	  first	  CGH	  arrays	   and	  protocols	  used	  during	   this	  new	  method,	  matrix-­‐CGH,	  were	  outlined	  [3,	   4].	   However,	   these	   initial	   methods	   for	   microarray	   construction	   were	   time	  consuming	   and	   difficult	   to	   perform.	   Later	   new	   methods	   were	   developed	   to	  increase	  the	  speed	  and	  ease	  of	  microarray	  construction	  [5].	  	  	  With	   the	   emergence	   of	   genomic	   resources	   generated	   as	   a	   result	   of	   the	  International	   Human	   Genome	   Sequencing	   project,	   the	   flexibility	   of	   microarray	  design	  was	  dramatically	  improved.	  It	  was	  now	  possible,	  for	  the	  first	  time,	  to	  use	  large	  insert	  clones,	  such	  as	  bacterial	  artificial	  chromosomes	  (BACs),	  to	  fully	  span	  the	  entire	  human	  genome	  using	  overlapping	  (tiling)	  clones.	  At	  the	  same	  time	  the	  improvement	   of	   microarray	   spotting	   technologies	   allowed	   for	   the	   metaphase	  chromosome	  spreads	  to	  be	  replaced	  by	  glass	  slides	  spotted	  with	  DNA	  fragments	  mapped	  to	  precise	  locations	  along	  the	  genome	  and	  arrayed	  on	  the	  slide	  in	  a	  grid	  formation.	   This	   approach	   initially	   increased	   the	   resolution	   of	   CGH	  methods	   by	  more	   than	   tenfold	   and	   allowed	   for	   smaller	   genetic	   differences	   to	   be	   assessed	  between	  two	  samples.	  The	  resolution	  of	  CGH	  was	  improved	  from	  approximately	  a	   maximum	   of	   5Mb	   when	   using	   metaphase	   chromosome	   spreads	   to	  approximately	   170Kb	   with	   BACs	   and	   40Kb	   with	   fosmid	   based	   insert	   clone	  arrays.	  Furthermore,	  it	  was	  now	  possible	  to	  imagine	  that	  two	  samples	  could	  be	  compared	   on	   one	   microarray	   to	   screen	   for	   genetic	   changes	   across	   the	   entire	  genome.	   Indeed,	   this	   approach	  was	  embraced	  by	   the	   community	   and	  has	  been	  used	   to	   screen	   for	   micro-­‐duplications	   and	   micro-­‐deletions	   in	   patients	   with	  constitutional	   rearrangements	   [6,	   7],	   cross-­‐species	   studies	   of	   evolution	   [8-­‐10],	  and	  studies	  of	  migration	  and	  ethnic	  evolution	  in	  humans	  [11].	  	  	  The	   resources	   used	   for	   the	   production	   of	   the	   first	   microarrays	   (large	   insert	  clones)	   were	   made	   widely	   available	   and	   have	   allowed	   for	   new	   microarrays	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covering	  the	  entire	  genome	  to	  be	  produced	  in	  increasingly	  high	  resolutions	  [12].	  On	   top	   of	   the	   increase	   in	   resolution,	   the	   ease	   of	   experimental	   and	   laboratory	  processing	  was	  improved	  and	  the	  number	  of	  experiments	  possible	  to	  run	  every	  day	  was	  significantly	   increased.	  As	   this	  new	  emerging	   technology	  grew,	   its	  use	  became	   more	   wide	   spread	   and	   large-­‐scale	   studies	   of	   copy	   number	   variation	  (CNV)	  were	  coined.	  The	  increase	  in	  both	  resolution	  and	  experimental	  processing	  ease	  had	  meant	   that	  CGH	  changed	   from	  a	   relatively	   time	   consuming,	   specialist	  field	   to	   a	   high-­‐throughout	   method	   suitable	   for	   use	   in	   large-­‐scale	   studies.	  However,	  the	  technology	  took	  a	  relatively	  long	  time	  to	  mature	  and	  even	  though	  it	  was	  utilized	  during	  small-­‐scale	  studies	  from	  as	  early	  as	  the	  mid	  1990s	  it	  was	  not	  until	  2006	  that	  the	   first	  comprehensive	  map	  of	  CNV	  in	  the	  human	  genome	  was	  published	  using	  a	  whole	  genome	  tiling	  BAC	  array	  [13].	  	  Recent	   advancements	   in	   array-­‐based	   comparative	   genomic	   hybridisation	  technology	  enable	  entire	  genomes	  to	  be	  scanned	  for	  copy	  number	  changes	  using	  high-­‐resolution	  oligonucleotide	  tiling	  arrays	  or	  single	  nucleotide	  polymorphism	  (SNP)	  genotyping	  arrays.	  In	  particular,	  it	  is	  now	  possible	  to	  design	  the	  content	  of	  arrays	   with	   a	   high	   degree	   of	   flexibility	   as	   a	   number	   of	   companies	   offer	   rapid	  custom	   array	   generation	   as	   a	   standard	   service.	   Due	   to	   the	   particular	   needs	   of	  specific	  experimental	  questions,	  microarrays	  frequently	  contain	  oligonucleotide	  probes	  displaying	  variable	  performance	  particularly	  when	  designs	  are	   targeted	  towards	  regions	  of	  the	  genome	  with	  complex	  architecture.	  For	  example,	  regions	  containing	  repetitive	  sequences	  are	   important	   for	  studies	  of	  both	  copy	  number	  variation	   (CNV)	   and	   copy	   number	   alterations	   (CNA)	   and	   often	   need	   to	   be	  included	   in	   array	   designs.	   Replication	   hot	   spots	   contain	   large	   numbers	   of	  repetitive	  structures	  and	  often	  underlie	  the	  mechanisms	  for	  copy	  number	  break	  point	   formation,	  which	   include	   non-­‐allelic-­‐homologous	   recombination	   (NAHR),	  non-­‐homologous	   end	   joining	   (NHEJ)	   and	   fork	   stalling	   and	   template	   switching	  (FosTes)	  mechanisms	  [14].	  	  Studies	   on	   CNV	   are	   often	   used	   to	   search	   for	   rare	   recurrent	   rearrangements	  associated	   with	   rare	   disease	   [15].	   	   Most	   of	   the	   studies	   to	   date	   have	   been	  relatively	   small	   scale	   due,	   in	   part,	   to	   the	   relative	   rarity	   of	   the	   disorders	   under	  study.	  More	  recently	  with	  resources	  such	  as	   the	  DECIPHER	  database	  becoming	  available	   [16],	   facilitating	   the	   sharing	   of	   genetic	   findings	   and	   international	  collaboration,	   an	   increased	  potential	   to	   study	   rare	  disease	  on	  a	   large-­‐scale	  has	  been	  realised.	  	  SNP-­‐genotyping	  arrays	  have	  been	  used	  extensively	  in	  large	  scale	  genome	   wide	   association	   studies	   (GWAS)	   to	   identify	   common	   genetic	   factors	  influencing	  health	   and	  disease.	   The	  GWAS	   study	   is	  most	   often	  used	   to	   identify	  susceptibility	   loci	   for	   common	   diseases,	   including	   Crohn’s	   disease	   [17],	   type1	  [18]	  and	  type2	  [19]	  diabetes	  along	  with	  a	  large	  variety	  of	  others.	  It	  is	  possible	  to	  detect	  CNV	  using	  genome-­‐wide	  SNP	  arrays	  however,	  the	  detection	  power	  is	  often	  limited	  and	   the	  development	  of	  new,	  high-­‐performance	  detection	  algorithms	   is	  an	   active	   area	   of	   research	   [20].	   Currently	   the	   only	   reliable	   array-­‐based	  technologies	  available	  for	  the	  detection	  of	  segmental	  uniparental	  disomy	  (UPD)	  or	  copy	  number	  loss	  of	  heterozygosity	  (LOH)	  are	  SNP	  genotyping	  chips	  [21,	  22].	  Segmental	  UPD	  occurs	  when	  a	  person	  receives	  two	  copies	  of	  a	  chromosome,	  or	  a	  chromosomal	  region,	  from	  one	  parent	  and	  no	  copies	  from	  the	  other	  parent.	  This	  mode	  of	  genetic	  transfer	  is	  known	  to	  cause	  several	  genomic	  disorders,	  including	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Prader-­‐Willi,	   Angelman	   and	   Beckwith	   Wiedemann	   syndromes	   [23].	   Loss	   of	  heterozygosity	  (LOH)	  is	  most	  often	  observed	  in	  conjunction	  with	  UPD,	  however,	  a	  subtle,	  yet	  often	  overlooked	  fundamental	  difference	  is	  that	  LOH	  can	  occur	  via	  random	   mutation	   events.	   	   Although	   the	   potential	   to	   extend	   genome-­‐wide	  association	  studies	  to	  include	  CNV	  has	  been	  realised	  for	  a	  relatively	  long	  period	  of	   time	   [24],	   its	   large-­‐scale	   application	   has	   been	   significantly	   hampered	   by	   a	  number	   of	   factors.	   Some	   of	   these	   factors	   include	   the	   poor	   understanding	   of	  ’benign’	   (neutral)	   CNVs,	   the	   heterogeneity	   of	   reference	   data,	   the	   differences	   in	  sensitivity	   across	   platforms	   as	   well	   as	   the	   relative	   difficulty	   of	   experimental	  handling,	  data	  analysis	  and	  data	   interpretation	  [25-­‐28].	  As	  a	  result	  of	  currently	  active	   large-­‐scale	   studies	   on	   genomic	   variation,	   including	   the	   Deciphering	  Developmental	   Disorders	   (DDD)	   [29]	   and	   the	   International	   Standards	   for	  Cytogenomic	   Arrays	   Consortium	   (ISCA)	   [30]	   projects,	   the	   amount	   of	   genome	  wide	   copy	  number	  data	   available	   for	   data	  mining	  will	   increase	  dramatically	   in	  the	   coming	   years.	   Scientific	   research	   groups	   across	   the	   globe	   are	   currently	  developing	  methodologies	   to	   enable	   the	   utilisation	   of	   these	   new	   rich	   datasets	  [31-­‐33].	   	   It	   is	  highly	   likely	  that	  there	  will	  be	  marked	  improvements	   in	  both	  the	  number	  of	  available	  data	  analysis	  methods	  and	   in	   the	  ability	   to	   interpret	   these	  data	  in	  the	  near	  future.	  	  DNA	   sequencing	   methods	   have	   been	   around	   for	   a	   long	   time	   but	   with	   the	  emergence	   of	   the	   next-­‐generation	   sequencing	   (NGS)	   technologies	   came	   a	  massive	  reduction	  in	  the	  cost	  and	  speed	  of	  sequencing	  an	  entire	  genome	  [34,	  35].	  The	   number	   of	   high	   profile,	   large-­‐scale	   studies	   using	   NGS	   to	   fine	  map	   genetic	  variation	  has	  seen	  huge	  increases	  in	  the	  last	  few	  years.	  Results	  from	  one	  of	  the	  most	   well	   known	   of	   these	   studies,	   the	   1000	   Genome	   Project,	   were	   published	  relatively	   recently	   [36].	   There	   have	   also	   been	   a	   large	   number	   of	   publications	  describing	   both	   the	   use	   of	  NGS	   to	   identify	   new	   candidate	   gene	   loci	   and	   in	   the	  development	   of	   new	   sequence	   analysis	   methodologies	   [37-­‐42].	   The	   most	  commonly	  observed	  approach	  to	  using	  these	  large	  sequence	  datasets	  is	  to	  filter	  the	  detected	  variants	  against	  variation	  databases	  such	  as	  “DBSNP”	  [43],	  apply	  a	  predictive	   analysis	   on	   the	   functional	   effect	   of	   the	   remaining	   variants,	   using	  methods	   such	   as	   “Polymorphism	   Phenotyping”	   (POLYPHEN)	   and	   “Sorting	  Intolerant	  From	  Tolerant”	  (SIFT)	  [44],	  and	  then	  to	  search	  for	  a	  common	  variant	  between	   cases	  which	   display	   a	   similar	   phenotypic	   trait.	   Although	   this	  method	  has	   been	   shown	   to	   be	   very	   effective	   and	   has	   resulted	   in	   a	   large	   number	   of	  publications	   on	   new	   candidate	   gene	   loci	   [45],	   it	   is	   clear	   that	   there	   is	   a	   lot	   of	  potential	   information	   contained	   in	   the	   variants	   removed	   during	   these	   filtering	  processes	  that	  is	  currently	  being	  poorly	  utilised.	  	  To	  fully	  understand	  the	  role	  that	  variation	  plays	  in	  making	  individuals	  different	  from	  one	  another,	  it	  is	  clearly	  essential	  that	  the	  necessary	  tools	  and	  expertise	  are	  available	   to	   allow	   the	   accurate	   interpretation	   of	   all	   the	   different	   flavours	   of	  genetic	  variation	  that	  can	  occur	  within	  an	  individual	  genome.	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1.2	   COPY	  NUMBER	  TECHNOLOGIES	  
1.2.1	   Fluorescence	  in	  situ	  hybridisation	  Fluorescence	   in-­‐situ	   hybridisation	   (FISH)	  has	   been,	   and	   remains,	   an	   important	  tool	   for	   both	   clinical	   diagnostics	   and	   scientific	   research	   [46].	   FISH	   uses	  fluorescently	  labelled	  probes	  to	  bind	  to	  complementary	  sequences	  of	  the	  genome	  and	  allows	  the	  visualisation	  of	  whole	  chromosomes	  using	  a	  confocal	  microscope.	  	  FISH	   can	   be	   used	   for	   a	   variety	   of	   purposes;	   it	   can	   detect	   large-­‐scale	   genomic	  rearrangements,	   such	   as	   deletions,	   duplications,	   inversions,	   and	   translocations	  (see	  Figure	   1-­‐1).	   It	  was	   extensively	  used	  during	   the	   completion	  of	   the	  human	  genome	   sequence	   to	   provide	   ”anchors”	   to	  which	   the	   sequence	  was	   assembled	  around	  [47].	  It	  remains	  the	  only	  reliable	  way	  to	  visualise	  genomic	  architecture	  in	  the	  context	  of	  whole	  chromosomes.	  	  
	  	  Figure	   1-­‐1:	   Fluorescence	   in	   situ	   hybridization	   (FISH)	   of	   metaphase	   human	  chromosomes.	  The	  probes	  are	  to	  the	  5p	  telomere	  (red)	  and	  to	  the	  HAPLN1	  gene	  at	  5q14	  (green)	  [cg.uchospitals.edu	  -­‐	  Stephanie	  Mewborn].	  	  
1.2.2	   Array	  Based	  Technologies	  
Array-­‐CGH:	  Nowadays,	   the	   use	   of	   clone-­‐based	   array-­‐CGH	   is	   less	   common	   and	   has,	   for	   the	  most	   part,	   been	   superseded	   by	   the	   higher	   resolution	   oligo	   nucleotide	   arrays.	  With	  an	  increase	  in	  the	  technology	  for	  microarray	  synthesis	  came	  the	  ability	  to	  produce	  in	  situ	  synthesised	  (oligo-­‐nucleotide)	  microarrays	  [48].	  	  The	  term	  oligo-­‐nucleotide	  array	  refers	   to	   the	   type	  of	  manufacturing	   technique	  used.	  For	  oligo-­‐nucleotide	   arrays	   the	   probes	   are	   short	   sequences	   of	   synthesised	   nucleotides	  designed	   to	   be	   complementary	   to	   specific	   regions	   of	   the	   genome.	   	   The	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manufacture	   of	   oligo-­‐nucleotide	   microarrays	   involves	   producing	   short	   oligo-­‐nucleotide	  sequences	  by	  synthesising	  the	  sequence	  directly	  on	  the	  array	  surface	  (in	  situ).	  Four	  main	  manufacturers,	  Affymetrix,	  Illumina,	  Agilent	  and	  NimbleGen,	  produce	   a	   variety	   of	   different	   oligo-­‐nucleotide	   microarrays	   tailored	   towards	  particular	  scientific	  questions.	  	  Among	  the	  different	  types	  of	  commonly	  used	  arrays	  are	  SNP	  genotyping	  arrays,	  Gene	   Expression	   arrays,	   Comparative	   Genomic	   Hybridisation	   arrays	   (array-­‐CGH),	   ChiP-­‐on-­‐chip	   arrays	   and	   alternative	   RNA	   splicing	   arrays.	   The	   design	   of	  oligo-­‐nucleotide	  probes	  for	  microarrays	  was	  described	  as	  early	  as	  2003	  with	  the	  development	   of	   the	   GenomePRIDE	   software	   [49].	   However,	   nowadays	  most	   of	  the	   array	   manufacturers	   provide	   there	   own	   software	   for	   custom	   microarray	  design,	   for	   example	   the	   e-­‐array	   website	   provided	   by	   Agilent	   allows	   the	   rapid	  design	   and	   ordering	   of	   custom	  microarrays.	   These	   different	   arrays	   come	   in	   a	  variety	   of	   different	   formats	   and	   can	   be	   customised	   with	   a	   large	   amount	   of	  flexibility.	  The	  number	  of	  probes	  available	  for	  use	  can	  vary	  between	  the	  different	  manufacturers	  but	  offer	  a	  vast	   increase	   in	   the	  effective	  resolution	  compared	  to	  large	   insert	   clone	   based	   arrays.	   The	   highest	   resolution	   study	   and	   most	  comprehensive	  variation	  map	  to	  date	  was	  run	  on	  a	  set	  of	  20	  NimbleGen	  arrays	  comprising	   of	   2.1	   million	   probes,	   giving	   a	   total	   of	   42	   million	   features	   evenly	  spaced	  across	  the	  entire	  genome	  [50].	  This	  array	  had	  a	  median	  probe	  spacing	  of	  50bp	  and	  delivered	  an	  effective	  resolution	  of	  250bp	  (5	  probes).	  Compared	  to	  the	  maximum	   resolution	   of	   large	   insert	   clone	   arrays	   using	   fosmid	   clones	   (approx.	  40kb)	   this	   offered	   a	   160-­‐fold	   increase	   in	   resolution.	   Compared	   to	   the	   original	  CGH	   methods,	   using	   metaphase	   chromosome	   spreads;	   the	   improvement	   in	  technology	  offered	  by	  oligo-­‐nucleotide	  arrays	  has	  given	  a	  minimum	  of	  a	  20,000	  fold	  increase	  in	  genomic	  resolution.	  	  Originally,	   the	   construction	   of	   spotted,	   large	   insert	   clone	   arrays	   relied	   on	   the	  extraction	  of	  DNA	   fragments	   from	   large	  numbers	  of	  bacterial	   cultures	   [5].	  This	  process	  often	  resulted	  in	  only	  small	  amounts	  of	  DNA	  being	  available	  for	  spotting	  and	  although	  sufficient	  for	  small-­‐scale	  projects	  was	  hardly	  scalable	  to	  the	  levels	  needed	   to	   produce	   whole	   genome	   tiling	   arrays	   or	   for	   the	   production	   of	   the	  numbers	  of	  arrays	  needed	  in	  large-­‐scale	  studies.	  To	  address	  this	  issue	  a	  number	  of	   different	   methods	   were	   developed	   including	   the	   use	   of	   degenerate-­‐oligonucleotide-­‐primed	   PCR	   (DOP-­‐PCR),	   developed	   at	   the	   Wellcome	   Trust	  Sanger	  Institute	  (WTSI)	  [51].	  DOP-­‐PCR	  was	  originally	  designed	  for	  general	  DNA	  amplification	   and	   as	   such	   allowed	   for	   the	   amplification	   of	   entire	   genomes	   in	   a	  single	  reaction.	  This	  meant	  it	  was	  possible	  to	  amplify	  large	  quantities	  of	  tens	  of	  thousands	  of	  DNA	  insert	  clones.	  After	  amplification,	  a	  common	  approach	  would	  be	  to	  spot	  the	  insert	  clones	  onto	  a	  glass	  slide	  utilising	  a	  robotic	  arm	  and	  an	  array	  of	   fine	  pins.	  The	  resulting	  grid	   formation	  on	   the	  slide	  contains	  a	  specific	   insert	  clone	   at	   each	   co-­‐ordinate	   (see	  Figure	   1-­‐2).	   These	   spotted	   arrays	   are	  normally	  generated	  using	  a	  random	  distribution	  of	  insert	  clones	  across	  the	  array	  to	  ensure	  that	   any	   spatial	   effects	   are	   evenly	   distributed	   throughout	   the	   genome	   and	   not	  confined	   to,	   for	  example,	   a	   single	   chromosome	   [52].	  The	  precise	  pattern	  of	   the	  grid	  layout	  and	  exact	  position	  of	  every	  insert	  clone	  is	  retained	  allowing	  for	  each	  individual	   clone	   to	   be	   mapped	   back	   to	   the	   genome	   during	   analysis.	   The	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maximum	  resolution	  of	  spotted	  arrays	  is	  limited	  to	  approximately	  40,000	  spots	  due	  to	  the	  minimum	  size	  of	  the	  fine	  needle	  arrays	  used	  during	  robotic	  spotting.	  
	  Figure	  1-­‐2	  An	  example	  of	  a	  spotted	  microarray	  containing	  large	  insert	  clones.	  For	   in	   situ	   oligo-­‐nucleotide	   array	   fabrication	   there	   are	   a	   number	   of	   different	  approaches	   taken.	   The	   solid	   supporting	   surfaces	   can	   vary,	   with	   Agilent	   and	  NimbleGen	   using	   glass	   slides,	   Affymetrix	   using	   silicon	   chips	   (gene	   chips)	   and	  Illumnia	   opting	   for	   microscopic	   beads	   in	   place	   of	   a	   solid	   surface.	   The	  performance	  of	   the	  different	  platforms	  can	  vary	  and	  the	  choice	  of	  which	  to	  use	  would	  generally	  depend	  on	  the	  precise	  scientific	  question	  being	  addressed	  [53].	  Agilent	  uses	  inkjet	  technology	  during	  the	  printing	  process,	  in	  which	  treated	  glass	  slides	  are	  used	  as	  the	  solid	  surface	  and	  oligo-­‐nucleotide	  monomers	  are	  printed	  in	  extremely	   small	   volumes	   (picolitres)	   to	   precise	   co-­‐ordinates	   on	   the	   slide	   (see	  
Figure	  1-­‐3).	  The	  in	  situ	  synthesis	  then	  begins	  and	  the	  process	  ends	  once	  60-­‐mer	  sequences	   have	   been	   produced.	   These	   technologies	   have	   enabled	   Agilent	   to	  rapidly	  and	  accurately	  produce	  large	  numbers	  of	  microarrays	  and	  have	  put	  them	  among	  the	  world	  leaders	  for	  the	  production	  of	  microarrays.	  It	  is	  also	  possible	  to	  perform	   a	   photolithographic	   process	   without	   the	   use	   of	   a	   mask,	   for	   example	  NimbleGen	   use	   maskless	   lithography	   for	   oligo-­‐nucleotide	   array	   fabrication.	  NimbleGen	  make	  use	  of	  a	  laser	  to	  shine	  light	  on	  specific	  co-­‐ordinates	  of	  the	  solid	  surface	  with	  a	  high	  degree	  of	  precision.	  
	  Figure	   1-­‐3	   An	   example	   a	   printed	   oligo-­‐nucleotide	  microarray	   fabricated	   using	  the	  Agilent	  SurePrint	  method.	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  The	   technique	   of	   array-­‐CGH	   involves,	   by	   definition,	   the	   comparison	   of	   DNA	  samples	  on	  an	  array.	  Irrespective	  of	  the	  type	  of	  array	  being	  used	  the	  same	  basic	  methodology	   applies.	   Both	   a	   test	   and	   reference	  DNA	   are	   differentially	   labelled	  with	  one	  of	  a	  number	  of	  different	   flurophores	  (usually	  either	  Cy3	  or	  Cy5).	  This	  process	  is	  most	  often	  performed,	  but	  not	  necessarily,	  by	  an	  overnight	  enzymatic	  reaction	   to	   allow	   the	   incorporation	   of	   labelled	   di-­‐deoxy	   nucleotide	   molecules	  into	   both	   the	   test	   and	   reference	   DNA	   in	   equal	   quantities.	   The	   removal	   of	   un-­‐incorporated	  nucleotides	  can	  then	  be	  achieved	  via	  filtration	  using	  a	  specific	  type	  of	   filtration	   column	   (Microcon	   YM-­‐30	   Millipore).	   The	   labelled	   DNA	   samples	  would	  then	  proceed	  through	  both	  a	  precipitation	  and	  resuspension	  procedure	  to	  result	  in	  both	  samples	  being	  mixed	  together	  in	  the	  same	  tube	  in	  the	  presence	  of	  some	  hybridisation	  buffer.	   	   The	  mixture	   can	   then	  be	  denatured,	   applied	   to	   the	  microarray	   (see	  Figure	   1-­‐4)	   and	   incubated	   over	   a	   period	   time	   at	   a	   particular	  temperature	  to	  allow	  hybridisation	  of	  the	  DNA	  molecules	  to	  the	  array	  [54].	  	  	  
	  	  Figure	  1-­‐4	  Illustration	  of	  applying	  fluorescently	  labelled	  DNA	  to	  a	  glass	  slide.	  After	   hybridisation	   has	   completed	   and	   the	   array	   has	   been	   removed	   from	  incubation	   it	   needs	   to	   go	   through	   various	   washing	   steps	   to	   remove	   any	   un-­‐specifically	   bound	   DNA	   fragments.	   These	   washes	   generally	   include	   both	   a	  stringent	  and	  non-­‐stringent	  wash	  buffer	  and	  agitation	  of	   the	  microarray	  within	  each	   solution	   for	   a	   specific	   period	   of	   time.	   After	   the	  washing	   steps,	   the	   arrays	  need	   to	   be	   carefully	   dried	   and	   scanned	   by	   a	   high-­‐resolution	   laser	   powered	  scanner	   (normally	   Agilent	   or	   Axon	   scanners).	   The	   scanning	   of	   the	  microarray	  results	  in	  a	  high-­‐resolution	  image	  containing	  a	  spot	  for	  each	  probe	  on	  the	  array	  with	   a	   specific	   intensity	   and	   colour.	   This	   image	   can	   then	   be	   analysed	   using	  various	   different	   image	   analysis	   software	   to	   produce	   two	   intensity	   values	   for	  each	  spot	  (one	  for	  each	  flurophore	  used).	  The	  relative	   intensity	  of	  each	  dye	  for	  each	   spot	   on	   the	   array	   can	   then	   be	   converted	   to	   a	   log2	   ratio	   and	   used	   to	  determine	  the	  relative	  amount	  of	  DNA	  sequence,	  complementary	  to	  each	  probe,	  that	  was	  present	  in	  each	  of	  the	  DNA	  samples	  (see	  Figure	  1-­‐5).	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  Figure	  1-­‐5	  Illustration	  of	  converting	  the	  relative	  signal	  intensity	  at	  each	  spot	  into	  a	  log2	  ratio.	  
SNP-­‐Genotyping	  Arrays	  The	  primary	  goal	  of	  a	  single	  nucleotide	  polymorphisms	  (SNP)	  Genotyping	  array	  is	   to	   detect	   SNPs	  within	   an	   individual	   compared	   to	   some	  population	   [55].	   The	  two	  main	  manufactures	   of	   SNP	   chips,	   Affymetrix	   and	   Illumnia,	   employ	   slightly	  difference	   technologies	   during	   array	   fabrication.	   Affymetrix	   uses	   silicon	   chips	  (gene	  chips)	  as	  a	  solid	  surface	  on	  which	  they	  immobilise	  oligonucleotide	  probes	  whereas	   Illumnia	   opts	   for	   microscopic	   beads	   in	   place	   of	   a	   solid	   surface.	  	  Affymetrix	   uses	   a	   classic	   photolithographic	   process,	   utilising	   semi-­‐conductor	  manufacturing	   techniques,	   to	   produce	   oligo-­‐nucleotide	   microarrays	   on	   silicon	  (quartz)	   chips.	   The	   most	   common	   methods	   for	   in	   situ	   synthesis	   of	   oligo-­‐nucleotide	   sequences	   use	   the	   process	   of	   photolithography	   (see	  Figure	   1-­‐6).	   A	  photolithographic	  process	  involves	  the	  use	  of	  light-­‐sensitive	  masks	  to	  block	  the	  passage	  of	  light	  to	  some	  areas	  of	  the	  solid	  surface	  and	  allowing	  it	  to	  pass	  through	  to	  others.	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  Figure	   1-­‐6	   Diagram	   showing	   the	   photolithographic	   process	   involved	   in	  producing	  an	  Affymetrix	  gene	  chip	  [affymetrix.com].	  The	  Illumina	  BeadArray	  technology	  uses	  self-­‐assembling	  silica	  beads,	  3	  microns	  in	   size	   and	   each	   of	   which	   is	   covered	   by	   thousands	   of	   copies	   of	   a	   specific	  oligonucleotide.	  These	  beads	  are	  contained	  in	  microwells	  on	  the	  surface	  of	  either	  fiber	  optic	  bundles	  or	  silica	  slides	  (see	  Figure	  1-­‐7).	  These	  microwells	  then	  act	  as	  the	  probes	  to	  which	  fluorescently	  labelled	  target	  DNA	  fragments	  can	  hybridise.	  	  	  	  
	  Figure	  1-­‐7	  Diagram	  showing	  BeadArrays	  using	  slica	  slides	  (left)	  and	  fiber	  optic	  bundles	  (right)	  [Illumina	  atlas-­‐biolabs.de].	  Both	  Affymetrix	   and	   Illumina	  Genotyping	   arrays	   come	   in	   a	   variety	   of	   different	  resolutions	   and	   can	   contain	   as	  many	   as	   2	  million	   oligonucleotide	   probes,	   they	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also	  come	  in	  a	  variety	  of	  formats	  to	  allow	  the	  processing	  of	  several	  samples	  on	  a	  single	  slide.	  They	  both	  can	  contain	  a	  combination	  of	  SNP	  (”rs”)	  and	  CNV	  (”cnv”)	  probes	  targeted	  towards	  specific	  locations	  within	  the	  genome.	  Whether	  a	  probe	  is	  targeted	  towards	  a	  SNP	  or	  a	  CNV	  location,	  all	  the	  probes	  on	  a	  Genotyping	  array	  can	  be	  used	  to	   infer	   the	  copy	  number	  of	   its	  genomic	   location.	   	  The	  Log	  R	  Ratio	  (LRR)	   and	   B-­‐allele	   frequency	   (BAF)	   values	   can	   be	   used	   individually	   or	   in	  combination	  to	  detect	  change	  point	  intervals	  across	  the	  genome	  [56].	  Although	   it	   may	   seem	   attractive	   to	   be	   able	   to	   perform	   both	   genome-­‐wide	  genotyping	   and	   copy	   number	   analysis	   on	   a	   single	   platform,	   in	   reality	   the	  performance	  of	  genotyping	  arrays	  for	  copy	  number	  discovery	  is	  severely	  limited	  compared	  to	  their	  array-­‐CGH	  counter	  parts	  [57].	  Genotyping	  arrays	  show	  limited	  performance	   partly	   due	   to	   a	   general	   poor	   response	   displayed	   by	   their	   probes.	  This	  may	  be	  due	  to	  the	  fact	  that	  the	  probes	  are	  shorter	  (approx.	  	  40bp)	  compared	  to	   array-­‐CGH	  probes	   (approx.	   60bp),	   a	  weaker	   intensity	   strength	   displayed	   by	  the	   fluorophores	   used	   during	   the	   labelling	   reactions	   or	   differences	   in	  experimental	   processing.	   It	   is	   also	   generally	   observed	   that	   the	   variance	   of	   the	  Log	  R	  ratio	   from	  a	  genotyping	  array	   is	  considerably	  greater	   than	   its	  equivalent	  (the	   Log2	   Ratio)	   from	   array-­‐CGH	   arrays.	   As	   a	   consequence	   of	   both	   of	   these	  factors	   the	  signal	   to	  noise	  ratio	  of	  genotyping	  arrays	  are	  on	  average	   far	  poorer	  than	   that	   of	   array-­‐CGH	   arrays	   and	   this	   has	   a	   large	   impact	   on	   the	   ability	   to	  confidently	  detect	  change	  point	  intervals	  [58].	  
1.2.3	   Sequence	  Based	  Technologies	  
Capillary	  Sequencing	  One	  of	   the	   first	  automated	  sequencing	   technologies	  developed	  was	   the	  Applied	  Biosciences	   377	   gel	   electrophoresis	   DNA	   sequencing	   machine.	   This	   machine	  could	  separate	   labelled	  DNA	  products	  on	  a	  polyacrylamide	  gel	  poured	  between	  two	   glass	   plates.	   The	   technology	   was	   improved	   with	   the	   introduction	   of	   the	  capillary	   electrophoresis	   sequencing	   machines	   developed	   by	   Applied	  Biosciences	  in	  later	  years,	  which	  used	  a	  denaturing	  flowable	  polymer	  to	  separate	  labelled	  DNA	  products.	  With	  the	  introduction	  of	  the	  ABI	  3700,	  a	  machine	  capable	  of	   processing	   96	   samples	   in	   one	   run,	   DNA	   sequencing	   became	   much	   more	  automated	   [59].	   The	   ease	   of	   use,	   throughput	   and	   consistency	   of	   results	   were	  much	   improved	   by	   this	   new	   technology	   [60].	   The	   Wellcome	   Trust	   Sanger	  Institute	  extensively	  used	  capillary	  sequencing	  for	  the	  completion	  of	  the	  human	  genome	  project	  [61].	  DNA	  sequencing	  could	  be	  performed	  by	  attaching	  four	  different	  fluorescent	  dyes	  to	  ddNTPs,	  allowing	  one	  reaction	   tube	  per	  sample.	  The	  reaction	   is	  achieved	  by	  adding	  unlabelled	  primer,	  buffer,	  the	  four	  dNTPs,	  the	  four	  fluorescently	  labelled	  ddNTPs	   and	   Taq	   polymerase	   (a	   thermostable	   polymerase	   enzyme)	   into	   a	  reaction	  tube.	  Cycles	  of	  denaturation	  and	  amplification	  are	  then	  performed	  and	  result	   in	   DNA	   fragments	   of	   different	   sizes	   having	   a	   fluorescently	   labelled	  terminator	  at	  their	  3’	  end	  (see	  Figure	  1-­‐8).	  These	  different	  sized	  fragments	  can	  then	   be	   separated	   by	   size	   and	   the	   sequence	   determined	   by	   capturing	   the	  emission	   spectra	   of	   the	   terminator	   molecule,	   this	   approach	   to	   sequencing	   is	  known	  as	  Sanger	  sequencing	  [62].	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  Figure	   1-­‐8	   Denaturation,	   annealing	   and	   extension	   processes	   of	   Sanger	  sequencing	  [appliedbiosystems.com].	  Products	  of	   the	   cycles	  of	  denaturation	  and	  amplification	   steps	  are	  delivered	   to	  the	   capillaries	   via	   an	   electrokinetic	   injection,	   where	   a	   high	   voltage	   charge	   is	  applied	  to	  the	  buffer	  and	  acts	  to	  force	  the	  negatively	  charged	  DNA	  fragments	  into	  the	  capillaries.	  The	  DNA	  fragments	  are	  pulled	  though	  the	  capillary	  by	  a	  positive	  electrode	  at	  the	  end,	   the	   polymer	   inside	   the	   capillaries	   acts	   to	   separate	   the	  DNA	   fragments	   by	  size	   based	  on	   their	   total	   charge.	   The	   electrophoretic	  mobility	   of	   the	   fragments	  can	  vary	  due	  to	  various	  conditions.	  For	  example	  the	  buffer	  type,	  concentration,	  pH,	   the	   run	   temperature	   and	   the	   amount	   of	   voltage	   can	   all	   affect	   the	   speed	   at	  which	  the	  fragments	  migrate.	  As	   the	   sample	   reaches	   the	   end	   of	   the	   capillary,	   the	   fluorescently	   labelled	  DNA	  fragments	  move	  across	  the	  path	  of	  a	  laser	  beam.	  The	  laser	  beam	  causes	  the	  dyes	  to	  fluoresce	  and	  an	  optical	  detection	  device	  detects	  the	  emission	  spectra.	   	  Since	  each	   fluorescent	  dye	   emits	   light	   at	   a	  different	  wavelength	   all	   four	   colours,	   and	  consequently	   all	   four	   bases,	   can	   be	   detected	   and	   read	   from	   a	   single	   capillary	  injection	  (see	  Figure	  1-­‐9).	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  Figure	   1-­‐9	   Diagram	   showing	   the	   Sanger	   sequencing	   process,	   resulting	   in	   a	  readable	  sequence	  of	  emission	  spectra	  [appliedbiosystems.com].	  
Next	  Generation	  Sequencing	  There	   is	   nowadays	   a	   number	   of	   different	   next	   generation	   sequencing	   (NGS)	  technologies	  available	  [63-­‐66].	  These	  include	  the	  Illumina	  Solexa,	  Roche	  454,	  ABI	  SOLiD	   and	   Pacific	   Biosciences	   PACBIO	   to	   name	   just	   a	   few.	   The	   sequencing	  technologies	  and	  protocols	  are	  under	  constant	  development	  and	  are	   leading	   to	  improvements	  in	  the	  quality	  and	  volume	  of	  the	  data	  that	  can	  be	  produced	  and	  to	  the	  cost	  of	  running	  an	  experiment.	  The	   original	   NGS	   technology	   was	   produced	   by	   Solexa	   and	   was	   acquired	   by	  Illumina	   in	   November	   2006	   for	   the	   price	   of	   600	   million	   dollars.	   The	   basic	  protocol	   used	   in	   a	   Solexa	   experiment	   generates	   large	   numbers	   of	   unique	  polymerase	   generated	   colonies	   that	   can	   be	   simultaneously	   sequenced.	   	   These	  reactions	  take	  place	  in	  parallel	  on	  the	  surface	  of	  a	  ”flow	  cell”	  which	  is	  then	  used	  as	   a	   surface	   for	   many	   thousands	   of	   parallel	   sequencing	   chemical	   reactions	   to	  occur.	  The	  DNA	  sample	  needs	  to	  be	  sheared	  to	  the	  correct	  size	  (approx.	  800bp).	  	  This	  is	  achieved	   using	   a	   compressed	   air	   device	   known	   as	   a	   nebulizer.	   Two	   unique	  adapter	   modules	   are	   then	   ligated	   to	   both	   ends	   of	   the	   fragments.	   Ligated	  fragments	  of	  the	  target	  library	  size	  (e.g.	  200bp)	  are	  isolated	  and	  amplified	  using	  a	  number	  of	  PCR	  cycles.	  Single	   stranded	   oligonucleotides	   complimentary	   to	   the	   sequences	   of	   the	  adapters	  molecules	  coat	  the	  surface	  of	  the	  flow	  cell.	  The	  single-­‐stranded	  ligated	  fragments	   from	   the	   sample	   preparation	   stage	   are	   bound	   to	   the	   surface	   of	   the	  flow	  cell.	  The	  reagents	  necessary	  for	  a	  polymerase	  extension	  reaction	  are	  applied	  to	   the	  surface	  of	   the	   flow	  cell.	  Priming	  can	   then	  occur	  when	  the	  distal	  end	  of	  a	  ligated	  fragment	  ”bridges”	  to	  a	  complementary	  oligo	  on	  the	  flow	  cell	  surface.	  By	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repeating	  a	  denaturation	  and	  extension	  cycle	  amplification	  of	  single	  molecules	  in	  millions	  of	  unique	  locations	  across	  the	  flow	  cell	  surface	  can	  occur	  (see	  Figure	  1-­‐
10).	  
	  Figure	  1-­‐10	  Diagram	  sample	  preparation,	  bridge	  amplification	  and	  denature	  and	  extension	  cycles	  [seqanswers.com].	  Automated	   cycles	   of	   extension	   and	   imaging	   can	   occur	   by	   loading	   a	   flow	   cell	  containing	  millions	  of	  unique	  clusters	  into	  the	  sequencer.	  The	  incorporation	  of	  a	  fluorescently	  labelled	  nucleotide,	  followed	  by	  high	  resolution	  imaging	  of	  the	  flow	  cell	  can	  now	  occur.	  The	  first	  image	  captured	  represents	  the	  data	  collected	  for	  the	  first	   base	   of	   the	   sequence.	   Signals	   above	   the	   background	   identify	   the	   physical	  location	  of	  a	  cluster	  and	  the	  precise	  fluorescent	  emission	  identifies	  which	  of	  the	  four	   bases	  was	   incorporated	   at	   that	   position.	   	   Each	  nucleotide	   base	   is	   labelled	  with	  a	  different	  coloured	  fluorescent	  dye	  that	  allows	  the	  sequence	  of	  each	  cluster	  to	  be	  read.	  A	  cycle	  is	  then	  repeated	  to	  generate	  a	  series	  of	  images	  representing	  a	  single	  base	  extension	  at	  each	  specific	  cluster.	  The	  exact	  sequence	  of	  each	  cluster	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is	  derived	  using	  an	  algorithm	  to	  detect	   the	  emission	  spectrum	  across	  all	  of	   the	  images	  for	  each	  cluster	  (see	  Figure	  1-­‐11).	  
	  Figure	   1-­‐11	   A	   diagram	   showing	   data	   collection,	   sequence	   determination	   and	  alignment	  [seqanswers.com].	  Each	  type	  of	  sequencing	  technology	  has	  different	  performances	  in	  various	  areas,	  for	   example,	   the	   length	  of	   reads,	   the	  density	   of	   reads	   and	   the	   amount	   of	   noise	  reduction	  they	  produce	  can	  vary	  across	  platforms.	  The	  original	  Solexa	  machines	  could	  only	  achieve	  short	  reads	  (approx.	  30-­‐60bp)	  but	   could	   achieve	   very	   high	   throughput.	   The	   454	   from	   Roche	   could	   produce	  much	  longer	  read	  (approx.	  400bp)	  but	  at	  a	  far	  lower	  throughput	  rate	  [64].	  	  The	  newly	  emerging	  PACBIO	  from	  Pacific	  Biosciences	  promises	  to	  deliver	  the	  ability	  to	   tune	   these	   types	   of	   parameters	   to	   suit	   individual	   purposes	   [67-­‐69].	   For	  example,	  they	  claim	  to	  be	  able	  to	  produce	  a	  relatively	  small	  number	  of	  long	  reads	  and	   a	   large	   number	   of	   short	   reads	   across	   a	   genomic	   location	   using	   a	  method	  called	  strobe	  sequencing	  [70].	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Striking	   the	   correct	   balance	   between	   these	   types	   of	   parameters	   are	   what	   the	  sequencing	   companies	   and	   R&D	   teams	   are	   working	   hard	   towards	   and	   there	  seems	  to	  be	  almost	  monthly	  releases	  of	  new	  and	  improved	  protocols.	  However,	  our	  ability	  to	  extract	  the	  maximum	  amount	  of	  useful	  information	  from	  these	  data	  using	   analytical	   methods	   is	   lagging	   behind	   at	   an	   ever-­‐increasing	   rate	   [71].	  Although	  a	  fair	  amount	  of	  these	  data	  can	  be	  utilised	  already	  there	  are	  still	  a	  lot	  of	  reads	  that	  are	  currently	  not	  interpretable	  [72]	  however,	  as	  the	  sequencing	  data	  quality	  improves	  so	  analytical	  methods	  also	  become	  robust.	  There	  is	  however	  a	  time	   cost	   associated	   with	   data	   improvement	   where	   either	   existing	   analytical	  methods	  need	  to	  be	  modified	  or	  new	  ones	  created	  [73].	  For	   copy	   number	   information	   there	   are	   currently	   two	  useful	   properties	   of	   the	  sequence	  data,	   the	   incorrect	  mapping	  of	   read	  pairs	  and	   the	  read	  depth	  at	  each	  genomic	  location.	  Although	  copy	  number	  from	  NGS	  is	  receiving	  a	  lot	  of	  attention	  from	   the	   community	   [27,	   74]	   the	   ability	   to	   accurately	   assign	   copy	   numbers	   is	  hampered	   by	   a	   number	   of	   factors.	   Among	   these,	   the	   differences	   in	   platform	  performances,	   technical	   noise,	   normalisation	   strategies	   and	   analytical	  approaches	   all	   conspire	   to	  make	   the	   interpretation	   of	   copy	   number	   from	  NGS	  data	  a	  challenging	  area	  of	  research.	  
	  
1.3	   COPY	  NUMBER	  DATA	  
1.3.1	   Single	  Colour	  Data	  Single-­‐channel	   (single	   colour)	  microarrays	   such	  as	   the	  Affymetrix	   gene	   chip	  or	  Illumina	  BeadArray	   provide	   a	   single	   distribution	   of	   intensity	   values	   from	   each	  probe	  on	  the	  array.	  As	  a	  result	  single-­‐channel	  (genotyping)	  arrays	  normally	  use	  a	  large	  reference	  set	  specific	  to	  each	  array	  format	  to	  normalise	  the	  intensity	  values	  against.	  This	  allows	  the	  relative	  intensity	  levels	  of	  each	  probe	  to	  be	  compared	  to	  a	   population	   mean	   and	   thus	   provide	   an	   estimate	   of	   the	   amount	   of	   genetic	  material	   present,	   for	   each	   probe,	   in	   the	   sample	   compared	   to	   the	   mean	   of	   a	  population.	  	  High-­‐density	  SNP	  genotyping	  platforms	  (single	  colour	  microarrays)	  produce	   an	   intensity	   value	   for	   each	   allele	   of	   a	   given	   SNP	  marker.	   The	   careful	  analysis	  of	  the	  signal	  intensities	  produced	  by	  these	  arrays	  can	  be	  used	  to	  identify	  regions	   with	   multiple	   SNPs	   that	   support	   deletions	   or	   duplications	   at	   specific	  locations	  throughout	  the	  genome	  [75,	  76].	  
Log	  R	  Ratio	  The	  Log	  R	  Ratio	  (LRR)	   is	  a	  normalized	  measure	  of	   the	  total	  signal	   intensity	   for	  the	  two	  alleles	  of	  a	  SNP	  marker.	  Specifically,	  it	  is	  the	  log2	  of	  the	  total	  signal	  from	  both	  alleles	  of	  a	  SNP	  marker	  divided	  by	  the	  average	  total	  signal	  from	  both	  alleles	  of	  the	  same	  SNP	  marker	  from	  the	  reference	  set.	  Let	  sX	  and	  sY	  equal	  the	  signal	  intensity	  observed	  in	  SNP	  allele	  (A)	  and	  SNP	  allele	  (B)	  from	  the	  test	  sample,	  respectively	  and	  let	  rX	  and	  rY	  equal	  the	  average	  signal	  intensity	   observed	   in	   SNP	   allele	   (A)	   and	   SNP	   allele	   (B)	   from	   the	   reference	   set,	  respectively.	  	  Finally	  let	  N	  equal	  the	  total	  number	  of	  SNP	  markers.	  We	  then	  calculate	  the	  LRR	  values	  thus:	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!""! = !"#! !"! + !"!!"! + !"!	   [1-­‐1]	  	  with	  n	  from	  1,	  2,	  ..,N.	  This	  transformation	  is	  often	  written	  in	  this	  form:	  	   ! = ! + !	   [1-­‐2]	  
and	   !"" = !"#! !"#$%&'%(!"#$"%&"' 	   [1-­‐3]	  	  where	   Rexpected	   is	   computed	   from	   linear	   interpolation	   of	   canonical	   genotype	  clusters	  obtained	  from	  a	  set	  of	  reference	  samples	  [76].	  
B-­‐Allele	  Frequency	  The	   B	   Allele	   Frequency	   (BAF)	   is	   a	   normalized	  measure	   of	   the	   allelic	   intensity	  ratio	  of	  two	  alleles.	  The	   BAF	   is	   a	   measure	   of	   the	   allelic	   intensity	   ratio:	   When	   a	   deletion	   CNV	   is	  present,	   BAF	   values	   cluster	   around	   0	   or	   1	   but	   are	   absent	   around	   0.5;	   when	  duplication	  is	  present,	  BAF	  values	  cluster	  around	  0,	  0.33,	  0.67,	  and	  1,	  reflecting	  the	  AAA,	  AAB,	  ABB,	  and	  BBB	  genotypes,	  respectively.	  The	  !	  value	   measures	   the	   relative	   allelic	   intensity	   ratio	   of	   two	   alleles	   and	   is	  calculated	  as	  ! = arctan !/! /(!/2)	  which	  ranges	  from	  0	  to	  1.	  	  The	  BAF	  refers	  to	  a	  normalized	  measure	  of	  relative	  signal	  intensity	  ratio	  of	  the	  B	  and	  A	  alleles:	  	  
!"# = 0, !"  ! < !!!0.5(! − !!!)/(!!" − !!!), !"  !!! ≤ ! < !!"0.5+ 0.5(! − !!")/(!!! − !!"), !"  !!" ≤ ! < !!!1, !"  ! ≥ !!! 	  
[1-­‐4]	  
	  To	  search	  for	  regions	  of	  LOH	  and	  UPD	  in	  SNP	  genotyping	  data	  the	  BAF	  is	  often	  used.	  BAF	  is	  a	  value	  between	  0	  and	  1	  and	  represents	  the	  proportion	  contributed	  by	  one	  SNP	  allele	  (B)	  to	  the	  total	  copy	  number	  (see	  Figure	  1-­‐12).	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Figure	  1-­‐12	  Illustration	  of	  the	  BAF	  (upper	  panel)	  and	  LRR	  (lower	  panel)	  values	  in	   chromosome	   20	   of	   a	   person	   with	   large	   (1	   Mb)	   deletion	   and	   duplication	  [scientificprotocols.org].	  
1.3.2	   Dual	  Colour	  Data	  Two-­‐channel	   (dual	   colour)	   microarrays	   are	   normally	   hybridized	   using	   cDNA	  prepared	   from	   two	  different	   samples	   labelled	  with	   two	  different	   fluorophores,	  usually	   Cy5	   and	   Cy3	   [77].	   The	   cytosine3	   dye	   has	   a	   fuorescence	   emission	  wavelength	   of	   570nm	   (green)	   and	   the	   cytosine5	   an	   emission	   wavelength	   of	  670nm	  (red).	  The	   two	  differentially	   labelled	   samples	  are	   combined	   in	   the	  presence	  of	  buffer	  and	  applied	  to	  a	  single	  microarray	  such	  that	  competitive	  hybridisation	  can	  occur.	  After	  an	  incubation	  period	  the	  microarray	  can	  be	  scanned	  using	  a	  laser	  beam	  to	  promote	   excitation	   of	   the	   fluorophores	   at	   the	   defined	   wavelength	   and	   the	  relative	  intensities	  measured.	  
Intensity	  Distributions	  The	   extracted	   intensities	   of	   each	   fluorophore,	   for	   each	   probe	   on	   the	   array	   can	  then	  be	  normalised	  in	  a	  number	  of	  ways	  to	  achieve	  similar	  ranges	  and	  scales	  and	  remove	  any	  bias	  between	  the	  two	  distributions.	  
Log2	  Ratio	  These	   intensity	  distributions	  can	   then	  be	   transformed	   into	  a	  Log2	  Ratio	   (L2R),	  which	  reflects	  the	  relative	  amount	  of	  genetic	  material	  present	  in	  each	  of	  the	  two	  samples	  for	  each	  of	  the	  probes	  on	  the	  array.	  Let	   c3	   and	   c5,	   equal	   the	   signal	   intensity	   extracted	   at	   the	   570nm	   and	   670nm	  wavelengths,	  respectively.	  Finally	  let	  N	  equal	  the	  total	  number	  of	  probes	  on	  the	  array.	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We	  then	  calculate	  the	  Log2	  Ratio	  values	  thus:	  !2!! = !"#! !3!!5!	   [1-­‐5]	  	  with	  n	  from	  1,	  2,	  ..,N.	  The	  L2R	  values	  can	  then	  be	  normalised	  in	  a	  number	  of	  different	  ways	  to	  remove	  some	  further	  technical	  biases.	  It	  is	  then	  possible	  to	  use	  the	  L2R	  values	  as	  a	  direct	  estimation	  of	   the	  relative	  difference	   in	  abundance	  of	  genetic	  material,	  between	  the	  two	  samples,	  at	  all	  of	  the	  genomic	  locations	  covered	  by	  the	  array.	  It	  should	  be	  noted	  that	  by	  using	  this	  two-­‐sample	  approach	  it	  is	  not	  possible	  to	  get	  an	   absolute	   copy	  number	   estimation	   for	   either	   of	   the	   samples,	   rather	   only	   the	  relative	   copy	   number	   between	   the	   two	   samples	   is	   available.	   One	   way	   to	  overcome	  this	  is	  to	  use	  a	  ”pooled”	  reference	  DNA	  to	  label	  and	  apply	  to	  the	  array	  in	  place	  of	  one	  of	  the	  samples	  [78].	  Using	  this	  approach	  it	  is	  possible	  to	  obtained	  the	  true	  copy	  number,	  of	  a	  given	  sample,	  at	  a	  given	  genomic	  location,	  compared	  to	  the	  population	  mean.	  It	  is	  generally	  believed	  that	  as	  few	  as	  100	  ”normal”	  DNA	  samples	  will	  provide	  a	  relatively	  accurate	  estimation	  of	  the	  population	  mean.	  
1.3.3	   Sequence	  Data	  The	   information	   that	   can	   currently	   be	   utilised	   from	   sequence	   data	   to	   estimate	  copy	   number	   (structural	   variants)	   comes	   in	   the	   form	   of	   either	   read-­‐pairs	   or	  read-­‐depth.	  
Read	  Pairs	  Paired-­‐end	  sequencing	  technology	  can	  be	  used	  to	  detect	  structural	  variants	  [79].	  	  Suppose	   a	   clone	   library	   for	   an	   individual	  with	   a	   clone	   size	   of	   150kb	   has	   been	  prepared.	  When	  these	  clones	  are	  sequenced	  and	  mapped	  back	  to	   the	  reference	  genome,	   the	   ends	   of	   the	   clones	  would	   be	   expected	   to	  map	   at	   an	   approximate	  distance	   of	   150kb	   away	   from	   each	   other	   in	   a	   forward	   reverse	   direction.	  Therefore,	   if	   any	   read	   pair	   that	   does	   not	   map	   in	   this	   manner	   it	   could	   be	   an	  indication	  of	  a	  structural	  rearrangement	  (see	  Figure	  1-­‐13).	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  Figure	   1-­‐13	   An	   illustration	   of	   incorrectly	   mapping	   read	   pairs	   –	  [saaientist.blogspot.com].	  	  	  As	  illustrated	  above	  (see	  Figure	  1.13)	  there	  are	  several	  possible	  outcomes	  when	  mapping	   read	  pairs	   back	   to	   the	   reference	   genome.	   Firstly	   the	  pairs	   could	  map	  back	  at	  the	  correct	  distance	  from	  one	  another	  and	  this	  indicates	  that	  there	  are	  no	  structural	   variants	   in	   this	   region	   for	   the	   sample	   compared	   to	   the	   reference	  genome.	  Secondly	  there	  is	  the	  situation	  where	  the	  read	  pairs	  map	  at	  an	  abnormal	  distance	  from	   each	   other.	   This	   indicates	   that	   the	   variant	   is	   either	   a	   deletion	   or	   an	  insertion	  at	  this	  position	  for	  the	  sample	  compared	  to	  the	  reference.	   If	   the	  pairs	  map	   a	   shorter	   distance	   away	   from	   each	   other	   it	   is	   evidence	   for	   a	   deletion	  whereas	   if	   they	   map	   too	   far	   apart	   it	   is	   evidence	   for	   an	   insertion.	   	   The	   final	  possibility	   is	   given	   when	   the	   read	   pairs	   map	   to	   the	   reference	   genome	   in	   the	  wrong	   orientation	   relative	   to	   each	   other.	   This	   type	   of	   read	   pair	   mapping	  discrepancy	  can	  indicate	  the	  presence	  of	  an	  inversion.	  
Read	  Depth	  In	  read	  depth	  data	  from	  NGS	  technology	  there	  is	  seemingly	  the	  perfect	  data	  set	  for	  copy	  number	  estimation	  [80].	  The	  amount	  of	  sequenced	  product	  produced	  is,	  in	   theory,	   directly	   related	   to	   the	   amount	   of	   starting	   genetic	   material	   in	   the	  sample.	  So	  if	  an	  individual	  contains	  more	  or	  less	  of	  a	  particular	  genetic	  sequence	  the	  proportion	  of	  this	  sequence	  should	  be	  reflected	  in	  the	  amount	  of	  sequenced	  product	  produced	  from	  the	  sequencing	  reaction.	  Thereby,	  it	  would	  be	  possible	  to	  simply	  count	  the	  number	  of	  reads	  for	  each	  of	  the	  sequences	  produced	  to	  get	  an	  estimation	   of	   the	   number	   of	   copies	   of	   that	   genetic	   sequence	   the	   sample	  contained.	   Indeed,	   this	   is	  possible	  and	  methods	  have	  been	  developed	   to	  utilise	  read	   depth	   in	   much	   the	   same	   way	   as	   the	   log2	   ratio	   from	   an	   array-­‐CGH	  experiment	  [81].	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  Figure	  1-­‐14	  An	  illustration	  of	  using	  read	  depth	  for	  copy	  number	  discovery	  [81].	  	  	  Short	   reads	   from	   an	   individual	  were	  mapped	   to	   the	   human	   reference	   genome	  and	   counted	   in	   a	   100bp	   non-­‐overlapping	   sliding	  window	   to	   produce	   the	   read	  depth	  data	  (see	  Figure	  1-­‐14).	  The	  counts	  were	  then	  centred	  on	  their	  mean	  and	  [81]	  applied	  their	  MCMC	  sampler	  to	  detect	  change	  point	  intervals	  from	  the	  data.	  One	  of	  the	  detected	  segments	  is	  shown	  above,	  it	  is	  a	  2653bp	  deletion	  locus.	  This	  demonstrates	  the	  potential	  read	  depth	  has	  for	  detecting	  copy	  number	  variation	  from	  NGS	  data.	  However,	   read	   depth	   data	   still	   has	   various	   associated	   problems;	   there	   are	   a	  number	  of	  biases	  (for	  example	  a	  GC	  bias),	  which	  need	  normalisation	  strategies	  to	  avoid.	   Additionally	   variable	   read	   qualities,	   achieved	   sample	   depths	   and	  constantly	  changing	  experimental	  protocol	  have	  a	   large	   impact	  on	  the	  utility	  of	  the	  data	  and	  on	  the	  associated	  analytical	  methodologies.	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1.4	   COPY	  NUMBER	  ANALYSIS	  METHODS	  
1.4.1	   Array-­‐CGH	  Data	  Normalisation	  
Dye	  Bias	  It	   is	  well	  established	   that	  a	  bias	  exists	  between	   the	   two	   fluorophores	  normally	  used	  in	  array-­‐CGH	  (Cy5	  and	  Cy3)	  [82]	  due	  to	  differential	  efficiency	  in	  enzymatic	  labelling.	  	  This	  bias	  manifests	  as	  a	  difference	  between	  the	  two	  resulting	  intensity	  distributions	  and	  if	   left	  uncorrected	  is	  highly	  likely	  to	  skew	  the	  ratio	  calculated	  during	   downstream	   analysis.	   Over	   the	   years	   there	   have	   been	   a	   number	   of	  different	  approaches	  taken	  for	  dye-­‐bias	  removal	   including	  both	  linear	  and	  non-­‐linear	   methods	   [83].	   These	   methods	   were	   primarily	   developed	   for	   the	  normalisation	  of	  expression	  microarrays	  and	  have	  more	  recently	  been	  applied	  to	  array-­‐CGH	  microarrays	  [84].	  The	  most	   commonly	   used	   and	  widely	   trusted	   dye	   bias	   normalisation	  methods	  tend	  to	  be	  based	  on	   lowess	  (locally	  weighted	  regression)	   techniques.	  However,	  standard	  regression	  techniques	  can	  be	  sensitive	  to	  outliers,	  which	  are	  common	  features	   of	   array-­‐CGH	   data.	   As	   a	   result,	   lowess-­‐based	   dye	   bias	   normalisation	  approaches	   normally	   use	   robust	   regression	   techniques,	   becoming	  computationally	   intensive	   and	   severely	   limiting	   if	   applied	   to	   microarrays	  comprising	  more	  than	  three	  hundred	  thousand	  probes	  [85].	  Normalisation	  methods	   based	   on	   fitting	   smoothing	   spline	   functions	   have	  most	  often	   been	   seen	   in	   relation	   to	   between-­‐chip	   quantile	   normalisation	   of	  microarrays	  [86]	  and,	  although	  promising	  work	  has	  been	  carried	  out	  previously	  [87],	   are	   still	   seldom	   applied	   to	   two-­‐colour	   array-­‐CGH	   microarray	   data.	   One	  possible	  explanation	  for	  this	   is	  that	  when	  fitting	  a	  spline	  curve	  only	  a	  subset	  of	  data	   is	   used	   and	   without	   appropriate	   action	   can	   lead	   to	   inaccurate	   data	  adjustment	  when	  applied	  to	  complex	  datasets	  [88].	  More	  recently	  we	  published	  a	  method	  (aCGH.Spline)	  using	  outlier	  exclusion	  and	  posterior	  interpolation	  allowing	  robust	  fitting	  of	  the	  two	  intensity	  distributions,	  independently	   towards	   their	   geometric	   mean	   using	   cubic	   spline	   interpolation	  [89].	  The	  cubic	  splines	  used	  in	  this	  study	  were	  of	  the	  form:	  	   !! ! = !! + !! ! − !! + !!(! − !!)! + (! − !!)!	   [1-­‐6]	  	  and	  if	  a	  given	  set	  of	  coordinates	  (knot	  points)	  are:	  	  	   !!,!! , !!,!! ,… (!!,!!) 	   [1-­‐7]	  	  the	  required	  set	  of	  n	  splines	  are:	  	  	   ! !! = !! , ! = 0,… ,! − 1	   [1-­‐8]	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  These	   were	   then	   computed,	   using	   Gaussian	   elimination,	   subject	   to	   the	   usual	  derivative	   constraints	   for	   the	   splines.	   Figure	   1-­‐15	   shows	   microarray	  normalisation	  plots	   (MAplots)	   for	   aCGH.Spline	   compared	   to	   a	  number	  of	   other	  dye	  bias	  normalisation	  approaches.	  
	  Figure	  1-­‐15	  MA-­‐plots	  showing	  normalisation	  quality	  of	   sample	  7	  when	  using	  6	  different	  normalisation	  methods.	  Panels	  showing	  one	  244k	  custom	  tiling	  Agilent	  array	   under	   six	   different	   normalisation	   methods,	   autosomes	   (black),	  chromosome	  X	  (red),	  chromosome	  Y	  (green).	   (A)	  Global	  median	  normalisation.	  	  (B)	   Standard	   lowess	   function	   in	  R.	   (C)	   qspline.normalize	  method	   from	   the	   affy	  biocondutor	  package.	   (D)	  printTipLoess	  method	   from	  the	  marray	  bioconductor	  package.	  (E)	  popLowess	  method.	  (F)	  aCGH.Spline	  method.	  It	  is	  clear	  that,	  when	  using	  only	  a	  global	  median	  normalization,	  dye	  bias	  removal	  will	  be	  compromised	  due	  to	  not	  accounting	  for	  any	  non-­‐linear	  effects	  (see	  
Figure	  1-­‐15	  A).	  Moreover,	  when	  using	  either	  the	  global	  spline	  fitting	  method	  ‘qspline.normalize’	  or	  the	  locally	  weighted	  regression	  method	  ‘R	  lowess’,	  where	  no	  prior	  outlier	  exclusion	  is	  applied	  we	  can	  observe	  an	  inaccurate	  adjustment	  of	  both	  outlier	  and	  non-­‐outlier	  data	  points	  (see	  Figure	  1-­‐15	  B	  and	  C).	  When	  using	  the	  robust	  regression	  methods,	  ‘marray’	  and	  ‘poplowess’,	  the	  adjustment	  of	  data	  points	  are	  not	  adversely	  affected	  by	  outlier	  values;	  however,	  the	  adjustment	  itself	  results	  in	  the	  distribution	  of	  data	  points	  being	  forced	  towards	  a	  normal	  distribution	  (see	  Figure	  1-­‐15	  D	  and	  E).	  With	  aCGH.Spline,	  by	  excluding	  outlier	  values	  prior	  to	  spline	  fitting	  and	  correcting	  them	  by	  posterior	  interpolation	  the	  distribution	  of	  data	  points	  closer	  to	  the	  true	  distribution	  (see	  Figure	  1-­‐15	  A	  and	  
F)	  but	  with	  most	  of	  the	  dye	  bias	  removed	  (see	  Figure	  1-­‐15	  F).	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Probe	  Bias	  One	   historical	   approach	   to	   removing	   the	   dye	   bias	   from	   array-­‐CGH	   data	   and	  improving	   the	   data	   quality	   was	   to	   perform	   the	   so-­‐called	   dye-­‐swap	   designed	  experiment	   [84].	   A	   dye-­‐swap	   design	   involves	   running	   two	   separate	   arrays	   for	  each	  hybridisation	  where	  the	  dye	  used	  to	  label	  the	  two	  DNAs	  being	  compared	  is	  switched	   between	   the	   first	   and	   second	   hybridisations.	   Although	   it	   can	   be	  effective,	   this	   is	   not	   a	   satisfactory	   solution	   as	   it	   involves	   combining	   two	  independent	  array	  profiles	  and	  doubles	  the	  cost	  of	  the	  experiment.	  On	  top	  of	  that	  the	  data	  quality	  of	  each	  experiment	  is	  likely	  to	  differ	  and	  needs	  to	  be	  combined	  to	  remove	  the	  effect	  of	  the	  dye	  bias.	  One	   alternative	   that	   has	   been	   considered	   previously	   [90]	   is	   the	   self-­‐self	  normalisation	  procedure.	  A	  self-­‐self	  array-­‐CGH	  experiment	  is	  defined	  as	  running	  the	   same	   sample,	   differentially	   labelled,	   against	   itself	   on	   an	   array.	   	   The	   theory	  was	  that	  by	  running	  the	  same	  sample	  against	  itself	  on	  the	  array,	  the	  differences	  that	  were	  seen	  between	  the	  two	  resulting	  intensity	  distributions	  would	  be	  due	  to	  the	   dye	   bias.	   Interestingly	   the	   differences	   seen	   when	   running	   a	   self-­‐self	  experiment	   cannot	   be	   fully	   explained	   by	   the	   dye	   bias	   and	   is	   not	   an	   effective	  method	   for	   removing	   it.	   Of	   course,	   the	   degree	   of	   dye	   bias	   present	   is	   likely	   to	  differ	   between	   replicate	   experiments	   and	   does	   not	   show	   a	   linear	   relationship	  [89].	   However,	   the	   type	   of	   noise	   detected	   by	   a	   self-­‐self	   experiment	   can	   be	  explained	   and	   utilised	   to	   remove	   a	   different	   type	   of	   technical	   bias	   that	   exists	  within	   microarray-­‐based	   data.	   Theory	   dictates	   that	   in	   a	   self-­‐self	   experiment	  every	  probe	  should	  report	  with	  a	  log2	  ratio	  of	  zero,	  for	  no	  copy	  number	  change,	  however	   in	  practice	   this	   is	  not	   the	  case	  even	  when	  correcting	   for	  any	  dye	  bias	  and	   each	   probe	   will	   report	   with	   a	   log2	   ratio	   either	   above	   or	   below	   zero	   (see	  
Figure	  1-­‐16).	  
	  	  Figure	  1-­‐16	  Left	  -­‐	  The	  correlation	  between	  the	  derived	  self-­‐self	  correction	  values	  and	   an	   array-­‐CGH	   array.	   Right	   -­‐	   The	   correlation	   between	   the	   derived	   self-­‐self	  correction	  values	  and	  the	  residuals	  of	  a	   linear	  regression	  against	  an	  array-­‐CGH	  array.	  This	   type	   of	   noise	   can	   be	   described	   as	   array	   specific	   and	   is	   an	   indication	   of	  systematic	  differences	  in	  probe	  efficiencies	  across	  the	  entire	  array.	  By	  running	  a	  number	  of	   self-­‐self	   calibration	  data	  across	  each	  array	  platform	  being	  used	   it	   is	  possible	  to	  start	   to	  estimate	  the	  average	  behaviour	  of	  each	  and	  every	  probe	  on	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the	   array.	   By	   using	   these	   values	   during	   normalisation	   it	   is	   possible	   to	   remove	  this	  systematic	  noise	  and	  greatly	  reduce	  the	  noise	  levels	  across	  an	  array.	  
Wave	  Bias	  Auto-­‐correlation	  was	  first	  linked	  with	  array	  data	  to	  describe	  the	  type	  of	  spurious	  false	  results	  occurring	  in	  association	  with	  non-­‐random	  probe	  placement	  during	  array	  manufacture.	  Computer	  simulations	  were	  used	   to	  show	  that	   large	  spatial	  biases	   across	   an	   array,	   those	   that	   could	   result	   from	  microarray	   hybridisation,	  could	   exclusively	   account	   for	   spurious	   correlations	   in	   the	   data	   [91].	  Moreover	  the	  presence	  of	  an	  auto-­‐correlation	  or	  genomic	  wave	  effect	  has	  been	  described	  as	  a	  specific	   type	  of	  systematic	  noise	  within	   the	   log2	  ratio	  values	  of	  array-­‐CGH	  data	   [92].	   This	   type	   of	   systematic	   noise	   appears	   to	   be	   present	   on	   most	  microarray	  platforms	  and	  without	  proper	  adjustment	  has	  the	  potential	  to	  cause	  large	  numbers	  of	  false	  discoveries.	  When	   using	   BAC	   large	   insert	   clone	   array	   a	   high	   correlation	   between	   the	   GC	  content	   of	   each	   BAC	   clone	   and	   the	   log2	   ratio	   it	   reported	   was	   described	  previously	  [92].	  This	  observation	  suggested	  that	  there	  could	  be	  a	  GC	  dependent	  bias	  during	  either	  DNA	   labelling	  or	  array	  hybridisation.	  Nevertheless,	  we	  were	  able	  to	  apply	  a	  GC	  based	  correction,	  using	  linear	  regressions,	  to	  BAC	  based	  array-­‐CGH	  data	  and	  remove	  most	  of	  the	  genomic	  wave	  effect	  [92].	  Here	  this	  approach	  was	   extended	   to	   operate	   on	   oligo-­‐nucleotide	   arrays	   (see	   Figure	   1-­‐17).	  Following,	   others	   have	   developed	   similar	  methods	   based	   on	   the	  GC	   content	   of	  probes	   to	   correct	   for	   the	   genomic	   wave	   effect	   seen	   on	   Affymetrix	   SNP	   arrays	  [93].	  They	  also	  observed	  that	  the	  magnitude	  of	  the	  wave	  effect	  could	  be	  linked	  to	  both	  the	  concentration	  and	  quality	  of	  DNA	  being	  applied	  to	  the	  array.	  The	  most	  recent	  method	   to	   be	   developed	   using	   a	   GC	   correction	   is	   the	   array-­‐CGH	  waves	  correction	  algorithm	  (WACA)	  [94].	  	  
Figure	  1-­‐17	  Left	   -­‐	  The	   correlation	  between	  GC	   correction	  values	   and	  an	  array-­‐CGH	   array.	   Right	   -­‐	   The	   correlation	   between	   GC	   correction	   values	   and	   the	  residuals	  of	  a	  linear	  regression	  against	  an	  array-­‐CGH	  array.	  The	  combination	  of	   these	  three	  normalisation	  strategies	  can	  be	  highly	  effective	  for	  the	  de-­‐noising	  of	  array-­‐CGH	  log2	  ratio	  data.	  Figure	  1-­‐18	  shows	  the	  effect	  of	  applying	   both	   a	   probe	   bias	   and	   a	   wave	   bias	   normalisation	   on	   the	   dye	   bias	  normalised	  log2	  ratio	  values	  from	  a	  single	  array-­‐CGH	  array.	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  Figure	  1-­‐18	  The	  effect	  of	  removing	  both	  the	  probe	  bias	  and	  the	  wave	  bias	  from	  an	   array-­‐CGH	   array.	   Top	   left-­‐original	   data	   values,	   Top	   right-­‐data	   values	   after	  removing	  the	  probe	  bias,	  Bottom	  left-­‐data	  values	  after	  removing	  the	  wave	  bias,	  Bottom	  right-­‐data	  values	  after	  removing	  both	  the	  probe	  and	  wave	  bias.	  Red	  line	  is	  a	  running	  median	  spanning	  301	  probes.	  Due	   to	   the	   special	   properties	   of	   wavelets	   they	   are	  most	   often	   used	   to	   extract	  information	   from	   data	   such	   as	   audio	   signals	   or	   images.	   Wavelets	   have	   a	   rich	  history	  in	  image	  analysis	  and	  signal	  processing	  and	  have	  been	  successfully	  used	  in	  the	  de-­‐noising	  of	  frequency-­‐based	  data	  for	  some	  time	  [95].	  The	  use	  of	  wavelet	  transform	  methods	  has	  previously	  been	  applied	  to	  the	  normalisation	  of	  the	  dye	  bias	  in	  array-­‐CGH	  data	  but,	  for	  the	  most	  part	  has	  not	  been	  seen	  often	  in	  relation	  to	  microarray	  data	  normalisation	  [85].	  More	   recently	   a	   dual-­‐tree-­‐complex-­‐wavelet	   approach	   has	   been	   described	   to	  remove	   scanner	   noise	   from	   microarray	   images	   derived	   from	   Affymetrix	  GeneChip	  arrays	   [96].	  Wavelets,	   having	  been	  highly	  useful	   in	   signal	  processing	  and	  image	  analysis,	  are	  often	  used	  to	  extract	  frequency-­‐based	  information	  from	  unknown	   signals.	   No	   model	   exists	   for	   the	   genomic	   wave	   and	   it	   shows	   non-­‐uniform	   (non-­‐stationary	   frequency)	   characteristics,	   giving	  different	   patterns	   of	  oscillation	   between	   replicate	   experiments.	   Surprisingly	   the	   use	   of	   wavelet	  transforms	   to	   correct	   for	   the	   genomic	   wave	   effect	   is	   yet	   to	   be	   fully	   explored.	  There	  is	  one	  relatively	  recent	  method	  described	  for	  the	  de-­‐noising	  of	  BAC	  large	  insert	  clone	  arrays	  showing	  small-­‐scale	  genomic	  rearrangements	  [97].	  However,	  the	   use	   of	   such	   methods	   is	   not	   commonplace	   and	   has	   yet	   to	   show	   its	   true	  potential	   to	   the	   microarray	   community.	   	   Due	   to	   the	   special	   properties	   of	  wavelets,	   we	  were	   able	   to	   use	   them	   as	   functions	   to	   operate	   on	   the	   log2	   ratio	  distribution	  of	  array-­‐CGH	  data	  and	  extract	  different	  scale	  components	  (octaves)	  relating	  to	  the	  genomic	  wave	  (see	  Figure	  1-­‐19).	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  Figure	  1-­‐19	  An	  example	  of	  using	  the	  wavelet	  based	  method	  to	  remove	  the	  wave	  bias	  from	  an	  aneuploidy	  sample	  run	  on	  an	  array-­‐CGH	  array.	  The	  green	  line	  is	  a	  running	  median	  spanning	  301	  probes.	  By	  developing	  the	  method	  it	  was	  possible	  to	  both	  increase	  our	  understanding	  of	  the	   genomic	   wave	   and	   to	   remove	   its	   presence	   from	   microarray	   based	   data	  without	  the	  need	  for	  GC	  content	  measures	  (method	  not	  published).	  There	  were	  however	  a	  few	  complications	  surrounding	  the	  application	  of	  wavelets	  and	  it	  was	  an	  absolute	  priority	   to	  ensure	   that	   the	  data	  were	  not	  corrupted	   in	  any	  way.	  As	  array-­‐CGH	  data	  are	  complex	  by	  nature	  and	  can	  contain	  large	  numbers	  of	  outliers	  with	  several	  distinct	  distributions	  of	  log2	  ratio	  values	  within	  one	  experiment,	  the	  correct	   use	   of	   appropriate	   filters	   and	   the	   development	   of	   methodologies	   to	  account	  for	  these	  features	  were	  essential.	  
1.4.2	   Change-­‐Point	  Detection	  Theory	  Whenever	  we	  talk	  about	  copy	  number	  variation	  within	  a	  genome,	  in	  reality	  what	  we	  are	  really	  talking	  about	  is	  change-­‐point	  detection.	  In	  other	  words,	  the	  point	  at	  which	  data	  features	  change	  for	  one	  state	  to	  another	  (in	  this	  case	  different	  copy	  number	  states).	  Formally	  change	  point	  detection	  is	  a	  statistical	  analysis	  to	  search	  for	  changes	  in	  the	  probability	  distribution	  of	  a	  stochastic	  process	  or	  time-­‐series.	  Most	   of	   the	   currently	   available	   methods	   for	   copy	   number	   discovery,	   with	   the	  exception	   of	   read-­‐pair	   data,	   result	   in	   the	   generation	   of	   datasets	   that	   can	   be	  thought	   of	   as	   time-­‐series.	   These	   datasets	   provide	   discrete	   measurements	  indexed	  by	  a	  time	  like	  parameter	  (genomic	  position	  in	  this	  case).	  	  Although	  there	  are	   many	   different	   approaches	   concerned	   with	   change	   point	   detection,	   at	   the	  root	   of	   all	   these	   methods	   one	   can	   find	   a	   hypothesis	   test;	   given	   some	  characteristics	  of	  the	  dataset,	  is	  the	  measurement	  y	  taken	  at	  time	  x	  significant.	  
Threshold	  Based	  Methods	  A	  simple	  yet	  often	  used,	  frequentist	  approach	  to	  change	  point	  detection	  is	  to	  use	  some	  threshold	  above	  which	  measurements	  within	  a	  dataset	  are	  considered	   to	  be	  significant.	  This	  threshold	  could	  be	  a	  static	  predefined	  value	  or	  better	  it	  could	  be	  dynamic	  and	  dependent	  on	  the	  dataset	  itself.	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A	   simple	   way	   to	   illustrate	   the	   use	   of	   dynamic	   thresholds	   for	   change	   point	  detection	  is	  to	  consider	  that	  our	  dataset	  shows	  normal,	  Gaussian	  ”white”	  noise,	  or	  that	  some	  measure	  of	  the	  normally	  distributed	  noise	  within	  the	  dataset	  can	  be	  obtained.	  In	  practice	  this	  is	  normally	  more	  difficult	  since	  real	  data	  are	  complex	  in	  nature	   and	   often	   not	   normally	   distributed	   however,	   for	   the	   purpose	   of	   this	  illustration	  let’s	  assume	  that	  it	  is.	  Since	  we	  are	  now	  working	  with	  normally	  distributed	  data	  we	  can	   start	   talking	  about	   a	   bell	   shaped	   frequency	   curve	   which	   is	   centred	   around	   the	   mean	   (see	  
Figure	  1-­‐20).	  As	  such	  we	  can	  now	  say	  with	  confidence	  that	  the	  probability	  that	  a	  measurement	  is	  above	  the	  mean	  is	  50%	  and	  the	  probability	  that	  a	  measurement	  is	  below	  the	  mean	  is	  also	  50%.	  
	  Figure	   1-­‐20	   The	   Frequency	   Distribution	   of	   Standard	   Normal	   Data	   -­‐	   The	  numbered	   line	   is	   marked	   in	   terms	   of	   the	   mean	   and	   the	   standard	   deviation	  [mathnstuff.com].	  	  	  Furthermore,	  we	  can	  define	  a	  function	  that	  perfectly	  describes	  the	  frequency	  of	  a	  set	  of	  measurements	  using	  only	  the	  mean	  and	  standard	  deviation.	  	  	  The	  function	  is	  defined	  as:	  ! !, !,! = 1(! 2!) !!!!(!!!! )! 	   [1-­‐9]	  	  where	  !	  is	  the	  distribution	  mean	  and	  !	  is	  its	  standard	  deviation.	  The	  distribution	  is	  said	  to	  be	  standard	  normal	  if	  ! = 0	  and	  ! = 1.	  
Hypothesis	  Testing	  One	   of	   the	   more	   important	   statistical	   tools	   for	   making	   decisions	   is	   that	   of	  Hypothesis	  Testing.	  The	  role	  of	  hypothesis	  testing	  is	  to	  decide	  of	  one	  from	  a	  set	  of	   possible	   outcomes	   (hypotheses)	   as	   a	   result	   of	   data	   measurements.	   A	   test	  result	  is	  considered	  as	  statistically	  significant	  if	   it	  has	  been	  predicted	  according	  to	   some	   significance	   level	   as	   being	   unlikely	   to	   have	   occurred	   due	   to	   sampling	  error	  (data	  noise)	  alone.	  For	  detecting	  copy	  number	  variation	  using	  time	  series	  (array	  based)	  data	  these	  decisions	   are	   normally	   based	   on	   data	   measurements	   displaying	   a	   continuous	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distribution	  (log2	  ratio	  values).	  The	  goal	  is	  to	  detect	  points	  at	  which	  these	  data	  measurements	  are	  likely	  to	  have	  changed	  from	  one	  copy	  number	  state	  to	  another	  (change	   points	   locations).	   It	   is	   possible	   to	   consider	   that	   the	   log2	   ratio	  distribution	   from	   any	   array-­‐CGH	   experiment	   is	   a	   mixture	   distribution	   with	   a	  finite	   set	   of	   mixture	   components	   (relating	   to	   different	   copy	   number	   states).	  These	   distributions	   can	   sometimes	   contain	   relatively	   large	   numbers	   of	  differences	   in	   copy	   number	   state	   (see	   Figure	   1-­‐19)	   and	   it	   can	   be	   difficult	   to	  assign	  the	  ‘normal	  copy	  number	  state’	  (copy	  number	  2).	  One	  approach	  that	  can	  be	   used	   for	   assigning	   the	   baseline	   (null)	   distribution	   is	   to	   use	   the	   mixture	  component	  that	  forms	  the	  greatest	  proportion	  of	  the	  population	  as	  a	  whole.	  Once	  the	  baseline	  (null	  distribution)	  has	  been	  defined	  it	  then	  becomes	  necessary	  to	  define	  a	  set	  of	  criteria	  by	  which	  one	  can	  test	  the	  probability	  of	  individual	  data	  points	  belonging	  to	  that	  null	  distribution.	  For	  illustration	  purposes	  let	  us	  set	  up	  a	  simple	   threshold	   test	   where	   we	   assume	   normal	   Gaussian	   (white)	   noise	   and	  define	   an	   outlier	   detection	   threshold	   as	   the	   mean	  ±3	   times	   the	   standard	  deviation	  of	  the	  log2	  ratio	  values	  from	  the	  null	  distribution.	  Additionally,	  to	  aid	  segmentation,	  let	  us	  add	  a	  time	  dependent	  parameter	  where	  we	  require	  at	  least	  three	  consecutive	  data	  measurements	  to	  exceed	  or	  remain	  within	  the	  threshold	  for	  defining	  the	  starting	  and	  ending	  points	  for	  an	  outlier	  segment	  (change	  point	  interval)	  respectively.	  
	  Figure	  1-­‐21	   Synthetically	   generated	  data	   showing	   three	   change	  point	   intervals	  detected	  using	  a	  simple	  threshold	  based	  approach.	  Above	  (see	  Figure	  1-­‐21)	  is	  the	  result	  of	  applying	  these	  threshold	  based	  rules	  in	  a	  forward	  direction	   to	   some	   synthetically	   generated	  data.	   The	  data	   contains	   one	  hundred	   normally	   distributed	   data	   points	   with	   a	   mean	   of	   zero	   and	   standard	  deviation	  of	  0.2.	  Three	  synthetic	  change	  point	  intervals	  were	  added	  with	  lengths	  of	   4,	   21	   and	   11;	   and	   means	   of	   -­‐2.3,	   -­‐1.2	   and	   1.1	   respectively.	   The	   detection	  threshold	  of	  0.6	  (see	  above)	  was	  used	  for	  defining	  data	  points	  outside	  of	  the	  null	  distribution	   and	   the	   three	   consecutive	   data	   point	   rule	   was	   used	   to	   define	   the	  starting	  and	  ending	  position	  for	  each	  change	  point	  interval.	  Using	  this	  approach	  all	  three	  known	  (synthetic)	  change	  point	   intervals	  were	  correctly	  detected	  (see	  
Figure	  1-­‐21).	  There	  were	  no	  false	  detections	  made	  and	  there	  was	  no	  one	  single	  data	  point	  predicted	  to	  be	  outside	  of	  the	  null	  distribution	  other	  than	  those	  inside	  the	  synthetic	  change	  point	  intervals.	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Segmentation	  Based	  Methods	  Segmentation	  methods	  are	  a	  particular	  type	  of	  change	  point	  detection	  that	  is	  not	  only	   concerned	   with	   finding	   discrete	   change	   point	   locations	   (or	   breakpoints)	  within	  data	  but	  in	  defining	  change	  point	  intervals	  (or	  segments).	  In	  reality,	  these	  methods	   are	   rather	   similar	   to	   standard	   change	   point	   detection	   methods,	  however	  they	  also	  include	  the	  definition	  of	  for	  how	  long	  a	  change	  was	  observed	  (i.e.	  its	  stating	  and	  ending	  point	  across	  the	  data	  index	  measure).	  There	  are	  a	  large	  number	  of	  different	  segmentation	  based	  change	  point	  detection	  methods	   but	   a	   well	   known,	   simple	   and	   good	   example	   comes	   in	   the	   form	   of	  CUSUM	  (or	  cumulative	  sum	  control	  chart),	  which	  was	  originally	  proposed	  by	  E.	  S.	  Page	  [98].	  As	   its	  name	   implies	  CUSUM	  charts	   are	   constructed	  by	   calculating	  a	   cumulative	  sum	   across	   the	   data.	   These	   cumulative	   sums	   can	   extend	   across	   all	   of	   the	   data	  measurements,	  be	  limited	  to	  particular	  sized	  segments	  or	  be	  started	  and	  ended	  defined	   by	   a	   certain	   set	   of	   criteria.	   For	   the	   case	   where	   we	   extend	   across	   the	  entire	  data:	  Let	   X	   equal	   the	   data	   measurements,	   let	   N	   equal	   the	   number	   of	   data	  measurements,	  and	  let	  S	  equal	  the	  cumulative	  sum.	  First	  we	  calculate	  the	  mean:	  ! = (!! + !!+,… ,!!)! 	   [1-­‐10]	  	  Then	  start	  by	  setting	  !! = 0,	  and	  follow	  by:	  !! = !!!! + (!! − !)	   [1-­‐11]	  with	  i	  from	  1,	  2,	  ..,N.	  The	  results	  of	  this	  method	  can	  be	  interpreted	  in	  a	  very	  intuitive	  manner.	  
	  Figure	   1-­‐22	   Cumulative	   sum	   of	   synthetically	   generated	   data	   containing	   three	  known	  change	  point	  intervals	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Above	   (see	   Figure	   1-­‐22)	   we	   show	   the	   cumulative	   sum	   across	   the	   data	  measurements	   from	  Figure	  1-­‐21	  assuming	  a	  mean	  of	   zero.	  As	  more	  values	   are	  added	  to	  the	  cumulative	  sum,	  if	  the	  majority	  of	  measurements	  were	  positive	  with	  respect	  to	  the	  mean	  the	  sum	  will	  steadily	  increase.	  	  As	  a	  result,	  a	  segment	  of	  the	  CUSUM	  chart	  that	  displays	  an	  upward	  slope	  indicates	  a	  period	  of	  time	  where	  the	  measurements	  tended	  to	  be	  above	  the	  mean.	  	  The	  inverse	  can	  also	  be	  stated	  for	  measurements	  that	  tended	  to	  be	  below	  the	  mean.	  	  The	   locations	   of	   the	   known	   (synthetic)	   change	   point	   intervals	   are	   clearly	  observed	   in	   the	   above	   plot	   (see	   Figure	   1-­‐22).	   The	   two	   synthetic	   deletions	  (starting	  at	  indexes	  10	  and	  35	  respectively)	  show	  the	  expected	  downward	  slope	  whereas	   the	   synthetic	   duplication	   (starting	   at	   index	   75)	   showing	   the	   expected	  upward	  slope	  across	  the	  CUMSUM	  chart.	  	  
State-­‐space	  Models	  	  State-­‐space	   models	   define	   a	   probability	   density	   over	   real-­‐valued	   observation	  vectors	  {!!}	  that	  are	  assumed	  to	  have	  been	  generated	  from	  a	  sequence	  of	  hidden	  state	   vectors	  {!!}.	   The	   hidden	   state	   vectors	   obey	   the	   Markov	   independence	  property	  and	  the	  model	  specifies	  that	  at	  any	  time	  step	  the	  observation	  vector	  is	  statistically	  independent	  from	  all	  other	  observation	  vectors	  (see	  Figure	  1-­‐23).	  	  
	  Figure	  1-­‐23	  Directed	  acyclic	  graph	  (DAG)	  showing	  the	  hidden	  state	  vector	  X!	  in	  white	  and	  the	  real-­‐valued	  observation	  vector	  Y!	  in	  grey.	  In	   the	   above	   graph	   (see	  Figure	   1-­‐23)	   each	   node	   is	   conditionally	   independent	  from	  its	  non-­‐decendants	  give	  its	  parents	  and	  the	  output	  vector	  !!	  is	  conditionally	  independent	   from	   all	   others	   given	   state	  !! .	   Furthermore,	  !! 	  is	   conditionally	  independent	   from	  !!,… ,!!!!	  given	  !!!!.	   The	   joint	  probability	  of	   the	   sequences	  of	  states	  !!	  and	  observations	  !!	  can	  therefore	  be	  formulated	  thus:	  
! !! ,!! = ! !! !(!!|!!) !(!!|!!!!)!(!!|!!)!!!! 	  	  
[1-­‐12]	  
Assuming	  the	  transition	  and	  output	  functions	  of	  the	  model	  are	  linear	  and	  time-­‐invariant	   and	   the	   distributions	   of	   the	   state	   and	   observation	   variables	   are	  multivariate	  Gaussian,	  the	  state	  transition	  function	  is:	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!! = !!!!! + !!	  	   [1-­‐13]	  where	  !	  is	   the	   state	   transition	  matrix	   and	  !!	  is	   zero-­‐mean	  Gaussian	  noise.	   The	  output	  function	  is:	  	   !! = ! = !"! + !!	  	   [1-­‐14]	  where	  !	  is	   the	   output	   matrix	   and	  !!	  is	   zero-­‐mean	   Gaussian	   output	   noise	   with	  covariance	  matrix	  !;	  !(!!|!!)	  is	  therefore	  also	  Gaussian:	  	   ! !! !! = (2!)!!/!|!|!!/!!"# − 12 (!! − !!!)′!!!(!! − !!!) 	  	  
[1-­‐15]	  
where	  !	  is	   the	   dimensionality	   of	   the	  !	  vectors.	   To	  model	   situations	   where	   the	  observation	   vector	   can	   be	   separated	   into	   input	   (predictor)	   and	   output	  (response)	  variables	  we	  can	  include	  a	  state-­‐transition	  function:	  	   !! = !!!!! + !!! + !!	  	   [1-­‐16]	  where	  !!	  is	  the	  input	  observation	  vector	  and	  !	  is	  the	  input	  matrix.	  The	   problem	   of	   estimating	   the	   posterior	   probabilities	   of	   the	   hidden	   variables	  given	   the	   sequence	   of	   observed	   variables	   in	   known	   as	   inference	   and	   can	   be	  separated	   into	   three	  main	  methods,	   filtering,	  smoothing	  and	  prediction.	  During	  filtering	  a	   recursive	  algorithm	  known	  as	   the	   ‘Kalman	   filter’	   is	  used	   to	   compute	  the	  probability	  of	   the	   current	  hidden	  state	  !!	  given	   the	   sequence	  of	   inputs	  and	  outputs	   up	   to	   time	   ! − !(!!| !!,… ,!! , !!,… ,!! ) .	   For	   smoothing,	   the	  probability	  of	  !!	  given	   the	   sequence	  of	   inputs	   and	  outputs	  up	   to	   time	  !,	  where	  ! > !	  is	  computed.	  	  The	  Kalman	  filter	  is	  used	  in	  the	  forward	  direction	  to	  compute	  the	   probability	   of	  !! 	  given	   {!!,…,!!}	   and	   !!,… ,!! .	   The	   backward	   recursions	  from	  !	  to	  !	  complete	  the	  computation	  and	  account	  for	  observations	  after	  time	  !.	  Finally,	   prediction	   is	   used	   to	   compute	   the	   probability	   of	   future	   states	   given	  observations	  up	  to	  time	  !.	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Hidden	  Markov	  Models	  Hidden	  Markov	  models	   also	   define	   probability	   distributions	   over	   sequences	   of	  observations	  {!!}.	  However,	   the	  output	  sequences	  are	   found	  by	  considering	   the	  observations	   at	   time	  !	  given	   a	   discrete	   hidden	   state	  !!	  and	   the	   probability	   of	  transitioning	  to	  another	  hidden	  state	  (transition	  probabilities).	  Using	  the	  Markov	  property,	  the	  joint	  probability	  can	  be	  represented	  exactly	  the	  same	  as	  for	  state-­‐space	  models	  by	  replacing	  !!	  with	  !!:	  	  	  	  
! !,!! = ! !! !(!!|!!) !(!!|!!!!)!(!!|!!)!!!! 	  	  
[1-­‐17]	  
Furthermore	  the	  conditional	  independencies	  follow	  the	  same	  form	  as	  previously	  (see	  Figure	  1-­‐23).	  Any	  given	  state	  is	  represented	  by	  one	  of	  !	  discrete	  values,	  !! ∈ {1,… ,!}	  and	  the	  transition	  probabilities	  !(!!|!!!!)	  are	  represented	  by	  a	  !×!	  transition	  matrix.	  Two	  algorithms	  are	  often	  used	  to	  solve	  two	  particular	  inference	  problems.	  First,	  the	   recursive	   ‘forward	   backward’	   algorithm	   is	   used	   to	   compute	   the	   posterior	  probabilities	   of	   the	   hidden	   states.	   The	   ‘Viterbi’	   algorithm,	   also	   consisting	   of	   a	  forward	   and	   backward	   step,	   is	   used	   to	   compute	   the	   most	   likely	   sequence	   of	  hidden	  states.	  The	  ‘Baum-­‐Welch’	  algorithm	  can	  be	  used	  to	  learn	  the	  parameters	  of	   the	   model.	   The	   Baum-­‐Welch	   algorithm	   makes	   use	   of	   the	   ‘expectation-­‐maximisation’	  (EM)	  algorithm	  and	  both	  a	  forward	  and	  backward	  step	  to	  find	  the	  maximum	   likelihood	   estimate	   for	   the	   parameters	   of	   the	   model	   given	   a	   set	   of	  observation	  sequences.	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1.4.3	   Copy	  Number	  Genotyping	  Similar	   to	   the	  well-­‐known	   and	  widely	   using	  methods	   for	   SNP	   genotyping	   [99-­‐102]	  it	  is	  also	  possible	  to	  perform	  copy	  number	  genotyping.	  The	  goal	  here	  is	  to	  assign	   discrete	   copy	   number	   states	   across	   samples	   for	   any	   given	   genomic	  location.	  This	  is	  an	  essential	  step	  for	  performing	  accurate	  association	  studies	  on	  copy	  number	  variation.	  Because	  for	  any	  given	  genomic	   location	  across	  samples	  we	   do	   not	   have	   discrete	   values,	   rather	   a	   continuous	   distribution	   of	   log2	   ratio	  values,	   the	   standard	   SNP	  genotyping	  methods	   cannot	   be	  used	  directly.	   Instead	  we	  need	   a	  way	   to	   confidently	   assign	   copy	  number	   state	   to	   individual	   samples,	  given	  the	  values	  observed	  across	  samples	  (see	  Figure	  1-­‐21).	  This	  is	  a	  relatively	  untapped	   field	   but	   is	   starting	   to	   receive	   more	   attention.	   One	   of	   the	   first	  publications	   describing	   an	   approach	   to	   address	   some	   of	   these	   problems	  modelled	  the	  quantitative	  CNV	  measurements	  using	  a	  Gaussian	  mixture	  model	  to	  assign	  copy	  number	  state	  [103].	  
	  Figure	  1-­‐24	  Examples	  of	  empirical	  CNV	  associations	  [103].	  (a)	  The	  coloured	  lines	  reflect	  the	  posterior	  probability	  distribution	  for	  each	  mixture	  component	  in	  the	  fitted	   mixture	   model.	   (b)	   The	   first	   panel	   shows	   normalized	   gene	   expression	  against	   copy	   number	  measurement.	   The	   second	   panel	   shows	   normalized	   gene	  expression	   against	   mixture	   model	   assignment.	   The	   third	   panel	   shows	   a	  histogram	   of	   copy	   number	  measurement	   and	   the	   coloured	   lines	   represent	   the	  posterior	  probability	  distribution	  for	  each	  of	  the	  five	  copy	  number	  classes	  in	  the	  fitted	  mixture	  model	  used	  in	  the	  LR	  trend	  test.	  
1.4.4	   Copy	  Number	  Tagging	  SNPs	  An	  interesting	  question	  that	  has	  received	  some	  attention	  is	  to	  what	  extent	  copy	  number	   variants	   (CNVs)	   are	   in	   linkage	   disequilibrium	   (LD)	   with	   single	  nucleotide	   polymorphisms	   (SNPs).	   This	   is	   an	   important	   question	   that	   can	  address	  how	  much	  of	   the	   impact	   that	  CNVs	  have	  on	  common	  disease	  has	  been	  indirectly	   explored	   using	   GWAS	   studies.	   A	   paper	   describing	   such	   an	   analysis	  [104]	  found	  that	  most	  of	  the	  CNVs	  that	  they	  could	  type	  well	  were	  on	  average	  well	  
	   34	  
tagged	  by	  a	  SNP.	  	  In	  fact	  they	  observed	  that	  for	  these	  types	  of	  CNV,	  those	  with	  a	  minor	  allele	  frequency	  (MAF)	  greater	  than	  10%,	  79%	  had	  an	  !!	  greater	  than	  0.8,	  indicating	  tagging	  almost	  to	  the	  same	  extend	  when	  SNPs	  are	  well	  tagged	  by	  other	  SNPs	  (see	  Figure	  1-­‐22).	  	  	  
	  Figure	  1-­‐25	  Histogram	  of	  maximum	  correlation	  !!	  between	  each	  CNV	  and	  a	  SNP	  within	  1MB	  of	  the	  ends	  of	  that	  CNV	  [104].	  This	   was	   an	   interesting	   observation	   and	   suggested	   that	   some	   CNVs	   could	   be	  intrinsically	   linked	   to	   certain	   SNPs.	   However,	   it	   is	   worth	   pointing	   out	   that	  although	   large-­‐scale	   GWAS	   studies	   have	   been	   carried	   out	   on	   a	   number	   of	  different	  common	  diseases	  the	  role	  that	  CNV	  plays	  to	  these	  disease	  has	  in	  no	  way	  been	  fully	  explored,	  indirectly	  or	  otherwise.	  
1.4.5	   Association	  Studies	  An	   association	   study	   in	   the	   area	   of	   genomics	   can	   broadly	   be	   described	   as	   the	  search	  for	  genetic	  associations	  that	  occur	  more	  frequently	  than	  can	  be	  explained	  by	   chance.	   The	   associations	   that	   one	   would	   generally	   search	   for	   are	   genetic	  variants	   that	   are	   more	   prevalent	   in	   one	   group	   of	   individuals	   compared	   to	  another.	  These	  comparisons	  can	  take	  various	  forms;	  most	  commonly	  it	  would	  be	  between	  a	   set	  of	  diseased	  subjects	  against	  healthy	   controls	   [105]	  but	   it	   can	  be	  based	  on	  any	  number	  of	  other	  factors,	  for	  example	  ethic	  origin	  could	  be	  explored	  [106].	  Genetic	  associations	  can	  be	  tested	  for	  between	  a	  phenotypic	  trait	  (such	  as	  eye	   colour)	   and	   a	   genetic	   marker	   (such	   as	   a	   SNP),	   or	   between	   two	   or	   more	  genetic	   markers	   and	   a	   phenotypic	   trait	   or	   even	   between	   the	   genetic	   markers	  themselves.	   The	   term	   linkage	  disequilibrium	   (LD)	   is	   used	   to	   describe	   the	  non-­‐random	   association	   of	   two	   or	  more	   genetic	  markers.	   Thus	   genetic	  markers	   in	  strong	  LD	  with	  each	  other	  form	  haplotypes	  more	  or	  less	  frequently	  than	  can	  be	  expected	  by	  chance.	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Case-­‐control	  Design	  A	  case-­‐control	  design	  is	  the	  standard	  approach	  to	  genetic	  association	  testing.	   It	  compares	  cases	  that	  have	  been	  diagnosed	  with	  a	  particular	  trait	  against	  controls	  that	  do	  not	  display	  the	  trait	  [107].	  A	  difference	  in	  the	  frequency	  of	  one	  or	  more	  genetic	  markers	  between	  cases	  and	  control	  can	  indicate	  that	  the	  presence	  of	  that	  genetic	   marker	   (or	   combination	   of	   markers)	   increases	   the	   likelihood	   of	  observing	  the	  specific	  trait.	  If	  an	  untested	  individual	  has	  the	  genetic	  marker	  (or	  combination)	   the	   chance	   that	   they	  will	   display	   the	   trait	   under	   study	   could	   be	  increased.	  
Trios	  The	  Trio	  design	   for	   association	   testing	   is	  based	  on	   comparing	   family	  members	  against	  one	  another	   and	   searching	   for	   either	   genetic	  differences	  or	   similarities	  [108].	   	   For	   example,	   consider	   the	   case	  where	   an	   offspring	   carries	   a	   particular	  disease	  but	  its	  parents	  do	  not.	  In	  this	  case	  one	  can	  direct	  the	  search	  towards	  de	  
novo	  variants,	   those	  that	  are	  observed	  in	  the	  offspring	  but	  not	   in	  either	  parent.	  	  The	  justification	  for	  this	  is	  that	  since	  neither	  parent	  displays	  the	  trait	  (disease	  in	  this	  case)	  it	  is	  unlikely	  that	  the	  variant	  (or	  variants)	  responsible	  will	  be	  observed	  in	   their	   genomes.	   This	   is	   almost	   certainly	   an	   over	   simplification	   since	   certain	  traits	  will	  often	  be	  controlled	  by	  a	  number	  of	  different	  variants	  or	  even	  a	  specific	  combination	  of	  variants.	  The	  analysis	  of	  different	  combinations	  of	  variants	  with	  respect	   to	   different	   combinations	   of	   phenotypic	   traits	   is	   an	   exciting	   area	   of	  research	  and	  promises	   to	  deliver	   further	   insight	   into	  genetic	  associations.	   	  The	  Trio	   design	   can	   also	   be	   extended	   into	   more	   complex	   situations	   such	   as	   large	  family	  pedigree	  analysis	  [109].	  	  	   	  
	   36	  
1.5	   COPY	  NUMBER	  MODES	  AND	  MECHANISMS	  The	   number	   of	   copies	   of	   a	   gene	   (or	   a	   sequence	   of	   nucleotide	   bases)	   is	   the	  number	  of	  copies	  of	  that	  particular	  gene	  (or	  sequence	  of	  nucleotide	  bases)	  in	  the	  genome	  of	  an	  individual.	  It	  was	  historically	  thought	  that	  all	  genes	  in	  the	  human	  genome	  occurred	  in	  two	  copies	  however	  it	  is	  now	  known	  that	  for	  many	  genes	  the	  copy	  number	  can	  be	  only	  one	  (heterozygous	  deletion),	  more	  than	  two	  (gain)	  or	  even	   zero	   (homozygous	   deletion).	   This	   collective	   set	   of	   genetic	   variation	   is	  known	  as	  copy	  number	  variation	  (CNV)	  and	  can	  lead	  to	  gene	  dosage	  imbalances	  [110].	  These	  changes	  in	  gene	  dosage	  influence	  most	  traits,	  contributing	  to	  what	  makes	  us	  all	  unique	  and	  includes	  the	  susceptibility	  and	  predisposition	  to	  various	  diseases	  [111-­‐113].	  Small	  or	  large	  sections	  of	  DNA	  can	  be	  gained	  or	  lost	  from	  any	  individual’s	  genome	  and	  these	  differences	  in	  the	  copy	  number	  of	  genes	  or	  genic	  elements	  (e.g.	  exons	  and	  enhancers)	  can	  have	  a	  dramatic	  effect	  on	  an	  individual’s	  health.	   Furthermore,	   since	   some	   CNVs	   effect	   gene	   dosage,	   resulting	   in	  differential	   gene	   product	   expression,	   they	   may	   play	   important	   roles	   in	   drug	  discovery	  and	  drug	  response	  prediction	  [114].	  
1.5.1	   Gene	  Dosage	  In	   some	  cases,	   for	   example	   the	  Bardet-­‐Biedl	   syndrome	   type	  5	   associated	  BBS5	  gene,	   both	   gene	   copies	   need	   to	   be	   perturbed	   for	  Bardet-­‐Biedl	   syndrome	   [115]	  symptoms	   to	   be	   present.	   Genes	   displaying	   biallelic	   modes	   of	   action,	   such	   as	  BBS5,	   can	   be	   termed	   Haplosufficent	   in	   that	   a	   change	   in	   gene	   dosage	   is	   not	  sufficient	  to	  cause	  the	  associated	  phenotypes.	  In	  other	  words	  a	  single	  functional	  gene	  copy	  produces	  enough	  product	  to	  retain	  the	  wild-­‐type	  condition,	  meaning	  that	  an	  abnormal	  or	  diseased	  state	  is	  not	  observed.	  	  On	  the	  other	  hand	  some	  genes,	  for	  example	  the	  Cornelia	  de	  Lange	  syndrome	  type	  1	  [116]	  associated	  NIPBL	  gene,	  act	  under	  a	  monoallelic	  mode	  of	  action	  and	  can	  be	   termed	   haploinsufficient	   or	   dosage	   sensitive.	   For	   genes	   with	   monoallelic	  modes	   of	   action	   a	   change	   in	   gene	   dosage	   (normally	   a	   decrease)	   results	   in	   the	  associated	   phenotypes.	   Some	   genes	   can	   have	   both	   biallelic	   and	   monoallelic	  modes	   of	   action,	   for	   example	   the	   LRP2	   gene	   causes	   Donnai-­‐Barrow	   syndrome	  with	   a	   biallelic	   mode	   of	   action	   (both	   copies	   are	   perturbed)	   but	   has	   been	  associated	  with	  general	  Intellectual	  disability	  with	  a	  monoallelic	  mode	  of	  action	  (single	  copy	  loss).	  
1.5.2	   X-­‐linked	  and	  Hemizygous	  	  In	   contrast	   to	   the	   autosomal	   chromosomes	   where	   both	   genders	   (male	   and	  female)	   have	   the	   same	   probability	   of	   inheriting	   a	   variant	   from	   their	   father	   or	  their	  mother,	  sex	  linkage	  is	  the	  phenotypic	  expression	  of	  an	  allele	  related	  to	  the	  chromosomal	   gender	   of	   an	   individual.	   The	   X	   chromosome	   in	   human	   males	   is	  termed	  hemizygous,	  meaning	   that	   it	   is	   present	   in	  only	  one	   copy.	  Hemizygosity	  can	  also	  be	  observed	  across	  the	  genome	  in	  males	  and	  females	  where	  one	  copy	  of	  a	  gene	   is	  deleted.	  X-­‐linked	   inheritance	  can	  be	  dominant	   [117-­‐119]	  or	  recessive	  [120-­‐122].	   Females	   affected	  with	   an	   X-­‐linked	   dominant	   disorders	   have	   a	   50%	  chance	  of	  passing	  the	  disorder	  on	  to	  an	  offspring	  of	  any	  gender.	  Sons	  of	  a	  male	  father	  with	  an	  X-­‐linked	  dominant	  disorder	  will	  never	   inherit	   the	  disorder	   from	  their	  father	  whereas	  daughters	  will	  inherit	  the	  disorder	  100%	  of	  the	  time.	  On	  the	  other	   hand	   females	   with	   X-­‐linked	   recessive	  mutations	   are	   considered	   carriers	  and	  do	  not	  normally	  display	  symptoms	  (can	  rarely	  display	  very	  mild	  or	  different	  
	   37	  
symptoms).	  However	  all	  males	  with	  a	  X-­‐linked	  recessive	  mutation	  will	  manifest	  with	   the	   disorder	   as	   they	   only	   have	   one	   copy	   of	   the	   X	   chromosome.	   Thereby	  male	   offspring	   of	   a	   female	   carrier	   will	   have	   a	   50%	   change	   of	   inheriting	   the	  disorder	  and	   female	  offspring	  will	   have	  a	  50%	  chance	  of	   inheriting	   the	   carrier	  state.	  
1.5.3	   Digenic	  and	  Polygenic	  In	   monogenic	   inheritance	   a	   single	   gene	   largely	   determines	   the	   presence	   of	   a	  phenotype	  or	  trait	  and	  mutations	  in	  one	  (dominant)	  or	  both	  (recessive)	  copies	  of	  the	   gene	   is	   sufficient	   for	   the	   trait	   to	   be	   expressed.	   For	  many	   of	   the	   yet	   to	   be	  understood	   genetic	   disorders	   it	   is	   likely	   that	  more	   complex	   situations	   such	   as	  dosage	  compensation,	  digenic	  or	  polygenic	  effects	  may	  hold	  the	  key	  [123,	  124].	  Digenic	  inheritance	  involves	  the	  interaction	  of	  two	  specific	  genes	  and	  mutations	  in	  at	  least	  one	  copy	  of	  both	  genes	  must	  be	  inherited	  for	  the	  associated	  phenotype	  to	   be	   expressed	   [125].	   Polygenic	   inheritance	   involves	   phenotypes	   that	   are	  influenced	   by	  more	   than	   one	   gene.	   Polygenic	   traits	   often	   display	   a	   continuous	  distribution,	   such	   as	   weight,	   height,	   head	   circumference	   and	   eye	   colour.	  Polygenic	   traits	   that	   are	   influenced	   by	   environmental	   factor	   are	   termed	  multifactorial.	  
1.5.4	   Mosaicism	  	  Mosaicism	   is	   when	   two	   or	  more	   populations	   of	   cells	   with	   different	   genotypes	  exist	   in	   one	   individual.	   For	   example	   a	   specific	   form	   of	   Klinefelter	   syndrome	  (XY/XXY	   mosaic)	   can	   occur	   when	   some	   of	   the	   patient’s	   cells	   contain	   XY	  chromosomes	  and	  some	  contain	  XXY	  chromosomes.	  Mosaicism	  can	  be	  present	  in	  the	  germline	  or	  somatic	  cells;	  somatic	  mosaicism	  is	  commonly	  caused	  by	  mitotic	  errors	   occurring	   during	   either	   mitotic	   recombination	   or	   somatic	   crossover,	  whereas	  germline	  mosaicism	  is	  a	  special	  form	  of	  mosaicism,	  where	  some	  but	  not	  all	  gametes	  carry	  a	  specific	  mutation.	  Certain	  genes	  can	  have	  a	  mosaic	  mode	  of	  action,	  such	  as	  the	  Proteus	  syndrome	  associated	  AKT1	  gene	  [126].	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1.6	   THESIS	  OVERVIEW	  	  In	  this	  thesis	  the	  development	  of	  novel	  analytical	  software	  for	  CNV	  detection	  and	  interpretation	  using	  a	  high-­‐resolution	  array-­‐CGH	  platform	  will	  be	  presented.	  As	  part	  of	   this	   research	   thesis	  all	  of	   the	  necessary	  analytical	   components,	   starting	  from	  raw	  array-­‐CGH	  data,	  obtaining	  a	  set	  of	  potentially	  clinically	  relevant	  CNVs,	  including	  data	  normalisation,	  CNV	  detection,	  CNV	  annotation	  and	  CNV	   filtering	  are	   developed.	   A	   fully	   versioned	   and	   extensively	   tested	   analytical	   pipeline	   is	  established;	   encompassing	   all	   described	   methods	   for	   standard	   use	   in	   a	   large-­‐scale	   genetic	   study	   based	   at	   the	   Wellcome	   Trust	   Sanger	   Institute	   (the	   DDD	  project).	  Finally	  the	  pipeline	  is	  applied	  to	  a	  set	  of	  over	  1000	  normal	  controls	  and	  results	  are	  presented	  focused	  on	  both	  the	  analytical	  validity	  of	  the	  methods	  and	  the	  scale	  and	  type	  of	  CNVs	  found	  in	  apparently	  healthy	  individuals.	  	  
Chapter	   2	   describes	   the	   full	   technical	   details,	   thorough	   assessment	   and	  improvement	   of	   four	  major	   analytical	   components.	   First	   the	   development	   and	  optimisation	  of	  a	  change	  point	  detection	  package,	  CNsolidate,	  is	  described,	  which	  makes	  use	  of	  multiple	  weighted	  change	  point	  detection	  algorithms	  and	  includes	  an	  adaptive	  learning	  algorithm	  for	  estimating	  individual	  algorithm	  weights	  given	  certain	  characteristics	  of	  the	  input	  data.	  Second	  a	  novel	  Bayesian	  framework	  for	  allowing	   array-­‐CGH	   sample	   tracking	   using	   copy	   number	   tagging	   SNPs	   is	  presented.	   A	   description	   of	   how	   the	   individual	   probabilities	   for	   the	  model	   are	  generated	  and	  updated	   followed	  by	  an	  assessment	   into	   the	  performance	  of	   the	  overall	   sample	   tracking	   values	   in	   terms	   of	   sample	   mismatches	   and	  discriminatory	   power	   is	   provided.	   Third,	   details	   of	   generating	   a	   combined	  common	  CNV	  reference	   set	   (CNV	  consensus)	  are	  presented,	  using	  a	  number	  of	  high	  quality	   studies	  with	  different	   sample	  sizes	  and	  spanning	   the	  genomic	  size	  range	   for	   common	   CNVs.	   Details	   of	   the	   effect	   that	   adding	  merged	   CNV	   events	  (CNVEs)	  called	  by	  CNsolidate	  has	  on	  the	  overall	  number,	  type	  and	  frequency	  of	  CNVEs	  within	   the	  CNV	   consensus	   are	   given.	  A	   general	   approach	   for	   classifying	  CNVs	  as	  either	  novel,	   rare	  or	  common	  based	  on	  positional	  similarity,	  CNV	  type	  states	  and	  population	  frequency	  estimates	  is	  described.	  Finally,	  details	  of	  a	  rule	  based	  approach	  to	   flagging	  CNVs	  of	  potential	  clinical	  significance	  are	  described	  and	   the	   results	   of	   filtering	   DDD	   patient	   CNV	   data	   in	   terms	   of	   the	   overall	  characteristics	   of	   flagged	   CNVs	   are	   provided.	   The	   discovery	   of	   an	   analytical	  complication	   based	   on	   the	   clinical	   filtering	   results	   and	   an	   association	   based	  analysis	  to	  search	  for	  problematic	  array-­‐CGH	  data	  points	  (probes)	  is	  performed.	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Chapter	   3	   describes	   the	   implementation	   of	   a	   large-­‐scale	   analytical	   pipeline	  encompassing	  all	  the	  analytical	  methods	  developed	  in	  Chapter	  2.	  Some	  general	  best	   practice	   approaches	   to	   generating	   a	   maintainable	   and	   robust	   code	   base	  using	  version	  control	  are	  described.	  Examples	  of	  using	  a	  large	  compute	  farm	  and	  making	  use	  of	   a	   load	   sharing	   facility	   (LSF)	   to	   increase	  pipeline	   throughput	   are	  shown.	   Finally	   details	   of	   the	   approach	   chosen	   for	   organising	   and	   maintaining	  pipeline	  data	  and	  results	  (inputs	  and	  outputs)	  using	  a	  structured	  file	  system	  and	  database	  are	  described.	  
Chapter	   4	   is	   made	   up	   of	   a	   manuscript	   currently	   under	   review	   in	   Genome	  Research	   and	   presents	   a	   detailed	   assessment	   of	   the	   performance	   for	   CNV	  discovery	   achieved	   by	   CNsolidate.	   It	   includes	   results	   and	   performance	  assessments	  of	  another	  algorithm	  (VICAR)	  which	  was	  developed	  by	  a	  colleague	  and	  which	  I	  incorporated	  into	  the	  DDD	  CNV	  analytical	  pipeline.	  The	  manuscript	  also	   includes	   a	   refinement	   of	   the	   CNV	  mutation	   rate	   by	   defining	   a	   set	   of	   high	  confidence	  de	  novo	  CNVs	  with	  a	  median	  resolution	  of	  15.2	  Kb.	  Finally	  suggestive	  evidence	   for	   a	   paternal	   bias	   in	   the	   formation	  mechanisms	   of	   de	   novo	   CNVs	   is	  presented	  by	  performing	  a	  parent	  of	  origin	  analysis.	  
Chapter	  5	  is	  made	  up	  of	  a	  drafted	  manuscript	  and	  presents	  results	  from	  applying	  the	  clinical	   filtering	  pipeline	   for	  CNVs	   to	  over	  1000	  normal	  control	   individuals.	  We	  show	  the	  overall	  number	  of	   flagged	  variants	  and	  report	  a	  surprisingly	  high	  potential	   feedback	   rate	   for	   CNVs	   detected	   in	   apparently	   healthy	   individuals.	  When	   looking	   in	   detail	   at	   the	   individual	   characteristics	   of	   flagged	   CNVs	   we	  present	   a	   small	   number	   of	   CNVs	   in	   genes	   relating	   to	   relatively	   common	   rare	  disorders	  or	  in	  genes	  thought	  to	  be	  associated	  with	  complex	  rare	  disorders	  such	  as	   autism	   and	   epilepsy.	   Additionally	   we	   discover	   two	   female	   control	   samples	  with	  CNVs	  in	  the	  X-­‐linked	  recessive	  gene	  STS	  and	  who	  are	  therefore	  predicted	  to	  be	  carriers	  of	  X-­‐linked	  Ichthyosis	  (XLI)	  disorder.	  	  Concluding	  remarks	  and	  future	  direction	  are	  detailed	  in	  Chapter	  6	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2 |	  Copy	  Number	  Discovery	  and	  Interpretation	  
2.1	   INTRODUCTION	  	  Individual	   change	   point	   detection	   algorithms	   often	   display	   variable	  performances	  [20,	  127-­‐129].	   	  The	  definition	  of	  an	  optimal	  set	  of	  parameters	  for	  achieving	   a	   certain	   level	   of	   performance	   is	   rarely	   straightforward,	   especially	  where	   data	   qualities	   vary.	   We	   propose	   a	   combined	   change	   point	   detection	  package,	   CNsolidate,	   which	   makes	   use	   of	   an	   expert	   voting	   system.	   Using	   this	  approach,	   it	   is	   possible	   to	   rank	   detections	   based	   on	   differential	   weighting	  functions	  between	  component	  algorithms	  (voters).	  CNsolidate	  derives	  all	  of	  its	  parameter	  definitions	  and	  weighting	  functions	  using	  a	   number	   of	   predictive	   variables	   drawn	   from	   the	   input	   data	   characteristics.	  	  Accurately	   ranking	   detections	   across	   data	   sets	   of	   variable	   qualities	   allows	   the	  use	  of	  a	  single	  threshold	  to	  control	  the	  balance	  between	  type	  1	  and	  type	  2	  error	  rates.	  CNsolidate	  has	  been	  primarily	  designed	   for	  direct	  use	   in	   the	  detection	  of	  copy	   number	   variable	   genomic	   regions	   for	   the	   Deciphering	   Developmental	  Disorders	   (DDD)	   project	   based	   at	   the	  Wellcome	  Trust	   Sanger	   Institute	   (WTSI)	  [29].	  	  	  A	  frequently	  used	  approach	  to	  filtering	  genomic	  variation	  data,	  obtaining	  a	  set	  of	  potentially	  interesting	  variants,	  is	  to	  use	  a	  control	  set	  of	  variation	  to	  compare	  the	  given	   test	   set	   against.	   Indeed,	   for	   the	   filtering	   of	   single	   nucleotide	  polymorphisms	   in	   GWAS	   studies	   the	   database	   dbSNP	   is	   often	   used	   to	   exclude	  variants	   that	   have	   been	   previously	   observed	   at	   a	   given	   frequency	   within	   the	  general	   population	   [130].	   For	   copy	   number	   variation	   there	   are	   a	   number	   of	  studies	  that	  have	  been	  performed	  to	  search	  for	  common	  CNV	  within	  the	  general	  population	   [13,	   50].	   Furthermore,	   databases	   such	   as	   dbVar	   [131]	   are	   now	  attempting	   to	   collate	   information	   across	   multiple	   studies	   of	   common	   CNV	   to	  provide	  a	  single	  resource	  for	  variant	  filtering.	  There	  are	  a	  number	  of	  problems	  when	  using	  generic	  genomic	  variation	  reference	  sets	   to	   filter	   variants	   against	   [132-­‐134].	  Different	   studies	   of	   genomic	   variation	  will	   have	   been	   performed	   using	   different	   sample	   sizes,	   will	   have	   utilised	  technologies	   of	   different	   resolutions	   and	   change	   detection	   will	   have	   been	  performed	   using	   algorithms	   displaying	   different	   sensitivities	   and	   specificities.	  Furthermore,	  data	  quality	  control	  and	  experimental	  processing	  will	  be	  different	  across	   multiple	   studies.	   The	   combination	   of	   all	   these	   factors	   can	   introduce	   a	  number	   of	   biases	   into	   any	   combined	   reference	   set	   resulting	   in	   a	   potentially	  inaccurate	   filtering	   process.	   Due	   to	   the	   mentioned	   difficulties,	   we	   elected	   to	  create	   a	   CNV	   consensus	   reference	   set	   incorporating	   a	   number	   of	   high	   quality	  studies.	   This	   section	  describes	   the	   integration	   of	   several	   control	   data	   sets	   into	  the	   single	   CNV	   consensus	   reference	   set.	   More	   generally,	   it	   gives	   an	   overview	  summary	  of	   the	  component	  data	  sets	   that	  make	  up	   the	  current	  CNV	  consensus	  set.	   The	   CNV	   consensus	   set	   has	   been	   created	   for	   direct	   use	   in	   determining	  potentially	   pathogenic	   variants	   for	   patient	   data	   generated	   as	   part	   of	   the	   DDD	  project	   based	   at	   the	   WTSI.	   The	   CNV	   consensus	   reference	   set	   is	   publically	  available	  for	  download	  from	  the	  DECIHPER	  database	  [16,	  135-­‐137].	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One	  very	  important	  aspect	  of	  the	  DDD	  project	  is	  that	  of	  accurate	  sample	  and	  data	  tracking	  throughout	  the	  various	  pipelines.	  This	  is	  critical	  to	  the	  overall	  success	  of	  the	   project	   since	   the	   data	   sets	   produced	   could	   potentially	   be	   used	   for	   direct	  clinical	   diagnosis	   via	   the	   regional	   NHS	   genetic	   services	   within	   the	   UK	   and	  Ireland.	  Although	  each	  variant	  reported	  will	  ultimately	  require	  validation	   in	  an	  accredited	  laboratory	  (regional	  genetic	  services),	   the	  DDD	  project	  takes	  sample	  and	   data	   tracking	   extremely	   seriously.	   A	   number	   of	   the	   existing	   WTSI	   data	  generation	  pipelines	  track	  their	  samples	  and	  data	  via	  a	  molecular	  barcode	  in	  the	  form	  of	  30	  SNPs	  typed	  using	  a	  Sequenom	  assay	  [138].	  The	  moment	  that	  a	  DNA	  sample	   enters	   the	   sample	   storage	   and	   extraction	   facilities	   (sample	   logistics)	   it	  has	  SNPs	  typed	  using	  the	  Sequenom	  platform.	  These	  SNP	  genotypes	  are	  stored	  in	  a	  large	  oracle	  database	  and	  can	  be	  used	  as	  a	  final	  check	  once	  any	  further	  data	  has	  been	  generated.	  If	  the	  SNP	  genotypes	  produced	  as	  a	  result	  of	  the	  sequencing	  or	  genotyping	   pipelines	   do	   not	   match	   those	   typed	   on	   the	   Sequenom	   assay	   for	   a	  given	  sample	  this	  indicates	  a	  sample	  /	  data	  tracking	  failure.	  For	  the	  Sanger	  genotyping	  and	  sequencing	  pipelines	  this	  lookup	  is	  trivial	  as	  the	  data	   types	   generated	   are	   the	   same	   as	   the	   Sequenom	   assay,	   specifically	   SNP	  genotypes.	   Thereby	   the	   check	   for	   sample	   /	   data	   concordance	   is	   simply	   the	  number	  of	  matched	  genotypes	  between	  the	  assays	  under	  question.	  Failures	  are	  defined	  using	  a	  threshold	  on	  the	  number	  of	  genotype	  ’mismatches’.	  	  For	  the	  high	  throughput	  array-­‐CGH	  laboratory	  and	  analytical	  pipelines	  there	  was	  no	  sample	  /	  data	  tracking	  facility	  available	  as	  standard	  at	  the	  WTSI.	  To	  maintain	  sample	  level	  information	   throughout	   the	   laboratory	   procedures	   the	   DDD	   informatics	   team	  has	  developed	  a	  laboratory	  information	  management	  system	  (LIMS)	  using	  a	  Java	  based	   (spring)	   framework.	   For	   the	   data	   tracking	   throughout	   the	   array-­‐CGH	  analytical	  pipelines	  we	  have	  developed	  a	  method	  that	  makes	  use	  of	  copy	  number	  tagging	   SNPs	   to	   allow	   the	   array-­‐CGH	   (continuous	   log2	   ratio)	   data	   to	   be	  correlated	   with	   SNP	   genotypes	   obtained	   via	   the	   Sequenom	   assay	   run	   during	  sample	  reception.	  The	  end	  result	   in	   terms	  of	   the	  service	  provided	  by	  the	  DDD	  project	   to	   the	  NHS	  genetic	  services	  is	  the	  feedback	  of	  potentially	  clinically	  relevant	  variants	  via	  the	  DECIPHER	   database.	   To	   this	   goal	   the	   DDD	   project	   has	   developed	   a	   number	   of	  variant	  filtering	  approaches	  including	  a	  rule-­‐based	  pipeline	  for	  prioritising	  CNVs	  of	  potential	  clinical	  interest.	  This	  pipeline	  incorporates	  information	  about	  CNVs	  in	   genes	   that	   have	   previously	   been	   associated	   with	   genomic	   disorders	   and	  additionally	   predictions	   of	   CNVs	   seen	   at	   low	   enough	   frequency	   in	   apparently	  healthy	   individuals	   to	  be	  of	   general	   clinical	   interest.	  The	  CNV	   filtering	  pipeline	  has	  been	  designed	   to	  allow	   iterative	   reporting	  rounds	  maintaining	   information	  across	  multiple	   clinical	   filtering	  versions.	  This	   allows	   the	  project	   to	  be	   initially	  cautious	   when	   predicting	   the	   clinical	   relevance	   of	   CNVs,	   refining	   the	   filtering	  rules	  as	  more	  data	  is	  obtained	  and	  as	  the	  understanding	  of	  the	  causes	  of	  genomic	  disorders	  is	  improved.	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2.2	   METHODS	  	  
2.2.1	   CNsolidate	  
Array	  Platforms	  The	  DDD	  project	  utilises	   two	  different	  array	   technologies	   in	   the	   form	  of	  array-­‐CGH	   and	   SNP	   genotyping	   platforms.	   The	   array-­‐CGH	   array	   is	   composed	   of	   two	  1Million	  probe	  Agilent	  arrays	  and	  has	  been	  heavily	  targeted	  towards	  genes	  and	  ultra-­‐conserved	   elements	   throughout	   the	   human	   genome.	   The	   entire	   set	   of	  GENCODE	  exons	   [139],	  along	  with	  regulatory	  and	  mRNA	  coding	  elements	  have	  been	  tiled,	  using	  a	  minimum	  of	  five	  oligo-­‐nucleotide	  probes,	  on	  the	  Agilent	  array-­‐CGH	  arrays.	  	  The	  rest	  of	  the	  array	  content	  is	  spent	  on	  ensuring	  the	  presence	  of	  an	  ultra	  high-­‐resolution	  backbone	  with	  a	  median	  probe	  spacing	  of	  5Kb.	  The	  SNP	  genotyping	  array	  is	  a	  customised	  version	  of	  the	  Illumina	  Omni-­‐one	  quad	  chip	  (SangerDDD_OmniExPlusv1_15019773_A).	  Extra	  content	  has	  been	  added	  to	  standardise	  the	  coverage	  of	  the	  array	  using	  a	  ”largest	  first”	  gap	  filling	  procedure.	  The	  gap	   filling	  process	   is	  aimed	  at	   targeting	   the	   largest	  gaps	   in	  array	  coverage	  first	   and	   additionally	   inserting	   the	   best	   quality	   probe	   within	   the	   ”central	   gap	  region”	  before	  moving	  to	  the	  second	  largest	  gap	  in	  array	  coverage.	  The	  two	  million	  probe	  Agilent	  array-­‐CGH	  array	  is	  used	  as	  the	  discovery	  platform	  due	  to	  both	  its	  higher	  density	  and	  improved	  sensitivity.	  All	  the	  results	  described	  for	   CNsolidate	   are	   derived	   from	   data	   sets	   generated	   using	   the	   Agilent	   2	   x	   1M	  custom	  array-­‐CGH	  microarray	  (Agilent;	  Amadid	  No.s	  031220/031221).	  
Component	  Algorithms	  CNsolidate	   uses	   the	   combination	   of	   12	   independent	   change	   point	   detection	  algorithms	   to	   detect	   data	   segments	   that	   are	   potentially	   different	   to	   the	  background	  within	  a	  time-­‐series.	  These	  algorithms’s	  encompass	  both	  published	  and	  novel	  methods	   and	  have	  been	   tuned	   in	   concert	   to	   achieve	  high	   sensitivity	  while	  maintaining	  an	  acceptable	   level	  of	  specificity	  across	  a	   large	  range	  of	  data	  qualities.	  By	  using	  a	   combination	  of	   algorithms	   to	  detect	   change	  points	   from	   time-­‐series	  data	  it	  is	  possible	  to	  rank	  segments	  based	  on	  some	  prior	  knowledge.	  This	  can	  be	  done	  according	  to	  both	  the	  particular	  combination	  of	  algorithms	  that	  detected	  a	  segment	   (’naive	   voting’)	   and	  by	   estimating	   each	   algorithms	  performance	  given	  specific	   predictive	   variables	   that	   can	   be	   measured	   from	   the	   input	   data	  characteristic	  (’expert	  voting’).	  In	   this	   section	   the	   12	   different	   change	   point	   detection	   algorithms	   currently	  included	  in	  CNsolidate	  are	  listed	  and	  a	  brief	  description	  of	  their	  methodologies	  is	  given.	   We	   reference	   previously	   published	   algorithms	   accordingly	   and	   denote	  novel	  change	  point	  detection	  algorithms	  using	  a	  *	  in	  their	  title	  declarations.	  
GADA	  -­‐	  Genome	  Alteration	  Detection	  Analysis	  First,	   the	   GADA	   algorithm	   [140]	   describes	   copy	   number	   across	   a	   time	   series	  using	   piece-­‐wise	   constant	   (PWC)	   vectors.	   The	   underlying	   mean	   hybridization	  intensity	  !!	  is	  PWC	  since	  it	  depends	  only	  on	  the	  number	  of	  DNA	  copies:	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!! = !! + !!	  where	  !!represents	  the	  log2	  of	  the	  relative	  hybridization	  intensity	  observed	  by	  probe	  !;	  !!represents	   change	   in	   hybridization	   intensity	   due	   to	   altered	   copy	  number,	  !!	  is	  a	  zero-­‐mean	  array	  noise.	  Any	   PWC	   vector	   x	   with	   K	   breakpoints	   can	   be	   represented	   by	   a	   linear	  combination	   of	   K	   step	   vectors	  !! 	  plus	   a	   constant	   vector	  !!.	   An	   empirical	   Bayes	  approach,	  SBL,	  is	  applied	  to	  infer	  locations	  of	  change	  indicative	  of	  copy	  number	  alteration.	   The	   SBL	   approach	   uses	   a	   maximum	   a	   posterior	   (MAP)	   estimate,	  where	   the	  observation	  model	  !(!|!)	  specifies	   the	  goodness	  of	   fit	  measure	  and	  the	  prior	  distribution	  for	  the	  weights	  !(!)	  specifies	  the	  sparseness	  measure.	  A	  suboptimal	  backward	  elimination	  (BE)	  procedure	  is	  used	  to	  rank	  the	  inferred	  breakpoints.	   Breakpoints	   with	   lower	   statistical	   evidence	   !! 	  are	   recursively	  eliminated	  given	  the	  chosen	  significance	  parameter	  T.	  
*ADM3	  -­‐	  Automated	  Detection	  Algorithm	  3	  ADM3	   is	   an	   interpretation	   of	   the	   ADM2	   algorithm,	   originally	   developed	   by	  Agilent	  Technologies	  and	  contained	  in	  the	  Genomic	  Workbench	  software.	  	  The	   ADM	   interval	   score	   is	   calculated	   using	   a	   vector	   of	   pairs	  !!, !"! , !!, !"! ,… , (!!, !"!)	  	  where	  !! 	  is	   the	   log-­‐ratio	  signal	   for	   the	  !!!	  probe	  and	  !"! 	  is	  the	  log-­‐ratio	  error	  for	  the	  !!!probe.	  	  Define	  !! = 1/(!"!)!,	  the	  ADM	  score	  S	  for	  interval	  !	  is	  defined	  as:	  ! ! = !!!!!! 	   [2-­‐1]	  A	   noise	   term	   T,	   the	   derivative	   log	   ratio	   spread,	   and	   a	   scaling	   constant	   F	   are	  applied	  to	  transform	  the	  ADM	  score	  relative	  to	  data	  quality.	  
CBS	  -­‐	  Circular	  Binary	  Segmentation	  CBS	   is	   a	   modification	   of	   binary	   segmentation	   first	   developed	   by	   [141].	   The	  version	   used	   is	   based	   around	   the	   ’dna.copy’	   bioconductor	   package.	   	   The	  modifications	   made	   are	   aimed	   towards	   increased	   speed	   performance	   and	  improved	   consistency	   across	   varying	   noise	   backgrounds.	   	   Let	  !!,!!,… ,!!	  be	   a	  sequence	   of	   random	   variables.	   An	   index	  !	  is	   called	   a	   change	   point	   if	  !! ,… ,!! 	  have	   a	   common	   distribution	   function	  !! 	  	   and	  !!!! 	  	   has	   a	   different	   common	  distribution	  function	  !! 	  until	  the	  next	  change-­‐point.	  In	   CBS,	   where	   the	   data	   are	   normally	   distributed	   with	   a	   known	   variance,	   the	  likelihood	  statistic	  for	  testing	  the	  null	  hypothesis	  is	  given	  by	  !! = !"!! ≤!!! |!!|	  where,	   !! = {1/! + 1/(! − !)}!!!{!!/! − (!! − !!)/(! − 1)}	   [2-­‐2]	  The	  null	  hypothesis	  of	  no	  change	  is	  rejected	  if	  the	  statistic	  exceeds	  the	  upper	  !!!	  percentile	   of	   the	   null	   distribution	   of	   Z	   and	   the	   location	   of	   the	   change-­‐point	   is	  estimated	  to	  be	  i	  such	  that  ! = |!!|.	  
	   44	  
SWArray	  -­‐	  Dynamic	  Programming	  Algorithm	  For	  the	  SWArray	  algorithm	  a	  modified	  version	  of	  the	   ’tilingArray’	  bioconductor	  package	   [142]	   was	   used.	   They	   developed	   an	   implementation	   of	   dynamic	  programming,	   combining	   a	   segmentation	   model	   with	   a	   mixture	   model.	   Their	  method	   combined	   the	   dynamic	   programming	   algorithm	   (DP)	   and	   expectation	  maximization	   (EM).	   This	   hybrid	   algorithm,	   called	   dynamic	   programming	  expectation	   maximization	   (DP-­‐EM)	   estimates	   the	   parameters	   of	   the	   model	   by	  maximum	  likelihood.	  Due	   to	   the	   computationally	   intensive	   nature	   of	   a	   dynamic	   programming	  approach,	   the	   method	   has	   been	   modified	   to	   use	   low-­‐cost	   matrices,	   thereby	  reducing	   the	   search	   space.	   CNsolidate	   pre-­‐segments	   the	   data	   into	  manageable	  data	  ’chunks’	  prior	  to	  applying	  the	  DP-­‐EM	  algorithm.	  These	  segments	  are	  offset	  and	  summed	  three	  times.	  
*CNCP	  -­‐	  Copy	  Number	  Change	  Points	  CNCP	   is	   based	   on	   the	   CUSUM	   (or	   cumulative	   sum	   control	   chart)	   approach	   to	  change	  detection	  originally	  developed	  by	  E.	  S.	  Page.	  In	   CNCP	   the	   cumulative	   sums	   are	   only	   allowed	   to	   extend	   across	   data	  measurements	  by	  defining	  a	  certain	  set	  of	  criterion	  and	  are	  reset	  once	  a	  change	  has	   been	   observed.	   The	   likelihood	   function	  !	  is	   based	   on	   the	   distribution	   of	   a	  number	  of	  data	  points	  preceding	  the	  current	  point	  in	  the	  control	  chart.	  	  	  Let	  X	  equal	  the	  data	  measurements,	  !	  equal	  the	  likelihood	  function,	  N	  equal	  the	  number	  of	  data	  measurements	  and	  S	  equal	  the	  cumulative	  sum.	  First	  we	  calculate	  the	  mean	  of	  X:	  ! = (!! + !!+,… ,+  !!)! 	   [2-­‐3]	  Then	  start	  by	  setting	  !! = 0  and	  !! = 0,	  !!!! = !! + ! − ! − !! 	   [2-­‐4]	  with	  i	  from	  1,	  2,	  ..,N.	  As	   more	   values	   are	   added	   to	   the	   cumulative	   sum,	   if	   the	   majority	   of	  measurements	  were	  positive	  with	   respect	   to	   the	  mean	   and	   likelihood	   function	  the	  sum	  will	  steadily	  increase.	  When	  the	  value	  of	  S	  exceeds	  a	  certain	  threshold	  a	  change	  has	  been	  found.	  Intuitively,	   a	   segment	   of	   the	   CUSUM	   chart	   that	   displays	   an	   upward	   slope	  indicates	  a	  period	  of	  time	  where	  the	  measurements	  tended	  to	  be	  above	  the	  mean	  given	  the	  likelihood	  function.	  
FastCall	  -­‐	  Fast	  Change	  Point	  Detection	  The	   FastCall	   [143]	   method	   is	   based	   on	   a	   mixture	   of	   truncated	   normal	  distributions.	  It	  classifies	  data	  segments	  into	  one	  of	  four	  states,	  loss,	  neutral,	  gain	  and	  multiple	   gain.	   FastCall	   requires	   as	   input	   ’pre-­‐detected’	   data	   segments	   and	  then	  models	  the	  mean	  level	  of	  a	  segment	  as	  a	  mixture	  of	   five	  truncated	  normal	  distributions.	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Due	   to	   the	   fast	   execution	   properties	   of	   FastCall	  We	  were	   able	   to	   use	   a	   greedy	  segmentation	   algorithm.	  Let,	  X	   equal	   the	   raw	   ratio	  values,	  !	  equal	   the	  mean	  of	  the	   current	   test	   segment,	  !! 	  equal	   the	   FastCall	   algorithm,	   s	   equal	   the	   FastCall	  state	  and	  N	  equal	  the	  length	  of	  X.	  !! = !!(!)	   [2-­‐5]	  with	  !	  and	   j	   from	  1, 2,… ,! − 1.	   The	   current	   test	   segment	  !	  is	   the	   mean	   of	   the	  raw	  ratio	  values,	  !	  from	  !… !.	  When	  the	  current	  state	  classification,	  !! 	  is	  equal	  to	  the	   previous	   classification,	   ! = ! + 1 	  and	   the	   process	   continues.	   When	   the	  current	  state	  classification	  !! 	  is	  not	  equal	  to	  the	  previous	  classification,	  ! = !	  and	  ! = ! + 1.	  This	  process	  operates	  on	  the	  raw	  ratio	  values	  from	  each	  chromosome	  separately	  and	  defines	  a	   state	  classification	  vector	  of	   the	  same	   length	   for	  each.	  These	  state	  classification	  vectors	  are	  then	  used	  to	  dictate	  the	  starting	  and	  ending	  positions,	   and	   the	   mean	   of	   outlier	   segments	   across	   the	   data	   measurements	  where	   consecutive	   state	   classifications	   are	   the	   same	   but	   not	   the	   normal	   state	  (copy	  number	  2).	  	  
*STFE	  -­‐	  Simple	  Threshold	  Feature	  Estimation	  STFE	   uses	   a	   noise	   dependent	   threshold	   and	   a	   self-­‐adjusting	   extension	   rule	   to	  estimate	  variable	  segments	  within	  time-­‐series	  like	  data	  measurements.	  We	  define	  T,	  the	  detection	  threshold,	  as:	  ! = !"  ×  !"	   [2-­‐6]	  where,	   nF	   is	   a	   threshold	   scaling	   factor	   and	   Dv	   is	   the	  68!! 	  percentile	   of	   the	  absolute,	  median	  normalised	  data	  measurements.	  The	  initial	  extension	  parameter,	  ! = 1.	  Let	  !!,!!,… ,!! 	  be	   the	   ordered	   data	   measurements,	   when	   any	  !! > ! ,	   the	  detection	  vector	  dI	  is	  defined	  as:	  !"! > !,!! , . . ,!!!! 	   [2-­‐7]	  As	  the	  length	  of	  dI	  increases	  E	  is	  adjusted	  by:	  ! = !(1− !! )	   [2-­‐8]	  where,	  L	  is	  the	  length	  of	  the	  detection	  vector	  and	  c	  is	  the	  number	  of	  data	  values	  !! < !	  inside	   the	   detection	   vector.	   Once	  ∑!" ≥ ! ≥ !,	   extension	   is	   terminated,	  ! = 1  and  ! = ! − ! + 1.	  
SMAP	  -­‐	  Segmental	  Maximum	  A	  Posteriori	  Approach	  The	   segmental	  maximum	   a	   posteriori	   approach	   to	   genome-­‐wide	   copy	   number	  profiling	  -­‐	  SMAP	  [144],	  used	  is	  based	  on	  a	  discrete-­‐index	  Hidden	  Markov	  Model	  and	  incorporates	  genomic	  distance	  and	  overlapping	  probes.	  	  They	  use	  a	  six-­‐state	  model	   in	   place	   of	   the	   conventional	   three-­‐state	   model.	   The	   version	   used	   is	   a	  modification	  of	  the	  available	  bioconductor	  package.	  Their	   HMM	   is	   a	   pair	  ℏ = (!, !),	   where	  ! = {!!}!!!! 	  is	   a	   set	   of	   N	   copy	   number	  states,	   such	   that	  !! ∈ !(1 ≤ ! ≤ !),	   and	  !(⊓,∧,Ω)	  are	  parameters	   for	   the	  model.	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The	   probability	   of	   starting	   in	   copy	   number	   state	  !!(1!")	  for	   data	   point	   one	   is	  specified	  by	  the	  initial	  probabilities,	  Π = {!}!!!! .	  Each	  pair	  of	  copy	  number	  states	  is	   connected	  by	  HMM	  specific	   transition	  probabilities	  ! = {!!"}!,!!!! 	  that	   specify	  the	  probabilities	   of	   transition	  between	   states	  !! 	  and	  !!(1!, !")	  between	  any	   two	  consecutive	  data	  points	  in	  the	  sequence.	  	  	  SMAP	  suggests	  a	  six	  state	  model	  by	  default	  but	  is	  not	  restricted	  to	  six	  states.	  In	  CNsolidate	  SMAP	  is	  used	  with	  only	  three	  states	  due	  to	  observed	  complications	  in	  detection	   performance	  when	   using	   the	   six	   state	  model	   across	   data	   of	   variable	  qualities.	  
*Vwalk-­‐	  Variance	  Spike	  Walking	  Vwalk	   makes	   use	   of	   self-­‐adjusting	   sliding	   windows	   to	   search	   for	   spikes	   in	  variance,	  characteristic	  of	  change-­‐point	  locations,	  across	  time-­‐series	  like	  data.	  We	  define	  the	  detection	  threshold	  vT	  as:	  !" = !"# ! !"	   [2-­‐9]	  where	  sf	  is	  a	  scaling	  factor	  and	  D	  are	  the	  data	  measurements.	  	  Using	   an	   initial	   window	   size	  !	  the	   data	   measurements	   are	   tested	   and	   where	  !"# !! ,… ,!!!! > !"	  a	  potential	  segment	  starting	  position	  has	  been	  found.	  Next	  the	  window	  size	  !	  is	  incremented	  so	  long	  as  !"# !! ,… ,!!!! < !,	  where	  !	  is	  	  !"# !!!!,!! /2.	  This	  continues	  until	  !"# !! ,… ,!!!! > !	  at	  which	  point	  the	  potential	  segment	  ending	  position	  has	  been	  found,	  ! = !	  and	  !	  equal	   the	   initial	  window	  size.	  We	  apply	  this	  process	  twice	  across	  the	  data	  measurements	  for	  each	  chromosome	  separately	   using	   two	  different	  window	   sizes.	   The	   first	  window	   size	   is	   small	   (4	  data	  points)	  and	   is	  aimed	  at	   increasing	  the	  sensitivity	  of	  outlier	  detection	   from	  the	   method,	   however	   this	   window	   size	   tends	   to	   over	   segment	   and	   result	   is	  multiple	  small	  detections.	  Thereby	  a	  second	  larger	  window	  size	  (20	  data	  points)	  is	  used	  and	  a	  final	  process,	  using	  fixed	  cut-­‐offs	  on	  mean	  ratio	  differences,	  is	  used	  to	  merge	  adjacent	  segments	  where	  appropriate.	  	  
*ViteRbi	  ViteRbi	  is	  a	  simple	  three	  state	  Hidden	  Markov	  Model	  using	  the	  standard	  Viterbi	  algorithm	  to	  compute	  the	  likely	  sequence	  of	  hidden	  states	  (’Viterbi	  path’).	  Given	  the	  model:	  !! ! = max!(! 1 , ! 2 ,… , ! ! − 1 ; ! 1 , ! 2 ,… , !(!)|! ! = !!)	   [2-­‐10]	  where	  !!(!)	  is	  the	  maximal	  probability	  of	  states	  of	  length	  t	  and	  end	  in	  state	  i.	  The	  Viterbi	  algorithm	  uses	  maximisation	  at	  the	  recursion	  and	  termination	  steps,	  and	  keeps	   track	   of	   arguments	   that	   maximize	  !!(!)	  by	   storing	   them	   in	   the	   N	   by	   T	  matrix	  !.	  The	  optimal	  state	  sequence	  is	  retrieved	  at	  the	  backward	  step:	  !! = !!!! !!!! , ! = ! − 1,! − 2,… ,1	   [2-­‐11]	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Finally,	  segments	  of	  the	  optimal	  state	  sequence	  vector	  q	  displaying	  a	  non-­‐normal	  state	  are	  split	  into	  discrete	  distance	  intervals.	  
*SMUG	  -­‐	  Stochastic	  Model	  Under	  ’Gain’	  SMUG	   is	   a	   non-­‐stationary	   Hidden	  Markov	  Model	   using	   a	   time-­‐inhomogeneous	  Markov	  chain.	  In	  other	  words,	  as	  the	  time	  spent	  in	  a	  state	  increases;	  the	  transition	  probabilities	  alter	   given	  a	  prior	   expectation	  on	   the	   likely	   time	   to	  be	   spent	   in	   that	  particular	  state.	  The	  Markov	  property	  remains	  unchanged.	  We	  can	  state	  that	  P	  depends	  on	  i,	  j	  and	  
n,	  and	  call	  it	  !!,!" 	  :	   !(!!!! = !|! = !,ℏ!)	   [2-­‐12]	  These	  can	  then	  be	  assembled	  into	  a	  transition	  matrix	  !!.	  The	   Chapman-­‐Kolmogorov	   Equations	   show	   that	   the	   m-­‐step	   transition	  probability	  !(!!!! = !|!! = !)	  is	   the	  (!, !)!!	  element	  of	   the	  matrix	  obtained	  via	  matrix	  multiplication.	  The	  behaviour	  of	  the	  population	  as	  a	  whole	  can	  be	  treated	  as	  time-­‐homogenous	  because	  of	  statistical	  equilibrium.	  
BCP	  -­‐	  Bayesian	  Change	  Points	  CNsolidates	   version	   of	   BCP	   is	   based	   on	   an	   R	   package	   [145]	   implementing	   a	  Bayesian	  approach	  to	  change	  point	  detection	  from	  Barry	  and	  Hartigan	  1993.	  In	   the	   original	   implementation	   by	   Barry	   and	   Hartigan,	   they	   assumed	   that	   the	  probability	  of	  a	  change	  point	  at	  a	  position	  i	  is	  p,	  independently	  at	  each	  i.	  In	  their	  Bayes	  procedure,	  under	  this	  assumption,	  !(!! ,!!),	  the	  prior	  distribution	  !!" 	  is	  choosen	  as	  !(!!,!)!!/(! − !)	  and	  the	  calculations	  are	  !(!!).	  In	  the	  Erdman	  and	   Emerson	   R	   implementation	   they	   use	   a	   MCMC	   approximation	   of	   the	   prior	  distribution	  that	  is	  !(!!).	  The	   algorithm	   uses	   a	   partition	  ! = (!!,!!,… ,!!) ,	   where	  !! = 1 	  indicates	   a	  change	  point	  at	  position	  ! + 1.	  In	  each	  step	  of	  the	  Markov	  chain,	  at	  each	  position	  
i,	  a	  value	  of	  !! 	  is	  drawn	  from	  the	  conditional	  distribution	  of	  !! 	  given	  the	  data	  and	  the	  current	  partition.	  The	  transition	  probability,	  p,	  for	  the	  conditional	  probability	  of	  a	  change	  point	  at	  the	  position	  ! + 1,	  can	  be	  obtained	  from	  the	  simplified	  ratio	  presented	  in	  Barry	  and	  Hartigan:	  !!1 − !! = !(!! = 1|!,!! , ! ≠ !)!(!! = 0|!,!! , ! ≠ !) = !!!! (1 − !)!!!!!!" [ !!/!(!!!!!!)(!!!)/!!! !"]!!!!!! (1 − !)!!!!" [ !!!!/!(!!!!!!)(!!!)/!!! !"]	  
[2-­‐10]	  
where,	  !!,!!,!! 	  and	  !! 	  are	   the	   within	   and	   between	   block	   sums	   of	   squares	  obtained	   when	  !! = 0	  and	  !! = 1  respectively,	   and	   X	   is	   the	   data.	  ! 	  and	  ! 	  are	  tuning	  parameters	  with	  values	  between	  0	  and	  1.	  BCP	  is	  both	  the	  most	  complex	  and	  the	  least	  reliable	  algorithm	  within	  CNsolidate.	  Currently	   it	   is	  not	  used	  under	   the	  default	   settings,	   as	   its	   successful	   completion	  cannot	  be	  guaranteed.	   In	   future	  releases	  of	  CNsolidate	  we	  hope	  to	   improve	  the	  performance	  and	  reliability	  of	  the	  BCP	  algorithm.	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Algorithm	  Combination	  Each	  individual	  algorithm	  results	  in	  the	  identification	  of	  a	  number	  of	  potentially	  significant	  segments	  throughout	  the	  genome.	  These	  segments	  contain	  a	  start	  and	  a	  stop	  position	  with	  a	  number	  of	  internal	  data	  points,	  they	  denote	  a	  region	  of	  the	  time-­‐series	   data	   that	   is	   potentially	   significantly	   different	   to	   the	   background	  noise.	  CNsolidate	   makes	   use	   transitive	   set	   theory	   to	   build	   up	   well-­‐ordered	   sets	   of	  ordinals	  for	  each	  chromosome	  separately.	  Each	  of	  these	  ordinals	  is	  itself	  a	  well-­‐ordered	  set	  of	  detected	  segments.	  	  
Constraints:	  We	  define	  the	  binary	  relationship	  R	  as,	  	   ! = !!(!!) ≤ !!(!!!!)  &    !!(!!) ≥ !!(!!!!) 	   [2-­‐14]	  where,	  !! 	  equal	  a	  well-­‐ordered	  set	  of	  segments	  from	  chromosome	  i,	  !! 	  equal	  the	  start	  position	  and	  !! 	  equal	  the	  stop	  position	  of	  segment	  k	  from	  set	  !! 	  
Transitive	  Clustering	  We	  use	  the	  binary	  relationship	  R	   to	  transitively	  cluster	  features	  to	  build	  up	  the	  ordinals	  (well-­‐ordered	  sets	  of	  detected	  segments).	  Given	   an	   initial	   ordinal	   OR,	   a	   subset	   of	   segments	   from	   the	   well-­‐ordered	  chromosomal	  set	  C,	  the	  ordinals	  are	  defined	  by:	  ∀!∈ !":∀!∈ !: !"  ! !"! ,!!   !ℎ!"   ∪ !",!!	   [2-­‐15]	  
Iterative	  Closure	  Full	   iterative	  closure	   is	  achieved	  once	   the	  set	  C	   can	  no	   longer	  provide	  member	  segments	  to	  any	  of	  its	  ordinals	  ORS.	  In	  other	  words,	  ∀!" ∈ !"#:  ∀!∈ !":  ∀!∈ !:   ≠ !(!"! ,!!)	   [2-­‐16]	  The	   result	   of	   this	   iterative	   process	   is	   a	   set	   of	   ordinals	   for	   each	   chromosome.	  	  Each	  ordinal	  is	  itself	  a	  well-­‐ordered	  set	  of	  detected	  segments.	  Furthermore,	  each	  ordinal	   contains	   information	   about	   which	   combination	   of	   algorithms	   and	   in	  which	  context	  each	  of	  its	  member	  segments	  were	  detected.	  
Feature	  Definition	  To	  define	  non-­‐overlapping,	  unique	  features	  from	  the	  well-­‐ordered	  chromosomal	  sets	   we	   apply	   a	   method	   based	   on	   the	   meeting	   combination	   and	   the	   meeting	  arrangement	  observed	  in	  each	  of	  the	  ordinals.	  The	  input	  to	  this	  method	  is	  two	  matrices	  for	  each	  ordinal,	  	   !"!,! = !"!,! ⋯ !"!,!⋮ ⋱ ⋮!"!,! ⋯ !"!,! 	   [2-­‐17]	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  And,	  	   !"!,! = !"!,! ⋯ !"!,!⋮ ⋱ ⋮!"!,! ⋯ !"!,! 	  	  
[2-­‐18]	  
	  Where,	  m	   is	   the	   internal	  breakpoint	   index,	   and	  n	   is	   the	  algorithm	   index	  across	  the	  ordinal.	  Thereby,	  !"!,!	  equal	  the	  meeting	  combination	  score	  and	  !"!,!	  equal	  the	  meeting	  arrangement	  score	  for	  algorithm	  one	  at	  breakpoint	  one	  respectively.	  We	  then	  define	  the	  weighted	  ordinal	  scoring	  vector	  !,	  as:	  ! = !"!,!!!!!!"!,!!!!! 	   [2-­‐19]	  	  The	  !	  values	  reflect	  the	  relative	  difference	  between	  the	  number	  of	  algorithms	  in	  agreement	  at	  a	  potential	  breakpoint	  location	  and	  the	  number	  of	  algorithms	  that	  show	   extension	   across	   a	   breakpoint.	  When	  !! 	  is	   greater	   than	   1,	   there	   is	   more	  evidence	  for	  a	  breakpoint	  than	  an	  extension	  and	  the	  ordinal	  is	  split.	  	  By	  default,	  we	  do	  not	  apply	  any	  weighting	   to	   the	   individual	  algorithms	  during	   this	   feature	  definition	   step.	  Meaning	   that,	   it	   is	   only	   the	  number	  of	   algorithms,	  not	   the	   type	  that	   is	   considered	   for	   the	  !	  values.	  However	   it	   is	  possible	   to	   incorporate	   some	  prior	  knowledge,	  for	  example,	  if	  a	  particular	  algorithm	  is	  known	  to	  over-­‐segment	  across	  regions	  its	  mc	  score	  could	  be	  down-­‐weighted.	  	  Conversely,	  if	  an	  algorithm	  is	   known	   to	   over-­‐extend	   across	   multiple	   breakpoints,	   its	   ma	   score	   could	   be	  down-­‐weighted.	  
Segment	  Exclusion	  and	  Breakpoint	  Mapping	  To	  exclude	  poor	  quality	  segments	  there	  are	  two	  hard	  constraints.	  The	  minimum	  absolute	  mean	  ratio	  of	  a	  segment,	  mRS	  and	  the	  minimum	  number	  of	  data	  points	  needed	  to	  define	  a	  segment	  mDP.	  All	  ordinals	  must	  obey	  these	  constraints	  to	  be	  placed	  into	  the	  filtered	  ordinal	  set	  FOR.	  ∀!∈ !": !"! !" ≥ !"#  &  !"! !" ≥ !"# ∶  ∪ !"#,!"!	   [2-­‐20]	  where,	  mR	  and	  mD	  equal	  the	  absolute	  mean	  ratio	  and	  the	  number	  of	  data	  points	  from	  the	  maximum	  union	  of	  each	  ordinal	  respectively.	  	  For	  breakpoint	  mapping,	  there	  is	  a	  single	  soft	  constraint,	  brkM,	  which	  defines	  the	  minimum	  absolute	  ratio	  value	  that	  is	  allowed	  at	  both	  ends	  of	  the	  ordinal.	   	  It	  is	  related	  to	  the	  mean	  ratio	  value	  of	  the	  ordinal,	  orM,	  or	  a	  defined	  threshold,	  brkT.	  	  	  !"#$ = max(!"#$, (!"#/2))	   [2-­‐21]	  If	  data	  points	  at	  either	  end	  of	  the	  ordinal	  are	  less	  than	  brkM,	  extension	  outside	  of	  the	   ordinal	   is	   attempted.	   If	   this	   fails,	   data	   points	   inside	   the	   ordinal	   are	   tested	  until	  the	  end	  values	  are	  greater	  than	  brkM.	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Segment	  Merging	  Finally,	  adjacent	  ordinals	  can	  be	  iteratively	  merged	  into	  a	  single	  ordinal	  so	  long	  as	  two	  constraints	  hold	  true.	  Let	  !"! 	  be	  the	  mean	  ratio	  of	  the	  ordinal	  and	  !"!	  be	  the	  number	  of	  data	  points	  in	  the	  ordinal,	  and	  let	  rp	  and	  sp	  be	  adjustment	  parameters.	  Define	   ! = !"!×  !"	   [2-­‐22]	  and	   ! = !"!×  !"	   [2-­‐23]	  Let	  ORN	  be	  the	  nearest	  neighbour	  to	  OR	  and	  let	  dr	  be	  the	  absolute	  difference	  in	  mean	   ratios	   and	   ds	   be	   the	   number	   of	   data	   points	   between	   OR	   and	   ORN	  respectively.	  	  	   !"  !" ≤ !  &  !"   ≤ !  !ℎ!"   ∪ !",!"#	   [2-­‐24]	  This	  process	  continues,	  across	  all	  ordinals	  ORS,	  selecting	  the	  nearest	  neighbour	  and	  testing	  R	  and	  S	  until	  full	  closure	  is	  achieved:	  ∀!∈ !"#: !" !"#   !"! >   !! > !"! > !!	   [2-­‐25]	  This	   is	   the	   final	   step	   in	   the	  definition	  of	   the	   locations	   of	   potentially	   significant	  change	  point	   intervals	  across	  the	  time-­‐series.	   It	  results	   in	  a	  well-­‐ordered	  set	  of	  ordinals,	  each	  of	  which	  is	  itself	  a	  well-­‐ordered	  set.	  
Weighting	  Functions	  To	  make	   the	   best	   use	   of	   all	   these	   results	   and	   to	   place	   a	  more	   reliable	   level	   of	  significance	   on	   each	   detected	   feature,	   we	   have	   created	   a	   score	   assignment	  method.	   This	   method	   makes	   use	   of	   a	   number	   of	   predictive	   variables	   and	   the	  estimated	   performance	   of	   each	   algorithm	   (‘voter’)	   across	   a	   range	   of	   data	  qualities.	   	   As	   a	   result	   it	   is	   possible	   to	   rank	   features	   according	   to	   some	   prior	  knowledge.	  Currently	  this	  knowledge	  is	  based	  on:	  1. Individual	  algorithm	  performances	  given	  three	  different	  measures	  of	  data	  noise	  characteristics	  2. The	   importance	   of	   three	   specific	   predictive	   variables	   on	   detection	  performance	  in	  general	  	  	  
Noise	  Dependent	  Algorithm	  Weights	  To	   estimate	   the	   performance-­‐based	   weights	   for	   each	   algorithm	   we	   test	   the	  detection	   accuracy	   of	   each	   algorithm	   using	   three	   different	   estimates	   of	   data	  noise	   levels.	  For	  each	  algorithm	  the	   false	  alarm	  rate	  was	   tested	  using	  over	  one	  million	  data	  simulations	  (see	  Appendix).	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First	   we	   use	   the	   rp68,	   the	   68th	   percentile	   of	   the	   absolute	  median	   normalised	  log2	  ratio	  values	  as	  an	  estimate	  of	  the	  amount	  Gaussian	  ‘white’	  noise	  present	  in	  the	  data	  set.	  Second	  the	  dLRs,	  the	  derivative	  log	  ratio	  spread:	  !"#$ = !"#(!)4(!"#$%& 0.5 )	   [2-­‐26]	  Where,	  d	  is	  an	  vector	  of	  differences	  between	  log2	  ratios	  of	  adjacent	  probes,	  erfinv	  is	  the	  Inverse	  Error	  Function	  and	  IQR	  is	  Inter	  Quartile	  Range.	  Third	  the	  dydLRs,	  or	  ‘wave	  score’:	  !"#$%! = !"#$ !"#$% 	   [2-­‐27]	  with	  i	  from	  1,	  2,	  ..,N.	  	  where	  dspan	  is	  a	  vector	  of	  log	  ratio	  values	  with	  an	  equally	  spaced	  index	  !	  and	  N	  is	  the	  maximum	  index	  spacing.	  	  	  !"!#$% = |!"#|	   [2-­‐28]	  where	  dDS	  is	  an	  array	  of	  differences	  between	  the	  dyDLR	  values.	  This	  value	  gives	  an	  estimate	  of	  the	  scale	  of	  auto-­‐correlation	  present	  in	  the	  data	  values.	  
	  Figure	   2-­‐1	   Noise	   dependent	  weight	   functions	   for	   11	   algorithms.	   Left	   -­‐	   Central	  noise	  measure	   vs.	  Weight.	   Middle	   -­‐	   Difference	   based	   noise	   vs.	  Weight.	   Right	   -­‐	  Wave	  based	  noise	  measure	  vs.	  Weight.	  Above	  (see	  Figure	  2-­‐1)	  the	  derived	  noise	  dependent	  weighting	  functions	  for	  11	  of	   CNsolidates	   algorithms	   is	   shown.	   BCP	   is	   excluded	   due	   to	   the	   fact	   that	   its	  successful	   completion	   cannot	   be	   guaranteed,	   as	   previously	  mentioned.	   Each	   of	  the	  noise	  values	  (central,	  difference	  and	  wave)	  has	  a	  different	  scale	  and	  has	  been	  rescaled	   onto	   a	   0-­‐0.5	   range	   for	   the	   purpose	   of	   display.	   These	   curves	   were	  generated	  by	  assessing	  the	  relationship	  between	  the	  noise	  ranges	  and	  the	  Type	  I	  and	  Type	  II	  error	  rates	  via	  a	  large	  number	  of	  data	  simulations	  (see	  Appendix).	  During	  these	  simulations	  we	  varied	  the	  three	  noise	  predictors	  and	  assessed	  the	  performance	  of	  each	  algorithm	  separately.	  Overall	   each	   algorithm	   displays	   a	   different	   relationship	   between	   its	   estimated	  performance	   and	   the	   various	   different	   data	   noise	   types	   and	   levels.	   Although	   a	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few	   algorithms	   show	   a	   general	   poor	   performance,	   being	   very	   sensitive	   to	  differences	   in	   noise	   levels,	   the	   majority	   of	   algorithms	   show	   reasonable	  performance	  across	  a	  large	  portion	  of	  the	  noise	  ranges.	  Interestingly	  most	  algorithms	  show	  the	  expected	  decrease	  in	  performance	  when	  noise	   levels	   increase,	   however	   a	   few	   display	   the	   inverse	   relationship	   to	   noise	  levels.	  This	   is	  useful	  as	   its	  means	  that	  at	  most	  combinations	  of	  noise	   types	  and	  levels	  there	  are	  a	  number	  of	  high	  performance	  (‘expert’)	  algorithms.	   	  The	  wave	  based	  noise	   estimation	   has	   the	   largest	   effect	   on	   algorithm	  performance	   across	  the	   board,	   with	   all	   algorithms	   displaying	   a	   decrease	   in	   performance	   as	   wave	  levels	  increase.	  
Feature	  Dependent	  Algorithm	  Weights	  Next,	  we	  estimate	  the	  false	  alarm	  rate	  given	  some	  predictive	  values	  that	  can	  be	  calculated	   from	   each	   detected	   segment.	   Again	   we	   estimate	   the	   relationship	  between	  each	  of	   these	  predictive	  variables	   and	   the	   false	   alarm	  rate	  via	   a	   large	  number	  of	  data	  simulations	  (see	  Appendix).	  Currently	   three	   predictive	   variables	   are	   used	  during	   this	  weighting	  procedure.	  The	  absolute	  mean	  ratio	  of	  a	  segment,	   the	  number	  of	  data	  points	   in	  a	  segment	  and	  the	  variance	  of	  the	  data	  points	  across	  the	  segment.	  	  	  
	  Figure	   2-­‐2	   Feature	   Dependent	   Weighting	   Functions;	   Left	   -­‐	   Ratio	   dependent	  weights.	  Right	  -­‐	  Number	  of	  data	  point’s	  dependent	  weights.	  Above	  (see	  Figure	  2-­‐2)	  the	  estimated	  weighting	  functions	  for	  the	  mean	  ratio	  of	  a	  segment	  and	  the	  number	  of	  data	  points	  in	  a	  segment	  respectively	  are	  shown.	  The	  ratio	  weighting	  function	  has	  an	  additional	  noise	  term,	  where	  increased	  levels	  of	  noise	  result	  in	  the	  weight	  being	  reduced	  across	  the	  range.	  In	  the	  left	  hand	  panel,	  the	  shade	  of	  the	  lines	  relates	  to	  a	  difference	  in	  noise,	  with	  noise	  increasing	  as	  the	  shades	  becomes	  lighter.	  In	  the	  right	  hand	  panel,	  the	  size	  weighting	  function,	  the	  curve	  plateaus	  at	  around	  100	  data	  points.	  Once	  a	  change	  point	  interval	  has	  100	  or	  more	  data	  points	  it	  was	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detected	  100%	  of	  the	  time.	  This	  is	  perhaps	  not	  too	  surprising	  but	  it	  does	  result	  in	  an	   added	   complication.	   A	   segment	   containing	   100	   data	   points	   will	   receive	  approximately	   the	   same	   size	   dependent	   weight	   component	   as	   one	   containing	  10,000	  data	  points	  using	  this	  weighting	  function.	  
Detection	  Scores	  
Weighted	  Confidence	  Score	  For	  each	  detection,	  we	  assign	  a	  weighted	  confidence	  score	  given	  the	  predictive	  values	  mentioned	  above.	  We	  define	  the	  weighted	  confidence	  score	  w	  as:	  	   ! = !" + !" + !"3 + (!"! ,!"! ,!"!)!!!! ! 2	   [2-­‐29]	  	  Where,	   fW,	  sW	  and	  vW	  equal	   the	   feature	  dependent	  weights	   for	   the	  mean	  ratio,	  size	  and	  variance	  respectively,	  cV	   ,	  dV	   ,	  wV	  equal	  the	  noise	  dependent	  weighted	  scores	   for	   the	  rp68,	   the	  dLRs	  and	   the	  dydLRs	   for	  algorithm	  k	  respectively,	  and	  where,	  N	  equals	  the	  total	  number	  of	  algorithms	  used.	  The	  weighted	  confidence	  score	  (w)	  is	  thus	  a	  composite	  value	  made	  up	  the	  noise	  dependent	  and	  feature	  dependent	  weighted	  scores.	  	  
	  Figure	   2-­‐3	   Relationship	   between	  weighted	   score	   and	   two	   predictive	   variables.	  	  Left	  -­‐	  Weighted	  score	  vs.	  mean	  ratio.	  Right	  -­‐	  Weighted	  Score	  vs.	  number	  of	  data	  points.	  The	  above	  plots	  (see	  Figure	  2-­‐3)	  show	  the	  relationship	  between	  the	  wscore	  and	  the	   two	   predictive	   variables	  mean	   log2	   ratio	   (left)	   and	   number	   of	   data	   points	  (right)	   for	  a	  number	  of	  CNV	  detections.	  Although	   there	   is	  a	  general	  correlation	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observable,	   as	   expected	   it	   is	   not	   perfect	   since	   the	  wscore	   is	   a	   composite	   value	  made	  up	  of	  multiple	  predictive	  values.	  	  	  
Local	  Significance	  Value	  Additionally,	   for	   each	   detection,	   we	   assign	   a	   p-­‐value	   calculated	   via	   the	   two	  sample	  Welch’s	   t-­‐test.	   The	   test	   is	   between	   the	   population	  mean	   of	   data	   points	  inside	  !!	  and	  those	  directly	  outside,	  but	  not	  inside	  another,	  detected	  segment	  !!.	  The	   number	   of	   data	   points	   drawn	   from	  directly	   outside	   the	   segment	   (on	   both	  sides)	   to	   make	   up	   the	   second	   distribution	   (with	   the	   population	   mean	  !!)	   is	  controlled	  by	  a	   factor	   f.	  Thereby	   the	  number	  of	  data	  points	   to	  draw	   from	  both	  sides	  of	   the	  segment	  dn	   is	  defined	  as,	  !" = !"/!	  where	  sn	  equal	   the	  number	  of	  data	  points	  inside	  the	  segment.	  	  By	  default	  we	  set	  f	  =	  2	  in	  CNsolidate	  meaning	  that	  half	  the	  number	  of	  data	  points	  within	   the	  segment	  are	  drawn	   from	  each	  side.	  These	  are	   then	  combined	   into	  a	  single	   distribution	   and	   compared	   to	   the	   distribution	   of	   data	   points	   inside	   the	  segment	  via	  the	  t-­‐test:	  
! = !! − !!!!!!!! 	   [2-­‐30]	  where	  
!!!!!! = !!!!! + !!!!!	   [2-­‐31]	  and	  !!	  is	   the	   unbiased	   estimator	   of	   the	   variance	   of	   the	   two	   samples,	  !!	  and	  !!	  equal	   the	   number	   data	   points	   in	   distribution	   1	   and	   2	   respectively	   and	   the	  degrees	  of	  freedom	  are	  calculated	  using	  the	  Welch–Satterthwaite	  equation:	  	   !. !.= (!!!/!! + !!!/!!)!(!!!/!!)!/(!! − 1)+ (!!!/!!)!/(!! − 1)	   [2-­‐32]	  	  Finally	  we	  use	  the	  Bonferroni	  correction	  for	  multiple	  testing	  where	  the	  p-­‐values	  are	  multiplied	  by	  the	  total	  number	  of	  tests	  (CNV	  detections).	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Figure	  2-­‐4	  P-­‐value	  generated	  by	  CNsolidate;	  Left	  -­‐	  P-­‐value	  vs.	  mean	  ratio,	  Right	  -­‐	  P-­‐value	  vs.	  number	  of	  data	  points.	  Above	  (see	  Figure	  2-­‐4)	  the	  relationship	  between	  the	  assigned	  p-­‐value,	  the	  mean	  ratio	  values	  (left)	  and	  the	  number	  of	  data	  points	  (right)	  of	  each	  segment	  across	  a	  number	   of	   different	   data	   sets	   is	   shown.	   Overall,	   high	   p-­‐values	   are	   rarely	  observed	  where	  either	  the	  absolute	  mean	  ratio	  or	  the	  number	  of	  data	  points	  in	  a	  segment	   is	   high.	   This	   is	   expected	   as	   both	   the	  mean	   ratio	   and	   number	   of	   data	  points	  within	  a	  segment	  can	  act	  as	  proxies	  for	  segment	  quality	  in	  general.	  CNsolidate	  aims	  to	  achieve	  high	  sensitivity	  while	  allowing	  the	  accurate	  ranking	  of	   detected	   segments.	   The	   local	   significance	   (p-­‐value)	   is	   provided	   only	   as	   an	  additional	   detection	   filtering	   option.	  We	   suggest	   that	   the	  weighted	   confidence	  score	  (wscore)	  should	  be	  used	  as	  the	  primary	  filtering	  value.	  
Score	  Calibration	  Using	  the	  detection	  scores	  defined	  above	  it	  is	  possible	  to	  rank	  detections	  within	  individual	  data	  sets.	  However,	  in	  some	  cases,	  it	  may	  still	  not	  be	  possible	  to	  set	  a	  single	  cut-­‐off	  to	  yield	  a	  certain	  level	  of	   ‘truth’	  across	  large	  numbers	  of	  data	  sets	  displaying	  variable	  qualities.	  To	  address	  this	  we	  have	  included	  a	  semi-­‐automated	  score	  calibration	  method	  which	  allows	  the	  score	  to	  be	  calibrated	  across	  data	  sets	  based	  on	  a	  desired	  level	  of	  truth.	   	  To	  use	  this	  adjustment	  strategy	  one	  needs	  to	  first	  define	  both	  a	  measure	  of	  truth	  and	  an	  ’estimator’.	  These	  can	  then	  be	  used	  in	  concert	   to	   approximate	   an	   adjustment	   function,	   allowing	   a	   single	   cut-­‐off	   to	   be	  defined	  on	  the	  ’filter’	  values	  to	  achieve	  a	  certain	  level	  of	  truth	  across	  data	  sets.	  
Score	  Adjustment	  For	   the	   adjustment	   to	   approximate	   a	   baseline	   truth	   level	   across	   different	  estimator	  backgrounds	  we	  fit	  curves	  describing	  the	  behaviour	  of	  the	  truth	  vector	  compared	  to	  the	  filter	  vector	  for	  all	  estimator	  levels.	  First,	  we	  fit	  a	  polynomial	  regression	  using	  the	  general	  model:	  !(!) = !! + !!! + !!!! + !!!!+,… , !!!!	   [2-­‐33]	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where	  !(!) 	  is	   the	  filter	  value	  at	  truth	   level	  t,	  x	   is	   the	  estimator	   level	  and	  n	  equal	  the	  maximum	  order	  of	  the	  polynomial.	  	  Next,	  we	  define	  the	  polynomial	  function	  !!	  as:	  !{!} = !!!! + !!!!!!!!+,… ,+!!!! + !!! + !!	   [2-­‐34]	  where	   x	   equal	   the	   estimator	   level,	  !!,!!,!!,… ,!! 	  are	   the	   constant	   coefficients	  obtained	  from	  !{!} 	  and	  n	  is	  the	  maximum	  order	  of	  the	  polynomial.	  	  Finally,	   we	   iterate	   over	   each	   discrete	   truth	   value	   t	   across	   the	   truth	   measure	  range	  T	  to	  define	  a	  vector	  of	  functions	  V:	  !! = !!:∀! ∈ !	   [2-­‐35]	  In	  other	  words,	  we	  derive	  a	  set	  of	  functions	  describing	  the	  filter	  value,	  across	  the	  given	  estimator	  background,	  across	  the	  given	  truth	  measure	  range.	  	  This	  general	  approach	  can	  be	  applied	  to	  any	  combination	  of	  truth,	  filter	  and	  estimator	  vectors	  to	  approximate	  the	  filter	  value	  needed	  to	  obtain	  a	  certain	   level	  of	   truth	  at	  each	  discrete	  estimator	  value.	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2.2.2	   Copy	  Number	  Tagging	  SNPs	  
Assay	  Selection	  A	  relatively	  small	  number	  of	  previously	  published	  studies	  [50,	  104]	  on	  CNV	  have	  reported	  the	  observation	  that	  particular	  copy	  number	  variable	  regions	  (CNVRs)	  can	  be	  ’tagged’	  by	  a	  particular,	  normally	  nearby,	  SNP.	  During	   the	   design	   of	   the	   DDD	   array-­‐CGH	   arrays	   we	   have	   included	   30	   three	  component	   ’SNP-­‐tagged’	   CNVRs	   from	   a	   study	   into	   population	   CNVs	   [50],	  additionally	  we	  have	  added	  the	  30	  SNP	  locations	  to	  the	  Sanger	  sample	  tracking	  system	  (sample	  logistics)	  via	  a	  custom	  Sequenom	  plex.	  This	  allows	  the	  required	  information	  to	  be	  generated	  such	  that	  the	  array-­‐CGH	  data	  can	  be	  correlated	  with	  the	  assay	  run	  when	  the	  sample	  enters	  the	  building	  (sample	  logistics).	  
Copy	  Number	  Assignment	  A	  CNV	  tagging	  SNP	  can	  be	  defined	  as	  a	  SNP	  genotype	  (or	  genotypes)	  that	  occurs	  at	  the	  given	  SNP	  location	  in	  the	  presence	  of	  a	  particular	  copy	  number	  state	  (or	  states)	   at	   the	   given	   CNVR	   more	   often	   than	   can	   be	   expected	   by	   chance.	  Correlating	  the	  observed	  SNP	  genotypes	  and	  copy	  number	  states	  for	  a	  given	  SNP	  and	   CNVR	   pair	   needs	   to	   be	   treated	   as	   a	   probabilistic	   estimate	   rather	   than	   the	  binary	  classification	  used	  for	  the	  sequencing	  and	  genotyping	  data	  tracking.	  This	  is	  mainly	  due	   to	   the	   fact	   that	   the	   frequency	  of	  observing	  a	  combination	  of	  SNP	  genotypes	  and	  copy	  number	  states	  at	  each	  given	  CNVR	  may	  not	  be	  observed	  at	  the	  same	  rate	  in	  all	  training	  data	  sets.	  The	  first	  critical	  step	  is	  to	  assign	  a	  copy	  number	  state	  to	  each	  SNP-­‐tagged	  CNVR	  for	   any	   given	   array-­‐CGH	   data	   set.	   Each	   such	   CNVR	   contains	   three	   probes	  replicated	   five	   times	  on	  each	  of	   the	  DDD	  array-­‐CGH	  array	  designs.	  To	  estimate	  the	   point	   at	  which	   copy	   number	   states	   change	   (log2	   ratio	   space)	  we	   used	   the	  mixture	  model	  based	  approach	  available	  within	   the	  CNVtools	  R	  package	   [103].	  CNVtools	  uses	   t-­‐distributions	   to	  define	  a	  number	  of	  components	   from	  an	   input	  data	  distribution.	  
Log2	  Ratio	  Clustering	  To	  define	  copy	  number	  state	  boundaries	  we	  applied	  the	  mixture	  model,	  based	  on	  t-­‐distributions,	  from	  CNVtools	  to	  the	  mean	  log2	  ratio	  for	  each	  of	  845	  DDD	  control	  data	  sets	  at	  each	  of	  the	  30	  SNP-­‐tagged	  CNVRs.	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  Figure	   2-­‐5	   Copy	   number	   state	   genotyping.	   Left	   -­‐	   Example	   of	   a	   ‘well-­‐clustered’	  CNVR.	  Right	  -­‐	  Example	  of	  a	  ‘poorly-­‐clustered’	  CNVR.	  Above	  (see	  Figure	  2-­‐5)	  are	  histograms	  showing	  two	  CNVRs	  included	  on	  the	  DDD	  array	  designs.	  For	  each	  CNVR	  the	  mean	   log2	  ratio	   for	  each	  control	   sample	  and	  the	   estimated	   copy	   number	   state	   boundaries	   are	   plotted.	   CNVR26371	   (left)	  displays	  a	  large	  dynamic	  range	  and	  well-­‐defined	  copy	  number	  state	  boundaries	  whereas;	   CNVR15591	   (right)	   displays	   a	   poor	   dynamic	   range	   and	   less	   accurate	  state	  classification.	  
Bayesian	  Approach	  to	  Data	  Tracking	  To	  generate	  a	  probabilistic	  measure	  of	  ‘sample	  similarity’	  for	  data	  tracking	  in	  the	  array-­‐CGH	   analytical	   pipeline	   we	   calculate	   the	   probability	   of	   observing	   copy	  number	  states	  given	  the	  observed	  genotypes	  using	  a	  Bayesian	  approach.	  For	  each	  CNVR:	   ! ! ! = ! ! ! !(!)!(!) 	   [2-­‐36]	  	  where,	  s	  is	  the	  estimated	  copy	  number	  state	  and	  g	  is	  the	  genotype.	  Then,	  for	  the	  overall	  measure:	  ! ! ! = !(!|!)! + !(!|!)!+,… ,+!(!|!)!! 	   [2-­‐37]	  	  where,	   S	   is	   all	   estimated	   states,	   G	   is	   all	   observed	   genotypes	   and	   n	   equal	   the	  number	  of	  CNVRs	  included.	  During	   the	   calculation	   of	   the	   overall	   similarity	   measure	   P(S|G)	   there	   is	   the	  opportunity	   to	   incorporate	   some	   additional	   information	   (weighted	   mean),	   for	  example,	  a	  measure	  of	  how	  well	  each	  CNVR	  could	  be	  clustered.	  Note:	   the	   datasets	   used	   here	   often	   have	   relatively	   high	   numbers	   of	   missing	  values,	  to	  maintain	  a	  consistent	  scale	  we	  elected	  to	  use	  the	  mean	  in	  place	  of,	  for	  example,	  the	  product.	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Empirical	  Parameter	  Estimation	  To	   empirically	   derive	   the	   values	   of	   P(g),	   P(s)	   and	   P(g|s)	  we	   used	   1690	   DDD	  control	  data	  sets.	  These	  data	  sets	  were	  generated	  for	  both	  DDD	  array-­‐CGH	  array	  designs	   using	   845	   DNA	   samples	   from	   normal	   control	   individuals.	   	   Each	  individual	  was	  assigned	  a	  copy	  number	  state	  for	  each	  of	  the	  30	  included	  CNVRs	  and	  a	  SNP	  genotype	  from	  the	  appropriate	  tagging	  SNP.	  Then	  to	  define	  P(g)	  and	  
P(s)	  we	  simply	  determined	  the	  frequency	  of	  observing	  each	  genotype	  and	  state	  respectively,	  for	  each	  CNVR	  individually.	  To	   define	  P(g|s),	   for	   each	   CNVR	  we	   determined	   the	   frequency	   of	   observing	   all	  possible	  genotype	  /	  state	  pairs	  at	  each	  CNVR	  individually.	  	  	  	  
	  Figure	   2-­‐6	   Copy	   number	   state	   frequency	   estimates.	   Left	   -­‐	   Cluster	   plot	   of	  CNVR26371,	  Right	  -­‐	  P(g|s)	  for	  each	  copy	  number	  state	  of	  CNVR26371.	  	  	  Above	   (see	   Figure	   2-­‐6)	   are	   two	   plots	   showing	   the	   SNP-­‐tagged	   copy	   number	  variable	  region	  CNVR26371.	  The	  left	  panel	  shows	  the	  derived	  copy	  number	  state	  boundaries	   and	   displays	   a	   good	   dynamic	   range.	   The	   right	   panel	   shows	   the	  estimated	  values	  of	  P(g|s)	  for	  each	  copy	  number	  state.	  We	  can	  observe	  across	  the	  845	  DDD	  control	  samples	  that:	  
• The	   copy	   number	   state	   1	   is	   observed	   in	   concert	   with	   the	   SNP	  genotype	  AG	  100%	  of	  the	  time.	  
• The	   copy	   number	   state	   2	   is	   observed	   in	   concert	   with	   the	   SNP	  genotype	  GG	  the	  majority	  of	   the	   time,	  with	   the	  AG	  genotype	  having	  been	  observed	  in	  only	  a	  few	  cases.	  
• Copy	   number	   state	   3	   is	   more	   difficult	   to	   correlate	   with	   any	   SNP	  genotype,	   having	   shared	   its	   observations	   between	   the	   AA	   and	   GG	  genotypes.	  
Dynamically	  Updating	  Probabilities	  This	  method	  uses	  a	  dynamic	  update	  for	  the	  estimates	  of	  P(g),	  P(s)	  and	  P(g|s)	  as	  well	   as	   the	   definition	   of	   copy	   number	   state	   boundaries	   for	   each	   CNVR.	   The	  justification	   for	   this	   is	   that	   as	   the	   amount	   of	   data	   generated	   increases,	   the	  reliability	  of	  all	  these	  estimates	  should	  also	  increase.	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This	  is	  quite	  a	  heavy	  analysis	  as	  each	  DDD	  data	  set	  comprises	  of	  approximately	  two	   million	   data	   points	   and	   the	   total	   number	   of	   samples	   for	   the	   project	   is	  expected	  to	  be	  greater	  than	  10000.	  As	  a	  result	  every	  time	  an	  update	  is	  required,	  all	   data	   sets	   generated	   to	   date	  must	   be	   accessed	   and	   the	   relevant	   data	   points	  extracted	  to	  allow	  the	  required	  calculations.	  To	  allow	  this,	  and	  other	  analysis,	  to	  occur	   in	   a	   timely	   fashion	  we	   have	   developed	   a	   novel	   data	   accessing	   approach.	  These	   methods	   are	   available	   as	   a	   stand-­‐alone	   R	   package	   called	   Rbin	   with	   no	  external	  dependencies.	  This	  package	  makes	  use	  of	  methods	   that	   can	  write	  C++	  classes	   to	   file	   in	   binary	   format	   and	   allows	   super	   fast	   data	   extraction	   using	  random	  access.	   	  The	  novel	  part	  of	   this	  method	   is	   the	   fact	   that	  C++	  data	  classes	  are	  written	  out	  in	  binary	  format	  and	  a	  single	  index	  and	  lookup	  is	  used	  to	  access	  any	  data	  range	  across	  multiple	  data	  sets	  sequentially	  or	  in	  parallel.	  The	  results	  of	  these	   accesses	   can	   be	   returned	   directly	   as	   large	   matrices	   in	   R,	   directed	   to	  standard	  output	  or	  written	   to	  a	   specified	   filename.	  Furthermore,	  any	  new	  data	  format	   can	   be	   simply	   defined	   and	   an	   index	   created	   via	   a	   number	   of	   intuitive	  function	  calls	  within	  the	  R	  interface.	  Additionally,	  these	  methods	  do	  not	  depend	  on	   any	   pre-­‐existing	   package	   such	   as	   the	   Rcpp	   package	   and	   the	   Rbin	   interface	  between	  C++	  and	  R	  is	  direct	  and	  fast	  (native).	  To	   give	   an	   example	   of	   performance	   characteristics	   for	   the	   level	   of	   expected	  usage,	  running	  on	  a	  Intel	  (R)	  Xeon	  (R)	  2.83GHz	  CPU	  with	  2G	  RAM,	  to	  query	  a	  data	  range	  comprising	  of	  1,903	  data	  points	  across	  10,000	  data	  sets,	   the	  method	  will	  return	   a	   1903	   x	   10003	  matrix,	   containing	   19,035,709	   data	   points,	   to	   R	  within	  9.75	   seconds.	   To	   give	   an	   example	   of	   extreme	   usage,	   to	   query	   the	   entire	  chromosome	   1	   (172,380	   data	   points)	   across	   10,000	   data	   sets	   the	  method	  will	  return	   a	   172,380	   x	   10,003	  matrix,	   containing	   1,724,317,140	   data	   points,	   to	   R	  within	  17.42	  minutes.	  Both	  examples	  given	  here	  use	  the	  sequential	   file	  reads,	   the	  parallel	  data	  access	  methods	   can	   potentially	   deliver	   superior	   performance.	   However,	   due	   to	   the	  overall	  extreme	  speed	  of	  these	  methods,	  it	  is	  highly	  likely	  that	  the	  performance	  of	  file	  access	  on	  the	  file	  system	  itself	  will	  be	  the	  major	  speed-­‐limiting	  factor.	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2.2.3	   CNV	  Consensus	  Reference	  Set	  
Genome	  Builds	  &	  Data	  Sources	  All	   data	   sources	   denoted	   by	   *	   were	   obtained	   with	   GRCH36	   (hg18)	   genomic	  mapping	   co-­‐ordinates.	   These	   data	   sources	   were	   subsequently	   lifted	   over	   to	  GRCH37	   (hg19)	   using	   the	   UCSC-­‐Galaxy	   lift	   over	   tool	   [146].	   Additionally,	   some	  data	   sources	   contained	   pre-­‐merged	  CNV	   locations	  with	   frequency	   information,	  others	  contained	  pre-­‐merged	  CNV	  locations	  with	  no	  frequency	  information	  and	  some	  contained	  raw	  call	   lists	   from	   individual	   samples.	  For	  my	  purposes	   it	  was	  most	   useful	   to	   obtain	   the	   raw	   call	   list	   format	   since	   it	   provided	   the	   greatest	  flexibility	   when	   defining	   merged	   CNV	   positions,	   frequencies	   and	   types	   across	  study	  sets.	  
Included	  Data	  Sets	  
• 42	  Million	  study	  -­‐	  raw	  call	  lists*.	  
• 42	  Million	  study	  -­‐	  genotyped	  regions*.	  
• WTCCC	  study	  -­‐	  merged	  Affy6	  data	  set*.	  
• 1000	  Genomes	  pilot	  -­‐	  merged	  deletions*.	  
• 1000	  Genomes	  pilot	  -­‐	  tandem	  duplications*.	  
• DDD	  study	  -­‐	  national	  blood	  service	  controls.	  
• DDD	  study	  -­‐	  generation	  Scotland	  controls.	  
DDD	  Control	  CNV	  Calls	  The	   DDD	   arrays	   were	   designed	   against	   GRCH37	   (hg19)	   genomic	   mapping	  positions.	   Detections	   where	   made	   across	   the	   two	   DDD	   control	   sets	   using	  CNsolidate	  with	  default	   settings	  and	  no	  hard	  cut-­‐offs.	  Calls	  where	   then	   filtered	  based	  on	  two	  specific	  quality	  measures:	  
• Adjusted	  Wscore	  above	  0.5.	  
• Local	  pvalue	  below	  0.01.	  All	   filtered	   calls	   from	   the	   DDD	   control	   sets	   were	   merged	   into	   a	   single	   list	   of	  CNVEs	   using	   an	   iterative	   reciprocal	   overlap	   rule	   (see	   Below).	   This	   set	   of	  common	   DDD	   control	   CNVs	   was	   then	  merged	   with	   the	   CNV	   consensus	   set	   v1	  using	  the	  same	  approach.	  
CNV	  Merging	  -­‐	  Study	  Sets	  Copy	  number	  variable	  regions	  from	  the	  42M	  study	  were	  obtained	  in	  the	  form	  of	  raw	  call	  lists	  (CNVRs)	  with	  no	  frequency	  information.	  These	  CNVRs	  were	  merged	  into	   an	   individual	   set	   of	   non-­‐overlapping	   CNV	   events	   (CNVEs)	   containing	  frequency	   and	   ’state	   type’	   information	   using	   the	   same	   approach	   as	   the	   DDD	  CNVRs	  (see	  Below).	  
Raw	  Call	  Lists	  First,	  we	  define	   the	  binary	   relationship	  Re	   as	   a	  0.5	   reciprocal	  overlap	  between	  two	  features	  within	  a	  set.	  
• Chromosomes	  are	  analysed	  separately	  
• Raw	  call	  lists	  are	  merged	  using	  Re	  
• The	  first	  two	  CNV	  features	  observed	  to	  share	  Re	  are	  grouped	  to	  form	  an	  initial	  cluster	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• Furthermore	   any	   feature	   within	   the	   remaining	   chromosomal	   set	  displaying	   Re	   with	   any	   feature	   from	   within	   the	   cluster	   are	   also	  added.	  
• Finally,	   once	   no	   more	   feature	   displays	   the	   required	   Re,	   the	   break	  point	   positions	   for	   the	   cluster	   are	  defined	   to	   be	  0.9	   of	   the	   inner	   to	  outer	  break	  point	  distances	  within	  the	  cluster.	  Additionally	   each	   raw	   call	   is	   tagged	  with	   a	   type	   such	   that	   each	   resulting	   CNV	  location	  can	  maintain	  its	  ‘type	  state’.	  For	   example,	   where	   all	   raw	   calls	   contributing	   information	   to	   a	   particular	  genomic	  position	  are	  only	   type1,	   the	  resulting	  merged	  genomic	  position	   is	  also	  type1.	   Where	   locations	   are	   a	   mix	   of	   types	   the	   associated	   type	   states	   are	  maintained.	  During	  this	  analysis	  the	  individual	  types	  are	  defined	  as	  -­‐1,	  1	  or	  0	  to	  denote	  deletion,	  duplication	  and	  deletion	  /	  duplication	  status	  respectively.	  
Pre-­‐merged	  Data	  Sets	  
42M	  Genotyped	  Regions	  The	   42M-­‐genotyping	   study	   estimates	   a	   set	   of	   CNV	   genotypes	   (copy	   number	  states)	  across	  450	  samples	  for	  4978	  merged	  CNV	  regions	  (CNVRs).	  To	  generate	  the	  frequency	  information	  first	  we	  convert	  the	  CNV	  genotypes	  into	  a	  type	  state	  (either	   -­‐1,	  0	  or	  1)	  and	  simply	  count	   the	  number	  of	  samples	   that	  contributed	  to	  each	   type	   for	  each	  CNVR.	  Although	  the	  42M	  genotyped	  genomic	  study	   is	  based	  on	  a	  subset	  of	  the	  42M	  call	  list	  they	  are	  treated	  as	  a	  separate	  study	  due	  to	  the	  fact	  that	  it	  was	  run	  on	  a	  different	  array	  and	  used	  a	  different	  sample	  size.	  
WTCCC	  study	  Affy6	  For	   the	  WTCCC	   study	   a	   detailed	   list	   of	   merged	   CNV	   locations	   with	   frequency	  information	   and	   the	   raw	   call	   lists	   for	   all	   5,919	   samples	   included	   in	   the	   study	  were	  obtained.	  The	  above	  method	  was	  used	  to	  integrate	  the	  merged	  deletion	  and	  duplication	  CNVEs	   to	  define	   type	   states	  of	   -­‐1,	   0	   and	  1.	  Then	   the	  merged	  break	  points	  of	  0.9	  between	  the	  inner	  and	  outer	  break	  point	  locations	  for	  each	  feature	  were	   used	   to	   define	   the	   CNV	   locations.	   Additionally,	   if	   two	   (or	  more)	  merged	  CNV	   features	   from	   the	   affy	   CNVE	   sets	  were	  merged,	   creating	   a	   feature	   of	   type	  state	  0,	   the	  number	  of	  observations	   from	  each	  of	   the	  contributing	  CNVEs	  were	  summed	  to	  maintain	  the	  frequency	  information.	  
1000	  Genomes	  Pilot	  For	   the	   merged	   deletion	   set	   from	   the	   1000	   Genomes	   pilot	   project,	   a	   list	   of	  merged	   CNVRs	  with	   no	   frequency	   information	  was	   obtained.	   Therefore,	   while	  awaiting	  further	  information,	  we	  class	  each	  of	  these	  merged	  CNV	  locations	  as	  a	  singleton	   observation.	   The	   1000	   Genomes	   pilot	   tandem	   duplication	   data	  were	  not	  pre-­‐merged	  so	  we	  applied	  the	  same	  rules	  as	  for	  feature	  merging	  of	  the	  42M	  &	  DDD	  calls	  sets.	  
Assigning	  Common,	  Rare	  and	  Novel	  CNV	  Status	  The	   overall	   goal	   of	   the	   CNV	   consensus	   set	   is	   to	   enable	   CNV	   detections	   to	   be	  accurately	   assigned	   to	   one	   of	   either	   common,	   rare	   or	   novel	   frequency	   status	  types.	  This	  is	  initially	  for	  direct	  use	  in	  filtering	  patient	  CNV	  detections	  from	  the	  DDD	   project	   but	   could	   also	   be	   applied	   to	   any	   study	   of	   CNV	   where	   frequency	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information	  of	  commonly	  observed	  CNV	  locations	  are	  required.	  To	  this	  goal	  we	  provide	  two	  different	  approaches	  to	  CNV	  status	  assignment.	  
Approach	  1	  -­‐	  Individual	  CNVE	  Sets	  In	  this	  approach	  any	  ‘test’	  CNV	  location	  is	  compared	  against	  all	  individual	  CNVE	  sets	  from	  the	  CNV	  consensus.	  This	  allows	  for	  different	  parameters	  to	  be	  chosen	  for	  individual	  CNVE	  sets.	  For	   example,	   consider	   where	   two	   sets	   from	   the	   CNV	   consensus	   shows	   quite	  different	   CNV	   characteristics	   (e.g.	   affy	   vs.	   1Gdup).	   Using	   this	   approach	   has	   the	  benefit	   that	   different	   criteria	   for	   both	   defining	   similarity	   (overlap	   and	   type	  status)	   and	   frequency	   binning	   (which	   frequency	   relates	   to	   common,	   rare	   and	  novel)	  can	  be	  set	  for	  different	  CNVE	  sets.	  
Approach	  2	  -­‐	  Combined	  CNV	  Consensus	  Set	  In	  this	  approach	  all	  of	  the	  component	  CNVEs	  sets	  are	  merged	  into	  an	  overall	  CNV	  consensus	  track.	  We	  choose	  to	  treat	  all	  CNVE	  sets	  identically	  during	  the	  merging	  steps	  and	  applied	  the	  standard	  0.5	  reciprocal	  overlap	  and	  0.9	  break	  adjustment	  parameters.	  We	  choose	  the	  maximum	  frequency	  between	  the	  contributing	  CNV	  locations	   from	   the	   individual	   CNVE	   sets	   as	   the	   frequency	   estimation	   for	   the	  resulting	   merged	   CNV	   consensus	   location.	   Type	   states	   of	   -­‐1,	   0	   and	   1	   were	  maintained	  as	  previously	  mentioned.	  The	  major	  benefits	  of	  this	  method	  compared	  to	  approach	  1	  are:	  
• The	  CNV	  consensus	   set	   is	  now	  a	   single	  data	   source	   containing	  CNV	  positional,	  frequency	  and	  type	  information.	  
• The	  type	  state	  information	  is	  determined	  across	  sets	  so	  the	  CNV	  type	  definition	   is	  more	   accurate	   from	   the	   consensus	   than	   the	   individual	  CNVE	  sets.	  
• The	  break	  point	   information	  of	  merged	  CNV	   locations	   across	  CNVE	  sets	   is	   likely	   to	   be	   more	   accurate	   due	   to	   the	   larger	   number	   of	  observations	  contributing	  to	  the	  consensus	  CNV	  location.	  
• It	   is	  easier	  to	  maintain	  and	  distribute	  the	  CNV	  consensus	  set	   in	  this	  format.	  
• Adding	   extra	   information	   into	   the	   consensus	   is	   more	   straight	  forward	  and	  does	  not	  require	  extra	  code	  /	  parameter	  definitions	  to	  deal	  with	  new	  CNVE	  sets.	  
• The	  display	  of	  data	  as	  tracks	  in	  data	  browsers	  is	  more	  intuitive	  and	  easier	  to	  implement.	  The	   CNV	   consensus	   reference	   set	   can	   be	  made	   available	   in	   flat	   txt	   file	   format	  containing	   all	   the	   required	   information	   for	   use	   in	   filtering	   genomic	   variants.	  	  However,	  it	  is	  also	  contained	  inside	  the	  CNsolidate	  package	  along	  with	  a	  number	  of	   intuitive	   functions	   to	  allow	   filtering	  using	  a	  number	  of	  different	  approaches.	  	  For	   the	   DDD	   project	   there	   is	   a	   dedicated	   SQL	   analysis	   database	   which	   stores	  information	   about	   each	   analytical	   process	   as	   data	   runs	   through	   the	   pipelines.	  This	  database	  has	   a	  number	  of	   tables	   that	   relate	   to	   various	   flavours	  of	   variant	  filtering	  including	  the	  current	  CNV	  consensus	  reference	  set.	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2.2.3	   CNV	  Filtering	  	  
Overview	  We	  have	  developed	  a	  CNV	  ranking	  and	  prioritisation	  system	  in	  the	  DDD	  project	  for	   flagging	   CNVs	   of	   potential	   clinical	   relevance	   [147].	   A	  major	   element	   of	   the	  DDD	  project	  is	  to	  facilitate	  a	  genetic	  diagnosis	  for	  patients	  and	  families	  who	  have	  been	   recruited	   into	   the	   study.	  CNVs	  meeting	   certain	   criteria	   relating	   to	   clinical	  interest	  are	  flagged	  by	  an	  automated	  filtering	  system	  prior	  to	  being	  reviewed	  in	  detail	  during	  a	  weekly	  multidisciplinary	  reporting	  meeting.	  
DD	  Gene	  to	  Phenotype	  Database	  The	   CNV	   filtering	   pipeline	  makes	   use	   of	   a	   valuable	   resource	   called	   the	  DDG2P	  (dd	   gene	   to	   phenotype)	   gene	   list	   that	   is	   downloadable	   from	   the	   DECIPHER	  database.	   The	   DDG2P	   is	   a	   manually	   curated	   database	   of	   gene	   to	   phenotype	  relationships	   containing	   primarily	   genes	   with	   some	   association	   to	  developmental	   disorders.	   The	   database	   contains	   gene	   names,	   genetic	  mechanisms,	  mutation	  consequences	  and	  linked	  phenotype	  terms.	  Each	  DDG2P entry	   is	   placed	   into	   one	   of	   four	   possible	   categories	   [“Confirmed	   DD	   Gene	   “,	  “Probable	   DD	   gene	   “,	   “Possible	   DD	   Gene	   “,	   “Both	   DD	   and	   IF”]	   based	   on	   the	  amount	   of	   evidence	   available	   for	   the	   described	   association.	   Each	   gene	   is	  associated	  with	  specific	  developmental	  phenotypes	  or	  syndromes	  via	  particular	  genetic	   mechanisms	   (autosomal	   dominant,	   autosomal	   recessive	   and	   X-­‐linked)	  and	   mutation	   consequences	   of	   the	   gene	   product	   (loss	   of	   function,	   activating	  mutation,	  increased	  gene	  dosage,	  etc.)	  Using	  DDG2P	  enables	  any	  rare	  variant	  in	  known	  DD	  genes	  with	  a	  predictable	  effect	  on	  the	  gene	  product	  to	  be	  flagged	  on	  the	  basis	  of	  inheritance,	  genotype	  and	  likely	  mutational	  consequence.	  	  Not	   all	   variants	   in	   genes	   known	   to	  be	   in	   association	  with	   one	  or	  more	   genetic	  disorder	  result	  in	  the	  phenotypic	  display	  of	  the	  associated	  symptoms	  [148].	  One	  reason	   for	   this	   is	   that	   the	   specific	   genetic	  mechanism	   needs	   to	   be	   considered.	  Other	   reasons	   for	   can	   include	   more	   complex	   situations	   such	   as	   dosage	  compensation	  [149],	  partial	  penetrance	  [150]	  and	  digenic	  and	  polygenic	  effects	  [151].	   The	   linked	   phenotypes	   included	   in	   the	   DDG2P	   database	   use	   the	   human	  phenotype	  ontology	  (HPO)	  [152-­‐155]	  to	  describe	  phenotypic	  traits.	  The	  use	  of	  a	  standard	  ontology	  and	  vocabulary	  for	  describing	  patient	  symptoms	  is	  key	  to	  the	  accurate	  phenotyping	  of	  patients	  in	  DDD	  study.	  As	  patients	  are	  recruited	  into	  the	  DDD	  study	  across	  the	  24	  different	  regional	  genetic	  services	  and	  each	  centre	  has	  a	  number	  of	  practicing	  clinicians,	  differences	   in	  phenotyping	  detail	  and	  quality	   is	  unavoidable.	   By	   using	   a	   fixed	   ontology	   these	   differences	   are	   minimized	   by	  forcing	   everyone	   to	   follow	   the	   same	   fixed	   set	   of	   terms	   and	   avoid	   problems	  relating	   to	   free	   text	   parsing.	   Each	   entry	   in	   the	  DDG2P	   has	   a	   number	   of	   linked	  HPO	  terms	  believed	  to	  be	  in	  association	  with	  the	  variant	  in	  the	  gene,	  however	  it	  was	   decided	   not	   to	   include	   any	   phenotype	   matching	   in	   the	   filtering	   pipeline.	  Instead	  all	  variants	  matching	  the	  mode	  and	  mechanism	  in	  any	  of	  the	  confirmed	  and	  probable	  DDG2P	  entries	  are	   flagged.	  Such	  variants	  are	  normally	  of	  general	  clinical	  interest	  and	  therefore	  it	  is	  important	  to	  prioritise	  them	  for	  clinical	  review	  as	  subtle	  differences	  in	  patient	  phenotypic	  display	  may	  not	  always	  be	  recognized	  immediately	  by	  a	  referring	  clinician.	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Filtering	  Rules	  I	  have	  implemented	  a	  rule-­‐based	  approach	  to	  CNV	  filtering	  and	  prioritisation	  for	  clinical	  review.	  This	  filtering	  package	  includes	  three	  main	  steps:	  	  1 Sample	  and	  Call	  QC	  criteria	  	  2 Variants	  in	  Developmental	  disorder	  genes	  3 Variants	  of	  uncertain	  significance	  (VOUS)	  	  
Figure	  2-­‐7	  Flow	  diagram	  of	  the	  CNV	  filtering	  pipeline	  rules.	  Above	   (see	   Figure	   2-­‐7)	   shows	   an	   overview	   summary	   of	   the	   CNV	   filtering	  pipeline	  for	  flagging	  CNVs	  of	  potential	  clinical	  relevance.	  	  White	  boxes	  denote	  QC	  steps,	  Blue	  boxes	  denote	  CNV	  call	   filtering	  steps,	  pink	  boxes	  show	  steps	  where	  samples	   and	   calls	   are	   removed,	   green	   boxes	   denote	   areas	   where	   reporting	   of	  variants	   become	   possible	   and	   orange	   denotes	   area	   where	   a	   manual	   review	   is	  required.	  	  
Sample	  and	  Call	  Quality	  Control	  	  Every	   dataset	   run	   through	   the	   CNV	   clinical	   filtering	   pipeline	   needs	   to	   pass	   a	  number	  of	  quality	  control	  (QC)	  parameters.	  Most	  importantly	  the	  dataset	  needs	  to	   pass	   the	   CNV	   sample-­‐dataset	   tracking	  method	   previously	   described.	   This	   is	  the	  most	  important	  QC	  step	  and	  ensures	  that	  the	  dataset	  under	  consideration	  is	  linked	  to	  the	  correct	  patient	  sample.	  On	  top	  of	  the	  data	  tracking	  QC	  a	  number	  of	  data	   quality	   QC	   checks	   are	   applied	   to	   ensure	   adequate	   data	   reliability.	   For	   all	  datasets	   the	   data	   quality	   QC	   is	   applied	   as	   an	   exclusively	   post	   CNV	   detection	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method.	   Perhaps	   the	   most	   informative	   predictions	   of	   CNV	   call	   quality	   for	   an	  entire	  sample	  can	  be	  assessed	  only	  once	  CNV	  detection	  has	  actually	  taken	  place.	  For	   sample	  QC	  we	  use	  an	  exclusively	  post-­‐calling	  approach	  and	  apply	  a	   robust	  clustering	  algorithm	  (“aberrant”)	  for	  outlier	  identification	  and	  exclusion	  [156]	  to	  the	   total	   number	   of	   passed	   CNVRs	   per	   sample	   and	   the	   proportion	   of	   passed	  novel	   CNVRs	  per	   sample.	  We	  define	   novel	   as	   CNVRs	   that	   do	  not	   share	   greater	  than	   80%	   of	   their	   boundaries	   with	   a	   copy	   number	   event	   (CNVE)	   of	   the	   same	  type,	   deletion	   or	   duplication,	   contained	   within	   the	   CNV	   Consensus	   list.	   Each	  array-­‐CGH	  sample	   is	  made	  up	  of	   two	  slides	  (2x	  1	  Million	  probe	  Agilent	  arrays)	  and	  any	  slides	  defined	  as	  outliers	  by	   the	  aberrant	   clustering	  method	  are	   failed	  and	  where	   either	   slide	   fails	   for	   a	   sample	   the	   overall	   sample	   is	   also	   failed	   (see	  
Figure	  2-­‐8).	  	  	  
	  Figure	   2-­‐8	   The	   number	   of	   CNV	   calls	   per	   array-­‐CGH	   slide	   vs.	   the	   proportion	   of	  novel	  CNV	  calls	  per	  slide.	  	  	  Above	   (see	   Figure	   2-­‐8)	   the	   results	   of	   applying	   the	   abberant	   method	   to	   the	  number	   of	   CNV	  detections	   against	   the	   proportion	   of	   novel	   CNV	  detections	   per	  slide	  is	  shown.	  Data	  points	  shown	  in	  red	  are	  assigned	  outlier	  status	  by	  abberant	  and	  are	  failed.	  For	  each	  sample,	  if	  either	  array-­‐CGH	  slide	  fails	  data	  quality	  QC	  the	  entire	  sample	  is	  failed	  and	  a	  repeat	  array-­‐CGH	  experiment	  is	  requested.	  Additionally	  further	  exclusions,	  at	  the	  sample	  level,	  are	  applied,	  based	  on	  a	  low	  sensitivity	   cut-­‐off	   of	   less	   than	   40	   QC	   passed	   detections	   and	   a	   deletion	   /	  duplication	   ratio	   of	   greater	   than	   10.	   Finally	  we	   use	   the	   data	   tracking	   check	   to	  ensure	   that	   the	   CNV	   data	   is	   consistent	   with	   the	   Sequenom	   data	   linked	   to	   the	  same	  sample	  identifier.	  Using	  the	  28	  copy	  number	  tagging	  SNPs	  allows	  the	  array-­‐CGH	  data	   to	  be	   correlated	  with	   the	  SNP	  genotypes	  obtained	  via	   the	  Sequenom	  assay	   run	   at	   sample	   reception.	   Both	   slides	   on	   the	   array-­‐CGH	   platform	   contain	  dedicated	  probes	  tiling	  the	  28	  CNVRs	  tagged	  by	  SNPs	  present	  on	  the	  Sequenom	  assay.	  First,	  CNVtools	  [103]	  is	  used	  to	  assign	  a	  copy	  number	  state	  to	  each	  SNP-­‐tagged	  CNVR	  and	  the	  probability	  of	  observing	  all	  copy	  number	  states	  (array-­‐CGH	  data)	   given	   all	   observed	   genotypes	   (Sequenom	   data)	   is	   calculated	   using	   the	  Bayesian	  framework	  previously	  described.	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For	  call	  QC	  of	  the	  array-­‐CGH	  data	  we	  apply	  the	  recommended	  detection	  quality	  filtering	   criteria	   from	   CNsolidate,	   comprising	   of	   a	  wscore	   above	   0.5,	   a	   p-­‐value	  below	  0.01,	  and	  the	  mean	  log2	  ratio	  below	  -­‐0.41	  for	  deletions	  and	  above	  0.36	  for	  duplications	  when	  passing	  individual	  CNV	  calls.	  	  A	   number	   of	   additional	   call	   QC	   parameters	   for	   CNVs	   applied	   to	   the	   clinical	  filtering	   pipeline	   are	   applied.	   All	   CNVs	   applied	   to	   the	   clinical	   filtering	   pipeline	  must	  be	   rare	   and	  exonic;	  we define rare as CNVRs that do not share greater than 
80% of their boundaries with a copy number event (CNVE) of the same type, deletion 
or duplication, observed at more than 1% in the CNV	  Consensus	  list.	  To	  determine	  whether	  a	  CNV	  is	  exonic,	  i.e.	  contains	  at	  least	  one	  exon	  within	  its	  boundaries,	  we	  use	  the	  GENCODE	  [139]	  gene	  set	  (version	  17).	  CNVs	  are	  defined	  as	  exonic	   if	  at	  least	   one	   exon	   from	   version	   17	   of	   the	   GENCODE	   gene	   list	   overlaps	   the	   CNVs	  boundaries	  by	  at	  least	  1	  base	  pair	  (any	  overlap).	  	  Finally	   a	   stringent	   quality	  measure	   to	  CNV	   calls	   that	  we	   term	   the	  MADR	   (mad	  region)	  is	  applied,	  the	  MADR	  is	  a	  measure	  of	  the	  relative	  difference	  in	  response	  (mean	   log2	   ratio)	   and	   regional	   noise	   (MAD)	   across	   samples.	   To	   calculate	   the	  MADR	  value	  estimate	  the	  noise	  of	  the	  CNV	  region	  across	  samples	  is	  needed.	  To	  do	  this	  we	  make	  use	  of	  the	  “Rbin”	  fast	  data	  access	  package	  previously	  described.	  For	   each	   detected	   CNV	   	   the	   log2	   ratio	   values	   for	   each	   probe	   within	   the	   CNV	  across	  all	  array-­‐CGH	  datasets	  available	  are	  extracted.	  Then	  the	  mean	  log2	  ratio	  (meanl2r)	   for	   each	   sample	   is	   used	   to	   calculate	   the	   median	   absolute	   deviation	  (MAD)	  of	  the	  mean	  log2	  ratio	  value	  across	  samples.	  This	  results	  in	  a	  single	  cross	  sample	   noise	   measure	   (mad_region)	   for	   each	   CNV.	   The	   MADR	   value	   is	   then	  calculated	  thus:	   !"#$ = !"#( !"#$%2!!"#_!"#$%&)	   [2-­‐38]	  	  The	  MADR	  value	  acts	  as	  a	  stringent	  cut-­‐off	  on	  CNV	  call	  quality	  and	  also	  as	  a	  proxy	  for	  common	  variation.	  It	  is	  a	  measure	  of	  the	  relative	  difference	  in	  probe	  response	  (mean	  log2	  ratio)	  and	  regional	  noise	  (MAD)	  across	  samples.	  CNV	  calls	  with	  high	  MADR	   values	   are	   far	   away	   from	   the	   background	   noise	   of	   the	   region	   and	   are	  highly	  likely	  to	  be	  genuine	  CNV	  events.	  Furthermore	  CNV	  regions	  with	  high	  noise	  across	   samples	   are	   likely	   to	   contain	   relatively	   large	   numbers	   of	   common	   CNV	  events.	   These	   regions	   may	   not	   always	   be	   included	   in	   the	   CNV	   consensus	  reference	  set	  in	  high	  enough	  numbers	  to	  be	  classed	  as	  a	  common	  CNV	  region	  so	  this	   additional	   stringent	   QC	   measure	   may	   also	   filter	   out	   poorly	   understood	  common	  CNV	  regions.	  	  As	   implied	  this	  additional	  QC	  measure	  has	  high	  stringency	  and	  may	  filter	  out	  a	  number	   of	   interesting,	   clinically	   relevant	   CNV	   events,	   however	   the	   decision,	   in	  the	  first	  instance,	  was	  to	  be	  very	  cautious	  for	  flagging	  CNVs	  of	  potential	  clinical	  interest.	  However	  the	  clinical	  filtering	  pipeline	  has	  been	  designed	  to	  be	  iterative	  in	  nature	  and	  can	  be	  easily	  rerun	  with	  different	  parameter	  definitions.	  
Flagging	  CNVs	  for	  Clinical	  Review	  To	  assign	  a	  filter	  status	  for	  CNVs	  and	  flag	  potentially	  clinically	  relevant	  CNVs	  for	  clinical	   review	  we	   need	   some	   specific	   information	   about	   the	   sample,	   CNV	   and	  gene.	   Due	   to	   the	   fact	   that	   no	   phenotype	   matching	   (HPO	   terms)	   is	   being	  
	   68	  
attempted	  the	  only	  sample	  level	  information	  needed	  is	  the	  stated	  gender	  of	  the	  sample.	  To	  obtain	  this	  information	  the	  sample	  ID	  (sanger_id)	  is	  used	  to	  query	  the	  DDD	  LIMS	  system	  to	  obtain	   the	  decipher_id	   (patient	   identifier	   for	   the	  decipher	  database),	   the	   stated	  gender	   is	   then	   compared	   to	   the	  genotyped	  data	   from	   the	  array-­‐CGH	   sample	   and	   if	   they	   match	   the	   filter	   will	   continue	   otherwise	   an	  automated	  email	  is	  sent	  to	  the	  DDD	  informatics	  team.	  The	  CNV	  level	  information	  is	  all	  contained	  within	  each	  CNV	  call	  and	  the	  gene	  level	  information	  is	  contained	  inside	  the	  DDG2P	  database.	  	  
Developmental	  Disorder	  Genes	  For	   flagging	   CNVs	   in	   DD	   genes	   we	   compare	   the	   mode	   and	   mechanism	   of	  confirmed	  and	  probable	  DD	  genes	   to	   the	   chromosome,	   copy	  number	   state	   and	  gender	  of	  rare,	  exonic	  QC	  passed	  CNV	  detections.	  	  Table	  2-­‐1	  Shows	  the	  rule-­‐based	  approach	  to	  CNV	  filtering	  for	  clinical	  relevance	  based	  on	  the	  DDG2P	  gene	  list.	  	  
CHR CNS SEX MODE MECH 
1,24 0 M,F Biallelic Uncertain, Loss of Function, Dominant Negative 
1,24 0,1 M,F Monoallelic Uncertain, Loss of Function, Dominant Negative 
1,24 >2 M,F Monoallelic Uncertain, Increased Gene Dosage 
23 0,1 M,F X-linked Dominant Uncertain, Loss of Function, Dominant Negative 
23 >2 M,F X-linked Dominant Uncertain, Increased Gene Dosage 
23 0,1 M Hemizygous Uncertain, Loss of Function, Dominant Negative 
23 >2 M,F Hemizygous Uncertain, Increased Gene Dosage 
	  The	   rules	  needed	   for	   flagging	  CNVs	  based	  on	   the	  DDG2P	  and	  CNV	  annotations	  can	  be	  collapsed	  into	  certain	  combinations	  of	  chromosomes,	  copy	  number	  states,	  modes	  and	  mechanisms	  (see	  Table	  2-­‐1).	  DD	  genes	  with	  a	  biallelic	  mode	  on	  any	  chromosomes,	  in	  both	  males	  and	  females	  with	  either	  uncertain,	  loss	  of	  function	  or	   dominant	   negative	   mechanisms	   are	   always	   flagged	   if,	   and	   only	   if,	   the	  estimated	  copy	  number	  state	  is	  zero	  (i.e.	  there	  is	  no	  predicted	  functional	  copy	  of	  the	  gene).	  For	  monoallelic	  DD	  genes	  firstly	  the	  rules	  are	  exactly	  the	  same	  except	  that	   single	   copy	   loss	   (heteroygous	   deletions)	   are	   also	   flagged.	   Secondly,	  monoallelic	  DD	  genes	  CNVs	  with	  a	  copy	  number	  state	  greater	  than	  2	  (gains)	  are	  flagged	   in	   they	   are	   found	   in	  DD	  genes	  with	   either	  uncertain	  or	   increased	   gene	  dosage	  mechanisms.	  DD	  genes	  with	  an	  X-­‐linked	  mode	  of	  action	  follow	  exactly	  the	  same	  rules	  as	  for	  monoallelic	  DD	  genes	  except	  clearly	  the	  CNV	  must	  be	  present	  on	   chromosome	  X.	   Finally	   for	  DD	  gene	  where	   the	  mode	  of	   action	   is	  defined	  as	  hemizygous,	  CNVs	  resulting	   in	  a	  predicted	  decrease	   in	  gene	  dosage,	   those	  with	  either	  uncertain,	  loss	  of	  function	  or	  dominant	  negative	  mechanisms,	  are	  flagged	  if	  the	  sample	  is	  male	  and	  if	  the	  copy	  number	  state	  is	  either	  zero	  or	  one	  (i.e.	  the	  predicted	   dosage	   of	   the	   gene	   has	   been	   decreased).	   Note	   that	   the	   reference	  sample	   is	   a	   pooled	   reference	  make	   up	   of	   500	  male	   individuals.	   For	   predicted	  gene	  dosage	   increases	   in	  hemizygous	  DD	  genes	  CNVs	   are	   flagged	   in	  both	  male	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and	  female	  samples	  if	  the	  copy	  number	  state	  is	  greater	  than	  2	  and	  the	  DD	  gene	  mechanism	  is	  either	  uncertain	  or	  increased	  gene	  dosage.	  	  
Variants	  of	  Uncertain	  Significance	  (VOUS)	  As	  well	  as	  flagging	  CNVs	  in	  genes	  whose	  function	  is	  well	  understood	  and	  which	  have	  been	  linked	  with	  developmental	  delay	  (DDG2P),	  CNVs	  whos	  contribution	  to	  clinical	  phenotypes	   is	  unclear	  are	  also	   flagged.	  The	  class	  of	  CNVs	   flagged	  using	  these	   rules	   are	   sufficiently	   rare	   in	   the	   general	   population	   such	   that	   they	   are	  normally	  of	  interest	  to	  the	  referring	  clinician	  even	  if	  their	  contribution	  to	  clinical	  phenotypes	   is	   poorly	   understood.	   To	   flag	   these	   types	   of	   variants	   a	   number	   of	  fixed	   cut-­‐offs	   on	   rarity	   and	   size	   given	   the	   inheritance	   classification	   for	   each	  detected	   CNV	   are	   used.	   As	   mentioned	   previously	   a	   cut-­‐off	   of	   less	   than	   1%	  population	  frequency	  is	  used	  to	  define	  CNVs	  as	  rare	  and	  additionally	  the	  MADR	  values	  are	  used	  as	  a	  CNV	  call	  quality	  measure	  and	  proxy	  for	  common	  CNVs.	  	  Table	  2-­‐2	  Size	  cut-­‐offs	   for	  different	  CNV	   inheritance	  classifications	  and	  parent-­‐affected	  states.	  	  
Inheritance Parents Affected CNV Size (Kb) 
paternal Father DEL=100, DUP=250 
maternal Mother DEL=100, DUP=250 
de novo Any DEL=100, DUP=250 
biparental Any DEL=100, DUP=250 
unknown Any DEL=500, DUP=500 	  For	  all	  rare	  CNVs	  detected	  we	  apply	  three	  size	  cut-­‐offs	  based	  on	  the	  inheritance	  classification	   of	   the	   CNV	   (see	  Table	   2-­‐2).	   For	   all	   CNVs	  where	   the	   inheritance	  classification	   is	   unknown	   we	   use	   a	   fixed	   cut-­‐off	   of	   500kb	   and	   any	   rare	   CNVs	  (losses	  or	  gains)	  greater	  than	  500kb	  in	  length	  are	  flagged	  for	  clinical	  review.	  For	  CNVs	   where	   no	   informative	   inheritance	   classification	   was	   made,	   if	   the	  inheritance	   is	   ‘de	  novo’	   or	  biparental	   the	   fixed	  size	   cut-­‐off	  used	   for	  deletions	   is	  100kb	   whereas	   for	   duplications	   it	   is	   250kb	   and	   any	   rare	   de	   novo	  deletion	   or	  duplication	  greater	  than	  100kb	  or	  250kb	  in	  length	  respectively	  are	  flagged.	  For	  patients	   who	   have	   either,	   or	   both	   parents	   affected,	   paternal	   and	   maternal	  inherited	   CNVs	   can	   be	   flagged	   so	   long	   as	   the	   father	   or	   the	  mother	   is	   affected,	  respectively.	   If	   the	   inheritance	   is	   classified	   as	   biparental	   and	   both	   parents	   are	  affected.	   Additionally	   male	   patients	   CNVs	   on	   chromosome	   X	   classified	   as	  maternal	  are	  flagged	  irrespective	  of	  the	  mother’s	  affected	  status.	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2.3	   RESULTS	  
2.3.1	   CNsolidate	  
Naive	  Voting	  One	  obvious	  way	  to	  increase	  one’s	  belief	  that	  individual	  change	  point	  detections	  may	  be	  robust	   is	  to	  naively	  consider	  how	  many	  algorithms	  are	  in	  agreement	  at	  the	   given	   change	   point	   location.	   This	   is	   a	   major	   benefit	   when	   using	   multiple	  algorithms	   and	   can	   be	   classed	   as	   a	   type	   of	   voting	   system	   (naive	   voting	   in	   this	  case).	   The	   figure	   below	   (see	   Figure	   2-­‐9)	   shows,	   for	   eight	   algorithms,	   the	  relationship	   between	   the	   number	   of	   algorithms	   that	   are	   in	   agreement	   and	   an	  estimate	  of	   the	  Type	   I	   and	  Type	   II	   error	   rates	   for	  all	  detections	  made	  across	  a	  single	  data	  set.	  	  
	  Figure	  2-­‐9	  Naive	  Voting	  Example	   -­‐	  CNsolidate	  version	  1.	  The	  background	  color	  denotes	  where	  detections	  were	  made	   (grey)	   and	  where	   they	  were	  not	   (black).	  The	  white	  line	  shows	  the	  number	  of	  algorithms	  in	  agreement,	  ranging	  from	  1-­‐8,	  left	   to	   right.	  The	   red	   line	   is	  an	  estimate	  of	   the	  Type	   I	   error	   rate	  using	   the	  CNV	  consensus	  set	  as	  the	  gold	  standard.	  The	  blue	  line	  is	  an	  estimate	  of	  the	  sensitivity	  assuming	  that	  all	  detections	  equal	  a	  sensitivity	  of	  1.	  The	  yellow	  line	  represents	  the	  size	  of	  the	  detection	  and	  the	  green	  line	  the	  mean	  log2	  ratio	  (response).	  The	  dashed	  red	  line	  shows	  the	  point	  on	  the	  graph	  were	  the	  FPR	  is	  closest	  to	  0.05.	  The	  algorithms	  are	  ranked,	   top	  to	  bottom,	  based	  on	  the	  total	  agreement	  across	  all	  detections	  (see	  Figure	  2-­‐9).	  This	  is	  an	  example	  of	  CNsolidate	  version	  1	  and	  in	  this	   case	   the	   recommended	  number	  of	   voters	   is	  3.	  CNsolidate	  version	  1	  uses	  a	  naive	  voting	  system,	  where	  all	  voters	  are	  considered	  to	  add	  equal	  weight	  to	  CNV	  detection	   call	   quality.	   	   Although	   this	   can	   be	   effective	   it	   is	   not	   the	   optimum	  approach	   to	   a	   voting	   system.	   Consider	   the	   case	   where	   one	   particular	   voter	  becomes	   unreliable	   given	   a	   particular	   class	   of	   data.	   Better	   to	   approximate	   the	  behaviour	   of	   each	   and	   every	   voter	   given	   certain	  measurable	   characteristics	   of	  the	  underlying	  data	  (‘expert	  voting’).	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Expert	  Voting	  The	  current	  version	  of	  CNsolidate	  uses	  an	  expert	  voting	  system	   in	  place	  of	   the	  naive	   approach.	   Rather	   than	   simply	   counting	   the	   number	   of	   algorithms	   in	  agreement	   at	   each	   change	   point	   detection,	   we	   derive	   a	   measure	   of	   detection	  quality	   (wscore).	   This	   value	   (wscore)	   is	   derived	   using	   the	   estimated	  performance	   of	   each	   algorithm	   given	   certain	   predictive	   variables	   that	   can	   be	  drawn	  from	  the	  input	  data	  characteristics	  (see	  Methods).	  	  
	  Figure	  2-­‐10	  Weighted	  Score	  vs.	  certain	  predictive	  variables.	  Top	  left	  -­‐	  wscore	  vs.	  number	   of	   probes.	   Top	   right	   -­‐	   wscore	   vs.	   size	   (bp).	   Bottom	   left	   -­‐	   wscore	   vs.	  	  absolute	  mean	  ratio.	  Bottom	  right	  -­‐	  wscore	  vs.	  number	  of	  algorithms.	  	  	  As	   indicated	   the	   wscore	   displays	   a	   range	   between	   0	   and	   1	   with	   increased	  detection	  quality	  tending	  towards	  1	  (see	  Figure	  2-­‐10).	  Although	  the	  number	  of	  algorithms	   in	  agreement	   is	   taken	   into	  account,	  due	  to	   the	  nature	  of	   the	  wscore	  calculation	   (weighted	   mean)	   the	   overall	   value	   is	   based	   on	   the	   estimated	  performance	   of	   each	   contributing	   algorithm	   given	   a	   number	   of	   predictive	  variables.	  Above	  (see	  Figure	  3.2)	  the	  raw	  (non-­‐adjusted)	  wscore	  plotted	  against	  a	   number	   of	   predictive	   variables	   is	   shown.	   Generally,	   as	   the	   wscore	   value	  increases	   so	   does	   the	   value	   of	   all	   predictive	   variables.	   This	   is	   expected	   as	   the	  predictive	   variables	   are	   thought	   to	   act	   as	   proxies	   for	   detection	   quality	   overall.	  However,	  there	  is	  some	  subtlety	  within	  the	  wscore	  values	  relating	  to	  individual	  algorithm	   performances	   given	   all	   the	   predictive	   values	   used	   during	   the	  calculation.	   We	   propose	   that	   this	   subtlety	   yields	   finer	   grain	   detection	   scoring	  than	  any	  of	  the	  individual	  predictive	  components	  individually.	  
Score	  Adjustment	  Having	   defined	   a	   detection	   quality	   measure	   (wscore)	   for	   CNV	   detection	   in	  individual	  data	  sets	  it	  is	  possible	  to	  calibrate	  the	  score	  across	  multiple	  data	  sets	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given	   some	  measure	   of	   ’truth’.	   To	   that	   goal	  we	   have	   developed	   an	   adjustment	  strategy	   (see	  Methods).	   	   Using	   this	  method	   it	   is	   possible	   to	   adjust	   the	  wscore	  values	  given	  any	  estimator	  value	  for	  any	  desired	  level	  of	  truth.	  
	  	  Figure	  2-­‐11	  Curves	  representing	  adjustment	  functions	  at	  discrete	  levels	  of	  truth	  using	  the	  dLRs	  noise	  value	  as	  the	  estimator.	  Predictor	  value	  (dLRs)	  vs.	  estimated	  wscore	  adjustment	  value.	  Above	   (see	   Figure	   2-­‐11)	   are	   some	   example	   curves,	   representing	   the	   derived	  adjustment	   functions	   for	   different	   levels	   of	   truth.	   In	   this	   example	   the	   total	  number	  of	  detections	  was	  used	  as	  the	  truth	  measure	  and	  a	  noise	  value	  (dLRs)	  as	  the	  estimator.	  The	  truth	  level	  is	  set	  at	  increments	  of	  1,	  between	  10	  and	  1200	  detections.	  	  Thus,	  for	  each	  of	  the	  functions,	  the	  truth	  baseline	  is	  relaxed	  across	  the	  noise	  range.	  The	  solid	  red	  line	  represents	  a	  truth	  baseline	  200	  detections.	  The	  default	  adjustment	  function	  within	  CNsolidate	  is	  based	  on	  a	  novelty	  target	  of	  0.25	   using	   the	   dLRs	   noise	   measure	   as	   the	   estimator.	   The	   different	   levels	   of	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’novelty’	  are	  defined	  via	  comparison	  against	  a	  gold	  standard	  reference	  set	  (CNV	  consensus	   set	   excluding	   the	   DDD	   controls)	   and	   the	   0.25	   novelty	   target	   is	   an	  adjustable	  parameter	  (see	  Figure	  2-­‐12).	  
	  	  Figure	  2-­‐12	  Applying	  different	  novelty	  targets	  to	  the	  DDD	  control	  data	  sets.	  Left	  -­‐	  Number	   of	   detections	   passing	   adjustment	   value	   vs.	   percentage	   novel.	   Right	   -­‐	  Histograms	   of	   percentage	   novel	   at	   three	   different	   adjustment	   function	   levels.	  Red	  -­‐	  0.4	  novelty	  target.	  Green	  -­‐	  0.3	  novelty	  target.	  Blue	  -­‐	  0.2	  novelty	  target.	  Above	   (see	  Figure	   2-­‐12)	   are	   plots	   showing	   the	  difference	  between	   applying	   a	  0.2,	   0.3	   and	   0.4	   novelty	   target	   to	   the	   845	   DDD	   control	   data	   sets.	   The	   novelty	  adjustment	   functions	  were	   defined	   using	   the	  DDD	   controls	   as	   the	   training	   set.	  Therefore	   it	   is	  not	   too	  surprising	   that	   the	  adjustment	   functions	  perform	  rather	  well,	  adjusting	  the	  majority	  of	  data	  sets	  close	  to	  the	  desired	  level	  of	  novelty.	  There	   is	   a	   certain	   degree	   of	   variance	   around	   each	   novelty	   target	   across	   the	  control	  data	  sets.	  This	  is	  expected	  as	  the	  adjustment	  function	  was	  defined	  using	  the	  data	  sets	  as	  a	  whole,	  not	  individual	  data	  sets.	  As	  the	  novelty	  target	  is	  relaxed,	  from	   0.2	   -­‐	   0.4,	   the	   variance	   in	   the	   number	   of	   detections	   across	   the	   data	   sets	  increase.	  This	   is	  not	  unexpected	  as	  by	   relaxing	   the	   truth	   target	   the	  adjustment	  functions	  are	  certain	   to	  become	   less	  reliable.	  This	   is	  due	  to	   the	   fact	   that,	   in	   the	  majority	   of	   cases,	   as	   truth	   targeting	   becomes	   more	   relaxed	   the	   number	   of	  options	  (wscore	  cut-­‐offs	  in	  this	  case)	  for	  individual	  data	  sets	  to	  reach	  the	  desired	  level	  of	  truth	  is	  likely	  to	  be	  increased.	  
Technical	  Replicates	  
Sample	  Selection	  A	  useful	  way	  to	  assess	  the	  consistency	  of	  any	  change	  detection	  method	  is	  to	  use	  technical	  replicates	  and	  look	  at	  concordance	  rates.	  In	  theory	  when	  the	  same	  DNA	  sample	   is	  applied	   to	  an	  assay,	  microarray	   in	   this	  case,	   the	  result	  of	  any	  change	  detection	  should	  be	  repeated	  across	  replicate	  experiments.	  Although	  there	  may	  be	   slight	   differences	   due	   to	   experimental	   factors	   or	   data	   artifacts	   the	   overall	  results	   should	   be	   consistent.	   The	   concordant	   results	   across	   replicate	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experiments	   of	   the	   same	   sample	   can	   be	   thought	   of	   as	   true	   detections	   or	   true	  positives	  (TP).	  To	  put	  it	  another	  way	  the	  discordant	  results	  can	  act	  as	  a	  proxy	  for	  the	  false	  positive	  (FP)	  rate.	  The	  DDD	  high	  thoughput	  array-­‐CGH	  laboratory	  makes	  use	  of	  a	  technical	  replicate	  in	  the	  form	  of	  the	  well	  known	  HapMap	  sample	  NA12878.	  This	  DNA	  sample	  has	  been	   used	   as	   a	   technical	   control	   in	   a	   number	   of	   previous	   studies	   [157-­‐162]	  including	  microarray	   and	   sequencing	   based	   projects.	   In	   the	  DDD	   the	   technical	  replicate	  NA12878	  is	  included	  on	  every	  96	  well	  plate	  and	  acts	  as	  a	  check	  for	  data	  quality.	   	  This	  sample	   is	  known	  to	  perform	  well	  on	  microarray	  assays	  and	  if	   the	  sample	   fails	  data	  QC	   this	   can	   indicate	   a	  problem	  with	   the	   entire	  plate.	   	  During	  this	   section	   we	   make	   use	   of	   50	   replicates	   of	   NA12878	   from	   both	   DDD	   array	  designs	   to	   allow	   us	   to	   estimate	   the	   false	   positive	   rate	   (or	   Type	   I	   error)	   for	  CNsolidate	   and	   its	   default	   8	   component	   algorithms	   (’voters’).	   These	   replicate	  data	   sets	  were	  not	   used	  during	   adjustment	   function	   training	   and	   so	   should	   be	  considered	  as	  a	  true	  test	  set.	  
False	  Positive	  Rate	  Estimation	  To	   enable	   an	   estimate	   of	   the	   false	   positive	   rate	   using	   technical	   replicates	   and	  allow	   us	   to	   plot	   receiver	   operator	   curves	   (ROC)	   two	   parameters	   need	   to	   be	  defined.	  A	  measure	  of	  truth	  and	  of	  segment	  similarity:	  
• A	   segment	   must	   be	   observed	   in	   at	   least	   80%	   of	   the	   technical	   replicates	  (40/50)	  to	  be	  classed	  as	  a	  true	  detection.	  
• Two	  segments	  must	  share	  a	  reciprocal	  overlap	  of	  0.5	  or	  greater	  to	  be	  classed	  as	  the	  same	  detection.	  This	   is	   a	   reasonably	   strict	   definition	   of	   truth	   and	   should	   ensures	   that	   the	  detections	  classed	  as	  true	  are	  highly	  reliable	  within	  the	  data	  set	  under	  question	  (50	   replicates	   of	   NA12878).	   All	   results	   described	   during	   this	   section	   use	   this	  definition	  of	  truth.	  
Component	  Algorithms	  The	   default	   option	   for	   CNsolidate	   is	   to	   use	   its	   eight	   highest	   performing	  algorithms	   for	   detection.	   The	   remaining	   four	   algorithms	   are	   considered	   to	   be	  less	  reliable	  and	  add	   little	  or	  nothing	   to	   the	  overall	  performance	  of	  CNsolidate.	  	  Additionally,	   running	   multiple	   algorithms	   has	   a	   cost	   in	   terms	   of	   speed	   and	  computational	   resources.	   This	   default	   option	   can	   easily	   be	   adjusted	  within	   the	  configuration	  settings	  for	  the	  CNsolidate	  package.	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  Figure	  2-­‐13	  ROC	  of	  CNsolidate	  and	  its	  default	  algorithms.	  False	  positive	  rate	  vs.	  true	  positive	  rate	  for	  the	  eight	  component	  algorithms.	  	  	  For	   any	   analysis	   of	   change	  detection	   the	  ultimate	   goal	   is	   to	  minimise	   the	   false	  positive	  rate	   (Type	   I	  error)	  while	  maximising	   the	   true	  positive	  rate	   (1-­‐	  Type	   II	  error).	   When	   looking	   at	   receiver	   operator	   (RO)	   characteristics,	   in	   general,	   an	  increased	  area	  under	   the	   curves	  denotes	   situations	   in	  which	  performances	  are	  improved.	  Above	   (see	   Figure	   2-­‐13)	   are	   RO	   curves	   for	   CNsolidate	   and	   each	   of	   its	   eight	  highest	  performing	  algorithms.	  CNsolidate	  displays	   superior	  RO	   characteristics	  compared	   to	   any	   of	   its	   component	   algorithms.	   Additionally,	   there	   are	   some	  differences	   in	   the	   RO	   performance	   of	   individual	   algorithms,	   however	   none	  display	  overall	  poor	  RO	  characteristics	   indicating	   that	  each	  algorithm	  has	  been	  reasonably	  well	  tuned.	  
RO	  Characteristic	  of	  the	  wscore	  CNsolidate	   aims	   to	   improve	   detection	   rates,	   allowing	   a	   larger	   number	   of	  detections	   to	   be	  made,	  while	   providing	   accurate	   ranking	   of	   detection	   qualities	  within	   and	   between	   data	   sets.	   To	   that	   goal	   we	   have	   developed	   the	   weighted	  confidence	  score	  (wscore).	  The	  overall	  aim	  of	  the	  wscore	  is	  to	  allow	  a	  single	  cut-­‐off	  to	  be	  set	  across	  multiple	  data	  sets	  to	  achieve	  a	  consistent	  level	  of	  truth.	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  Figure	  2-­‐14	  RO	  characteristic	  of	  CNsolidates	  wscore.	  False	  positive	  rate	  vs.	  True	  positive	  rate	  across	  the	  wscore	  space.	  Above	  (see	  Figure	  2-­‐14)	  shows	  the	  same	  ROC	  curve	  as	  figure	  2-­‐13	  however	  the	  colour	   of	   the	   line	   relates	   to	   the	   wscore	   and	   the	   dashed	   red	   line	   denotes	   the	  defined	   cut-­‐off	   (0.5	  wscore).	   The	   adjustment	   function,	   by	   definition,	   results	   in	  the	  wscore	  cut-­‐off	  being	  set	  at	  0.5.	  The	  scale	  of	  the	  wscore	  across	  the	  RO	  space	  is	  highly	   optimal,	  with	   increased	   values	  decreasing	   the	   false	  positive	   rate.	  As	   the	  cut-­‐off	  on	  the	  wscore	  is	  relaxed	  the	  true	  positive	  rate	  increases	  sharply	  while	  the	  false	  positive	  rate	  increases	  gradually.	  Using	  the	  defined	  cut-­‐off	  (0.5	  wscore)	  CNsolidate	  achieves	  a	  true	  positive	  rate	  of	  approximately	   0.8	   with	   a	   false	   positive	   rate	   of	   approximately	   0.05.	   During	  studies	   of	   CNV	   using	   microarray	   based	   assays	   a	   false	   positive	   rate	   of	   0.05	   is	  generally	   considered	   to	   be	   acceptable.	   Furthermore,	   in	   our	   hands,	   the	   overall	  concordance	   rate	   of	   any	   two	   replicate	   microarrays	   is	   approximately	   0.8,	  suggesting	  that	  the	  true	  positive	  rate	  reported	  here	  is	  close	  to	  optimal.	  
RO	  Characteristic	  of	  Other	  Predictive	  Variables	  An	  approach	  often	  taken	  to	  change	  point	  detection	  from	  microarray-­‐based	  data	  is	   to	   run	   an	   algorithm	   to	   detect	   variable	   data	   segments	   and	   then	   filter	   the	  detections	   based	   on	   various	   factors	   (e.g.	   mean	   ratio	   &	   number	   of	   probes).	  CNsolidate	   incorporates	   these,	   and	   other,	   variables	   into	   the	   calculation	   of	   the	  wscore.	  Below	  (see	  Figure	  2-­‐15)	  are	   further	  RO	  curves	  displaying	  the	  effect	  of	  using	  some	  different	  variables	  as	   the	  predictor	   for	   segment	  quality	   in	   terms	  of	  RO	  space.	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  Figure	  2-­‐15	  RO	  characteristic	  of	  wscore	  vs.	  some	  other	  variables.	  	  	  Clearly	  when	  looking	  at	  the	  RO	  characteristic	  of	  the	  variables,	  the	  wscore	  is	  best	  for	  predicting	  detection	  quality	  and	  displays	  the	  best	  performance	  across	  the	  RO	  space	   (see	  Figure	   2-­‐15).	   Interestingly	   the	  mean	   ratio	   displays	   rather	   poor	  RO	  characteristics	  with	  the	  false	  positive	  rate	  increasing	  rapidly	  above	  the	  0.2	  true	  positive	   rate.	   The	   number	   of	   data	   points	   (probes)	   seems	   to	   be	   a	   far	   better	  predictor	  of	  detection	  quality	  than	  the	  mean	  ratio.	  The	   naive	   voting	   system	   (number	   of	   algorithms)	   displays	   the	   second	   best	   RO	  characteristic.	  The	  difference	  between	  the	  number	  of	  algorithms	  and	  the	  wscore	  predictors	  denotes	  the	  improvement	  in	  detection	  quality	  scoring	  when	  using	  the	  expert	  compared	  to	  the	  naive	  voting	  systems	  within	  CNsolidate.	  This	  difference	  is	   a	   highly	   significant	   improvement.	   Furthermore,	   any	   improvements	   tending	  towards	  the	  upper	  end	  of	  the	  RO	  space	  (high	  performance)	  quickly	  become	  much	  harder	  to	  achieve.	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2.3.2	   Copy	  Number	  Tagging	  SNPs	  The	  method	  described	  earlier	  (see	  Methods)	  for	  the	  tracking	  of	  array-­‐CGH	  data	  is	   incorporated	   as	   a	   final	   check	   in	   the	   high-­‐throughput	   array-­‐CGH	   analytical	  pipeline	   for	   the	   DDD	   project.	   This	   is	   the	   last	   chance	   available	   to	   detect	   any	  tracking	  problems	  during	  the	  sample	  or	  data	  flow	  throughout	  the	  experimental	  and	  analytical	  pipelines.	  
Sample	  Swap	  Detection	  	  
	  Figure	  2-­‐16	  Data	  Tracking	  Values	  vs.	  Noise	  in	  the	  DDD	  Control	  Data	  Sets.	  	  Left	  -­‐	  DDD	   array	   design1.	   Right	   -­‐	   DDD	   array	   design2.	   Red	   -­‐	   Potentially	   mismatched	  samples.	  Above	  (see	  Figure	  2-­‐16)	  are	  plots	  for	  the	  data	  tracking	  values,	  P(S|G),	  against	  a	  measure	  of	  data	  noise	  (dLRs)	  across	  all	  DDD	  control	  samples	  for	  both	  DDD	  array	  designs.	   The	   majority	   of	   data	   sets	   display	   a	   posterior	   probability	   of	   a	   sample	  match	  of	  greater	  than	  0.8.	  There	  is	  a	  clear	  trend	  displayed	  that	  when	  data	  noise	  levels	   increase	   (larger	   values	   of	   the	   dLRs	   measurement)	   the	   posterior	   data	  tracking	  values	   tend	   to	  decrease.	  This	   is	  understandable	  as	   the	   tracking	  values	  rely	   on	   an	   accurate	   estimate	   of	   copy	   number	   state,	   derived	   for	   the	  mean	   log2	  ratio,	   at	  a	  number	  of	  different	  CNVR	   locations.	  As	   the	  variance	  of	  all	   log2	  ratio	  values	   increase	   (increased	   noise)	   the	   estimate	   of	   copy	   number	   state	   becomes	  less	   reliable.	   The	   two	   data	   sets	   highlighted	   with	   a	   red	   cross	   are	   samples	   that	  were	  previously	  flagged	  by	  the	  laboratory	  as	  a	  potential	  sample	  swap.	  
Sample	  Swap	  Resolution	  The	  two	  data	  sets	  (samples)	  highlighted	  previously	  both	  display	  only	  moderate	  noise	  measurements	  (dLRs	  <	  0.2)	  however	  the	  data	  tracking	  values	  in	  both	  cases	  are	  low	  (posterior	  probability	  <	  0.6).	  Additionally	  there	  was	  a	  mismatch	  between	  the	  expected	  gender	  and	   that	   reported	   from	  the	  array	   (derived	   from	  the	  mean	  log2	  ratio	  on	  the	  X	  chromosome)	  in	  both	  cases.	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  Figure	   2-­‐17	   Swapping	   the	   aCGH	  data	   for	   two	  potentially	  mismatched	   samples.	  	  Left	  -­‐	  DDD	  array	  design1.	  Right	  -­‐	  DDD	  array	  design2.	  Red	  -­‐	  Potential	  mismatched	  samples.	  Normally,	  samples	  failing	  the	  tracking	  values	  but	  passing	  all	  other	  QC	  (e.g.	  	  data	  noise	  levels)	  would	  be	  failed	  immediately	  and	  a	  new	  sample	  would	  be	  requested.	  However,	  due	  to	  both	  the	  fact	  that	  these	  are	  control	  samples	  (not	  to	  be	  reported	  to	   the	  clinical	   teams)	  and	  that	   the	  samples	  were	   flagged	  by	   the	   laboratory	  as	  a	  potential	  sample	  swap	  it	  was	  possible	  to	  resolve	  the	  swap	  using	  the	  data	  tracking	  method.	  To	  do	   this	  we	   simply	   swapped	   the	   sample	   IDs	   for	   the	  array-­‐CGH	  data	  and	  re-­‐run	  the	  data	  tracking	  approach	  (see	  Figure	  2-­‐17).	  This	  process	  extracts	  the	   SNP	   genotypes	   typed	   on	   the	   Sequenom	   assay	   in	   sample	   logistics	   from	   an	  oracle	  database	  and	  then	  compares	  the	  SNP	  genotype	  against	  the	  estimated	  copy	  number	  state	  at	  each	  of	  the	  CNVRs	  using	  the	  method	  described	  previously	  (see	  
Methods).	   As	   a	   result	   of	   switching	   the	   sample	   IDs	   on	   the	   array-­‐CGH	  data	   sets	  above,	  the	  data	  tracking	  values	  were	  increased	  above	  the	  defined	  cut-­‐off	  and	  the	  reported	   genders	   were	   no	   longer	   mismatched.	   This	   example	   acts	   as	   a	   nice	  positive	   control	   and	   demonstrates	   the	   utility	   of	   the	   data	   tracking	   method	   of	  resolving	  sample	  swaps	  based	  on	  CNV	  tagging-­‐SNPs.	  
Sample	  Swap	  Discrimination	  Having	  developed	  the	  previously	  mentioned	  method	  for	  array-­‐CGH	  data	  tracking	  it	  is	  necessary	  to	  define	  a	  cut-­‐off	  on	  the	  tracking	  values	  to	  discriminate	  between	  a	   sample	  match	   and	   a	   sample	  mismatch.	   To	   do	   this	   the	  DDD	   control	   data	   sets	  were	  used	  to	  look	  at	  the	  difference	  and	  discrimination	  power	  of	  the	  data	  tracking	  values	  by	  generating	  a	  real	  and	  a	  null	  distribution	  of	  tracking	  values.	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  Figure	  2-­‐18	  Expected	  vs.	  Null	  distributions	  of	  the	  data	  tracking	  values.	  Left	  -­‐	  DDD	  array	  design1.	  Right	  -­‐	  DDD	  array	  design2.	  Above	  (see	  Figure	  2-­‐18)	  the	  DDD	  control	  data	  tracking	  values	  (having	  resolved	  the	  sample	  swap	  mentioned	  previously)	  for	  both	  DDD	  array	  designs	  are	  shown.	  The	   points	   plotted	   in	   green	   are	   the	   data	   tracking	   values	   using	   the	   sample	   ID	  supplied	   from	   the	   laboratory	   management	   system	   (the	   real	   distribution).	   The	  points	  plotted	  in	  red	  are	  the	  data	  tracking	  values	  after	  offsetting	  the	  sample	  IDs	  by	  one,	  resulting	   in	  all	  sample	  IDs	  being	   ’incorrect’	   (the	  null	  distribution).	   	  The	  two	   distributions	   (real	   &	   null)	   are	   quite	   different,	   displaying	   considerably	  different	   means	   and	   variances.	   The	   difference	   between	   these	   distributions	  denotes	   the	   discriminatory	   power	   of	   the	   data	   tracking	   values.	   Using	   this	  observation	  we	  have	  initially	  set	  the	  data	  tracking	  failure	  cut-­‐off	  at	  a	  value	  of	  0.7.	  	  However,	  as	  more	  data	  are	  processed,	  the	  estimate	  of	  both	  the	  probabilities	  and	  the	   copy	   number	   state	   boundaries	   should	   improve	   using	   our	   dynamic	  probability	  updating	  approach	  (see	  Methods).	  Due	  to	  the	  fact	  that	  the	  data	  generated	  from	  an	  array-­‐CGH	  experiment	  are	  very	  different	  to	  that	  produced	  from	  the	  Sequenom	  assay	  our	  method	  is	  considerably	  more	  complicated	  than	  that	  used	  for	  the	  genotyping	  or	  sequencing	  pipelines	  at	  the	   Wellcome	   Trust	   Sanger	   Institute.	   As	   a	   result	   the	   discriminatory	   power	  displayed	  here	  is	  rather	  limited	  in	  comparison	  and	  we	  do	  not	  attempt	  to	  resolve	  sample	   swaps	   as	   standard	   practice.	   Situations	   such	   as	   plate	   rotations	   would	  almost	   certainly	   be	   detected	   using	   this	   approach	   and	   could	   potentially	   be	  resolved.	  However	  due	   to	   the	   complex	  nature	   of	   trying	   to	   correlate	   SNPs	  with	  CNVRs	   it	   would	   not	   be	   appropriate	   to	   attempt	   sample	   swap	   resolution	   for	  patient	  data	  generated	  from	  the	  DDD	  project.	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2.3.3	   CNV	  Consensus	  Reference	  Set	  All	   copy	   number	   variable	   regions	   (CNVRs)	   from	   each	   of	   the	   individual	   studies	  included	   in	   the	  CNV	  consensus	  were	  merged	   into	  separate	  sets	  of	  CNVEs	  using	  the	  previously	  defined	  method	  (see	  Methods).	  In	  this	  section	  we	  take	  a	  detailed	  look	  at	  various	  properties	  of	  each	  of	  these	  sets.	  
Size	  Distribution	  -­‐	  Study	  Sets	  An	   interesting	  and	  useful	  aspect	  of	   creating	  a	  CNV	  consensus	   from	  a	  variety	  of	  data	   sources	   is	   that	   each	   technology	   displays	   a	   different	   sensitivity	   across	   the	  genome	  size	  range.	  Below	  (see	  Figure	  2-­‐19)	  the	  size	  range	  of	  CNVRs	  included	  in	  the	  CNV	  consensus	  from	  each	  of	  the	  individual	  data	  sources	  is	  shown:	  
	  Figure	  2-­‐19	  CNV	  Consensus	  -­‐	  study	  set	  size	  distributions.	  This	   combination	   of	   study	   sets	   achieves	   reasonable	   coverage	   of	   CNV	   events	  across	   the	   genomic	   size	   range	   for	   CNVs.	   The	   DDD	   arrays	   gives	   good	   coverage	  across	  the	  entire	  size	  range	  whereas,	  for	  example,	  the	  1G	  dup	  set	  contains	  mostly	  small	   CNVEs	   and	   the	   Affy6	   set	   contains	  mostly	   larger	   CNVEs.	   The	   ’dual’	   spike	  observed	  at	  the	  lower	  tail	  of	  the	  DDD	  size	  range	  is	  likely	  due	  to	  a	  difference	  in	  the	  achieved	  coverage	  of	  individual	  exons	  (single	  exon	  CNVs)	  in	  the	  DDD	  design.	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Reciprocal	  Overlap	  Thresholds	  
Study	  CNVE	  Sets	  Next	  (see	  Figure	  2-­‐20),	  for	  a	  number	  of	  the	  study	  sets,	  is	  plotted	  the	  proportion	  of	  CNVEs	   from	   that	   study	   set	   that	   is	   overlapped	  by	   each	  of	   the	  others,	   using	   a	  reciprocal	  overlap	  threshold	  ranging	  from	  0	  to	  1.	  
	  Figure	  2-­‐20	  Overlap	  measures	  between	  study	  set	  CNVEs.	  It	  can	  be	  observed	  (see	  Figure	  2-­‐20)	  that	   in	  all	  cases	  as	  the	  reciprocal	  overlap	  threshold	   tends	   toward	   1	   the	   proportion	   of	   CNVEs	   overlapped	   between	   the	  different	  study	  sets	  decreases.	  This	  is	  explained	  by	  the	  fact	  that	  each	  study	  assay	  is	  of	  a	  different	   resolution	  and	  as	   the	  overlap	   threshold	  gets	   closer	   to	  an	  exact	  match	   (reciprocal	   overlap	   tending	   toward	   1)	   the	   probability	   of	   two	   studies	  sharing	   CNVEs	   is	   certain	   to	   decrease.	   Overall	   there	   is	   a	   fair	   amount	   of	  discordance	   between	   the	   4	   different	   study	   sets,	   showing	   that	   each	   is	   able	   to	  capture	  different	   locations	  of	   variation	   throughout	   the	   genome.	  The	  overlap	  of	  the	  affy6	  CNVEs	  is	  best	  for	  the	  DDD	  control	  set	  which	  is	  likely	  due	  to	  the	  larger	  sample	  sizes	  of	  both	  the	  Affy6	  and	  DDD	  control	  studies,	  5919	  &	  845	  respectively.	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Study	  Call	  Sets	  Below,	  (see	  Figure	  2-­‐21),	  similar	  plots	  are	  shown	  but	  comparing	  between	  study	  call	  sets	  instead	  of	  CNVEs	  where	  appropriate.	  Raw	  call	   lists	  were	  only	  available	  for	  the	  42M,	  WTCCC	  and	  DDD	  studies.	  
	  Figure	  2-­‐21	  Overlaps	  between	  study	  set	  Call	  lists.	  Here	  it	  can	  be	  observed	  that:	  
• In	   all	   cases	   the	   proportion	   of	   overlap	   between	   call	   lists	   tails	   off	   towards	   a	  reciprocal	  overlap	  of	  1.	  
• For	  Affy6,	  the	  DDD	  call	  list	  shows	  a	  greater	  overlap	  than	  the	  42M.	  
• For	  DDD,	  the	  42M	  call	  list	  shows	  a	  greater	  overlap	  than	  the	  Affy6.	  
• For	  the	  42M,	  the	  DDD	  call	  list	  shows	  a	  greater	  overlap	  than	  the	  Affy6.	  	  This	  suggests	  that	  the	  DDD	  call	  set	  display	  better	  consistency	  when	  compared	  to	  different	  studies.	  The	  fact	  that	  the	  DDD	  call	  list	  shows	  the	  most	  similarity	  to	  both	  the	  Affy6	  and	  42M	  call	  lists	  indicates	  that	  the	  quality	  of	  CNV	  calls	  in	  the	  DDD	  list	  is	   reasonable.	  Furthermore,	   this	  observation	   indicates	   that	   the	  DDD	  array-­‐CGH	  array	  achieves	  a	  relatively	  good	  capacity	  for	  detecting	  CNVs	  across	  the	  genomic	  size	  range.	  These	  observations	  are	  also	  consistent	  when	  considering	  the	  different	  resolutions	  and	  sample	  sizes	  of	  the	  three	  studies.	  The	  42M	  study	  has	  the	  highest	  resolution	   but	   the	   lowest	   sample	   size	  whereas	   the	   Affy6	   study	   has	   the	   lowest	  resolution	  but	  the	  largest	  sample	  size.	  The	  DDD	  controls	  has	  both	  high	  resolution	  and	   reasonable	   sample	   size	   and	   therefore	   is	   able	   to	   detect	   42M	   detected	  variation	  that	  the	  Affy6	  study	  was	  not	  and	  visa	  versa.	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Types	  and	  Frequency	  Bins	  
WTCCC	  -­‐	  Affy6	  merged	  CNVEs	  The	   Affy6	   WTCCC	   data	   set	   (see	   Figure	   2-­‐22	   and	   Table	   2-­‐3)	   has	   the	   largest	  sample	   size	   of	   all	   the	   studies	   in	   the	   CNV	   consensus.	   There	   are	   a	   total	   of	   5919	  samples	  that	  contribute	  raw	  calls	  into	  both	  the	  deletion	  and	  duplication	  merged	  CNVE	  set	  from	  the	  WTCCC.	  
	  Figure	   2-­‐22	   Affy	   6	   CNVE	   size	   (left)	   and	   frequency	   (right)	   distributions.	   Top	   -­‐	  Exclusively	  deletion	   sites.	  Middle	   -­‐	  Exclusively	  duplication	   sites.	  Bottom	   -­‐	   Sites	  including	  both	  deletion	  and	  duplication	  CNV	  events.	  Table	  2-­‐3	  Affy6	  merged	  CNVE	  set	  at	  discrete	  frequency	  bins.	  	   Singleton	   Doubleton	  to	  1%	   1%	  to	  5%	   Above	  5%	  All	   7103	   3636	   259	   186	  Deletion	   4048	   1823	   127	   123	  Duplication	   3055	   1198	   62	   24	  DelDup	   0	   615	   70	   39	  	  Overall	   the	   Affy6	   CNVE	   set	   shows	   relatively	   good	   separation	   across	   the	  frequency	  bins,	  with	  clearly	  decreasing	  numbers	  of	  CNVEs	  as	  the	  frequency	  bin	  range	   tends	   towards	   higher	   values	   (see	  Table	   2-­‐3).	   The	   overall	   singleton	   rate	  (approximately	  63%)	  is	  relatively	  high	  due	  to	  the	  large	  sample	  size.	  The	  overall	  number	   of	   CNVEs	   is	   relatively	   low	   reflecting	   the	   marked	   decrease	   in	   CNV	  detection	  sensitivity	  when	  using	  SNP	  genotyping	  (Affy6)	  compared	  to	  array-­‐CGH	  platforms.	  
	   85	  
42M	  -­‐	  Merged	  Raw	  Calls	  The	   42M	   study	   (merged	   raw	   calls)	   has	   a	   low	   sample	   size,	   with	   a	   total	   of	   40	  samples	   contributing	   to	   the	   raw	   call	   list.	   It	   is	   however,	   a	   very	   high	   resolution	  study,	   containing	   42	   million	   probes	   evenly	   spread	   across	   the	   genome	   with	   a	  median	  probe	  spacing	  of	  50bp	  (see	  Figure	  2-­‐23	  and	  Table	  2-­‐4).	  
	  Figure	  2-­‐23	  42M	  size	  (left)	  and	  frequency	  (right)	  distributions.	  Top	  -­‐	  Exclusively	  deletion	   sites.	   Middle	   -­‐	   Exclusively	   duplication	   sites.	   Bottom	   -­‐	   Sites	   including	  both	  deletion	  and	  duplication	  CNV	  calls.	  Table	  2-­‐4	  42M	  merged	  CNVE	  set	  at	  discrete	  frequency	  bins.	  	   Singleton	   Doubleton	  to	  1%	   1%	  to	  5%	   Above	  5%	  All	   7351	   0	   9037	   4121	  Deletion	   4630	   0	   5682	   1944	  Duplication	   2721	   0	   3245	   1312	  DelDup	   0	   0	   110	   865	  	  The	   clear	   observation	   that	   the	   merged	   CNVE	   set	   from	   the	   42M	   study	   has	   no	  events	   within	   the	   doubleton	   to	   1%	   frequency	   (see	   Table	   2-­‐4)	   range	   is	   a	  consequence	  of	  its	  small	  sample	  size	  (40	  samples).	  This	  is	  explained	  by	  the	  fact	  that	  a	  CNV	  observed	  in	  two	  independent	  samples	  occurs	  at	  a	  5%	  frequency	  in	  the	  42M	   study.	   Even	   though	   the	   sample	   size	   is	   small	   the	   singleton	   rate	   overall	   is	  relatively	   low	   (approximately	   36%)	   and	   the	   overall	   number	   of	   CNVEs	   is	  relatively	  high	  suggesting	  that	  the	  CNV	  call	  quality	  and	  detection	  sensitively	  was	  relatively	  good	  in	  the	  42M	  study.	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DDD	  -­‐	  Merged	  Raw	  Calls	  The	  DDD	   arrays	   contribute	   both	   high	   resolution	   and	   a	   reasonable	   sample	   size	  into	   the	   CNV	   consensus.	   The	   array	   provides	   a	   good	   compromise	   between	  backbone	  resolution	  and	   targeted	  genomic	  element	  coverage	   (see	  Figure	   2-­‐24	  and	  Table	  2-­‐5).	  
	  Figure	  2-­‐24	  DDD	  size	  (left)	  and	  frequency	  (right)	  distributions.	  Top	  -­‐	  Exclusively	  deletion	   sites.	   Middle	   -­‐	   Exclusively	   duplication	   sites.	   Bottom	   -­‐	   Sites	   including	  both	  deletion	  and	  duplication	  CNV	  calls.	  Table	  2-­‐5	  DDD	  merged	  CNVE	  set	  at	  discrete	  frequency	  bins.	  	   Singleton	   Doubleton	  to	  1%	   1%	  to	  5%	   Above	  5%	  All	   11789	   7916	   2362	   671	  Deletion	   6138	   2949	   757	   179	  Duplication	   5651	   2579	   361	   57	  DelDup	   0	   1679	   1244	   435	  	  Overall	   the	  DDD	  CNVE	  set	  shows	  good	  coverage	  across	   the	  genomic	  size	  range	  (see	   Figure	   2-­‐24).	   Furthermore,	   due	   to	   the	   relatively	   high	   sample	   size	   the	  separation	   across	   the	   frequency	   bins	   shows	   good	   separation	   and	   the	   expected	  decrease	   as	   the	   frequency	   range	   tends	   towards	   one	   (see	   Table	   2-­‐5).	   The	  singleton	  rate	  is	  relatively	   low	  (approximately	  52%)	  and	  the	  overall	  number	  of	  CNVEs	   is	  high,	   indicating	  good	  CNV	  call	  quality	  and	  detection	  sensitivity	   in	   the	  DDD	  control	  samples.	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DDD	  Controls	  in	  the	  CNV	  Consensus	  
CNV	  Consensus	  version1	  -­‐	  without	  DDD	  The	   CNV	   consensus	   set	   version1	   contains	   all	   study	   sets	   excluding	   the	   DDD	  control	   data	   set.	   Below	   (see	  Figure	   2-­‐25)	   the	   size	   (left)	   and	   frequency	   (right)	  distribution	  of	  CNVEs	  contained	  inside	  the	  CNV	  consensus	  version1	  is	  shown.	  
	  Figure	   2-­‐25	   CNV	   consensus	   v1	   size	   (left)	   and	   frequency	   (right)	   distributions.	  	  Top	  -­‐	  Exclusively	  deletion	  sites.	  Middle	  -­‐	  Exclusively	  duplication	  sites.	  Bottom	  -­‐	  Sites	  including	  both	  deletion	  and	  duplication	  CNV	  calls.	  Table	  2-­‐6	  CNV	  consensus	  version	  1	  CNVE	  set	  at	  discrete	  frequency	  bins.	  	   Singleton	   Doubleton	  to	  1%	   1%	  to	  5%	   Above	  5%	  All	   15327	   7251	   6084	   5833	  Deletion	   10634	   5991	   5240	   4368	  Duplication	   4689	   889	   356	   600	  DelDup	   0	   417	   226	   1081	  	  Overall	   the	   combined	   CNV	   consensus	   reference	   set	   achieves	   good	   coverage	  across	   the	   genomic	   range	   without	   the	   DDD	   CNVE	   set	   (see	   Figure	   2-­‐25).	   The	  overall	   number	   of	   CNVEs	   shows	   a	   marked	   increase	   compared	   to	   individual	  studies	  and	  the	  singleton	  rate	  (approximately	  44%)	  is	  between	  that	  of	  the	  Affy6	  (large	  sample	  size)	  and	  42M	  (small	  sample	  size)	  studies,	  suggesting	  a	  reasonable	  refinement	  of	  the	  positional	  and	  the	  frequency	  based	  estimates	  for	  CNVEs	  when	  combining	  information	  across	  studies	  (see	  Tables	  2-­‐3,	  2-­‐4,	  2-­‐5	  &	  2-­‐6).	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CNV	  Consensus	  version2	  -­‐	  with	  DDD	  Below	  (see	  Figure	  2-­‐26)	  shows	  the	  same	  plots	  as	  in	  Figure	  2-­‐25	  except	  that	  the	  DDD	  controls	  sets	  have	  been	  added	  into	  the	  CNV	  consensus.	  
	  Figure	   2-­‐26	   CNV	   consensus	   v2	   size	   (left)	   and	   frequency	   (right)	   distributions.	  	  Top	  -­‐	  Exclusively	  deletion	  sites.	  Middle	  -­‐	  Exclusively	  duplication	  sites.	  Bottom	  -­‐	  Sites	  including	  both	  deletion	  and	  duplication	  CNV	  calls.	  Table	  2-­‐7	  CNV	  consensus	  version	  2	  CNVE	  set	  at	  discrete	  frequency	  bins.	  	  	  	   Singleton	   Doubleton	  to	  1%	   1%	  to	  5%	   Above	  5%	  All	   23390	   12698	   7894	   6862	  Deletion	   14665	   8085	   5857	   4692	  Duplication	   8718	   2840	   640	   688	  DelDup	   0	   1722	   1128	   1802	  	  By	   integrating	   the	   DDD	   control	   CNVEs	   into	   the	   CNV	   consensus	   the	   number	   of	  CNV	   locations	   has	   increased	  by	   approximately	   32%	   (see	  Table	   2-­‐7).	  However	  the	   overall	   singleton	   rate	   has	   only	   been	   increased	   by	   2%,	   indicating	   that	   by	  incorporating	  the	  CNV	  calls	  made	  by	  CNsolidate	  across	  the	  DDD	  control	  samples	  the	  CNV	   consensus	  has	   a	   significant	   increase	   in	   the	  number	   of	   CNVE	   locations	  with	  more	  than	  one	  observation	  across	  studies	  (not	  singleton).	  	  	  There	  are	  5,448	  merged	  genomic	  locations	  in	  the	  DDD	  merged	  CNVE	  set	  that	  do	  not	   show	   any	   overlap	   (at	   least	   1	   base	   pair)	   with	   the	   version	   1	   of	   the	   CNV	  consensus.	  The	   singleton	   rate	  within	   these	  5,448	  CNVEs	   totally	  unique	   to	  DDD	  study	   is	   approximately	   42%,	   a	   similar	   rate	   to	   the	   overall	   combined	   CNV	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consensus	   with	   and	   without	   the	   DDD	   CNVE	   set.	   	   Below	   (see	   Table	   2-­‐8)	   the	  numbers	  in	  the	  different	  frequency	  bins	  of	  the	  DDD	  CNVEs	  that	  had	  no	  overlap	  with	  any	  CNVE	  from	  version	  1	  of	  the	  CNV	  consensus	  is	  presented:	  Table	   2-­‐8	   DDD	   CNVEs	   -­‐	   no	   overlap	  with	   CNV	   consensus	   version	   1	   at	   discrete	  frequency	  bins.	  	   Singleton	   Doubleton	  to	  1%	   1%	  to	  5%	   Above	  5%	  All	   3182	   1468	   558	   240	  Deletion	   1615	   555	   159	   45	  Duplication	   1567	   561	   82	   22	  DelDup	   0	   354	   316	   172	  	  The	   overall	   characteristics	   of	   the	   5,448	  merged	   CNVE	   locations	   unique	   to	   the	  DDD	   CNVE	   set	   (see	  Table	   2-­‐8)	   are	   encouraging.	   The	   separation	   between	   the	  frequency	  bins	  shows	  good	  separation	  and	  the	  expected	  decrease	  in	  numbers	  as	  the	  frequency	  range	  tends	  towards	  one.	  The	  number	  of	  exclusively	  deletion	  and	  duplication	   events	   shows	   a	   ratio	   of	   approximately	   one,	   suggesting	   that	   the	  sensitivity	   for	   detecting	   CNV	   regions	   unique	   to	   the	   DDD	   control	   samples	   and	  array	  design	  was	  near	  equivalent	  for	  deletions	  and	  duplications	  using	  CNsoliate.	  The	  combination	  of	  these	  characteristics	  give	  a	  good	  indication	  that	  the	  DDD	  raw	  call	  list	  was	  made	  up	  of	  high	  quality	  CNV	  detections.	  For	  example,	  the	  number	  of	  singletons	  observations	   in	  a	  control	   set	  of	   common	  variation	  can	  act	  as	  a	  good	  sanity	   check,	  where	  studies	  display	  unusually	  high	  singleton	   rates	   (CNVEs	   that	  were	  observed	  in	  single	  samples)	  this	  can	  be	  an	  indication	  that	  the	  study	  under	  question	  may	  have	  higher	  than	  desired	  false	  positive	  rate.	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Combined	  CNV	  Consensus	  Overview	  The	   full	   combined	  CNV	   consensus	   set	   is	   composed	  of	   a	   set	   of	   non-­‐overlapping	  CNVEs	   that	   were	   merged	   across	   all	   studies	   and	   contain	   combined	   positional	  information,	   frequency	   estimates	   and	   type	   states	   (see	  Methods).	   Additionally	  each	  CNVE	   retains	   a	   ’study	   tag’	   that	   relates	   to	   the	  number	   and	   type	  of	   studies	  that	  contributed	  information	  to	  the	  positional,	  frequency	  and	  type	  definitions	  of	  the	  CNVE.	  Below	  (see	  Figure	  2-­‐27)	  is	  a	  summary	  of	  the	  CNVEs	  contained	  inside	  the	  full	  CNV	  consensus	  set.	  
	  Figure	  2-­‐27	  Left	  -­‐	  Size	  distribution	  of	  CNVEs	  in	  the	  combined	  CNV	  consensus	  set	  Right	  -­‐	  Standard	  error	  of	  CNVEs	  in	  the	  combined	  CNV	  consensus	  set.	  	  	  In	  both	  panels,	   the	   colour	   scale	  bar	  on	   the	   right	  denotes	   the	   specific	   study	   tag	  (which	  studies	  contribute	  to	  a	  particular	  CNVE).	  The	  left	  panel	  displays	  the	  size	  distribution	   of	   all	   CNVEs,	   it	   is	   clear	   to	   see	   that	   each	   study	   tag	   contributions	  CNVEs	  displaying	  a	  different	  range	  of	  genomic	  sizes.	  	  Overall,	   the	   combined	   CNV	   consensus	   set	   achieves	   good	   coverage	   across	   the	  entire	   genomic	   range	   for	   CNVs.	   Sequencing	   based	   studies,	   such	   as	   the	   1000G	  data	   sets,	   contribute	   mostly	   smaller	   CNVEs,	   whereas	   the	   microarray	   based	  studies,	   such	   as	   the	   42M	   data	   sets,	   contribute	   a	   range	   of	   CNVEs	   including	   the	  typical	   larger	   structural	   rearrangements	   (see	   Figure	   2-­‐27).	   The	   right	   panel	  displays	   the	   standard	   error	   associated	   with	   each	   CNVE.	   This	   varies	   between	  study	  tags	  due	  to	  differences	  in	  the	  sample	  sizes	  of	  individual	  study	  sets	  and	  the	  number	  of	  observations	  made	  at	  each	  CNVE	  (see	  Figure	  2-­‐27).	  
CNV	  Consensus	  Set	  Visualisation	  The	   CNV	   consensus	   set	   can	   be	   made	   available	   to	   anyone	   who	   has	   a	   need	   to	  accurately	   filter	  CNV	  data	  based	  on	  positional,	   frequency	  and	  type	   information.	  The	   CNV	   consensus	   set	   is	   in	   use	   for	   CNV	   filtering	   in	   a	   number	   of	   different	  projects	  based	  at	  the	  Wellcome	  Trust	  Sanger	  Institute	  and	  beyond.	  	  Furthermore,	  the	   positional,	   frequency	   and	   type	   information	   can	   be	   visualised	   using	   online	  web	   based	   resources	   such	   as	   DECIPHER	   [16],	   ENSEMBL	   [163-­‐166]	   and	   UCSC	  [167].	   	   For	   example	   below	   (see	   Figure	   2-­‐28)	   is	   a	   screen	   shot	   of	   a	   section	   of	  chromosome1	  from	  the	  CNV	  consensus	  displayed	  in	  the	  UCSC	  genome	  browser.	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  Figure	  2-­‐28	  UCSC	  Screen	  Shot	  of	  the	  CNV	  Consensus	  Reference	  Set.	  	  	  The	   CNV	   consensus	   set	   is	   displayed	   as	   the	   top	   track	   with	   the	   Database	   of	  Genomic	   Variants	   (DGV)	   [168]	   track	   directly	   underneath	   it	   (see	  Figure	   2-­‐28).	  The	  colour	  of	   the	  bars	   in	   the	  CNV	  consensus	   track	  denotes	   the	  CNVEs	   type	  set	  and	   the	   shade	  denotes	   the	   frequency	  estimate.	  The	   two	   tracks,	  CNV	  consensus	  and	  DGV	   show	   a	   fair	   degree	   of	   similarity,	   especially	   in	   complex	   regions	   of	   the	  genome	   containing	   large	   numbers	   of	   segmental	   duplications	   (bottom	   track).	  	  This	   is	   expected	  as	  genomic	   regions	   flanked	  by	   segmental	  duplications	   tend	   to	  contain	  large	  numbers	  of	  common	  copy	  number	  variation	  due	  to	  CNV	  formation	  mechanisms	   such	   as	   Non-­‐allelic	   homologous	   recombination.	   The	   major	  difference	   between	   the	   CNV	   consensus	   set	   and	   the	   DGV	   is	   the	   fact	   that	   the	  consensus	   set	   incorporates	   information	   from	   only	   a	   small	   number	   of	   carefully	  selected	  studies	  and	  additionally	  provides	  an	  estimate	  of	  population	   frequency	  and	  state	  type	  for	  each	  of	  its	  CNVEs.	  
Defining	  Common,	  Rare	  and	  Novel	  CNVs	  using	  the	  CNV	  Consensus	  Set	  For	   annotating	   population	   frequency	   information	   onto	   CNV	   calls	   made	   from	  patient	   data	   in	   the	   DDD	   project	   we	   choose	   to	   define	   three	   frequency	   bins,	  common,	  rare	  and	  novel.	  All	  patient	  CNV	  calls	  in	  the	  DDD	  project	  are	  annotated	  with	  one	  of	  these	  frequency	  bins	  by	  applying	  a	  number	  of	  overlap	  and	  frequency	  rules	  during	  comparison	  to	  the	  CNV	  Consensus	  reference	  set.	  
Parameters	  The	   CNV	   Consensus	   is	   split	   into	   two	   sets	   (common	   and	   rare)	   based	   on	   the	  observed	   population	   frequency	   using	   approach	   1	   (see	   Methods).	   Common	  CNVEs	  are	  defined	  as	  those	  observed	  at	  greater	  than	  or	  equal	  to,	  and	  rare	  CNVEs	  as	   those	   observed	   at	   less	   than,	   1%	  population	   frequency	   from	  within	   the	   CNV	  consensus	  set.	  All	  ‘test’	  (patient)	  CNV	  calls	  are	  compared	  against	  both	  frequency	  sets	  (common	  and	  rare)	  by	  CNV	  type	  (deletion	  or	  duplication),	  meaning	  that	  test	  deletion	   calls	   are	   only	   compared	   against	   CNVEs	   observed	   as	   only	   deletion,	   or	  deletion/duplication	   (complex)	   events	   and	   test	   duplication	   calls	   are	   only	  compared	  against	  CNVEs	  observed	  as	  only	  duplication,	   or	  deletion/duplication	  (complex)	   events	   from	   the	   CNV	   consensus.	   For	   every	   test	   CNV	   two	   overlap	  measures	   are	   calculated,	   maximum	   forward	   overlap	   and	   maximum	   backward	  overlap,	  where	  the	  maximum	  forward	  overlap	  is	  the	  maximum	  proportion	  of	  the	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test	  CNV	  call	  overlapped	  by	  a	  CNVE	  of	  the	  given	  frequency	  bin	  and	  CNV	  type	  and	  the	  maximum	  backward	  overlap	  is	  the	  proportion	  of	  the	  given	  CNVE	  overlapping	  the	  test	  CNV	  call	  (see	  Figure	  2-­‐29).	  	  
	  Figure	   2-­‐29	   The	   common	   forward	   and	   backward	   overlap	  measures	   calculated	  when	  comparing	  CNV	  calls	  from	  204	  DDD	  patient	  samples	  to	  the	  CNV	  Consensus.	  	  	  	  Above	   (see	  Figure	   2-­‐29)	   is	   a	  plot	   showing	   the	   forward	  and	  backward	  overlap	  measures	   for	  CNV	   calls	   in	  204	  DDD	  patient	   samples	   compared	   to	   the	   common	  (>1%	  population	   frequency)	   CNVEs	   from	   the	   CNV	   consensus	   reference	   set.	   To	  define	   test	   (patient)	   CNV	   calls	   as	   common	   cut-­‐offs	   on	   both	   the	   forward	   and	  backward	   overlap	   measures	   needed	   to	   be	   defined.	   Cleary	   test	   CNV	   calls	   with	  both	   a	   forward	   and	   backward	   overlap	   measure	   of	   one	   should	   be	   classed	   as	  common	  since	  the	  breakpoint	   locations	  of	   the	  test	  CNV	  are	  exactly	  the	  same	  as	  the	  common	  CNVE	  from	  the	  CNV	  consensus	  set.	  Conversely,	  test	  CNV	  calls	  with	  both	  a	  forward	  and	  backward	  overlap	  measure	  of	  zero	  should	  not	  be	  classed	  as	  common	  since	  they	  share	  no	  overlap	  with	  a	  common	  CNVE	  of	  the	  given	  CNV	  type	  from	   the	   CNV	   consensus.	   However	   exactly	   where	   to	   define	   the	   cut-­‐offs	   is	  somewhat	   arbitrary	   and	   is	   highly	   likely	   to	   be	   influenced	   by	   the	   resolution	  achieved	  by	  the	  array	  used	  for	  test	  CNV	  calling	  and	  the	  resolution	  of	  the	  studies	  included	   in	   the	   reference	   set.	  As	   the	  CNV	  consensus	   reference	   set	   containing	  a	  number	   of	   studies	   and	   achieves	   good	   coverage	   of	   the	   genomic	   size	   range	   (see	  
Figure	  2-­‐27)	  we	  choose	  to	  use	  a	  relatively	  strict	  cut-­‐off	  for	  defining	  CNV	  states	  (common,	  rare	  and	  novel).	  We	  use	  a	  greater	   than	  0.8	   forward	  overlap	   for	  defining	  common	  and	  rare	  CNV	  calls	  where	   ‘test’	  CNV	  calls	  with	  a	   forward	  overlap	  measure	  of	  greater	  than	  0.8	  for	  common	  and	  rare	  CNVEs	  of	  the	  given	  type	  from	  the	  CNV	  consensus	  reference	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set	   are	   defined	   as	   common	   and	   rare	   respectively.	  We	   define	   test	   CNV	   calls	   as	  novel	  when	  neither	  the	  “common	  forward	  overlap”	  or	  the	  “rare	  forward	  overlap”	  measure	  are	  greater	  than	  0.8.	  We	  choose	  to	  ignore	  the	  backward	  overlap	  during	  these	  definitions	  and	  assume	  high	  enough	  similarity	  so	  long	  as	  greater	  than	  80%	  (forward	   overlap	   >	   0.8)	   of	   the	   ‘test’	   CNV	   call	   is	   encompassed	   by	   the	   reference	  CNVE.	  	  	  
	  Figure	   2-­‐30	   Highlighting	   the	   overlap	   cut-­‐off	   definitions	   for	   defining	   common,	  rare	  and	  novel	  CNV	  states	  using	  the	  CNV	  consensus	  reference	  set.	  The	   above	   plot	   (see	   Figure	   2-­‐30)	   highlights	   the	   defined	   cut-­‐off	   on	   positional	  similarity	  for	  defining	  CNV	  frequency	  states.	  The	  red	  line	  shows	  the	  operational	  cut-­‐off	  used	  on	  the	  forward	  overlap	  measure.	  The	  blue	  line	  shows	  the	  position	  on	  the	   graph	   if	   we	   were	   to	   use	   the	   same	   cut-­‐off	   (0.8)	   on	   the	   backward	   overlap	  measure.	   Choosing	   to	   ignore	   the	   backward	   overlap	  measure	   for	   defining	   CNV	  frequency	  states	  is	  almost	  certainly	  an	  over	  simplification	  as	  CNVs	  encompassing	  different	  areas	  of	  the	  genome	  are	  likely	  to	  confer	  different	  phenotypic	  effects	  and	  should	  not	  strictly	  be	  classed	  as	   the	  same	  event.	  For	  example,	  a	  small	   test	  CNV	  call	   affecting	   a	   specific	   genomic	   location	   (e.g.	   a	   single	   exon)	   may	   result	   in	   an	  altered	   function	  of	   the	  gene	  product	   compared	   to	  a	   lowered	  or	   increased	  gene	  dosage	  conferred	  by	  either	  a	  deletion	  or	  duplication	  of	  an	  entire	  gene(s).	  Overall	  the	   positional	   effects	   of	   CNVs	   inside,	   outside	   or	   including	   genes	   are	   generally	  poorly	   understood.	   However,	   given	   the	   previously	   mentioned	   problems	  associated	  with	  different	  assay	  resolutions,	  using	  a	  strict	  greater	  than	  0.8	  cut-­‐off	  on	  the	  forward	  overlap	  measure	  alone	  is	  a	  reasonable	  compromise	  for	  assigning	  a	  population	  frequency	  estimate	  to	  individual	  CNV	  calls.	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2.3.4	   CNV	  Filtering	  	  
Sample	  Set	  We	   applied	   CNV	   detection	   using	   CNsolidate,	   CNV	   frequency	   state	   definitions	  using	  the	  CNV	  consensus	  reference	  set	  and	  CNV	  filtering	  for	  clinical	  relevance	  to	  1288	  QC	  passed	  proband	  (patient)	  array-­‐CGH	  datasets	  from	  the	  DDD	  project.	  	  	  
Variant	  Description	  The	  1288	   array-­‐CGH	  datasets	   all	   passed	   quality	   control	   (data	   quality	   and	  data	  tracking)	  given	  the	  previous	  described	  methods	  and	  parameter	  definitions	  (see	  
Methods).	   They	   were	   therefore	   eligible	   for	   further	   analysis	   and	   ultimately	  reporting	  of	  clinically	  relevant	  variants	  using	  the	  DECIPHER	  database	  back	  to	  the	  clinical	  services	  throughout	  the	  UK	  and	  Ireland.	  	  
	  
	  	  Figure	  2-­‐31	  Left	  –	  the	  number	  of	  QC	  passed	  CNV	  calls	  per	  array-­‐CGH	  slide,	  Right	  –	   the	   number	   of	   QC	   passed	   CNV	   calls	   per	   array-­‐CGH	   slide	   vs.	   1-­‐novelty	   (the	  proportion	  of	  CNV	  calls	  previously	  observed	  in	  the	  CNV	  consensus	  reference).	  Overall	   the	   QC	   parameters	   used	   for	   passing	   individual	   samples	   based	   on	   data	  quality	   used	   were	   relatively	   relaxed.	   This	   is	   because	   it	   was	   important	   to	  maximize	  the	  number	  of	  patients	  within	  the	  DDD	  study	  who	  could	  potentially	  be	  provided	   with	   a	   diagnosis.	   Furthermore	   every	   flagged	   variant	   is	   manually	  reviewed	  by	  a	  panel	  of	  experts	  prior	   to	  being	  deposited	   in	  DECIPHER.	  Even	  so	  both	   the	  number	  of	   CNV	   calls	   per	   slide	   and	   the	  1-­‐novelty	   values	   are	   relatively	  consistent	  across	  all	  1288	  samples	  (see	  Figure	  2-­‐31).	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CNVs	  Flagged	  for	  Clinical	  Review	  Overall	   382	   unique	   CNVs	   were	   flagged	   from	   a	   total	   of	   232/1288	   individual	  samples,	  a	  potential	  feedback	  rate	  of	  18%.	  There	  was	  a	  median	  of	  0,	  mean	  of	  0.31	  and	  maximum	  of	  10	  CNVs	   flagged	  per	  sample	  (see	  Figure	   2-­‐32),	   reflecting	   the	  relatively	   high	   stringency	   applied	   for	   call	   quality	   control	   (see	   Methods).	  Furthermore	   greater	   than	   80%	   of	   samples	   had	   a	   previously	   uninformative	  microarray	  result	  from	  the	  clinical	  services	  and	  front	  line	  microarray	  diagnostic	  testing	  normally	  results	  in	  less	  than	  a	  20%	  diagnostic	  rate	  [169].	  
	  Figure	  2-­‐32	  the	  number	  of	  CNVs	  flagged	  for	  clinical	  review	  per	  sample.	  As	  shown	  (see	  Figure	  2-­‐32)	  the	  majority	  of	  samples	  had	  zero	  CNVs	  flagged	  for	  clinical	  review	  and	  across	  the	  samples	  with	  at	  least	  one	  flagged	  CNV	  there	  was	  a	  median	  of	  1,	  mean	  of	  1.6	  and	  maximum	  of	  10	  flagged	  CNVs.	  This	  shows	  that	  the	  parameters	   used	   for	   clinical	   filtering	   were	   optimal	   in	   terms	   of	   providing	  relativity	   low	   numbers	   of	   flagged	   CNVs	   per	   sample.	   Although	   this	   relates	   to	   a	  potentially	   low	   feedback	   rate	   it	   ensures	   a	   low	   burden	   on	   the	   manual	   review	  stage.	  Furthermore,	  the	  CNV	  filtering	  pipeline	  has	  been	  designed	  to	  be	  iterative	  in	  nature	  and	  further	  rounds	  of	  variant	  filtering	  and	  review	  can	  happen	  over	  the	  course	  of	  the	  DDD	  project	  where	  filtering	  parameters	  should	  be	  adjusted.	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Flagged	  Variant	  Breakdown	  by	  Filtering	  Route	  As	  described	  previously	  the	  CNVs	  flagged	  for	  clinical	  review	  can	  come	  down	  one	  of	  two	  different	  routes,	  either	  flagged	  based	  on	  size	  and	  frequency	  alone	  (VOUS)	  or	   due	   to	   affecting	   a	   gene	   previously	   associated	  with	   developmental	   disorders	  (DDG2P).	   Overall	   165	   (43%)	   of	   flagged	   CNVs	   came	   down	   the	   VOUS	   route	   and	  were	  flagged	  based	  on	  size	  and	  frequency	  alone	  whereas	  217	  (57%)	  came	  down	  the	   DD	   gene	   route	   and	   were	   flagged	   due	   to	   overlapping	   a	   DD	   gene	   with	   the	  correct	  mode	  and	  mechanism	  (see	  Methods).	  Overall	  there	  were	  27	  homozygous	  deletions,	  266	  heterozygous	  deletions	  and	  89	  gains	   flagged	  across	  both	   the	  DD	  gene	  and	  VOUS	  filtering	  routes.	  	  Table	  2-­‐9	  The	  number	  of	  CNVs	  of	  copy	  number	  0,	  1	  and	  greater	  than	  2	  flagged	  for	  clinical	  review	  via	  either	  the	  DD	  gene	  or	  VOUS	  filtering	  route	  	   Copy	  number	  0	   Copy	  Number	  1	   Copy	  Number	  >	  2	  DD	  Gene	  Route	   25	   187	   5	  VOUS	  Route	   2	   79	   84	  	  Reviewing	   the	   numbers	   displayed	   (see	   Table	   2-­‐9)	   it	   was	   clear	   that	   for	  homozygous	   deletions	   (copy	   number	   =	   0)	   there	   was	   a	   greater	   than	   ten-­‐fold	  increase	  in	  the	  number	  of	  variants	  flagged	  via	  the	  DD	  gene	  route	  compared	  to	  the	  VOUS	   route.	   This	   was	   not	   unexpected	   as	   the	   rate	   of	   large	   rare	   homozygous	  deletions	  is	  very	  low	  across	  the	  genome	  [170]	  and	  these	  types	  of	  events	  result	  in	  zero	   copies	   of	   all	   effected	   genes	   and	   therefore	   have	   a	   high	   prior	   likelihood	   of	  causing	  extreme	  phenotypes	  [171-­‐174].	  	  There	  was	  no	  observable	  bias	  between	   the	  number	  of	   losses	  and	  gains	   flagged	  via	   the	   VOUS	   route	   indicating	   that	   the	   capacity	   for	   detecting	   and	   prioritizing	  large	   rare	   CNVs	   for	   clinical	   review	   was	   near	   equivalent	   for	   losses	   and	   gains.	  However	   for	   the	   DD	   gene	   route	   there	   was	   a	   significant	   enrichment	   for	   losses	  compared	   to	   gains	   (fisher	   P<	   2.2e-­‐16),	   this	   enrichment	   is	   almost	   certainly	  dominated	   by	   the	   bias	   for	   loss	   of	   function	   genes	   within	   the	   DDG2P	   database;	  with	  72%	  of	   entries	  having	   loss	   of	   function	  or	  dominant	  negative	  mechanisms	  and	   only	   3.5%	  having	   either	   increased	   gene	   dosage	   or	   activating	  mechanisms.	  Furthermore	  the	  loss	  of	  one	  or	  more	  functional	  gene	  copy	  is	  clearly	  more	  likely	  to	   result	   in	   a	   genetic	   disorder	   than	   simply	   an	   increase	   in	   the	   number	   of	  functional	   gene	   copies.	   Therefore	   unless	   the	   gene	   transcript	   is	   interrupted	   or	  truncated	  by	  a	  gain	  in	  copy	  number,	  resulting	  in	  impaired	  gene	  product	  function	  (disruptive	   duplications)	  we	   can	   expect	   a	   greater	   number	   of	   genetic	   disorders	  caused	  by	  CNVs	  to	  be	  a	  result	  of	  a	  loss	  compared	  to	  a	  gain	  of	  genetic	  material.	  The	   size	   distribution	   of	   CNVs	   flagged	   via	   the	   DD	   gene	   or	   VOUS	   route	   are	  understandably	   very	   different	   due	   to	   fixed	   parameters	   on	   CNV	   length	   for	  variants	  flagged	  via	  the	  VOUS	  route.	  For	  the	  DD	  gene	  route	  there	  was	  a	  minimum	  of	   44	   bp,	   a	  median	   of	   7.8	   Kb	   and	   a	  maximum	  of	   77	   kb	  whereas	   for	   the	   VOUS	  route	   there	  was	  a	  minimum	  of	  103	  kb,	  a	  median	  of	  713	  Kb	  and	  a	  maximum	  of	  14.6	  mb	  across	  all	  flagged	  CNV	  sizes.	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Recurrently	  Mutated	  DD	  Genes	  The	   specific	   version	   of	   the	   DDG2P	   gene	   list	   (version	   1.2)	   used	   for	   this	   run	   of	  clinical	   filtering	   contained	   a	   total	   of	   1,204	   unique	   entries	   with	   1,055	   discrete	  genes.	  All	  217	  CNVs	   flagged	  via	   the	  DD	  gene	  route	  contained	  a	   total	  of	  only	  35	  discrete	  DD	  genes	  indicating	  a	  high	  rate	  of	  recurrently	  mutated	  DD	  genes	  across	  the	  1,288	  samples.	  
	  Figure	  2-­‐33	  Number	  of	  CNVs	  flagged	  via	  the	  DD	  gene	  route	  per	  DD	  gene	  Overall	   the	   number	   of	   CNVs	   observed	   per	   DD	   gene	   shows	   three	   clear	   outliers	  (see	  Figure	  2-­‐33)	  in	  terms	  of	  the	  number	  of	  times	  they	  were	  hit	  by	  single	  CNVs	  (FMR1,	  SHANK3	  and	  CHD7).	  Otherwise	  six	  genes	  with	  greater	   than	  three	  CNVs	  were	  observed	  and	  a	  long	  tail	  with	  three	  or	  fewer	  flagged	  CNVs.	  The	  three	  genes	  (FMR1,	  SHANK3	  and	  CHD7)	  with	  the	  greatest	  number	  of	  flagged	  CNVs	  indicated	  a	  potential	  problem	  with	   the	   filtering	  pipeline	  due	   to	  being	  observed	  at	   a	  high	  enough	  frequency	  (4%,	  2.8%	  and	  2.7%	  respectively)	  across	  the	  1,288	  sample	  to	  arise	  suspicion.	  Furthermore	   during	   the	   clinical	   review	   meeting	   we	   had	   observed	   variants	   at	  these	   three	   genes	   that	   were	   high	   quality	   CNV	   calls	   however	   the	   phenotypes	  listed	   for	   the	   patients	   were	   often	   irrelevant	   and	   not	   associated	   with	   the	  described	  genomic	  syndrome	  for	  the	  particular	  DD	  gene.	  	  As	  a	  result	  we	  concluded	  that	  a	  number	  of	  probes	  on	  the	  array-­‐CGH	  array	  were	  potentially	  poorly	  performing	  and	  appearing	  as	  deletion	  calls	   in	  a	  subset	  of	  the	  patient	   data.	   This	   effect	   was	   not	   observed	   in	   control	   data	   and	   CNVs	   at	   FMR1,	  SHANK3	  and	  CHD7	  were	  not	  present	  in	  the	  CNV	  consensus	  set.	  Presumably	  this	  effect	  was	  observed	  due	  to	  differences	  in	  DNA	  sources	  and	  quality	  for	  the	  patient	  compared	   to	   the	   control	   samples.	   The	   patient	   DNA	   was	   obtained	   as	   either	  extracted	  blood	  or	  saliva	  DNA	  from	  a	  large	  variety	  of	  different	  sources	  whereas	  the	  control	  data	  was	  generated	  from	  cell	  line	  extracted	  DNA.	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Defining	  Problem	  Probes	  for	  Removal	  Prior	  to	  CNV	  Calling	  Due	   to	   the	   observations	   described	   above	   an	   association-­‐based	   test	   was	  undertaken	  for	  every	  probe	  present	  of	  the	  array-­‐CGH	  platform	  across	  the	  1,288	  samples.	  We	  defined	  two	  different	  sample	  sets	  to	  compare:	  -­‐ Sample	  set	  1:	  
o 129	   samples:	   containing	   a	   deletion	   call	   at	   either	   SHANK3,	  CHD7	  or	  FMR1.	  -­‐ Sample	  set	  2:	  
o 1,159	   samples:	   containing	   no	   deletion	   call	   at	   either	   SHANK3,	  CHD7	  or	  FMR1.	  	  Two	  different	  measures	  of	  probe	  performance	   for	  each	  probe	   (1.92	  Million	   for	  each	  sample)	  between	  sample	  set	  1	  and	  sample	  set	  2	  were	  calculated:	  1) The	  absolute	  difference	  between	  the	  mean	  log2	  ratios	  between	  sets	  2) A	  Mann-­‐Whitney	  test	  between	  all	  probe	  values	  between	  sets	  	  Overall	  there	  were	  1,288	  datasets	  containing	  1,915,129	  array-­‐CGH	  probes	  each,	  equally	  a	  total	  of	  2,466,686,152	  data	  points	  to	  compare.	  To	  achieve	  this	  analysis	  in	  a	  timely	  fashion	  we	  made	  use	  of	  the	  load	  sharing	  facility	  (LSF)	  available	  on	  the	  compute	   farm	   at	   the	   Welcome	   Trust	   Sanger	   Institute.	   There	   was	   a	   balance	  needed	  between	  the	  number	  of	  executed	  jobs,	   the	  number	  of	   file	  reads	  and	  the	  memory	  requirements	  for	  each	  job.	  	  Table	  2-­‐10	  Three	  different	  approaches	  to	  running	  a	  probe	  association	  test	  across	  1288	  sample	  for	  1.9	  Million	  probes	  on	  a	  compute	  cluster.	  
	   #	  Jobs	   #	  File	  Reads	   Memory	  1	  job	  per	  probe	   1915129	   1288	   low	  1	  job	  per	  chromosome	   24	   102778590	   low	  1	  job	  per	  chromosome	  (chunked)	   24	   128800	   moderate	  	  The	   third	   option	   displayed	   above	   (see	  Table	   2-­‐10)	   was	   used	   to	   perform	   the	  probe	  association	  test	  across	  the	  1,288	  samples.	  Using	  this	  approach	  one	  job	  per	  chromosome	   (24	   jobs)	  was	  executed	  and	  each	   chromosome	  was	   split	   into	  100	  chunks.	   For	   each	   of	   the	   100	   chromosome	   chunks	   intensity	   data	   for	   all	   probes	  within	  the	  chunk	  across	  all	  1,288	  samples	  were	  read	  into	  memory	  and	  the	  probe	  performance	  measures	  were	  calculated	  before	  outputting	  an	  indexed	  output	  file	  containing	  the	  results.	  This	  approach	  only	  required	  a	  moderate	  amount	  of	  memory	  and	  the	  number	  of	  file	  reads	  was	  also	  moderate	  (128,800)	  being	  far	  below	  the	  limit	  on	  the	  number	  of	  file	  reads	  allowed	  per	  job	  (1	  Million)	  running	  under	  LSF	  at	  the	  WTSI.	  However,	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each	  job	  still	  required	  128,800	  sequential	   file	  reads	  extracting	  a	  median	  of	  805	  data	   points	   per	   file	   read	   (a	  median	   of	   1,036,840	   total	   data	   points	   per	   chunk)	  meaning	  that	  each	  job	  could	  be	  potentially	  quite	  slow.	  For	  example,	  assuming	  a	  0.1	   second	   per	   file	   read	   each	   job	   would	   have	   taken	   a	   total	   of	   3.6	   hours	   to	  complete.	  However	  by	  using	   the	   fast	  data	   indexing	  C++	  package	  (Rbin)	  all	   jobs	  completed	  in	  a	  total	  of	  42	  minutes	  (including	  job	  scheduling	  wait	  time).	  	  
Probe	  Association	  Results	  Using	   the	   approach	   above	   we	   obtained	   two	   performance	   measures	   for	   every	  probe	  on	  the	  array-­‐CGH	  platform.	  
	  Figure	  2-­‐34	  Absolute	  mean	  difference	  between	   the	  mean	   log2	   ratios	  of	   sample	  set	  1	  and	  sample	   set	  2	   for	  1.92	  Million	  array-­‐CGH	  probes,	  ordered	  by	  genomic	  location	  Above	   (see	   Figure	   2-­‐34)	   the	   first	   performance	   measure	   calculated	   for	   every	  probe	   on	   the	   array-­‐CGH	   platform	   is	   shown.	   By	   setting	   an	   arbitrary	   cut-­‐off	   of	  greater	   than	   0.2	   on	   the	   absolute	   difference	   between	   log2	   ratio	   values	   from	  sample	  set	  1	  compared	  to	  sample	  set	  2	  (excluding	  the	  problematic	  chromosome	  Y)	  we	  would	  remove	  a	  total	  of	  1,535	  probes	  (0.08%	  of	  total	  probes)	  that	  show	  a	  marked	  difference	  in	  mean	  log2	  ratio	  values	  between	  the	  two	  sample	  sets.	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Figure	   2-­‐35	   -­‐log10(P)	   from	   a	  Mann-­‐Whitney	   test	   between	   all	   probe	   log2	   ratio	  values	   for	   sample	   set	   1	   compared	   to	   sample	   set	   2	   for	   1.92	  Million	   array-­‐CGH	  probes,	  ordered	  by	  genomic	  location.	  Above	   (see	   Figure	   2-­‐35)	   the	   results	   when	   using	   the	   more	   sensitive	   Mann-­‐Whitney	   test	   to	   assess	   differences	   in	   probe	   performance	   between	   the	   two	  sample	  sets	  is	  shown.	  After	  applying	  a	  multiple	  testing	  correction	  (Bonferroni)	  at	  the	   0.01	   significance	   threshold	   we	   observed	   90,048	   probes	   (4.7%	   of	   total	  probes)	  with	  a	  significant	  different	  between	  the	  two	  sample	  sets.	  
	  Figure	  2-­‐36	  Probe	  performance	  measure	  for	  all	  probes	  covering	  the	  FMR1	  gene.	  Left:	   -­‐log10(p).	   Right:	   Abs	   mean	   ratio	   difference.	   Red	   dashed	   line:	   defined	  performance	  measure	  cut-­‐offs.	  Red	  dots:	  probes	  with	  an	  additional	  Kolmogorov-­‐Smirnov	  test	  value	  of	  zero.	  Across	  the	  FMR1	  gene	  locus	  there	  was	  a	  clear	  cluster	  of	  probes	  near	  the	  5’	  end	  that	  showed	  significant	  differences	  in	  performance	  between	  the	  two	  sample	  sets	  based	  on	  both	  probe	  performance	  measures	  assessed	  (see	  Figure	  2-­‐36).	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Figure	   2-­‐37	   Probe	   performance	  measures	   for	   all	   probes	   covering	   the	   SHANK3	  gene.	  Left:	  -­‐log10(p).	  Right:	  Abs	  mean	  ratio	  difference.	  Red	  dashed	  line:	  defined	  performance	  measure	  cut-­‐offs.	  Red	  dots:	  probes	  with	  an	  additional	  Kolmogorov-­‐Smirnov	  test	  value	  of	  zero.	  There	  were	  a	  number	  of	  probe	  clusters	  across	  the	  entire	  SHANK3	  gene	  showing	  significant	   differences	   in	   performance	   between	   the	   two	   sample	   sets	   based	   on	  both	  probe	  performance	  measures	  assessed	  (see	  Figure	  2-­‐37).	  
	  Figure	  2-­‐38	  Probe	  performance	  measure	  for	  all	  probes	  covering	  the	  CHD7	  gene.	  Left:	   -­‐log10(p).	   Right:	   Abs	   mean	   ratio	   difference.	   Red	   dashed	   line:	   defined	  performance	  measure	  cut-­‐offs.	  Red	  dots:	  probes	  with	  an	  additional	  Kolmogorov-­‐Smirnov	  test	  value	  of	  zero.	  Across	  the	  CHD7	  gene	  locus	  the	  was	  a	  clear	  cluster	  of	  probes	  near	  the	  5’	  end	  and	  a	   small	   cluster	   towards	   the	   3’	   end	   that	   showed	   significant	   differences	   in	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performance	   between	   the	   two	   sample	   sets	   based	   on	   both	   probe	   performance	  measures	  assessed	  (see	  Figure	  2-­‐38).	  	  
Probe	  Removal	  Results	  The	  distributions	  of	  the	  two	  probe	  performance	  measures	  assessed	  at	  the	  three	  problematic	   genes	   (FMR1,	   SHANK3	  &	  CHD7)	  displayed	   a	  high	  degree	  of	   visual	  correlation.	  The	  Mann-­‐Whitney	  test	  p	  values	  were	  more	  sensitive	  to	  differences	  in	   probe	   performance	   between	   the	   two	   sample	   sets	   and	   a	   greater	   number	   of	  probes	  fall	  below	  the	  defined	  cut-­‐off.	  For	  the	  probes	  showing	  the	  most	  significant	  differences	   between	   sample	   set1	   and	   sample	   set2	   both	   performance	   measure	  cut-­‐offs	   resulted	   in	   their	   removal	   (all	   probes	   removed	   based	   on	   the	   absolute	  difference	   between	   mean	   log2	   ratios	   were	   also	   removed	   based	   on	   the	   Mann-­‐Whitney	  p	  values).	  Overall	  we	  decided	  to	  remove	  probes	  based	  on	  the	  Mann-­‐Whitney	  p	  values	  and	  defined	  a	  5.22158e-­‐09	  P	  value	  cut-­‐off	  relating	  to	  a	  0.01	  significance	  values	  after	  correcting	   for	   1,915,129	   independent	   tests.	   This	   resulted	   in	   removing	   4.7%	  of	  the	  total	  number	  of	  probes	  on	  the	  array.	  	  
Figure	   2-­‐39	   Proportion	   of	   probes	   per	   chromosome	   removed	   using	   Mann-­‐Whitney	  p	  values	  	  It	  was	  important	  to	  ensure	  that	  relatively	  even	  coverage	  across	  the	  genome	  was	  maintained	   after	   probe	   removal.	   Above	   (see	   Figure	   2-­‐39)	   the	   proportion	   of	  probes	   removed	   per	   chromosome	   across	   the	   array-­‐CGH	   platform	   is	   shown.	  Overall	   less	   than	  15%	  of	   the	  probes	   from	  any	  chromosome	  were	  removed	  and	  for	  most	  chromosomes	  less	  than	  5%	  of	  probes	  were	  removed.	  Chromosomes	  19	  and	  22	  had	  the	  highest	  proportion	  of	  probes	  removed.	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  Figure	  2-­‐40	  Average	  GC	  content	  per	  chromosome	  [blog.kokocinski.net].	  Interestingly	   when	   comparing	   the	   proportion	   of	   probes	   removed	   per	  chromosome	   with	   the	   average	   GC	   content	   per	   chromosome	   a	   remarkable	  similarity	   was	   observed	   (see	   Figures	   2-­‐39	   &	   2-­‐40).	   Overall	   the	   GC	   rich	  chromosomes	  tended	  to	  have	  more	  probes	  removed	  using	  the	  Mann-­‐Whitney	  p	  values	   for	   probe	   performance	   between	   the	   two	   sample	   sets.	   This	   is	   not	   too	  surprising	  when	  you	  consider	  that	  PCR	  amplification	  of	  GC-­‐rich	  DNA	  sequences	  is	   often	   more	   difficult	   due	   to	   the	   formation	   of	   secondary	   structure	   such	   as	  hairpins	  and	  a	  higher	  melting	  temperature	  [175].	  Therefore	  where	  DNA	  quality	  and	  concentration	  vary	  the	  amplification	  of	  GC-­‐rich	  DNA	  sequences	  is	  likely	  to	  be	  affected	  resulting	  in	  poor	  performance	  for	  probes	  with	  a	  high	  GC	  content.	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Number	  of	  Genic	  Probes	  Removed	  On	   top	   of	   ensuring	   overall	   even	   probe	   coverage	   across	   chromosome,	   perhaps	  more	   importantly	   it	   was	   necessary	   to	   ensure	   that	   the	   coverage	   of	   individual	  genes	   and	   exons	  would	  not	   be	   compromised	  by	   removing	  problematic	  probes.	  We	  compared	  the	  number	  of	  array-­‐CGH	  probes	  overlapping	  every	  exon	  from	  the	  GENCODE	  gene	  set	  (version	  17)	  before	  and	  after	  probe	  removal.	  Table	  2-­‐11	  The	  number	  of	  probes	  removed	  and	  the	  number	  of	  GENCODE	  exons	  with	  that	  number	  of	  probes	  removed	  after	  probe	  removal.	  
	  
	  Figure	  2-­‐41	  Number	  of	  array-­‐CGH	  probes	  per	  GENCODE	  exon	  before	   (left)	  and	  after	  (right)	  probe	  removal.	  The	   overall	   exon	   coverage	   of	   the	   array-­‐CGH	   platform	   was	   not	   severely	  compromised	  by	  removing	  4.7%	  of	  probes	  on	  the	  array	  due	  to	  their	  differential	  performance	  between	  sample	  sets	  of	  differing	  DNA	  quality	   (see	  Figure	   2-­‐41	  &	  
Table	  2-­‐11)	  The	  majority	  (84%)	  of	  GENCODE	  exons	  had	  zero	  probes	  removed,	  11%	  and	  3%	  of	  targeted	  GENCODE	  exons	  had	  only	  a	  single	  probe	  or	  two	  probes	  removed	  respectively.	  Collectively	  less	  than	  2%	  of	  all	  targeted	  exons	  had	  greater	  than	  two	  probes	  removed	  and	  the	  median	  number	  of	  probes	  per	  exon	  remained	  at	  3	  before	  and	  after	  probe	  removal	  (see	  Figure	  2-­‐41).	  Next	   we	   compared	   the	   number	   of	   probes	   per	   DDG2P	   entry	   before	   and	   after	  probe	  removal	  to	  ensure	  that	  the	  diagnostic	  power	  of	  the	  array-­‐CGH	  platform	  for	  genes	   previously	   associated	   with	   developmental	   disorders	   was	   not	  compromised	  by	  the	  probe	  removal	  strategy	  (see	  Figure	  2-­‐42).	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  Table	  2-­‐12	  The	  number	  of	  probes	  removed	  and	  the	  number	  of	  DD	  gene	  with	  that	  number	  of	  probes	  removed	  after	  probe	  removal.	  
	  Figure	  2-­‐42	  Number	  of	  array-­‐CGH	  probes	  per	  DDG2P	  gene	  before	  (left)	  and	  after	  (right)	  probe	  removal.	  Overall	   14%	  of	  DDG2P	   entries	   had	   zero	   probes	   removed	   and	   41%	  of	   had	   less	  than	  3	  probes	  removed.	  More	  than	  80%	  had	  less	  than	  ten	  probes	  removed	  and	  94%	   had	   less	   than	   twenty	   probes	   removed	   (see	   Table	   2-­‐12).	   The	   median	  number	  of	  probes	  per	  DD	  gene	  remained	  at	  97	  before	  and	  after	  probe	  removal.	  	  Based	   on	   the	   results	   presented	   above	   it	   was	   decided	   to	   implement	   the	   probe	  removal	  strategy	  using	   the	  Mann-­‐Whitney	  p	  values	  resulting	   in	  removing	  4.7%	  of	   the	   probes	   on	   the	   array-­‐CGH	   platform	   as	   a	   standard	   step	   in	   the	   array-­‐CGH	  analytical	  pipeline	   for	   the	  DDD	  project.	  Because	  this	  change	   involved	  removing	  data	   points	   from	   the	   raw	   (input)	   data	   before	   any	   analytical	   processing	   could	  occur	  it	  was	  necessary	  to	  increment	  the	  main	  acgh-­‐pipeline	  version	  number	  (see	  
Chapter	  3)	  and	  re-­‐run	  the	  entire	  pipeline	  for	  all	  data	  processed	  to	  date.	  	  
Filtering	  Results	  Before	  and	  After	  Probe	  Removal	  The	  main	   pipeline	   version	  number	  was	   incremented	   from	  0.1	   to	   1.0.0	   and	   the	  entire	  pipeline	  was	  re-­‐run	  for	  all	  available	  data	  sets.	  Originally	  there	  were	  1,395	  QC	  passed	  array-­‐CGH	  datasets	  using	  pipeline	  version	  0.1,	  of	  which	  99.5%	  passed	  sample	  QC	  using	   the	  new	  pipeline	  version	   (1.0.0).	  Seven	  samples	   failed	  at	  post	  calling	  QC	  as,	  due	   to	   the	   removal	  of	  probes,	   some	  CNV	  call	   characteristics	   (e.g.	  number	   of	   calls,	   breakpoint	   locations,	   mean	   log2	   ratios,	   wscore)	   were	  understandably	   slightly	  different	  between	   the	  pipeline	  versions	  and	  due	   to	   the	  nature	   of	   the	   post	   calling	   QC	  methods	   (see	  Methods)	   slight	   differences	   in	   the	  characteristics	   of	   individual	   CNV	   calls	   can	   result	   in	   sample	   and	   data	   QC	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differences	   in	  both	  directions	  (the	  QC	  cut-­‐offs	  are	  not	  static,	   fixed	  parameters).	  However,	  overall	  for	  the	  vast	  majority	  of	  samples	  (1388/1395)	  the	  QC	  results	  for	  both	   sample	   and	   data	   quality	   checking	   remained	   the	   same	   after	   the	   pipeline	  version	  was	  incremented	  to	  1.0.0.	  	  Table	  2-­‐13	  Summary	  statistics	  for	  the	  number	  of	  CNV	  calls	  made	  using	  pipeline	  version	  0.1	  and	  1.0.0	  
Pipeline	  Version	   #	  Calls	   #	  Rare	  Calls	   #	  Flagged	   #	  Reported	  
0.1	   330803	   92532	   411	   57	  
1.0.0	   301409	   78965	   225	   39	  	  Using	  pipeline	   version	  1.0.0,	  which	   included	   the	   removal	   of	   poorly	  performing	  array-­‐CGH	  probes	  prior	  to	  CNV	  detection,	  there	  were	  less	  CNV	  detections	  made	  overall	  with	  a	  median	  of	  217	  CNV	  calls	  per	  sample	  compared	  to	  238	  per	  sample	  when	  using	  pipeline	  version	  0.1	  (see	  Figure	  2-­‐43).	  The	  number	  of	  rare	  calls	  also	  decreased	   slightly	   when	   using	   pipeline	   1.0.0,	   with	   a	   median	   number	   of	   56	  compared	  to	  66	  when	  using	  pipeline	  version	  0.1.	  The	  number	  of	  CNVs	  flagged	  for	  clinical	   review	   was	   decreased	   almost	   two-­‐fold	   when	   using	   the	   new	   pipeline	  version	   suggesting	   that	   recurrent	   CNV	   calls	   at	   problematic	   regions	   (e.g.	   FMR1,	  SHANK3	  and	  CHD7)	  may	  have	  been	  avoided.	  However,	  a	  relatively	  large	  number	  of	  CNVs	  that	  had	  previously	  been	  reported	  during	  the	  manual	  step	  and	  had	  been	  deposited	   in	   DECIPHER	   using	   results	   from	   pipeline	   0.1	   were	   apparently	   no	  longer	  called	  using	  the	  pipeline	  version	  1.0.0	  (see	  Table	  2-­‐13).	  	  
	  Figure	  2-­‐43	  The	  number	  of	  CNV	  calls	  made	  per	  slide	  using	  pipeline	  version	  0.1	  (previous	  calls)	  vs.	  pipeline	  version	  1.0.0	  (new	  calls).	  As	  expected	  each	  slide	  had	  slightly	  less	  CNV	  calls	  using	  the	  new	  compared	  to	  the	  old	  pipeline.	  For	  the	  new	  pipeline	  version	  results,	  4.7%	  of	  the	  array-­‐CGH	  probes	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had	  been	  removed	  and	  not	  used	   for	  CNV	  detection	   therefore	   it	  would	  be	  more	  difficult	  or	  even	  impossible	  for	  the	  new	  pipeline	  to	  call	  CNVs	  including	  signal	  or	  dominated	  by	  probe	  signals	  that	  were	  no	  longer	  used	  for	  CNV	  detection.	  	  
	  Figure	   2-­‐44	   The	   proportion	   of	   new	   calls	   (pipeline	   1.0.0)	   previously	   detected	  (pipeline	  0.1)	  per	  sample.	  Due	   to	   the	   removal	   of	   probes	   across	   the	   array-­‐CGH	   platform	   the	   exact	  breakpoint	   (change	   point)	   location	   and	   change	   point	   interval	   (distance)	   are	  liable	  to	  some	  change	  between	  pipeline	  versions.	  Overall	  the	  majority	  of	  samples	  show	   very	   high	   similarity	   between	   pipeline	   versions,	   with	   the	   proportion	   of	  previously	  detected	  CNV	  calls	  tailing	  off	  very	  quickly	  below	  90%	  (see	  Figure	  2-­‐
44).	  The	  small	  number	  of	  samples	  with	  greater	  than	  100%	  previously	  detected	  CNV	  calls	  can	  be	  explained	  by	  CNV	  intervals	  that	  were	  split	   into	  more	  than	  one	  event	  in	  the	  new	  pipeline	  compared	  to	  the	  old	  pipeline	  results.	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Figure	   2-­‐45	   The	   number	   of	   CNVs	   flagged	   for	   clinical	   review	   per	   sample	   using	  pipeline	  version	  0.1	  vs.	  pipeline	  version	  1.0.0.	  Overall	   the	   number	   of	   CNVs	   flagged	   for	   clinical	   review	  was	   decreased	   almost	  two-­‐fold	   following	   the	   pipeline	   version	   increment	   (see	   Table	   2-­‐13).	  Furthermore	   the	   number	   of	   flagged	   CNVs	   per	   sample	  was	   decreased	   between	  versions	   (see	   Figure	   2-­‐45),	   indicating	   that	   problematic	   CNV	   calls	   recurrently	  made	   in	   relatively	   large	   numbers	   of	   samples	   had	   been	   avoided	   in	   the	   new	  pipeline	  version	  results.	  	  
	  Figure	  2-­‐46	  The	  number	  of	  CNVs	   flagged	   for	  clinical	   review	  per	  DD	  gene	  using	  pipeline	  version	  0.1	  vs.	  pipeline	  version	  1.0.0.	  The	   number	   of	   CNVs	   flagged	   for	   clinical	   review	   per	   DD	   gene	   was	   decreased	  considerably	  between	  pipeline	  versions.	  This	  was	  encouraging	  as	  the	  reason	  for	  apply	   the	   probe	   removal	   strategy	   and	   incrementing	   the	  main	   pipeline	   version	  was	   the	  observation	  of	   relatively	   large	  numbers	  of	   flagged	  CNVs	   in	  specific	  DD	  genes	   which,	   after	   manual	   review	   and	   although	   being	   high	   quality	   CNV	   calls,	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were	   deemed	   to	   be	   spurious	   results	   and	   not	   associated	   with	   specific	   patient	  phenotypes.	  	  The	  CNV	   calls	   in	   the	   three	  main	   genes	   that	  had	   initially	   indicated	   the	  problem	  (FMR1,	   SHANK3	   and	   CHD7)	   has	   decreased	   dramatically	   between	   pipeline	  versions	  (see	  Figure	  2-­‐46).	  However,	  there	  were	  some	  additional	  genes	  that	  had	  not	  previously	  been	  observed	  as	  having	  high	  recurrent	  rates	  across	  samples	  that	  had	   also	   seen	   a	  decrease	   in	   the	  number	  of	   times	   they	  were	   flagged	   for	   review	  between	  pipeline	  versions.	  This	  suggested	  that	   the	  probe	  removal	  strategy	  had	  worked	  rather	  well	  and	  on	  top	  of	  removing	  problematic	  calls	  at	  FMR1,	  SHANK3	  and	  CHD7	  had	  also	  resulted	  in	  decreasing	  the	  rate	  of	  recurrently	  flagged	  CNVs	  in	  other	   DD	   genes.	   These	   recurrently	   flagged	   CNVs	   in	   additional	   DD	   genes	   were	  highly	  likely	  to	  also	  be	  spurious	  due	  to	  both	  the	  relatively	  high	  (implausible)	  rate	  across	   samples	   and	   the	   fact	   that	   the	   behaviour	   of	   the	   probes	   instrumental	   in	  detecting	  the	  previously	  flagged	  CNVs	  were	  significantly	  associated	  with	  that	  of	  the	  known	  problematic	  probes.	  
CNV	  Calls	  in	  CHD7,	  SHANK3	  &	  FMR1	  between	  pipeline	  versions	  The	  most	   straightforward	   and	   logical	  way	   of	   assessing	   the	   effect	   of	   the	   probe	  removal	  strategy	  was	   to	   look	  at	   the	  number	  and	   type	  of	  CNV	  calls	  made	  at	   the	  three	  defined	  problem	  genes	  (FMR1,	  SHANK3	  and	  CHD7).	  Reasoning	  that	   if	   the	  strategy	   had	   been	   successful	   in	   removing	   poorly	   performing	   probes	   that	  were	  the	  cause	  of	   false	  positive	  CNV	  calls	   in	   samples	  with	  no	  associated	  phenotypes	  these	  CNV	  calls	  would	  no	  longer	  be	  made.	  	  	  	  Table	  2-­‐14	  The	  number	  of	  CNVs	  flagged	  of	  clinical	  review	  at	  CHD7,	  SHANK3	  and	  FMR1	  between	  pipeline	  version	  0.1	  and	  1.0.0.	  
Gene	   #	  Flagged	  pipeline	  0.1	   #	  Flagged	  pipeline	  1.0.0	  CHD7	   35	   1	  SHANK3	   36	   3	  FMR1	   57	   0	  	  Above	  (see	  Table	  2-­‐14)	  that	  the	  number	  of	  flagged	  CNVs	  at	  CHD7,	  SHANK3	  and	  FMR1	   show	   a	   massive	   decrease	   for	   the	   results	   from	   pipeline	   version	   1.0.0	  compared	  to	  0.1.	  There	  were	  no	  CNV	  calls	  remaining	  at	  FMR1,	  3	  at	  SHANK3	  and	  1	  at	  CHD7.	  It	  should	  be	  noted	  that	  not	  all	  probes	  in	  these	  problematic	  genes	  were	  defined	  as	  poor	  quality	  and	  we	  should	  expect	  to	  still	  be	  able	  to	  call	  good	  quality	  CNV	  calls	   in	  FMR1,	  SHANK3	  and	  CHD7	  using	  the	  remaining	  probes	  (74,	  43	  and	  202	  respectively).	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  Figure	  2-­‐47	  Remaining	  SHANK3	  CNV	  calls	  in	  pipeline	  1.0.0	  results.	  The	  above	  plot	  (see	  Figure	  2-­‐47)	  shows	  images	  of	  the	  log2	  ratio	  profiles	  across	  the	   three	   remaining	  SHANK3	  CNV	  calls,	   the	   red	  bar	   indicates	   the	   change	  point	  interval	   defined	   by	   CNsolidate.	   All	   problematic	   array-­‐CGH	   probes	   have	   been	  removed	  and	  the	  probes	  indicating	  single	  copy	  deletions	  in	  the	  three	  individual	  samples	   are	   all	   deemed	  high	  quality.	   The	  data	   noise	   profile	   of	   the	   background	  and	  change	  point	   locations	   in	  all	   three	  samples	   indicate	  high	  quality	  CNV	  calls.	  Furthermore	   all	   patients	  presented	  with	  Autism-­‐like	  phenotypes	   and	  deletions	  at	   SHANK3	   are	   the	   most	   common	   cause	   of	   Phelan-­‐McDermid	   syndrome,	   a	  syndrome	  that	  often	  includes	  a	  degree	  of	  autism	  [176].	  	  	  	  
Previously	  Reported	  Variants	  Fifty-­‐seven	  CNV	  calls	  had	  been	  reported	  via	  DECIPHER	  to	  the	  clinical	  diagnostic	  teams	   using	   results	   from	  pipeline	   0.1.	   Of	   the	   57	   previously	   reported	   CNVs,	   39	  were	  called	  using	  pipeline	  1.0.0	  with	  exactly	   the	  same	  breakpoint	   locations,	  17	  were	  called	  with	  only	  slight	  differences	  in	  breakpoint	  locations	  between	  pipeline	  versions	  and	  one	  previously	  reported	  CNV	  call	  at	  CHD7	  was	  no	  longer	  present	  in	  the	  1.0.0	  version	  results.	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  Figure	  2-­‐48	  Left	  –	  the	  count	  of	   the	  number	  of	  CNV	  calls	  made	  by	  pipeline	  1.0.0	  inside	  a	  reported	  CNV	  called	  using	  pipeline	  0.1;	  Right	  –	  the	  forward	  overlap	  the	  (old	  to	  new	  CNV	  call)	  vs.	  the	  backward	  overlap	  (new	  to	  old	  CNV	  call).	  The	   majority	   of	   the	   CNV	   calls	   show	   high	   degrees	   of	   similarity	   in	   breakpoint	  locations	   between	   the	   two	   pipeline	   version	   numbers	   (see	   Figure	   2-­‐48).	   Two	  CNVs	  show	  slight	  decreased	  backwards	  overlap	  values,	   indicating	   that	   the	  new	  CNV	   calls	   are	   slightly	   larger	   than	   the	   old	   CNV	   calls.	   One	   CNV	   calls	   shows	   a	  marked	   decrease	   in	   the	   forward	   overlap	   value	   indicating	   the	   change	   point	  interval	  is	  smaller	  in	  the	  CNV	  call	  made	  using	  the	  new	  pipeline	  version.	  One	  CNV	  call	   shows	   zero	   forward	   and	   zero	   backward	   overlap	   values	   meaning	   that	   it	  missing	   from	   the	   new	  pipeline	   version	   results,	   however	   the	   CNV	   call	  was	   also	  deprecated	  in	  DECIPHER	  due	  to	  an	  alternative	  diagnosis	  and	  no	  CHARGE,	  KAL5	  or	  IHH	  like	  phenotypes	  displayed	  in	  the	  patient	  which	  could	  result	  from	  a	  CNV	  at	  CHD7	  [177].	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2.4	   DISCUSSION	  	  
Conclusions	  -­‐	  CNsolidate	  We	  have	  developed	  a	  change	  point	  detection	  package,	  CNsolidate	  that	  makes	  use	  of	  multiple	   change	   detection	   algorithms	   and	   an	   expert	   voting	   system	  with	   the	  goal	  of	  increasing	  detection	  rates	  and	  detection	  consistency	  across	  multiple	  data	  sets.	  The	  benefit	  of	  using	  multiple	  change	  point	  detection	  algorithms	  to	  increase	  ones	  confidence	  in	  individual	  detections	  using	  a	  naive	  voting	  system	  (consensus)	  and	   an	   expert	   voting	   (integrating	   prior	   knowledge)	   approach	   has	   been	  demonstrated.	   Evidence	   was	   presented,	   in	   the	   form	   of	   an	   analysis	   of	   receiver	  operator	   characteristics,	   to	   show	   that	   by	   using	   its	   combined	   approach,	  CNsolidate,	   delivers	   improved	   performance	   compared	   to	   any	   of	   its	   individual	  components	  algorithms.	  Examples	   of	   using	   the	   score	   adjustment	   strategy	   to	   allow	   detection	   quality	  scores	  to	  be	  ranked	  between	  data	  sets	  based	  on	  a	  desired	  level	  and	  type	  of	  truth	  has	  been	  shown.	  Again	  using	  a	  ROC	  analysis	  we	  demonstrated	  the	  ability	  to	  set	  a	  single	  threshold	  on	  the	  detection	  quality	  measure	  (adjusted	  wscore)	  to	  obtain	  a	  consistent	   level	   of	   performance	   across	  multiple	   data	   sets	   (50	   replicates	   of	   the	  DDD	  control	  sample	  NA12878).	  Moreover,	  by	  comparing	  the	  performance	  of	  the	  adjusted	   wscore	   for	   defining	   detection	   quality	   against	   a	   number	   of	   other	  approaches	   to	   detection	   filtering	   we	   found	   that	   the	   wscore	   generated	   by	  CNsolidate	  performed	  best	  for	  predicating	  CNV	  call	  quality.	  	  CNsolidate	  contains	  a	  number	  of	   individual	  change	  point	  detection	  algorithms,	   including	  previously	  published	   and	   novel	   methodologies,	   however	   it	   is	   made	   available	   as	   a	   stand-­‐alone	  analytical	  package	  with	  no	  external	  dependencies.	  This	  not	  only	  provides	  a	  given	  user	  with	   a	   simple	   one-­‐step	   installation	  procedure	  but	   also	   ensures	   that	  the	  consistency	  of	  the	  package	  is	  maintained.	   	  Changes	  or	   improvements,	  made	  externally,	   to	   any	   methods	   contained	   inside	   CNsolidate	   are	   likely	   to	   be	   only	  updated	  within	  CNsolidate	  once	  a	   review	  process,	   relating	   the	  cost-­‐benefit	  and	  maintenance	  of	  analytical	  consistency,	  has	  been	  undertaken.	  The	   large	   number	   of	   parameter	   definitions	   within	   CNsolidate	   are	   contained	  inside	   a	   single	   configuration,	   allowing	   modifications	   to	   be	   made	   with	   relative	  ease.	   CNsolidate	   contains	   a	   large	   number	   of	   data	   simulation	   methodologies,	  semi-­‐automating	   the	   tuning	   procedure	   for	   individual	   algorithms	   and	   the	  associated	   weighting	   functions	   (see	   Appendix).	   Overall	   we	   found	   that	   1)	  combining	  information	  between	  multiple	  change	  point	  detection	  algorithms;	  and	  
2)	   integrating	   prior	   knowledge	  when	   generating	   a	   confidence	   score	   (wscore);	  resulted	   in	   an	   increase	   in	   detection	   performance	   and	   consistency	   across	  relatively	  large	  numbers	  of	  datasets.	  	  
Conclusions	  –	  CNV-­‐tagging	  SNPs	  We	   have	   developed	   a	   novel	   analytical	   approach	   for	   the	   tracking	   of	   array-­‐CGH	  data	  using	  copy	  number	  tagging	  SNPs.	  This	  was	  important	  to	  the	  DDD	  project	  to	  provide	  a	  level	  of	  confidence	  that	  the	  data	  going	  through	  the	  analytical	  pipelines	  were	   from	   the	   expected	   individual	   (sample).	   	   The	   method	   developed	   uses	   a	  probabilistic	   approach	   to	   determining	   sample	   mismatches.	   By	   applying	   this	  approach	  to	  control	  data	   it	  was	  possible	   to	  detect	  and	  resolve	  a	  known	  sample	  mismatch.	   Additionally,	   using	   random	   data	   sampling,	   the	   presented	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discriminatory	  power	  of	  the	  approach	  was	  relatively	  good	  for	  high	  quality	  (low	  noise)	   data	   and	   as	   data	   quality	   decreased	   the	   discriminatory	   power	   of	   the	  tracking	   values	   also	   decreased.	   The	   method	   also	   constantly	   updates	   the	  parameters	  of	  the	  model	  using	  a	  fast	  lookup	  and	  recalculation	  of	  some	  necessary	  parameters.	   It	   is	   expected	   that	   as	   more	   data	   are	   added	   into	   the	   model	   the	  discriminatory	  power	  of	  the	  tracking	  values	  are	  likely	  to	  improve	  overall.	  	  Because	  of	  the	  large	  data	  sets	  in	  question	  this	  functionality	  relies	  heavily	  on	  the	  ability	   to	   extract	   the	   necessary	   information	   in	   a	   timely	   fashion.	   We	   have	  developed	   a	   novel	   data	   storage	   and	   accessing	  method	   using	   a	   specific	   type	   of	  binary	   format	   and	   random	   access	   data	   reading	   methods.	   These	   accessor	  methods	   display	   impressive	   performance	   characteristics	   and	   allow	   the	   lookup	  and	  update	  to	  execute	  in	  a	  fraction	  of	  the	  time	  that	  would	  otherwise	  be	  required.	  
Conclusions	  –	  CNV	  Consensus	  The	   CNV	   consensus	   reference	   set	   has	   been	   created	   using	   a	   number	   of	   high	  quality	   studies	   into	   common	   genomic	   variation.	   This	   set,	   being	   made	   up	   of	  predicted	  high	  quality	  data	  sets,	  can	  aid	  the	  accurate	  filtering	  of	  variants	  across	  the	   genomic	   range.	   By	   combining	   the	   data	   sets	   into	   the	   CNV	   consensus	   we	  achieve	  good	  coverage	  of	   common	  variation	  across	  a	   large	  genomic	  size	   range.	  Having	   included	   both	   sequencing	   and	   array-­‐based	   studies	   into	   the	   CNV	  consensus	   the	   positional	   information	   from	   small	   genomic	   regions	   up	   to	   the	  larger	   structural	   rearrangements	   has	   been	   included.	   	   By	   combining	   these	  different	  data	  sets	  it	  was	  possible	  to	  not	  only	  define	  regions	  of	  common	  genomic	  variation	   but	   also	   give	   an	   estimate	   of	   the	   population	   frequency	   at	   each	   CNVE.	  This	   is	   important	   for	   accurate	   and	   flexible	   filtering	   procedures,	   for	   example	  having	   observed	   a	   variant	   only	   once	   (singleton)	   in	   a	   study	   containing	   5,919	  samples	  is	  very	  different	  to	  observing	  a	  variant	  multiple	  times	  across	  a	  number	  of	  different	  studies.	  	  Providing	   an	   accurate	   estimate	   of	   population	   frequency	   for	   common	   CNVEs	  allows	   filtering	   methods	   to	   group	   variants	   into	   different	   categories	   using	  different	   frequency	   cut-­‐offs.	   For	   example,	   one	   could	   define	   different	   frequency	  cut-­‐offs	  to	  classify	  a	  test	  variant	  into	  common,	  rare	  or	  novel	  CNV	  types.	  We	  have	  provided	  a	  general	  approach	  for	  calculating	  the	  positional	  similarity	  of	  test	  CNVs	  to	  CNVEs	  contained	  inside	  the	  CNV	  consensus	  reference	  set,	  maximising	  both	  the	  forward	  and	  backward	  overlap	  values	  to	  find	  the	  frequency	  of	  the	  most	  similar	  CNVE	   in	   terms	   of	   their	   genomic	   coordinates.	   Additionally,	   the	   CNV	   consensus	  provides	   a	   state	   type	   value.	   This	   is	   important	   because,	   having	   observed	   only	  duplication	  type	  variation	  at	  a	  given	  genomic	  location	  in	  studies	  of	  common	  CNV	  does	   not	   necessarily	   mean	   that	   a	   deletion	   at	   the	   same	   location	   would	   not	   be	  harmful.	   There	   are	   a	   number	   of	   genes	   in	   which	   an	   increase	   in	   dosage	  (duplication)	  is	  tolerated	  whereas	  a	  loss	  of	  one	  (heterozygous	  deletion)	  or	  both	  (homozygous	  deletion)	  copies	  can	  result	  in	  extreme	  phenotypes.	  The	  ACP5	  gene	  when	   homozygously	   deleted	   can	   cause	   certain	   pathological	   states	   such	   as	  Sjogrens	   syndrome	   [178],	   whereas	   certain	   pathological	   states	   can	   result	   from	  the	   duplication	   of	   other	   genes,	   for	   example	   the	   duplication	   syndrome	   of	   the	  MECP2	  gene	  [179].	  Importantly	  the	  approach	  developed	  for	  assigning	  population	  frequency	   estimates	   to	   test	   CNVs	   takes	   this	   information	   into	   account	   and	   only	  compares	  deletions	  to	  exclusively	  deletion	  or	  deletion	  and	  duplication	  sites;	  and	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only	   compares	   duplications	   to	   exclusively	   duplication	   or	   deletion	   and	  duplication	  sites.	  Finally,	  the	  CNV	  consensus	  set	  can	  be	  visualised	  using	  online	  resources	  such	  as	  DECIPHER,	  ENSEMBL	  and	  UCSC.	  Additionally,	  the	  CNV	  consensus	  set	  is	  provided	  as	  a	  data	  source,	  along	  with	  a	  number	  of	  functions	  relating	  to	  CNV	  interpretation,	  within	  the	  CNsolidate	  package.	  We	  explicitly	  provide	  two	  different	  approaches	  to	  variant	   filtering	   using	   either	   the	   separate	   merged	   study	   sets	   or	   the	   complete	  combined	  CNV	  consensus.	  For	  the	  DDD	  analytical	  pipeline	  we	  preferentially	  use	  approach	   one	   to	   variant	   filtering,	   comparing	   any	   test	   CNV	   location	   against	   all	  individual	  CNVE	  sets	  from	  the	  CNV	  consensus.	  Using	  this	  approach	  ensured	  that	  problems	  encountered	  when	   combining	   information	  across	   studies	  of	  different	  sizes	   and	   effective	   genomic	   resolution	   was	   avoided.	   For	   example,	   adding	   the	  number	  of	  samples	  together	  to	  generate	  a	  combined	  frequency	  measure	  can	  be	  problematic	   if	   the	   operational	   genomic	   resolution	   of	   each	   study	   is	   not	   well	  understood.	   For	   illustration	   purposes	   imagine	   the	   case	   where	   a	   single	   small	  deletion	  is	  detected	  in	  a	  high	  resolution	  study	  with	  20	  samples,	  if	  we	  use	  the	  “in	  study”	  frequency	  we	  calculate	  the	  value	  at	  (0.05).	  However	  if	  we	  combined	  this	  information	  with	  a	   larger	  study	  containing	  5000	  samples	   that	  did	  not	  have	   the	  capacity	   to	  detect	  CNVs	  at	   the	  same	  position	  and	  did	  not	   take	   that	   information	  into	  account	  we	  would	   incorrectly	  assume	  a	  “cross	  study”	   frequency	  of	  0.0002.	  This	   is	   a	   general	   problem	  with	   combining	   information	   from	   large	   numbers	   of	  studies	  to	  use	  as	  reference	  sets	  for	  filtering	  common	  genomic	  variation.	  The	  CNV	  consensus	  aims	  to	  address	  some	  of	  these	  issues	  and	  provides	  two	  approaches	  to	  matching	   CNVs	   with	   population	   frequency	   information.	   Furthermore	   for	  approach	  2	  we	  have	  estimated	  the	  functional	  resolution	  of	  each	  platform	  used	  in	  the	   CNV	   consensus	   and,	   for	   each	   genomic	   location,	   only	   combine	   information	  across	  studies	   that	  could	   theoretically	  have	  detected	  variation	  at	   the	  particular	  locus.	  However,	   the	  operational	  detection	   resolution	   is	  hard	   to	  estimate	  as,	   for	  example,	   each	   study	   used	   different	   analytical	   methodology	   (change	   point	  detection	  algorithms)	  displaying	  differential	  performances.	  
CNV	  Filtering	  We	   have	   designed	   a	   CNV	   filtering	   strategy	   for	   flagging	   variants	   of	   potential	  clinical	   significance	   and	   implemented	   a	   fully	   versioned	   and	   adaptable	   CNV	  filtering	  pipeline	  for	  all	  CNV	  calls	  made	  by	  CNsolidate	  for	  the	  DDD	  project.	  This	  pipeline	   is	   of	   critical	   importance	   to	   the	   ability	   to	   feed	   results	   from	   the	   DDD	  project	  back	   to	   the	  clinical	   teams	  across	   the	  UK	  and	   Ireland.	  We	  make	  use	  of	  a	  dedicated	   resource	   (DDG2P)	   linking	   types	   of	   variation	   to	   genes	   previously	  associated	  with	  genomic	  disorders	  and	  additionally	  providing	  gene	  to	  phenotype	  associations	  using	  the	   fixed	  term	  HPO	  ontology	  [152].	  Key	  to	   the	  ability	   to	   link	  CNVs	   with	   specific	   genes	   contained	   inside	   the	   DDG2P	   is	   the	   mode	   and	  mechanism	  annotations,	  meaning	  that	  the	  effect	  that	  a	  CNV	  overlapping	  any	  DD	  gene	  might	  have	  can	  be	  predicted	  based	  on	  the	  copy	  number	  state	  of	  the	  CNV.	  The	   filtering	   pipeline	   flags	   CNVs	   for	   clinical	   review	   using	   one	   of	   two	   different	  routes	   that	   we	   term	   the	   VOUS	   and	   the	   DD	   gene	   routes.	   CNVs	   flagged	   via	   the	  VOUS	   route	   are	   large	   enough	   and	   observed	   at	   low	   enough	   frequency	   in	   the	  general	  population	  to	  be	  thought	  of	  as	  having	  general	  clinical	  significance.	  On	  the	  other	  hand,	  CNVs	  flagged	  via	  the	  DD	  gene	  route	  are	  very	  specific	  and	  display	  the	  correct	   copy	  number	  state	   to	  have	  a	  high	   likelihood	  of	   causing	   the	  phenotypes	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previously	   described	   for	   the	   specific	   gene.	   We	   did	   not	   apply	   any	   phenotype	  matching,	   using	   the	  HPO	   terms	   to	  match	  patient	   records	   in	  DECIPHER	   to	   gene	  entries	  in	  the	  DDG2P,	  rather	  simply	  considered	  all	  flagged	  CNVs	  to	  be	  of	  general	  clinical	  interest	  and	  relied	  on	  the	  expertise	  of	  clinical	  specialists	  to	  interpret	  the	  meaning	   and	   importance	   of	   such	   CNVs	   with	   respect	   to	   patient	   information.	  Rather	   than	   attempting	   to	   automatically	   interpret	   the	   clinical	   significance	   of	  CNVs	   detected,	   the	   DDD	   project	   prioritises	   and	   tracks	   CNVs,	   enabling	   clinical	  interpretation,	  patient	  feedback	  and	  ultimately	  a	  potential	  diagnosis	  for	  patients	  and	  their	  family.	  Furthermore	  all	  information	  for	  detected	  CNVs	  across	  the	  DDD	  project	  cohort	   is	  maintained	   in	  dedicated	  databases	  and	   file	  systems	  as	  well	  as	  detailed	  patients	  records	  in	  DECIPHER	  facilitating	  the	  search	  for	  novel	  variants	  to	  gene	  function	  discovery	  in	  a	  research	  setting	  [180].	  The	   overall	   results	   from	   filtering	   CNVs	   for	   clinical	   significance	   using	   two	  different	   versions	  of	   the	   acgh-­‐pipeline	  have	  been	  presented.	  To	   ensure	  patient	  confidentiality	   and	   avoid	   ethical	   issues	   results	   were	   presented	   using	   global	  summery	  statistics	  rather	  than	  providing	  specific	  findings	  in	  individual	  patients.	  No	   incidental	   findings	   were	   discussed	   and	   no	   patient	   identifiable	   information	  was	  given.	  A	  specific	  technical	  problem	  noticed	  due	  to	  a	  relatively	  large	  number	  of	   flagged	  CNVs	   in	  specific	  DD	  genes	  was	  described,	  a	  detailed	  assessment	   into	  the	   cause	   was	   presented,	   a	   solution	   was	   implemented	   and	   evidence	   that	   the	  sensitivity	   for	  detecting	  CNVs	  using	   the	  array-­‐CGH	  platform	  was	  maintained	  at	  an	  acceptable	  level	  was	  provided.	  Overall	  the	  performance	  of	  the	  clinical	  filtering	  component	   in	   the	   acgh-­‐pipeline	   was	   initially	   relatively	   low	   in	   terms	   of	   total	  numbers	   of	   flagged	   variants.	   This	  was	   a	   deliberate	   choice	   by	   the	   DDD	   project	  since	   the	  manual	   review	  and	   feedback	  of	  variants	   is	  a	   time	  consuming	  process	  and	   the	   available	   resources	   (primarily	   clinicians’	   time)	   needed	   to	   be	   carefully	  balanced.	   Furthermore,	   the	   parameters	   chosen	   for	   flagging	   variants	   were	  initially	  set	   to	  be	  high	  stringency	   in	  terms	  of	  detection	  confidence	  to	  ensure	  all	  flagged	  variants	  were	  high	  quality	   resulting	   in	   a	   low	   false	  positive	   rate.	  As	   the	  DDD	   project	   progresses	   these	   parameters	   and	   filtering	   rules	   are	   likely	   to	   be	  relaxed,	  potentially	  increasing	  the	  diagnosis	  rate	  from	  CNVs.	  The	  clinical	  filtering	  component	  has	  been	  developed	  to	  allow	  changes	  in	  filtering	  logic	  to	  be	  applied	  with	   relative	   ease	   using	   version	   control	   and	   configurable	   parameters.	  Furthermore,	   the	   data	   storage	   structures	   have	   been	  designed	   to	   accommodate	  changes	   to	   the	  pipeline	  versions	  and	  analytical	   results	  obtained	   from	  the	  acgh-­‐pipeline.	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3 |	  DDD	  Pipeline	  Development	  
	  
3.1	   OVERVIEW	  	  The	  DDD	   array-­‐CGH	   pipeline	   is	   built	   to	   run	   in	   batch	   on	   a	   load	   sharing	   facility	  (LSF)	   and	   stores	   results	   in	   both	   a	   dedicated	   file	   system	   and	   database.	   A	  dedicated	   POSTGRESQL	   database	   and	   file	   system	   to	   store	   and	   maintain	   all	  analytical	   information	   generated	   by	   the	   DDD	   array-­‐CGH	   pipeline	   has	   been	  developed.	  	  The	   file	   system	   structure	   is	   key	   to	   the	   accurate	   maintenance	   of	   analytical	  information,	  more	  so	  than	  the	  database.	  The	  file	  system	  is	  a	  tree-­‐like	  structure,	  based	  on	  a	  running	  integer	  using	  a	  pad	  and	  split	  approach.	  	  This	  ensures	  that	  the	  file	  system	  is	  structured	  and	  that	  each	  directory	  only	  contains	  a	  maximum	  of	  100	  directories.	   For	   storing	   results	   at	   scale	   it	   is	   important	   to	   ensure	   that	   single	  directories	  do	  not	  contain	  too	  many	  items.	  As	  the	  number	  of	  items	  in	  a	  directory	  increases	   the	  performance	   of	   simple	   file	   system	  operations,	   such	   as	   listing	   the	  contents	  of	  a	  directory,	  becomes	  severely	  compromised	  and	  has	  the	  potential	  to	  add	   considerable	   overhead	   to	   input	   /	   output	   (I/O)	   speed.	   The	   second	   last	  directory	   in	   the	   full	   path	   for	   each	   sample	   is	   the	   ’sanger	   id’,	   followed	   by	   the	  specific	   experiment	   (array-­‐CGH	   slide)	   ids;	   this	   allows	   all	   data	   for	   any	   given	  sample	   to	   be	   easily	   found.	   Additionally,	   the	   information	   contained	   under	   the	  directories	  for	  a	  given	  sample	  contains	  all	  the	  information	  stored	  in	  the	  database.	  This	  means	   that	   the	   database	   can	   be	   rebuilt	   from	   the	   file	   system	   at	   any	   given	  time.	  Furthermore	  the	  entire	  file	  system	  is	  backed	  up	  at	  regular	  intervals	  adding	  extra	  security	  against	  potential	  data	  loss.	  	  There	   is	   a	   dedicated	   database	   and	   file	   system	   accessor	   and	   storage	   package,	  written	   purely	   in	   R,	   allowing	   querying	   of	   data	   across	   the	   file	   system	   and	  database	  tables	  using	  specific	  R	  class	  definitions.	  For	  the	  general	  user	  this	  hides	  a	  lot	  of	  the	  complexity	  within	  the	  data	  storage	  structure	  and	  allows,	  for	  example,	  simple	  queries	  to	  retrieve	  all	  analytical	  information	  for	  a	  sample	  using	  its	  sanger	  id	  as	   input	  to	  a	  single	  command	  inside	  the	  R	   interface.	  This	   is	  of	  particular	  use	  for	   others	   within	   the	   DDD	   project	   wanting	   to	   query	   the	   data	   but	   who	   have	  limited	  technical	  knowledge	  of	  the	  SQL	  language	  and	  the	  file	  system	  structure.	  	  	  	  The	  structure	  of	  the	  SQL	  database	  is	  overall	  very	  simple	  and	  effectively	  only	  has	  eight	  independent	  tables	  with	  no	  explicit	  foreign	  key	  relationships.	  The	  decision	  to	   implement	   an	   unnormalisaed	   database	   structure	  was	   taken	   early	   on	   as	   the	  expectation	  was	  that	  the	  results	  would	  eventually	  be	  subsumed	  by	  a	  larger	  more	  complicated	   variant	   database	   housed	   at	   the	   Wellcome	   Trust	   Sanger	   Institute.	  Results	  from	  the	  DDD	  array-­‐CGH	  pipeline	  are	  now	  being	  incorporated	  into	  a	  new	  database	  structure	  that	   is	  planned	  to	  drive	  further	  analytical	  work	  for	  the	  DDD	  project.	  CNsolidate	  is	  an	  integral	  part	  of	  the	  DDD	  array-­‐CGH	  pipeline,	  containing	  the	  greatest	  number	  and	  most	  complex	  analytical	  software	  components	  of	  all	  the	  internal	  DDD	  analytical	  pipelines.	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3.2	   IMPLEMENTATION	  	  The	   array-­‐CGH	   pipeline	   implemented	   for	   the	   DDD	   project	   is	   an	   automated	  analytical	  pipeline	  including	  the	  following	  main	  analytical	  steps:	  -­‐ Archival	  	  -­‐ Normalisation	  -­‐ Detection	  -­‐ Annotation	  -­‐ Quality	  Control	  -­‐ Filtering	  -­‐ Storage	  All	   steps	   are	   executed	   in	   batch	   using	   a	   single	   command	   and	   all	   results	   are	  archived	   in	   a	   reliable	   and	   ordered	   way.	   At	   the	   end	   of	   each	   batch	   run	   an	  automated	  summary	  report	  is	  generated	  detailing	  technical	  information	  relating	  to	  time	  taken	  and	  any	  potential	  errors	  encountered	  during	  data	  processing.	  The	  entire	  pipeline	  is	  very	  large	  and	  complex	  but	  can,	  for	  the	  most	  part,	  be	  used	  as	   a	   "blackbox"	   unless	   something	   specific	   goes	  wrong.	   The	   execution	   is	   driven	  via	  a	  single	  input	  file	  (“keyfile”)	  and	  each	  individual	  step	  can	  be	  executed	  using	  this	  keyfile	  as	  the	  input.	  The	  keyfile	  is	  generated	  by	  querying	  the	  DDD	  laboratory	  management	   system	   (LIMS)	   the	   first	   time	  an	   acgh	  plate	   is	   run,	   however	   it	   can	  also	  be	  "re-­‐generated"	  from	  the	  analysis	  database	  in	  some	  cases.	  For	  example	  for	  the	  automated	  re-­‐run	  of	  any	  processing	  failures	  using	  the	  “checker”	  script	  a	  new	  keyfile	  is	  generated	  containing	  the	  required	  information	  and	  used	  as	  the	  input	  to	  the	  main	  pipeline	  execution	  scripts.	  This	  “checker”	  script	  is	  fully	  automated	  and	  runs	  weekly	  under	  the	  time-­‐based	  job	  scheduler	  CRON.	  	  	  
Version	  Control	  A	  very	   important	  aspect	  of	  developing	  maintainable	  software	   is	   that	  of	  version	  control,	   especially	   if	   multiple	   developers	   are	   working	   on	   the	   same	   code	   base.	  Although	   I	   was	   the	   main	   developer	   of	   the	   acgh-­‐pipeline	   for	   the	   DDD	   project	  others	  have	  contributed	  to	  specific	  areas	  (methods	  not	  described	  in	  this	  thesis)	  and	   it	   was	   important	   that	   changes	   made	   to	   the	   main	   code	   base	   by	   any	   one	  individual	  did	  not	  affect	  the	  work	  of	  others.	  Therefore	  it	  was	  necessary	  to	  ensure	  a	  reliable	  way	  of	  maintaining	  software	  components	  and	  resolving	  any	  conflicts	  in	  code	   changes	   before	   commits	   were	   made.	   To	   do	   this	   we	   choose	   to	   use	   the	  version	  control	  system	  Git	  and	  to	  create	  a	  dedicated	  software	  repository	  named	  “acgh-­‐pipeline”.	  There	  is	  a	  relatively	  big	  following	  and	  preference	  for	  using	  Git	  compared	  to	  other	  version	   control	   systems	   at	   the	   WTSI	   and	   in	   the	   Bioinformatics	   community	  generally.	  The	  main	  advantage	  of	  Git	  compared	  to	  other	  version	  control	  systems	  such	  as	  Subversion	  is	  its	  relative	  simplicity	  of	  use,	  for	  example	  its	  branching	  and	  merging	  functionality	  are	  very	  intuitive	  and	  easy	  to	  perform.	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  Firstly	   the	   root	   contains	   two	   files	   that	   are	   often	   found	   in	   software	   package	  distributions,	   a	   “Makefile”	   that	   controls	   the	   installation	   of	   all	   software	  components,	  and	  a	  “README”	  file	  that	  lists	  important	  information	  and	  provides	  guidelines	   on	   installation	   and	   usage.	   Next	   we	   find	   three	   directories	   with	  standard	   names	   and	   purposes.	   The	   “init”	   directory	   is	   a	   generic	   place	   where	  useful	   software	   code	   can	   be	   placed,	   it	   is	   normally	  where	   useful	   scripts	   rather	  than	  self	  contained	  software	  components	  will	   reside.	  Under	   the	  “init”	  directory	  there	  are	  normally	  several	  subdirectories	  named	  as	  the	  programming	  language	  they	  contain	  (e.g.	  perl)	  and	  within	  these	  subdirectories	  the	  layout	  is	  for	  the	  most	  part	   free	   to	   choice,	   although	   of	   course	   should	   still	   ideally	   be	   logical.	   Next	   the	  “src”	  directory	  is	  the	  place	  where	  complied	  project	  elements	  are	  normally	  placed	  and	   should	   contain	   complete	   self-­‐contained	   software	   components,	   for	   example	  libraries	  written	  in	  C,	  C++	  or	  R	  should	  be	  included	  inside	  this	  directory.	  Finally	  the	  “util”	  directory	  is	  where	  utility	  items	  should	  be	  placed	  and	  is	  normally	  used	  for	  configuration	  and	  execution	  pipeline	  elements.	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Software	  Installation	  The	   installation	   of	   the	   entire	   software	   package	   for	   the	   acgh-­‐pipline	   has	   been	  made	   relatively	   easy	   by	   including	   a	   dedicated	   “Makefile”	   within	   the	   package	  distribution.	   The	   Makefile	   is	   a	   script	   used	   by	   the	   functionally	   of	   the	   unix	  command	   “make”.	   All	   installation	   locations	   and	   resource	   requirements	   are	  contained	   within	   the	   Makefile	   as	   variables	   and	   all	   installation	   steps	   are	  contained	  as	  rules	  to	  the	  “make”	  command.	  	  To	  install	  the	  acgh-­‐pipeline	  all	  that	  is	  required	  is	  that	  the	  user	  types	  “make”	  on	  the	  command	  line	  within	  the	  acgh-­‐pipeline	  package	  root.	  However,	  it	  is	  certainly	  required	   that	   the	   information	  within	   the	  Makefile	   is	   set	   correctly.	   This	   can	   be	  achieved	   by	   either	   editing	   the	   Makefile	   in	   place	   or	   by	   passing	   the	   variables	  specific	   values	   to	   “make”	   on	   the	   command	   line.	   So	   long	   as	   all	   the	   installation	  paths,	   required	   software	  versions	   and	  pipeline	   resources	   are	   available,	   “make”	  will	  install	  all	  software	  package	  components	  into	  the	  correct	  locations	  under	  the	  desired	   installation	   root	   and	   will	   only	   return	   successful	   if	   no	   step	   in	   the	  installation	  procedure	  failed.	  	  There	   are	   6	   rules	   contained	   inside	   the	   Makefile	   that	   control	   the	   entire	  installation	  procedure.	  These	  rules	  are	  named:	  	   -­‐ createcnsoldiate	  -­‐ createpipeline	  -­‐ copyscripts	  -­‐ createconfig	  -­‐ installRpackages	  -­‐ clean	  	  First,	  the	  createcnsoldiate	  step	  attempts	  to	  make	  the	  installation	  root,	  R	  library	  root,	  obtains	  and	  unzips	  a	   fresh	  copy	  of	   the	  acgh-­‐pipeline	  code	  base	  via	  the	  Git	  command	   archive.	   Next	   the	   createpipeline	   step	   sets	   up	   the	   software	   package	  layout	   by	   attempting	   to	   make	   all	   subdirectories	   beneath	   the	   installation	   root.	  Then	  the	  copyscripts	  step	  copies	  all	  pipeline	  scripts	  into	  place	  and	  uses	  the	  “sed”	  command	  to	  modify	  items	  in	  the	  scripts	  relating	  to	  the	  location	  of	  the	  installation	  root.	   	   Next	   the	   installRpackages	   step	   installs	   all	   included	   R	   packages	   (internal	  and	  external)	  into	  the	  defined	  R	  library	  location.	  Finally	  the	  clean	  step	  removes	  all	   “step	   execution	   files”	   generated	   by	   steps	   1	   to	   6.	   Each	   step	   creates	   a	   “step	  execution	   file”	   using	   the	   UNIX	   “touch”	   command,	   indicating	   that	   the	   step	   has	  been	   a	   success.	   Each	   individual	   step	   depends	   on	   the	   existence	   of	   the	   “step	  execution	   file”	   from	   the	   previous	   step	   and	   will	   not	   execute	   if	   that	   file	   is	   not	  present.	  The	  last	  step	  (clean)	  removes	  all	  “step	  execution	  files”	  including	  its	  own.	  	  The	   precise	   version	   of	   the	   acgh-­‐pipeline	   installed	   is	   controlled	   using	   the	   Git	  “tags”	   functionality.	   A	   Git	   tag	   is	   used	   to	   label	   a	   specific	   point	   in	   the	   version	  control	  history	  and	  that	  point	  becomes	  a	  stable	  pipeline	  version.	  This	  tag	  is	  set	  as	  a	  parameter	  in	  the	  Makefile	  and	  the	  createcnsoldiate	  step	  uses	  that	  tag	  to	  obtain	  the	  correct	  version	  of	  the	  acgh-­‐pipeline.	  This	  means	  that	  stable	  pipeline	  versions	  can	  be	  maintained	  while	  at	  the	  same	  time	  working	  on	  future	  releases	  using	  the	  same	  Git	  repository.	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Pipeline	  Configuration	  All	  pipeline	  parameters	  are	  configurable	  using	  a	  single	  JSON	  formatted	  config	  file	  that	   is	   intrinsically	   linked	   to	   a	   pipeline	   version	   (/acgh-­‐pipeline-­‐VERSION/templates/config.json).	  Below	  are	  the	  available	  parameters	  and	  their	  descriptions:	  
• version:	  pipeline	  version	  
• git_version:	  git	  tag	  of	  pipeline	  version	  
• project:	  project	  used	  for	  farm	  bsubs	  (defaults	  to	  ddd)	  
• genome_assembly:	  current	  genome	  build	  
• R.version.main:	  version	  of	  R	  to	  use	  (defaults	  to	  /software/R-­‐2.13.0/bin/R)	  
• paths:	  
o load_all_packages:	  the	  command	  to	  load	  all	  ddd	  R	  packages	  
o ddd_data_dir:	  the	  output	  root	  for	  the	  file	  system	  directory	  structure	  
o ddd_gene_list:	  the	  location	  of	  the	  current	  dd	  gene	  list	  
o cnv.execute.all:	  location	  of	  main	  pipeline	  driver	  script	  
o cnv.start:	  location	  of	  analytical	  flow	  (order)	  control	  script	  
o cnv.execute:	  location	  of	  normalisation,	  detection,	  annotation	  &	  tracking	  script	  
o cnv.detection:	  location	  of	  main	  CNV	  analysis	  script	  	  
o cnv.execute.seq.sample.check:	  location	  of	  sequenom	  family	  check	  script	  
o cnv.track:	  location	  of	  CNV	  tracking	  analysis	  control	  scipt	  
o cnv.insert.qc:	  location	  of	  QC	  control	  script	  
o cnv.insert.variants:	  location	  of	  variant	  insertion	  control	  script	  
o cnv.inherit.all:	  location	  of	  inheritance	  classification	  control	  script	  	  
o cnv.filter.all:	  location	  of	  clinical	  reporting	  filter	  control	  script	  
o vis.data.location:	  location	  of	  data	  browser	  output	  files	  	  
o vis.acgh.script:	  location	  of	  data	  browser	  file	  generation	  aCGH	  data	  script	  
o vis.snp.script:	  location	  of	  data	  browser	  file	  generation	  SNP	  data	  script	  
o rbin_index1:	  location	  of	  binary	  index	  file	  for	  DDD	  aCGH	  array1	  
o rbin_index2:	  location	  of	  binary	  index	  file	  for	  DDD	  aCGH	  array2	  
o mad_bin_file:	  location	  of	  large	  index	  file	  for	  DDD	  control	  data	  	  
o black.list:	  location	  of	  the	  list	  of	  probes	  to	  remove	  prior	  to	  CNV	  detection	  	  
o snp.map:	  location	  of	  index	  file	  for	  SNP	  data	  	  
o snp.family.link:	  location	  of	  index	  file	  for	  family	  relationships	  of	  SNP	  data	  
o snp.directory.location:	  location	  of	  index	  file	  for	  SNP	  directory	  structure	  
o seq_package_root:	  location	  of	  sequenom	  family	  check	  package	  
• headers:	  
o key.file:	  keyfile	  header	  
• db:	  
o analysis:	  name	  of	  analysis	  database	  
o lims:	  name	  of	  LIMS	  database	  
o decipher:	  name	  of	  DECIPHER	  database	  
• penncnv:	  
o exescript:	  location	  of	  penncnv	  execution	  script	  
o hmmfile:	  location	  of	  penncnv	  hmm	  configuration	  file.	  
o pfbfile:	  location	  of	  penncnv	  pfb	  file	  
• qc.thresholds.acgh:	  	  
o processed_dLRs:	  dLRs	  QC	  cut-­‐off	  
o wave_estimate:	  wave	  estimate	  QC	  cut-­‐off	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o sig_inten:	  signal	  intensity	  cut-­‐off	  
o sig_noi:	  signal	  to	  noise	  QC	  cut-­‐off	  
o bg_noise:	  background	  noise	  QC	  cut-­‐off	  
o repro:	  reproducibility	  QC	  cut-­‐off	  
o posterior:	  tracking	  posterior	  QC	  cut-­‐off	  
o low_sens:	  low	  sensitivity	  QC	  cut-­‐off	  
o del_dup_cut:	  deletion/duplication	  ratio	  QC	  cut-­‐off	  
• qc.thresholds.acgh.call:	  	  
o adjw_score:	  adjusted	  wscore	  call	  QC	  cut-­‐off	  
o p_value:	  p-­‐value	  call	  QC	  cut-­‐off	  
o del_cut:	  mean	  ratio	  deletion	  call	  QC	  cut-­‐off	  
o dup_cut:	  mean	  ratio	  duplication	  call	  QC	  cut-­‐off	  
• qc.thresholds.acgh.call.filtering:	  	  
o common_forward:	  CNV	  consensus	  forward	  overlap	  filter	  QC	  cut-­‐off	  
o common_backward:	  CNV	  consensus	  backward	  overlap	  filter	  QC	  cut-­‐off	  
o del_size:	  deletion	  size	  filter	  QC	  cut-­‐off	  
o dup_size:	  duplication	  size	  filter	  QC	  cut-­‐off	  
o non_inherit_size:	  size	  filter	  for	  non-­‐classified	  CNV	  filter	  QC	  cut-­‐off	  This	   configuration	   json	   object	   is	   passed	   around	   all	   pipeline	   control	   processes	  such	  that	  the	  information	  contained	  within	  the	  pipeline	  configuration	  is	  available	  to	  all	  analytical	  pipeline	  elements.	  This	  has	  a	  very	  useful	  consequence	  and	  means	  that	   all	   configurable	   pipeline	   parameter	   definitions	   only	   need	   to	   be	   set	   in	   one	  place	  and	  there	  is	  only	  one	  file	  that	  needs	  to	  be	  modified	  if	  parameters	  are	  to	  be	  changed.	   Overall	   there	   are	   a	   great	  many	  more	   parameters	   used	   by	   CNsolidate	  and	   the	   acgh-­‐pipeline	   than	   appear	   in	   the	   config	   file,	   however	   all	   external	  resources	   and	   important	   pipeline	   parameters	   are	   contained	   in	   the	   json	   object	  and	   are	   configurable.	   Furthermore,	   additional	   config	   parameters	   can	   easily	   be	  added	   to	   the	   json	   object	   if	   they	   are	   required	   by	   any	   particular	   pipeline	  component.	  
Automatic	  configuration	  during	  pipeline	  installation	  As	  described	  above	  the	  installation	  of	  the	  entire	  acgh-­‐pipeline	  is	  controlled	  by	  a	  single	  file,	  the	  “Makefile”.	  This	  file	  contains	  all	  the	  information	  needed	  to	  install	  the	  package	  under	  any	  LINUX	  based	  operating	  system.	  Additionally	  it	  contains	  all	  the	   information	   needed	   to	   set	   up	   the	   pipeline	   for	   standard	   use,	   specifically	   it	  contains	  all	  external	  and	  internal	  resource	  requirements,	  software	  versions	  and	  the	  root	  of	  the	  result	  storage	  file	  system.	  When	  the	  pipeline	  is	  installed	  using	  the	  Makefile	  a	  configuration	  object	   is	  created	  and	  place	   into	   the	  correct	   location	   in	  the	  pipeline	  software	  installation	  path	  based	  on	  the	  information	  contained	  inside	  the	   Makefile.	   Although	   it	   is	   possible	   to	   edit	   this	   configuration	   after	   the	  installation	   procedure,	   it	   is	   not	   necessary	   and	   the	   specific	   pipeline	   resources	  requirements	  and	  installation	  locations	  only	  need	  to	  be	  defined	  once	  within	  the	  Makefile	  before	  installation.	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3.3	   EXECUTION	  	  Below	  are	  the	  commands	  and	  an	  explanation	  of	  each	  step	  for	  running	  the	  acgh-­‐pipeline.	  The	  pipeline	   is	  executed	  using	  a	   single	   “bsub”	   command	   that	  will	   run	  the	   pipeline	   from	   start	   to	   finish,	   however	   it	   is	   possible	   to	   run	   each	   individual	  step	  in	  the	  pipeline.	  Below	  are	  details	  of	  each	  of	  the	  main	  individual	  steps:	  
Main	  steps	  in	  acgh-­‐pipeline:	  
• Generating	   "keyfile"	   containing	   links	   between	   acghplate,	   sanger_id	   and	  slide_id	  for	  data	  to	  be	  processed	  (normally	  an	  acgh	  plate).	  
• Archiving	   of	   image	   and	   feature	   extraction	   files	   for	   all	   data	   sets	   to	   be	  processed.	  
• Copy	  input	  files	  onto	  data	  processing	  location	  (/lustre).	  
• Execute	  acgh-­‐pipeline:	  
o Insert	  sample	  level	  information	  to	  database	  
o Run	   Sequenom	   family	   relationship	   test	   and	   store	   result	   in	  database.	  
o Run	  normalisation,	  CNV	  detection	  and	  annotation	  (CNsolidate)	  for	  slide1	  &	  slide2	  for	  each	  data	  set	  (sanger_id).	  
o Run	  data	  tracking	  method	  (CNV	  tagging	  SNPs)	  for	  both	  files	  (using	  coordinates	   in	   db	   the	   sequenom	   data	   and	   the	   binary	   formatted	  data	  file	  output	  from	  CNsolidate).	  
o Run	   inheritance	   classification	   (VICAR)	   for	   all	   detected	   CNVs	   in	  proband	  (currently	  using	  SNP	  genotyping	  data	  -­‐	  moving	  to	  exome	  data	  in	  future).	  
o Run	  CNV	  clinical	  reporting	  filter.	  
o Run	   database	   insert	   for	   all	   variants	   (fully	   annotated	   including	  clinical	  filter	  results).	  
o Run	  database	   insert	   for	  QC	  steps	  and	  apply	  QC	  criteria	   (pass	  and	  fail	  samples	  based	  on	  quality	  and	  data	  tracking	  values).	  
o Run	  browser	  file	  generation	  (cBrowse	  input	  files).	  
o Run	   processing	   checker	   script	   (make	   sure	   that	   any	   processing	  failures	  are	  detected	  and	  re-­‐run).	  
Main	  execution	  command:	  The	   acghpipeline	   software	   is	   versioned	   under	   GIT	   and	   installed	   in	   the	  /software/ddd/acgh-­‐pipeline	  directory.	  
• All	  following	  examples	  assume	  that	  the	  acgh-­‐pipline	  version	  is	  1.0.0	  The	   normal	   output	   location	   for	   the	   acgh-­‐pipeline	   is	   /nfs/ddd1	   that	   is	   only	  writable	  by	  user	  ddd.	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Switch	  to	  ddd	  user	  and	  login	  to	  farm	  
The	   entire	  pipeline	   can	  be	   executed	  using	   a	   utility,	   this	   utility	   is	   aliased	   in	   the	  ddd	  users	  bash	  profile	  and	  is	  executed	  using	  acghVERSION.	  	  So	  for	  VERSION	  1.0.0	  the	  base	  command	  would	  be	  acgh1.0.0.	  
• It	   queries	   the	   LIMS	   using	   the	   acghplate_id	   and	   generates	   a	   keyfile	   that	  acts	  as	  input	  for	  all	  the	  subsequent	  steps.	  
• The	  keyword	  "execute-­‐all"	  executes	  all	  the	  steps	  listed	  above	  from	  start	  to	  finish.	  
Main	  execution	  of	  acgh-­‐pipeline	  	  
This	  results	   in	  all	  data	  sets	  being	  processed,	  all	  output	   files	  being	  stored	   in	  the	  directory	   structure	   and	   all	   values	   being	   inserted	   into	   the	   database	   for	   all	   data	  sets	  on	  the	  acgh	  plate.	  
	  
Running	  Individual	  Steps:	  The	  main	  steps	  in	  the	  acgh-­‐pipeline	  can	  also	  be	  run	  individually	  using	  the	  same	  utility,	  each	  individual	  step	  is	  executed	  as	  follows:	  
	  
Generate	  a	  keyfile:	  The	  main	  input	  to	  all	  individual	  steps	  is	  a	  "keyfile"	  as	  mentioned	  previously.	  The	  first	  step	  to	  run	  the	  acgh-­‐pipeline	  is	  normally	  the	  generation	  of	  a	  keyfile	  based	  on	  an	  acghplate	  id.	  	  




sudo	  -u ddd bash	  
ssh	  -i /nfs/users/nfs_d/ddd/.ssh/ddd_dsa	  farm2-login	  
bash	  
acgh1.0.0 execute-all --plateid 239361 --scannerroot 
/nfs/ddd0/DDD_ScannerData/	  --fedest /nfs/ddd1/ddd_acgh_fe_files/	  --
imagedest /nfs/ddd1/ddd_acgh_images/	  --processingdirectory 
/lustre/scratch113/projects/ddd/users/ddd/DDD_ANALYSIS/	  --outputdir 
/nfs/ddd1/ddd_data/	  
acgh1.0.0	  keyfile --plateid 239361	  > 239361_keyfile_`date '+%Y-%m-
%d'`.txt	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The	  key	  word	  "keyfile"	  and	  the	  argument	   -­‐-­‐plateid	  are	  required	  and	  result	   in	  a	  query	  to	  the	  LIMS	  to	  collect	  the	  relevant	  information	  in	  the	  appropriate	  format.	  The	  output	  is	  given	  to	  stdout	  and	  should	  be	  saved	  to	  a	  temporary	  file	  for	  use	  in	  the	   subsequent	   steps.	   In	   this	   case	   we	   simply	   name	   it	   as	   plate_id	   underscore	  “keyfile”	  	  underscore	  “now	  time”	  in	  year-­‐month-­‐day	  format	  using	  the	  UNIX	  date	  command	  .	  	  
Archive	  image	  and	  feature	  extraction	  files	  from	  ddd0	  to	  ddd1:	  The	   normal	   flow	   of	   data	   for	   the	   acgh-­‐pipeline	   goes	   from	   directories	   under	  "/nfs/ddd0/DDD_ScannerData/"	  to	  "/nfs/ddd1/".	  The	  next	  step	  in	  the	  pipeline	  is	  to	   find	   the	   relevant	   files	   on	   ddd0,	   copy	   them	   to	   ddd1,	   carrying	   out	   an	   md5	  checksum	  and	  delete	  the	  files	  from	  ddd0	  if	  the	  checksums	  match.	  This	  is	  done	  for	  image	   files	   and	   feature	   extraction	   files	   separately.	   Again	   the	   main	   input	   is	   a	  keyfile	   and	   all	   data	   files	   associated	   which	   the	   slide	   ids	   contained	   inside	   the	  keyfile	  will	  be	  archived.	  	  
Archiving	  image	  files	  for	  a	  keyfile	  
	  
 The	  key	  word	  "archive"	  and	  the	  arguments	  -­‐-­‐keyfile,	  -­‐-­‐root,	  -­‐-­‐dest	  and	  -­‐-­‐type	  are	  required.	  The	  -­‐-­‐type	  argument	  with	  a	  value	  of	  0	  results	  in	  the	  archiving	  of	  image	  files	  only.	  By	  default	  the	  -­‐-­‐root	  and	  -­‐-­‐dest	  locations	  are	  checked	  to	  be	  exactly	  the	  same	  as	  above	  and	  if	  either	  is	  different	  this	  step	  will	  not	  execute.	  This	  is	  aimed	  to	  avoid	  any	  mishaps	  but	  this	  behaviour	  can	  of	  course	  be	  overridden	  if	  required.	  
	  
Archiving	  feature	  extraction	  files	  for	  a	  keyfile	  
 Changing	  the	  -­‐-­‐type	  argument	  to	  1	  results	  in	  the	  archiving	  of	  feature	  extraction	  files	  only.	  Notice	  that	  the	  -­‐-­‐dest	  location	  is	  different	  than	  for	  the	  image	  files.	  
	  
Overriding	  the	  default	  archive	  behaviour	  
acgh1.0.0	  archive --keyfile 239361_keyfile_DATE.txt --scannerroot 
/nfs/ddd0/DDD_ScannerData/ --imagedest /nfs/ddd1/ddd_acgh_images/ 
--type image	  
acgh1.0.0	  archive --keyfile 239361_keyfile_DATE.txt --scannerroot 
/nfs/ddd0/DDD_ScannerData/ --fedest /nfs/ddd1/ddd_acgh_fe_files/ -
-type fe	  
acgh1.0.0	  archive --keyfile 239361_keyfile_DATE.txt --scannerroot 
SOME_ROOT --dest SOME_DESTINATION --type image --override 1 	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Providing	   the	   -­‐-­‐override	   argument	   with	   a	   value	   of	   1	   results	   in	   the	   checking	  constraints	  on	  the	  -­‐-­‐root	  and	  -­‐-­‐dest	  arguments	  being	  removed.	  
	  
Copying	  data	  input	  files	  to	  lustre:	  The	  archiving	  of	  image	  and	  feature	  extraction	  files	  results	  in	  all	  data	  files	  for	  an	  acghplate	  being	  stored	  in	  the	  destination	  directory	  under	  a	  sub	  directory	  named	  by	  the	  acghplate	  id.	  Each	  data	  file	  is	  named	  by	  the	  slide	  id	  it	   is	  associated	  with.	  Any	  keyfile	  contains	  the	  number	  of	  rows,	  each	  of	  which	  contains	  the	  acghplate	  id	  and	  the	  slide	  ids	  for	  a	  given	  sample	  (sanger_id).	  This	  step	  copies	  all	  the	  relevant	  files	  from	  the	  storage	  directory	  to	  lustre	  ready	  for	  data	  processing.	  
	  
Copying	  data	  files	  to	  lustre	  
	  Again	   there	   are	   some	   checks	   in	   place	   and	   this	   stage	   to	   avoid	   any	   would	   be	  mishaps.	  It	  is	  ensured	  that	  the	  -­‐-­‐storageroot	  argument	  contains	  "ddd1"	  and	  that	  the	  -­‐-­‐processingdirectory	  contains.	  This	  behaviour	  can	  be	  overridden	  using	  the	  -­‐-­‐override	  argument	  with	  a	  value	  of	  1.	  
Executing	  the	  main	  CNV	  analysis	  step:	  This	   is	   the	  main	  analytical	   step	   in	   the	  pipeline	  and	  executes	  all	   the	  heavy	  data	  processing	  (it	  will	  take	  approximately	  2.5	  hours	  to	  complete).	  The	  step	  includes,	  insertion	  of	  sample	  level	  information	  into	  the	  database	  (sample_info	  table),	  data	  normalisation,	  cnv	  detection,	  cnv	  annotation	  and	  data	  tracking.	  
	  
Executing	  the	  main	  CNV	  analysis	  step	  
 The	   keyword	   "execute-­‐cnv"	   and	   the	   arguments	   -­‐-­‐keyfile,	   -­‐-­‐inputdir	   and	   -­‐-­‐outputdir	   are	   required.	   All	   files	   related	   to	   the	   slide	   ids	   inside	   the	   -­‐-­‐keyfile	   are	  expected	  to	  be	  inside	  the	  -­‐-­‐inputdir.	  A	  job	  array	  is	  submitted	  where	  each	  element	  is	   a	   row	   in	   the	   -­‐-­‐keyfile	   (limited	   to	  300	  activate	   jobs).	  Each	  element	  of	   the	   job	  array	   submits	   a	   sequence	   of	   bsubs	   and	   all	   data	   processing	   occurs	   in	   "/tmp"	  space.	   After	   completion	   all	   output	   from	   this	   step	   is	   moved	   to	   its	   dedicated	  storage	  location	  under	  the	  main	  -­‐-­‐outputdir	  (normally	  /nfs/ddd1/ddd_data/).	  	  The	   -­‐-­‐outputdir	   argument	   specified	   at	   this	   step	   is	   checked	   against	   the	   value	  inside	   the	  pipeline	  configuration	   file	  and	   if	   they	  do	  not	  match	   the	  step	  will	  not	  
acgh1.0.0	  copy-to-lustre --keyfile 239361_keyfile_DATE.txt --
storageroot /nfs/ddd1/ddd_acgh_fe_files/ --processingdirectory 
/lustre/scratch113/projects/ddd/users/ddd/DDD_ANALYSIS/	  
acgh1.0.0	  execute-cnv --keyfile 239361_keyfile_DATE.txt --inputdir 
/lustre/scratch113/projects/ddd/users/ddd/DDD_ANALYSIS/239361/ --
outputdir /nfs/ddd1/ddd_data/	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execute.	  This	  behaviour	  can	  be	  overridden	  using	  the	  -­‐-­‐override	  argument	  with	  a	  value	  of	  1.	  	  
Executing	  the	  variant	  insertion	  and	  clinical	  reporting	  filter:	  The	  next	  step	  in	  the	  pipeline	  is	  to	  insert	  all	  the	  "call	  QC"	  passed	  variants	  into	  the	  database	   (production	   analysis_live)	   and	   run	   the	   clinical	   reporting	   filter	   to	   flag	  variants	  for	  clinical	  reporting.	  
 
 
 This	   step	   executes	   a	   job	   array	  where	   each	   element	   is	   a	   row	   in	   the	   keyfile.	   All	  sample	  level	  information	  (most	  importantly	  file	  locations)	  is	  already	  inserted	  in	  the	  database.	  First	  each	   job	   looks	  up	   the	   location	  of	   the	  variant	  output	   files	  on	  disk	  from	  the	  database	  and	  attempts	  to	  insert	  all	  variants	  passing	  the	  QC	  criteria	  (found	   in	   the	   config	   file).	   The	   insertion	   includes	   inserting	   elements	   into	   the	  variant,	  acgh_variant,	  acgh_run	  and	  acgh_run_acgh_variant	  tables.	  Next	  all	  of	  the	  inserted	   variants	   (acgh_variant)	   are	   passed	   though	   the	   clinical	   reporting	   filter,	  this	  results	  in	  an	  update	  of	  the	  "filter_flag"	  value	  in	  the	  "acgh_variant"	  table.	  
	  
Executing	  the	  sample	  level	  QC	  step:	  The	  next	  step	  is	  the	  sample	  level	  QC	  for	  all	  data	  sets	  inside	  the	  keyfile. 
 
 	  This	  step	  applies	  the	  defined	  QC	  criteria	  (see	  config	  file)	  for	  slides	  first,	  if	  either	  slide	   fails	   QC	   both	   slides	   (the	   sample)	   fails.	   Additionally,	   where	   there	   are	  replicates	  of	  the	  same	  sample	  (sanger_id)	  only	  the	  best	  quality	  data	  set	  (based	  on	  specific	   QC	   parameters)	   is	   passed.	   Furthermore,	   where	   we	   have	   a	   replicate	  person	  with	  an	  alternative	  id	  (alternative	  sample)	  only	  the	  ‘best’	  quality	  sample	  for	  that	  person	  is	  passed.	  	  Note:	  due	  to	  the	  way	  the	  QC	  steps	  work,	   if	  we	  re-­‐run	  the	  QC	  across	  all	  datasets	  (but	  the	  number	  of	  datasets	  is	  different	  to	  previously	  e.g.	  additional	  data)	  the	  QC	  results	   for	   samples	  will	   be	   slightly	  different	   (i.e.	   small	  number	  of	   samples	   that	  previously	   failed	  may	  now	  pass	  and	  vis	  versa).	  This	   complication	   is	  due	   to	   the	  fact	   that	   the	  entire	  dataset	  as	  a	  whole	   is	  used	  during	   the	  QC	  steps.	  Due	   to	   this	  when	  we	  are	  applying	  qc	  to	  new	  data	  the	  entire	  dataset	  is	  interrogated	  but	  the	  qc	  result	  is	  only	  calculated	  for	  the	  new	  data.	  Therefore	  anytime	  we	  want	  to	  re-­‐run	  QC	  for	  the	  entire	  dataset	  one	  need	  to	  be	  aware	  that	  the	  result	  may	  differ	  slightly	  to	  the	  previous	  QC	  classifications.	  
	  
	  
acgh1.0.0	  execute-filter --keyfile 
239361_keyfile_DATE.txt 	  
acgh1.0.0	  execute-qc --keyfile 239361_keyfile_DATE.txt	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Executing	  the	  browser	  (cBrowse)	  file	  generation:	  This	   is	   the	   final	   data	   processing	   step	   in	   the	   acgh-­‐pipeline,	   it	   creates	   json	  formatted	   input	   files	   for	   the	  data	  browser.	  These	   include	  acgh,	   snp	  genotyping	  and	  exome	  data.	  
	  
 
 Note:	   currently	   the	   dedicated	   output	   location	   for	   cBrowse	   file	   is	  "/nfs/ddd0/Data/cBrowse"	   however	   this	   directory	   currently	   has	   >2000	  directories	  inside.	  This	  is	  an	  issue	  that	  needs	  to	  be	  resolved,	  the	  way	  the	  browser	  (cBrowse)	  searches	  for	  input	  files	  needs	  to	  be	  modified	  and	  then	  an	  appropriate	  directory	  structure	  should	  be	  created.	  	   	  
acgh1.0.0	  execute-browser --keyfile 
239361_keyfile_DATE.txt 	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3.4	   PERFORMANCE	  	  
Pipeline	  flow	  description	  For	  each	  sample	  data	  set	  there	  are	  two	  experiment	  datasets	  (acgh	  slides)	  to	  be	  processed	   by	   the	   acgh-­‐pipeline,	   each	   for	   which	   contains	   approximately	   one	  million	   data	   points.	   The	   overall	   pipeline	   flow	   is	   controlled	   using	   a	   “job	   array”	  indexed	  per	  sample,	  meaning	  that	  for	  each	  pipeline	  element	  (sample	  run)	  there	  are	  two	  independent	  processes	  executed	  (one	  for	  slide1	  and	  one	  for	  slide2).	  The	  main	   analytical	   process	   for	   each	   independent	   slide	   consists	   of	   26	   individual	  steps.	   Each	   element	   in	   the	   job	   array	   relates	   to	   a	   sample	   (two	   slides)	   and	   the	  entire	  job	  array	  is	  limited	  to	  300	  simultaneously	  running	  jobs.	  The	  first	  general	  process	   in	   the	   pipeline	   is	   to	   collect	   all	   the	   information	   for	   each	   sample	   (two	  slides),	  input	  this	  information	  into	  the	  database	  and	  execute	  two	  processes	  (one	  for	  each	  slide)	  that	  perform	  the	  main	  analytical	  steps	  (26	  steps).	  Additionally	  a	  third	   process	   is	   executed	   whose	   role	   is	   to	   wait	   until	   both	   main	   analytical	  processes	  have	  completed	  before	  allowing	  the	  pipeline	  to	  continue.	  We	  do	  not	  go	  into	  the	  full	  details	  of	   the	  pipeline	  flow	  control	  here	  but	  briefly	   it	  makes	  use	  of	  the	   LSF	   functionality	   of	   pre-­‐	   and	   post-­‐	   execution	   commands	   as	  well	   as	   the	   –w	  arguments	   to	   control	   the	   various	   job	   dependency	   states.	   Furthermore	   the	  memory	  usage	  is	  set	  using	  the	  –R	  arguments	  and	  request	  slightly	  higher	  memory	  than	   the	   predicated	   requirements	   such	   that	   processing	   failures	   are	   keep	   to	   a	  minimum.	  After	  both	  main	  analytical	  processes	  have	  run	  it	  is	  the	  third	  jobs	  role	  to	  execute	  the	  sample	  tracking,	  data	  quality	  control	  and	  clinical	  filtering	  steps	  for	  each	  person.	  The	  data	  for	  both	  acgh	  slides	  are	  required	  for	  the	  final	  steps	  to	  run	  correctly,	  which	  is	  why	  a	  relatively	  complex	  job	  dependency	  monitoring	  process	  was	  necessary	  to	  implement.	  	  	  
Main	  analytical	  process	  performance	  The	   main	   execution	   steps	   of	   the	   acgh-­‐pipeline	   consist	   of	   26	   individual	   steps.	  During	  processing	  of	  each	  slide	  a	  log	  file	  is	  written	  to	  disk	  containing	  information	  about	  which	  steps	  have	  completed	  and	  how	  long	  they	  took	  from	  start	  to	  finish.	  This	  log	  file	  is	  useful	  for	  monitoring	  results	  and	  pipeline	  performance,	  allowing	  any	   processing	   failures	   to	   be	   investigated	   in	   further	   detail.	   The	   log	   file	   will	  indicate	  for	  any	  processing	  failure	  the	  precise	  point	  in	  the	  analytical	  pipeline	  that	  the	  particular	  job	  (process)	  failed	  (stopped).	  There	  are	  a	  number	  of	  reasons	  why	  jobs	  can	   fail	  both	  due	  or	  not	  due	   to	   the	  acgh-­‐pipeline	  software	  components.	   In	  the	  case	  where	  there	  was	  a	  real	  problem	  with	  one	  of	  the	  acgh-­‐pipeline	  software	  components	  the	  log	  file	  provides	  a	  useful	  pointer	  for	  a	  developer	  to	  interrogate	  the	  relevant	  point	  in	  the	  pipeline	  in	  search	  for	  the	  precise	  code	  block	  causing	  the	  problem.	  A	  number	  of	   issues	  outside	  the	  control	  of	   the	  acgh-­‐pipeline	  can	  cause	  processing	  failures,	  such	  as	  network	  outage,	  LSF	  issues	  and	  disk	  space	  limits.	  This	  section	  will	  describe	  the	  performance	  of	  the	  acgh-­‐pipeline	  in	  terms	  of	  time	  taken	  for	  each	  of	  the	  26	  main	  analytical	  steps	  across	  8,852	  datasets,	  each	  dataset	  contains	  approximately	  one	  million	  data	  points	  (acgh	  slide).	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  Figure	  3-­‐1	  The	  time	  in	  minutes	  for	  the	  main	  analytical	  steps	  of	  the	  acgh-­‐pipeline	  to	  run.	  Left	  –	  DDD	  acgh	  array1,	  Right	  –	  DDD	  acgh	  array2.	  Red	  –	  median	  time	  for	  each	  step	  across	  4,426	  slides	  of	  array1	  and	  array2	  The	  above	  plots	  (see	  Figure	  3-­‐1)	  show	  the	  cumulative	  time	  taken	  for	  each	  of	  the	  26	  steps	  contained	   in	   the	  main	  analytical	  process	   for	  array1	  and	  array2	  within	  the	  DDD	  acgh-­‐pipeline.	  Overall	  the	  median	  time	  taken	  from	  start	  to	  finish	  of	  the	  main	  analytical	  steps	  are	  2.5	  and	  2.3	  hours	  for	  array1	  and	  array2	  respectively.	  	  Probes	  (data	  points)	  across	  the	  entire	  genome	  are	  shared	  between	  the	  two	  DDD	  acgh	   arrays	   and	   both	   array1	   and	   array2	   contain	   12	   different	   chromosomes	  (making	  up	  the	  total	  of	  24	  chromosomes).	  One	  reason	  that	  array1	  tends	  to	  take	  slightly	   longer	   to	   complete	   than	  array2	   is	   the	   fact	   that	   array1	   contains	   the	   sex	  chromosomes	   (chromosome	   X	   and	   chromosome	   Y).	   CNV	   detection	   on	   the	   sex	  chromosomes	   is	   often	   more	   difficult	   due	   to	   difference	   in	   the	   dose	   response	  (mean	   log2	   ratio)	   between	   males	   and	   females,	   the	   normal	   copy	   number	   on	  chromosome	   X	   and	   Y	   in	   males	   is	   one	   whereas	   in	   females	   the	   normal	   copy	  number	   is	   two	   for	   chromosome	   X	   and	   zero	   for	   chromosome	   Y	   [181].	  Furthermore	   the	   pseudoautosomal	   regions	   (PAR1	   and	   PAR2)	   can	   cause	  additional	   problems	   to	   CNV	   calling.	   CNsolidate	   uses	   the	   approach	   of	   median	  normalizing	  each	  chromosome	  such	  that	  the	  normal	  copy	  number	  is	  represented	  by	  a	  log2	  ratio	  centred	  on	  zero	  and	  and	  for	  chromosome	  X	  CNV	  calls	  made	  in	  the	  pseudoautosomal	  regions	  in	  females	  are	  excluded.	  Each	  sample	  on	  the	  DDD	  acgh	  arrays	   is	   run	  against	  a	  pooled	  DNA	  reference	  made	  up	  of	  500	  male	   individuals	  therefore	   the	   PAR1	   and	   PAR2	   regions	   normally	   falsely	   appear	   as	   deletions	   in	  females	  due	  to	  the	  median	  normalization	  of	  the	  chromosome	  X.	  This	  additional	  CNV	  detection	  complexity	  adds	  a	  small	  amount	  of	  time	  to	  the	  overall	  processing	  time	  of	  array1	  compared	  to	  array2.	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  Figure	  3-­‐2	  The	   total	   time	   in	  minutes	   for	  each	  slide	   to	  be	  processed	   through	  all	  main	  analytical	  steps	  ordered	  by	  date	  and	  time.	  Above	   (see	  Figure	   3-­‐2)	   are	   two	  plots	   showing	   the	   total	   time	   in	  minutes	   taken	  from	  start	   to	   finish	  of	   steps	  1-­‐26	   from	  4,426	  slides	  on	  array1	  (left)	  and	  array2	  (right)	  ordered	  by	  chronological	  time.	  The	   noticeable	   periodicity	   is	   due	   to	   differences	   in	   compute	   resource	   usage	  institute	  wide	  at	  different	  points	  in	  time.	  The	  main	  limitation	  on	  processing	  time	  for	   the	   acgh-­‐pipeline	   is	   the	   speed	   of	   reading	   and	  writing	   to	   and	   from	   the	   file	  system.	  The	  parallel	  distributed	  file	  system	  (Lustre)	  used	  at	  the	  Sanger	  institute	  provides	  high-­‐performance	  I/O	  throughput	  however	  it	  is	  a	  shared	  resource.	  Due	  to	  particular	  pressures	  on	  project	   time	   lines	  or	  specific	  needs	   to	  perform	   large	  compute	  volume,	  the	  number	  of	  processes	  (jobs)	  hitting	  the	  file	  system	  can	  vary	  considerably	  at	  any	  given	  time.	  Noticeable	  trends	  in	  compute	  time	  for	  individual	  pipelines	  can	  often	  be	  correlated	  with	  large	  Sanger	  project	  data	  release	  dates.	  At	  other	  times	  it	  can	  just	  be	  a	  busy	  time	  with	  many	  people	  needing	  to	  process	  large	  data	  volumes	  or	  sometimes	  it	  can	  be	  due	  to	  a	  mistake	  made	  on	  the	  individual	  or	  project	   level	   where	   large	   numbers	   of	   erroneous	   jobs	   are	   causing	   problems	  institute	  wide.	  The	   greater	   variance	   in	   compute	   time	   given	   the	   year-­‐month-­‐day	   observed	   for	  array1	   compared	   to	   array2	   can	   be	   explained	   by	   the	   fact	   that	   array1	   contains	  both	  sex	  chromosome	  (X	  and	  Y)	  whereas	  array2	  has	  no	  sex	  chromosomes.	  The	  added	   complexity	  mentioned	   previously	   in	   relation	   to	   calling	   CNVs	   on	   the	   sex	  chromosomes	   in	   females	   results	   in	   higher	   variance	   in	   compute	   time	   in	   array1	  compared	  to	  array2.	  	  	  	  	  
	   131	  
	  
3.5	   DISCUSSION	  	  A	  large-­‐scale	  analytical	  pipeline	  incorporating	  the	  analytical	  methods	  described	  in	  this	  thesis	  has	  been	  implemented.	  This	  pipeline	  is	  fully	  automated,	  under	  tight	  version	   control	   and	   is	   in	   standard	   use	   in	   the	   DDD	   project	   for	   detecting	   and	  interpreting	  CNVs	  using	  a	  high-­‐resolution	  array-­‐CGH	  platform.	  There	  have	  been	  four	   stable	   acgh-­‐pipeline	   version	   releases	   for	   the	   DDD	   project	   to	   date	   where	  specific	  changes	  (improvements)	  to	  analytical	  components	  have	  been	  made.	  One	  example	   of	   a	   change	   to	   the	   main	   pipeline	   version	   number	   is	   described	   in	  
Chapter	   2	   under	   CNV	   filtering	   where	   a	   major	   change	   to	   the	   CNV	   detection	  performance	  by	  excluding	  poorly	  performing	  probes	  prior	  to	  running	  CNsolidate	  was	  made.	   Other	   reasons	   for	   incrementing	   the	   main	   pipeline	   version	   number	  included,	  adding	  additional	  rules	  into	  data	  and	  call	  quality	  control,	  changes	  to	  the	  filtering	  logic	  for	  flagging	  CNVs	  for	  clinical	  review	  and	  an	  institute	  wide	  change	  to	  the	  version	  of	  LSF	  used	  at	  the	  WTSI.	  	  	  The	   DDD	   acgh-­‐pipeline	   was	   developed	   to	   be	   high	   throughput	   and	   achieve	  reasonable	   processing	   speed	  with	   a	  median	   of	   2.5	   and	   2.3	   hours	   for	   the	   DDD	  array-­‐CGH	   array1	   and	   array2	   respectively.	   The	   pipeline	   is	   setup	   to	   allow	   300	  simultaneously	   running	   jobs	   by	   default.	   Although	   the	   total	   number	   of	  simultaneous	  jobs	  can	  easily	  be	  modified	  using	  a	  limit	  of	  300	  is	  predicated	  to	  be	  sufficient	  and	  deliver	  a	  reasonable	   time	  period	   to	  run	  all	  datasets	   for	   the	  DDD.	  Currently	  5,651	  samples	  (11,302	  1	  million	  probe	  slides)	  have	  been	  run	  through	  the	  latest	  version	  of	  the	  acgh-­‐pipeline	  for	  the	  DDD	  project.	  All	  results	  have	  been	  generated	   and	   stored	   in	   both	   the	   file	   system	   and	   database	   structures	   and	   are	  actively	  being	  used	  to	  both	  provide	  clinical	  diagnosis	  to	  patient	  samples	  within	  the	  DDD	  and	  to	  further	  our	  understanding	  of	  the	  role	  that	  CNVs	  play	  in	  a	  number	  of	  rare	  disorders.	  Even	  if	  it	  were	  necessary	  to	  re-­‐run	  the	  acgh-­‐pipeline	  from	  start	  to	  finish	  for	  all	  DDD	  datasets	  (expected	  to	  be	  approximately	  10,000	  samples)	  it	  would	   take	   approximately	   3.5	   days	   to	   obtain	   all	   results	   and	   fully	   populate	   the	  data	  storage	  areas	  based	  on	  the	  median	  time	  taken	  to	  run	  the	  slowest	  step	  (the	  26	  main	  analytical	  processes	  on	  DDD	  array1).	  	  I	  have	  provided	  a	   fully	  version	  controlled	  repository	   for	  all	  analytical	  code	  and	  software	   packages	   that	   make	   up	   the	   DDD	   acgh-­‐pipeline	   along	   with	   detailed	  documentation	   explaining	   how	   to	   install	   and	   execute	   the	   pipeline	   in	   an	  automated	  fashion.	  By	  using	  the	  tagging	  (-­‐-­‐tags)	  functionality	  provided	  by	  Git	  it	  was	  possible	  to	  provide	  specific	  frozen	  versions	  of	  the	  acgh-­‐pipeline	  that	  can	  be	  easily	   cloned	   using	   the	  main	   pipeline	   version	   number.	   The	   acgh-­‐pipeline	   code	  base	   can	   relatively	   easily	  be	   installed	   for	  use	   in	  different	  projects	  based	  at	   the	  Sanger	   institute	   or	   elsewhere.	   All	   that	   is	   required	   is	   for	   the	   Makefile	   to	   be	  modified	   such	   that	   all	   required	   software	   versions,	   resources	   and	   data	   storage	  locations	  are	  available	  and	  valid.	  The	  one	  major	  complication	  is	  that	  the	  pipeline	  code	  base	  assumes	  the	  presence	  of	  a	  load	  sharing	  facility	  (LSF)	  and	  if	  a	  different	  workload	  management	   platform	  were	   to	   be	   used	   a	   relatively	   large	   number	   of	  pipeline	  scripts	  within	  the	  acgh-­‐pipeline	  repository	  would	  need	  to	  be	  modified.	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Perhaps	  the	  most	  important	  aspect	  of	  developing	  a	  large	  scale	  analytical	  pipeline	  is	   that	   of	   data	   loss	   prevention.	   A	   specific	   file	   system	   structure	   and	   database	  design	   has	   been	   developed	   to	   ensure	   accurate	   and	   reliable	   maintenance	   of	  analytical	   results.	  The	   file	  system	   is	  ordered	  and	  structured	   in	  such	  a	  way	   that	  missing	   data	   or	   corrupted	   file	   formats	   can	   be	   detected	   using	   checking	   scripts	  that	  crawl	  the	  file	  system	  and	  detect	  any	  unexplained	  data	  errors.	  These	  errors	  can	  be	  reported	  back	  as	  summary	  emails	  and	  correlated	  with	  specific	  data	  inputs	  such	   that	   any	   detected	   data	   loss	   (missing	   data)	   can	   be	   investigated	   relatively	  easily.	   With	   any	   large	   scale	   analytical	   process	   processing	   errors,	   potentially	  resulting	  in	  data	  loss,	  is	  almost	  unavoidable	  and	  it	  is	  therefore	  important	  to	  have	  robust	   safe	   guards	   in	   place	   to	   ensure	   that	   such	   situations	   can	   be	   noticed	   and	  corrected.	  	  	  	  Moreover,	   the	   structure	   and	   information	   contained	   in	   analytical	   results	   should	  be	   carefully	   considered	  before	   generating	   large	   volume	  of	   data.	   The	  main	   goal	  here	   is	  to	  ensure	  that	  the	  output	  of	  an	  analytical	  process	   is	  both	  easy	  to	  access	  and	   to	  understand	   for	   a	   casual	  user.	  This	   can	   sometimes	  be	   a	   challenging	   task	  where	   data	   characteristics	   are	   complex	   and	   results	   are	   hard	   to	   interpret.	   The	  acgh-­‐pipeline	   implemented	   in	   the	  DDD	  project	   includes	  a	  dedicated	   file	  system	  and	  database	  assessing	  package	  made	  up	  of	  a	  number	  of	  intuitive	  function	  calls	  developed	  in	  the	  R	  programming	  language.	  This	  has	  several	  useful	  applications;	  including	  giving	  others	  with	  little	  or	  no	  knowledge	  of	  the	  data	  storage	  structures	  access	  to	  the	  analytical	  results	  with	  relative	  ease,	  abstracting	  out	  common	  code	  elements	   that	   can	   be	   used	   by	   analytical	   process	   elements	  without	   the	   need	   to	  rewrite	   “boiler	  plate”	   code,	  when	   there	   is	  a	  need	   to	  change	  aspects	  of	   the	  data	  storage	  structures	  all	  (or	  most)	  code	  changes	  are	  restricted	  to	  a	  single	  package	  (the	  data	  assessor	  package).	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4 |	   Improved	  CNV	  discovery	  algorithms	  enable	  an	  exon-­‐level	  
resolution	  map	  of	  CNV	  and	  reappraisal	  of	  the	  CNV	  mutation	  
rate.	  	  
4.1	   OVERVIEW	  	  Copy	  number	  variation	   (CNV)	  accounts	   for	  major	  differences	   in	  DNA	  sequence	  between	   genomes,	   however	   its	   prevalence	   at	   the	   single	   exon	   or	   gene	   level	  remains	   relatively	   under-­‐categorised.	   We	   describe	   a	   novel	   approach	   for	   CNV	  discovery	  that	  combines	  multiple	  discovery	  algorithms	  using	  dynamic	  weighting	  according	   to	   the	   noise	   properties	   of	   the	   underlying	   data.	   Our	  meta-­‐algorithm,	  CNsolidate,	  ranks	  detections	  based	  on	  differential	  weighting	  functions,	  allowing	  tuning	  of	  Type	  1	  and	  Type	  2	  error	  rates.	  We	  applied	  this	  meta-­‐algorithm	  to	  926	  apparently	   healthy	   controls	   using	   exon-­‐targeted	   array	   comparative	   genomic	  hybridization	   (exon-­‐CGH),	   and	   demonstrate	   that	   CNsolidate	   substantially	  outperforms	   individual	   algorithms.	   We	   also	   present	   VICAR,	   a	   novel	   Bayesian	  framework	  for	  the	  classification	  of	  CNV	  inheritance	  states	  using	  SNP	  genotyping	  data.	   Using	   exon-­‐CGH	   and	   single	   nucleotide	   polymorphism	   (SNP)	   genotyping	  across	   1,766	   normal	   control	   samples	  we	   present	   a	  map,	   including	   inheritance	  classifications,	  for	  CNVs	  ranging	  in	  size	  from	  44	  bp	  to	  8.5	  Mb.	  With	  a	  resolution	  of	  15.2	  kb	  we	  estimate	  the	  CNV	  mutation	  rate	  at	  1.9  ×  10!!  by	  detecting	  16	  high	  confidence	  rare	  de	  novo	  CNVs	  across	  840	  parent-­‐offspring	  transmissions.	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4.2	   INTRODUCTION	  	  Copy	   number	   variants	   (CNVs)	   are	   a	   major	   cause	   of	   phenotypic	   variation	   in	  humans	   [182-­‐185]	   and	   numerous	   rare	   developmental	   disorders	   have	   been	  associated	   with	   specific	   CNVs	   affecting	   dosage	   sensitive	   genes	   or	   defined	  syndromic	   regions	   [186,	   187].	   A	   large	   number	   of	   these	   genotype-­‐phenotype	  correlations	  have	  been	  observed	  in	  small-­‐scale	  studies	  of	  specific	  patient	  groups	  [188,	  189]	  or	  by	  collaborative	  efforts	  to	  share	  genetic	  data	  for	  rare	  disease	  [135].	  CNVs	   have	   been	   associated	   with	   a	   number	   of	   complex	   diseases	   [190,	   191].	  Studies	  into	  schizophrenia	  [192]	  and	  autism	  [193]	  have	  demonstrated	  the	  utility	  of	   leveraging	   previously	   generated	   single-­‐nucleotide	   polymorphism	   (SNP)	  genotyping	   data	   from	   SNP	   based	   genome-­‐wide	   association	   studies	   (GWAS)	   to	  search	  for	  novel	  CNV	  associations.	  However,	   CNV	   studies	   have	   historically	   been	   limited	   by	   either	   sample	   size	   or	  technological	  constraints	  [13,	  50,	  104,	  194].	  Research	  into	  the	  underlying	  cause	  of	   specific	   clinical	   conditions	   has	   predominantly	   used	   array	   comparative	  genomic	  hybridization	  (array-­‐CGH)	  as	  the	  CNV	  discovery	  platform	  [195]	  due	  to	  its	  superior	  sensitivity	   (dose	  response)	  and	  genomic	  coverage	  capability	   [196].	  Yet,	  the	  resolution	  to	  detect	  CNVs	  affecting	  single	  genes	  that	  is	  achieved	  by	  most	  commercial	   and	   custom	   array-­‐CGH	   designs	   is	   highly	   variable	   due	   to	   technical	  difficulties	  during	  probe	  design	  [197]	  or	  to	  an	  insufficient	  total	  number	  of	  probes	  available	   for	   the	   array	   platform.	   Furthermore,	   the	   difficulty	   and	   cost	   of	   array-­‐CGH	   experimental	   protocols	   generally	   inhibit	   its	   standard	   application	   in	   large-­‐scale	  research	  studies	  [198].	  The	  SNP-­‐based	  GWAS	  studies	  of	  complex	  diseases	  have	  generally	  had	  sufficient	  sample	  sizes	  to	  search	  for	  common	  CNVs	  with	  small	  effect	   sizes	   [199,	   200],	   but	   SNP	   genotyping	   arrays	   in	   general	   have	   a	   limited	  resolution	  to	  detect	  single-­‐exon	  CNVs	  due	  to	  the	  distribution	  of	  SNPs	  across	  the	  genome	  [201].	  CNV	  studies	  can	  also	  be	   limited	  by	  the	  analytical	  methods	  used	  to	  detect	  CNVs,	  and	   in	   the	   availability	   of	   parental	   data,	   to	   determine	   the	   inheritance	   states	   of	  CNVs.	  	  Change	  point	  detection	  algorithms	  used	  to	  call	  CNVs	  often	  produce	  highly	  discordant	  results	  when	  applied	  to	  the	  same	  dataset	   [128].	  Furthermore,	  when	  applied	  to	  datasets	  of	  differing	  qualities,	  most	  algorithms	  tend	  to	  display	  highly	  variable	   results	   that	   can	   sometimes	   be	  modeled	   as	   a	   function	   of	   the	   signal-­‐to-­‐noise	   ratio	   of	   the	  underlying	  data	   [202].	   Combining	   information	   from	  multiple	  algorithms	  can	   improve	  CNV	  calling	  consistency	  across	  datasets	   [203-­‐205],	  but	  most	  approaches	  simply	  use	  a	  consensus	  (naïve	  voting)	  approach	  to	  combining	  information	   from	   different	   callers.	   For	   example,	   the	   CNV	   detection	   approach	  used	  in	  the	  1000	  Genomes	  Project	  used	  an	  estimated	  false	  discovery	  rate	  (FDR)	  rate	  of	   greater	   than	  10%	   to	  disregard	   the	  putative	  detections	   least	   concordant	  with	   consensus	   [36].	   Although	   such	   approaches	   can	   improve	   CNV	   detection	  quality	   (specificity)	   compared	   to	   single	   algorithms,	   the	   potential	   for	   a	   loss	   of	  power	   (sensitivity)	   is	   certainly	   increased.	   By	   requiring	   a	   certain	   number	   of	  algorithms	   to	   be	   in	   agreement	   for	   a	   call	   to	   be	   made	   (consensus	   calling)	   the	  overall	   false	   negative	   rate	   (FNR)	   becomes	   a	   function	   of	   the	   union	   of	   the	   FNRs	  from	   all	   callers.	   Previous	   studies	   have	   inferred	   inheritance	   patterns	   for	   CNVs	  detected	   using	   SNP	   genotyping	   data	   however,	   the	   approach	   used	   for	   inferring	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inheritance	  is	  often	  heuristic,	  for	  example	  using	  a	  simple	  call	  overlap	  rule	  [206],	  or	   	   manual,	   to	   mitigate	   the	   high	   false	   negative	   rate	   associated	   with	   most	  platforms	  and	  analytical	  pipelines,	  especially	  for	  smaller	  variants	  [207].	  To	   facilitate	   further	   CNV	   research,	   we	   present	   an	   exon-­‐resolution	   CNV	   map	  generated	   from	   926	   healthy	   UK	   individuals	   using	   an	   exon	   focused	   array-­‐CGH	  platform	   composed	   of	   two	   1	   million	   probe	   Agilent	   arrays	   (exon-­‐CGH),	   and	  determine	   the	   inheritance	   states	   of	   CNVs	   detected	   from	   exon-­‐CGH	   in	   420	  offspring	   using	   parent-­‐offspring	   SNP	   genotyping	   from	   a	   812K	   probe	   Illumina	  chip.	  We	  also	  describe	   a	   software	  package	  and	   framework	   for	  data	   integration	  developed	  in	  the	  process	  of	  generating	  this	  map	  (see	  Methods).	   	  These	  include	  1)	   a	   change	   point	   detection	   package,	   CNsolidate,	   that	   includes	   a	   performance	  based	   learning	  algorithm	  to	  define	  differential	  weighting	   functions	   for	  multiple	  algorithms	  given	  certain	  predictive	  variables	  drawn	  from	  the	  input	  data;	  and	  2)	  a	  novel	  automated	   inheritance	  classification	  method,	  VICAR,	  which	  builds	  on	  one	  of	   the	  most	   frequently	   used	   software	   packages	   for	   identifying	   CNVs	   from	   SNP	  data,	   pennCNV	   [208].	   VICAR	   is	   a	   post-­‐CNV	   calling	   tool	   that	   uses	   a	   Bayesian	  framework	  to	  classify	  the	  inheritance	  of	  CNVs	  of	  interest	  identified	  in	  the	  exon-­‐CGH	  offspring	  data.	  	  CNsolidate	  is	  available	  as	  Supplementary	  Software.	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4.3	   METHODS	  
	  
Samples	  The	   control	   individuals	  used	  here	  are	   from	   two	  different	   sample	   sets	   from	   the	  United	  Kingdom	  (UK).	  The	  first	  set	  of	  control	  samples	  is	  565	  individuals	  from	  the	  UK	   blood	   donor	   service	   (UKBS)	   who	   gave	   general	   consent	   for	   anonymised	  inclusion	  into	  genetic	  studies.	  The	  second	  set	  of	  control	  samples	  come	  from	  the	  Generation	   Scotland	   study	   and	   are	   made	   up	   of	   420	   parent-­‐offspring	   trios.	   To	  ensure	   that	   the	  select	  offspring	  are	   true	  controls	   for	   the	  DDD	  study,	   they	  were	  assessed	  for	  the	  presence	  of	  suspected	  learning	  disabilities	  as	  this	  is	  a	  common	  phenotype	   in	   children	   with	   undiagnosed	   developmental	   disorders.	   	   Offspring	  were	   eligible	   for	   selection	   if	   they	   had	   measurements	   that	   fell	   within	   two	  standard	   deviations	   for	   the	   mean	   on	   four	   cognitive	   metrics:	   Logical	   Memory	  from	   the	   Wechsler	   Memory	   Scale	   II;	   Digit	   Symbol	   form	   the	   Wechsler	   Adult	  Intelligence	   Scale	   III;	   Verbal	   Fluency;	  Mill	   Hill	   Vocabulary	   Scale.	   The	   complete	  Generation	  Scotland	   trios	  were	  genotyped	  using	   the	  DDD	  custom	   Illumina	  SNP	  chip,	  and	  the	  Generation	  Scotland	  offspring	  samples	  and	  the	  UKBS	  samples	  were	  run	  on	  the	  exon-­‐CGH	  platform.	  
Array	  platforms	  
Exon-­‐CGH	   Platform:	   The	   exon-­‐CGH	   array	   is	   composed	   of	   two	   1Million	   probe	  Agilent	  arrays	  and	  has	  been	  heavily	  targeted	  towards	  genes	  and	  ultra-­‐conserved	  elements	   throughout	   the	   human	   genome.	   The	   entire	   set	   of	   GENCODE	   genes,	  along	   with	   regulatory	   and	   mRNA	   coding	   elements	   have	   been	   tiled,	   using	   a	  minimum	  of	   five	  oligo-­‐nucleotide	  probes.	  The	  rest	  of	  the	  array	  content	   is	  spent	  on	   ensuring	   the	   presence	   of	   a	   high-­‐resolution	   backbone	   retaining	   a	   median	  probe	  spacing	  of	  5	  kb.	  
SNP	  Genotyping	  Platform:	  The	  SNP	  genotyping	  array	  is	  a	  customised	  version	  of	  the	   Illumina	  Omni-­‐one	  quad	  chip.	  Extra	  content	  has	  been	  added	  to	  standardise	  the	   coverage	   of	   the	   array	   using	   a	   ”largest	   first”	   gap	   filling	   procedure.	   The	   gap	  filling	  process	   is	  aimed	  at	   targeting	  the	   largest	  gaps	   in	  array	  coverage	   first	  and	  additionally	   inserting	   the	   best	   quality	   probe	   within	   the	   ”central	   gap	   region”	  before	   moving	   to	   the	   second	   largest	   gap	   in	   array	   coverage.	   In	   total,	   the	   chip	  includes	   811,844	   mapped	   markers	   (1,734	   are	   unmapped;	   i.e.	   are	   assigned	   to	  chromosome	   only)	   with	   a	   median	   intermarker	   distance	   of	   2,378	   bp	   (omitting	  unmapped	  markers).	  
Validation-­‐CGH	   Platform:	   The	   validation	   aCGH	   array	   is	   the	   8	   x	   60k	   Agilent	  format	   and	   designed	   for	   the	   validation	   of	   exon-­‐CGH	   calls	   in	   26	   samples.	   It	  contains	   10,000	   control	   probes,	   randomly	   selected	   from	   the	   exon-­‐CGH	   design	  that	   are	  not	   called	   in	   any	  of	   the	  26	   individuals	   (evenly	   spread	  between	   the	  22	  autosomes).	  It	  also	  contains	  300	  CNV	  tracking	  probes	  and	  30	  gender	  markers	  to	  allow	  data	   tracking	  between	   the	  exon-­‐CGH	  and	  validation	  aCGH	  platforms.	  The	  remaining	  48,760	  probes	  tile	  9,008	  CNV	  regions	  called	  across	  the	  wscore	  range.	  
CNsolidate	  –	  Multiple	  weighted	  algorithms	  and	  expert	  voting	  system	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See	  Chapter	  2	  
VICAR	  -­‐	  Variant	  Inheritance	  Classification	  Algorithm	  in	  R	  
Model	  VICAR	   (Variant	   Inheritance	   Classification	   Algorithm	   in	   R)	   combines	   the	  information	   from	   the	   offspring	   exon-­‐CGH	   CNV	   calling	   results	  with	   Log	   R	   ratio	  (LRR)	  and	  B-­‐allele	  Frequency	  (BAF)	  data	   from	  SNP	  genotyping	  of	   the	  complete	  parent-­‐offspring	  trios	  to	  determine	  whether	  a	  CNV	  identified	  from	  the	  exon-­‐CGH	  data	  is	  de	  novo	  or	  inherited.	  	  Given	  that	  the	  purpose	  of	  this	  process	  is	  to	  classify	  selected,	  potentially	  pathogenic	  CNVs	  in	  children	  with	  developmental	  delay,	  the	  model	   is	   based	   on	   the	   following	   plausible	   assumptions:	   the	   CNV	   of	   interest	   is	  rare	  at	  a	  population	  level;	  a	  rare	  duplication	  will	  not	  occur	  at	  the	  same	  location	  as	  a	   rare	  deletion	   in	  members	  of	   the	  same	   family,	   and	  vice	  versa;	   there	  are	  no	  back-­‐mutations	  to	  the	  copy-­‐neutral	  state.	  	  As	  the exon-CGH data only indicates the 
presence of a CNV (and not whether it is homozygous or heterozygous) and the DDD 
project is primarily focused on rare CNVs, we use a two-state model based on 
presence or absence of the CNV, rather than considering all five possible states (copy 
neutral and heterozygous and homozygous deletions and duplications). If	  c,	   	  f,	  and	  m	  are	  binary	  CNV	  indicators	  taking	  value	  1	  in	  the	  presence	  of	  a	  CNV	  and	   0	   otherwise,	   for	   the	   offspring,	   father,	   and	  mother	   respectively;	  DSNP	   is	   the	  trio	  SNP	  data;	  and	  DaCGH	   is	   the	  offspring	  exon-­‐CGH	  data,	   then	   the	  model	  can	  be	  written	  as:	  ! !,!, ! !!"# ,!!"#$ ∝ ! !!"# !,!, !    ∙ ! !,!|! ∙   !(!|!!"#!) [4-­‐1]	  	  
The terms are described in more detail below. !(!|!!"#$)  incorporates information from the CNV identification in the offspring 
via the false-positive rate of the discovery method.   ! !,! !   is broken down into further constituent terms: ! !,! ! = ! !|!,! ∙   ! ! ∙   !(!)!(!)  [4-­‐2]	  
 ! !|!,!  is the transmission probability for the trio configuration, incorporating a 
size-specific estimate of the mutation rate. ! !  and ! !  are defined as the 
probability of randomly selecting a region of the genome of the size of the CNV 
identified that overlaps a known CNV by at least 50%.   ! !!"# !,!, ! ,  the joint likelihood of a trio configuration, is based on the 
likelihoods provided by an external software package; we assume the package used 
provides estimates for five copy number states (copy neutral and heterozygous and 
homozygous deletions and duplications) for the genomic region identified in the 
offspring exon-CGH data.  However, as we are using a two-state model, we reduced 
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the 125 possible five-state trio configurations to the eight configurations needed, 
combining the likelihoods for each individual in a way that gives appropriate weight 
to each state contributing to the likelihood.  We only consider the possibility of 
heterozygous CNVs in the parents, because we only consider potentially causal 
CNVs, but all five states are possible in offspring.  The weightings also include the 
size-specific CNV mutation rate (see Supplementary Table 2).   
 
Implementation 
VICAR is currently implemented as a package for the R software.  Data sources for 
the model are user-specified; details relating to its use in the DDD project are as 
follows: !(!|!!"#$)  is the false-positive rate associated with the wscore produced by 
CNsolidate for the CNV identified in the exon-CGH offspring data. We performed a 
CNV validation experiment on 9008 CNVs spanning the wscore range using a custom 
designed array-CGH array (Above). We estimated the false positive rate by 
calculating the proportion of false classifications made between the discovery and 
validation array at discrete wscore interval. 
The size-specific CNV mutation rate incorporated in the terms ! !|!,!  and ! !!"# !,!, !  is estimated from details to follow. ! !  and ! !  are estimated using the DDD control datasets. 
The individual state-specific likelihoods that are incorporated into ! !!"# !,!, !  
are calculated by PennCNV using the LRR and BAF data from the SNP genotyping 
dataset. 
VICAR returns the posterior probabilities for all models and also provides a “hard” 
classification of inheritance status based on user-specified thresholds relating to (i) 
declaring the presence of an inherited or de novo CNV (default is 0.95); (ii) declaring 
the absence of a CNV in the offspring (default is 0.99); (iii) the minimum number of 
probes needed to attempt inheritance classification (default is five probes).  Possible 
classifications are: 
- de novo: CNV identified in offspring but not in either parent; 
- paternal: CNV identified in father and offspring;  
- maternal: CNV identified in mother and offspring;  
- biparental: CNV identified in both parents and offspring;  
- no CNV: no CNV identified in offspring (with or without parental CNV); 
- inconclusive: This will be returned for two reasons:  
o (i) no model had a posterior probability greater than the threshold for 
classification 
o (ii) neither de novo nor inherited models had posterior probabilities 
above the classification thresholds; 
- insufficient: there were less SNPs in the region than the probe threshold.	  	   	  
	   139	  
De	  novo	  CNV	  Parent	  of	  Origin	  Analysis	  
The origin of each de novo CNV was investigated by identifying inheritance-
informative positions, sites where one can determine from which parent the child's 
alleles originated. Such positions include all sites for which parents are opposite 
homozygotes (e.g. AA and BB), and, on average, half of sites in which one parent is 
homozygous and the other is heterozygous (e.g. AA and AB). Parents sharing the 
same genotype are not informative. De novo deletions will result in a single allele 
remaining in the child, with a B allele frequency of 0, corresponding to the loss of a B 
allele, or 1, corresponding to the loss of a A allele. De novo duplications will result in 
an extra allele in the child, with a B allele frequency of 0.33, corresponding to a gain 
of an A allele, or 0.66, corresponding to a gain of B allele. In five de novo CNV 
cases, there were no informative sites for which the inheritance could be tracked. 
	  
CNV	  Consensus	  Reference	  Set	  –	  Defining	  Common,	  Rare	  and	  Novel	  CNVs	  
See	  Chapter	  2.	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4.4	   RESULTS	  
	  
Sample	  cohort	  Apparently	   healthy	   controls	   were	   analysed	   as	   part	   of	   the	   Deciphering	  Developmental	   Disorders	   (DDD)	   project,	   a	   UK	  wide	   collaboration	   based	   at	   the	  Wellcome	  Trust	  Sanger	   Institute	   involving	  24	  UK	  and	   Ireland	  regional	  genetics	  services	   [29].	   We	   include	   two	   different	   normal	   control	   sample	   sets	   for	   CNV	  detection	   and	   inheritance	   classification:	   565	   individuals	   from	   the	   UK	   blood	  donor	  service	  (UKBS)	  and	  420	  trios	  from	  the	  Generation	  Scotland	  study	  [209].	  	  
CNV	  discovery	  algorithm:	  CNsolidate	  We	   developed	   a	   novel	   detection	   method,	   CNsolidate,	   for	   CNV	   discovery	   using	  array-­‐CGH	   data.	   CNsolidate	   incorporates	   12	   independent	   CNV	   discovery	  algorithms	   and	   weights	   each	   algorithm	   based	   on	   its	   estimated	   performance	  (Type	   I	   and	   Type	   II	   error	   rates)	   across	   a	   range	   of	   data	   noise	  metrics	   that	   are	  estimated	  from	  the	  input	  data.	  	  These	  weights	  were	  estimated	  through	  extensive	  simulations	  of	  input	  data	  with	  different	   noise	   properties.	   We	   performed	   over	   one	   million	   data	   simulations,	  varying	   three	   specific	   noise	   types	   (see	   Methods)	   and	   generated	   the	   noise	  dependent	   weighting	   functions,	   for	   each	   algorithm	   separately,	   by	   fitting	  polynomial	  curves	  to	  the	  estimated	  Type	  I	  error	  rate	  across	  the	  given	  noise	  value	  range.	  CNsolidate	   calculates	   a	   combined	  CNV	  confidence	  measure	   (wscore)	   for	  each	  copy	  number	  variable	  region	  (CNVR)	  detected	  (see	  Methods).	  The	  wscore	  displays	  a	  zero	  to	  one	  range	  with	  higher	  quality	  calls	  tending	  towards	  a	  value	  of	  one.	  	  
CNsolidate	  Type	  I	  and	  Type	  II	  error	  rates	  	  To	  estimate	  the	  Type	  I	  and	  Type	  II	  error	  rates,	  using	  CNsolidate,	  we	  generated	  73	  replicates	   of	   the	   HapMap	   sample	   NA12878	   on	   two	   custom	   designed	   Agilent	   1	  million	  probe	  arrays	  that	  collectively	  target	  each	  exon	  with	  5	  probes	  and	  include	  a	  backbone	  of	  ~700,	  000	  non-­‐coding	  probes.	  We	  defined	  true	  positives	  (TP)	  as	  CNVs	  that	  were	  called	  in	  greater	  than	  80%	  (59)	  of	  replicates,	  and	  defined	  CNVs	  to	   be	   the	   same	   if	   they	   shared	   greater	   than	   a	   50%	   reciprocal	   overlap	   (see	  
Methods).	  	  Overall	  we	  defined	  12634	  TPs	  above	  the	  default	  wscore	  threshold	  of	  0.5,	   90%	   of	   which	   (11372)	   were	   defined	   as	   common	   and	   had	   been	   observed	  during	  previous	  studies	  at	  a	  population	  frequency	  greater	  than	  one	  percent	  (see	  
Methods).	  	  	  We	   estimated	   the	  mean	   true	   positive	   rate	   (TPR)	   and	  mean	   false	   positive	   rate	  (FPR)	  for	  different	  wscore	  thresholds	  (see	  Figures	  4-­‐1	  &	  4-­‐2).	  We	  found	  using	  a	  wscore	   threshold	  of	  0.5	   for	  CNV	  calls	   from	  CNsolidate,	   results	   in	  a	  TPR	  of	  0.82	  and	   a	   FPR	   of	   0.052,	   across	   all	   replicates	   and	   chose	   to	   use	   0.5	   as	   our	   default	  wscore	  cut	  off.	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CNsolidate	  Performance	  Compared	   to	   its	   eight	   (default)	   component	   algorithms	   used	   individually,	  CNsolidate	   displays	   the	   best	   performance	   in	   terms	   of	   receiver	   operator	   curve	  (ROC)	  space	  (see	  Figure	  4-­‐1).	  	  
	  Figure	   4-­‐1	   Receiver operator curve showing the ROC space using 73 technical 
replicates for CNsolidate and its eight default algorithms.	  There	  are	  some	  differences	  in	  the	  ROC	  performance	  of	  individual	  algorithms,	  but	  no	   one	   in	   particular	   displays	   overall	   poor	   ROC	   characteristics	   indicating	   that	  each	  algorithm	  has	  been	  reasonably	  well	  tuned.	  Furthermore,	  CNsolidate,	  using	  a	  default	  wscore	  threshold	  of	  0.5,	  achieves	  an	  11%	  increase	  in	  TPR	  for	  a	  0.05	  FPR	  compared	  to	  the	  highest	  performing	  individual	  algorithm.	  	  
	  Figure	   4-­‐2	   Left:	   Receiver	   operator	   curve	   showing	   the	   ROC	   space	   using	   73	  technical	   replicates	   and	   CNsolidate;	   colored	   curve	   is	   the	   overall	   ROC	  performance	  colored	  by	  the	  wscore	  range	  (color	  scale	  on	  the	  right	  hand	  side	  of	  the	  panel);	  the	  ROC	  performance	  of	  individual	  datasets	  are	  shown	  in	  grey.	  Right: 
Receiver operator curve showing the ROC space using 73 technical replicates and 
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CNsolidate given different predictors of call quality; the red, green, yellow, black and 
blue curves show the ROC performance when using the absolute mean log2 ratio, the 
number of aCGH probes, the p-value, the number of algorithms and the wscore as the 
call quality predictors respectively. 
 
The	   wscore	   is	   highly	   negatively	   correlated	   with	   FPR,	   with	   increased	   wscore	  values	  decreasing	  the	  false	  positive	  rate.	  As	  the	  wscore	  threshold	  is	  relaxed,	  the	  TPR	  increases	  quickly	  while	  the	  FPR	  increases	  much	  more	  slowly	  (see	  Figure	  4-­‐
2).	   We	   compared	   the	   ROC	   space	   observed	   when	   using	   a	   number	   of	   different	  measures	   to	   predict	   call	   quality	   (see	   Figure	   4-­‐2).	   The	   wscore	   generated	   by	  CNsolidate	   performed	   best	   in	   terms	   of	   ROC	   space	   compared	   to	   any	   other	  measure	  of	  call	  quality	  that	  we	  assessed.	  The	  number	  of	  algorithms	  contributing	  to	   the	  detection	  of	   a	  CNV	  performed	   second	  best,	   however	  we	   still	   observed	  a	  significant	   0.068	   increase	   in	   sensitivity	   when	   using	   expert	   voting	   (wscore)	  compared	   to	   naïve	   voting	   (number	   of	   algorithms).	   The	   p-­‐value	   generated	   by	  CNsolidate	  (see	  Methods)	  provided	  a	  reasonable	  measure	  of	  call	  quality	  but	  at	  a	  FPR	  of	  0.05	  was	  only	  able	  to	  achieve	  a	  TPR	  of	  0.54.	  We	  observed	  that	  both	  the	  number	  of	  array-­‐CGH	  probes	  and	  the	  absolute	  mean	  ratio	  to	  be	  poor	  predictors	  of	  call	  quality	  overall,	  having	  lower	  than	  0.5	  TPR	  with	  a	  FPR	  of	  0.05.	  	  	  
CNV	  validation	  	  We	  selected	  9008	  CNVs,	  spanning	  the	  wscore	  range,	  detected	  by	  CNsolidate	  in	  26	  samples,	   for	   validation	   using	   a	   custom	   designed	   8x60K	   CGH	   array	   (see	  
Methods).	   We	   used	   a	   similar	   approach	   as	   [50]	   for	   validating	   CNV	   calls.	   We	  calculated	   the	  Pearson	   correlation	  of	   the	  mean	   log2	   ratio	   values	   across	   the	  26	  samples	   between	   the	   discovery	   and	   validation	   arrays	   to	   define	   a	   measure	   of	  truth.	  We	  observed	  a	  clear	  2-­‐component	  distribution	  of	  correlation	  values	  across	  all	  CNV	  calls	  and	  applied	  a	  nonparametric	  EM	  algorithm	  [210]	  to	  determine	  the	  mixing	  proportions	  for	  each	  component	  (see	  Figure	  4-­‐3).	  	  
	  Figure	  4-­‐3	  Left:	  Histogram	  showing	  the	  Pearson	  correlation	  values	  for	  9,008	  CNV	  between	  the	  discovery	  and	  validation	  aCGH	  platforms.	  The	  colored	  curves	  show	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the	  result	  of	  fitting	  a	  nonparametric	  EM	  algorithm	  to	  the	  correlation	  values.	  The	  red	  curve	  shows	  the	  ‘false’	  (not	  validated)	  CNV	  calls	  and	  the	  green	  curve	  shows	  the	  ‘true’	  (validated)	  CNV	  calls.	  The	  dashed	  red	  and	  green	  lines	  show	  the	  mixing	  proportions	   for	   the	   false	   and	   true	   distributions	   respectively.	   Right:	   A plot 
showing the proportion of true (validated) CNV calls across the wscore range.	   The	  black	  line	  show	  the	  proportion	  of	  true	  CNV	  calls	  across	  the	  wscore	  range	  overall	  and	   the	   red	   and	   blue	   lines	   show	   the	   proportion	   of	   true	   CNV	   calls	   across	   the	  wscore	  range	  for	  deletions	  and	  duplications	  respectively.	  Correlation	  values	  greater	   than	   the	  mean	  of	   the	  mixing	  proportions	   (0.5)	  were	  used	   to	   define	   true	   CNV	   calls,	   reasoning	   that	   the	   log2	   ratio	   values	   were	  sufficiently	   correlated	   across	   all	   26	   samples	   between	   the	   discovery	   and	  validation	   results.	   We	   then	   calculated	   the	   proportion	   of	   true	   (validated)	   CNV	  calls	  across	  the	  wscore	  range	  for	  all	  CNV	  calls	  and	  for	  losses	  and	  gains	  separately	  (see	  Figure	  4-­‐3).	  We	  observed	  that	  as	  the	  wscore	  tended	  towards	  a	  value	  of	  one	  the	  proportion	  of	  true	  classifications	  sharply	  increased	  for	  both	  losses	  and	  gains.	  At	   the	   default	   0.5	   wscore	   threshold	   the	   proportion	   of	   true	   classifications	   was	  greater	  than	  80%	  for	  both	  losses	  and	  gains.	  Although	  this	  could	  potentially	  relate	  to	  a	  FPR	  of	  20%,	  it	  should	  be	  noted	  that	  this	  approach	  conflates	  the	  FPR	  from	  the	  discovery	  array	  with	  the	  FNR	  on	  the	  validation	  array.	  Furthermore,	  others	  have	  shown	   that	   reproducibility	   in	   replicate	   experiments	   on	   the	   same	   array	   is	  typically	   less	   than	  70%	   for	  most	   platforms	   [202].	  As	   the	  wscore	   increased	   the	  proportion	   of	   true	   gains	   increased	   slightly	   faster	   than	   the	   proportion	   of	   true	  losses,	   indicating	   that	   that	   the	   wscore	   was	   slightly	   better	   calibrated	   for	  predicting	   gain	   call	   quality.	   For	   both	   gains	   and	   losses,	   the	   proportion	   of	   true	  classifications	  plateaued	  at	  100%	  above	  a	  wscore	  value	  of	  0.628.	  	  
Algorithm	  for	  inferring	  CNV	  inheritance:	  VICAR	  For	  the	  classification	  of	  inheritance	  states	  of	  a	  predetermined	  CNV	  (in	  this	  case	  detected	  by	  array-­‐CGH)	  using	  SNP	  genotyping	  chip	  data	  (B-­‐allele	  frequency	  and	  logR	   ratio)	   we	   developed	   a	   novel	   Bayesian	   framework,	   Variant	   Inheritance	  Classification	   Algorithm	   in	   R	   (VICAR).	   VICAR	   uses	   the	   copy	   number	   state	  likelihoods	   for each trio (or duo) member estimated	   by	   PennCNV	   [208],	   and	  combines	   these	  with	   the	   size	   and	   call	   quality	  measure	   for	   identified	   CNV,	   and	  estimates	   of	   the	   mutation	   rate	   and	   frequency	   for	   CNVs	   of	   similar	   size	   to	  determine	   the	   most	   likely	   inheritance	   configuration.	   Since	   the exon-CGH data 
indicates only the presence of a CNV (but not the number of copies), VICAR	  currently	   uses a two-state model based on presence or absence of the CNV, 
collapsing the five possible copy number states considered by PennCNV. VICAR 
returns the posterior probabilities for all models, permitting user-defined thresholds to 
be applied for trio classification (see	  Methods).	  	   
Sensitivity	  of	  de	  novo	  classification	  We	   modeled	   the	   sensitivity	   for	   de	   novo	   classifications	   from	   VICAR	   using	   SNP	  genotyping	  data	  generated	  on	  children	  with	  previously	   identified	  de	  novo	  CNVs	  causing	   developmental	   disorders	   	   (Wessex	   Regional	   Genetics	   Laboratory).	  Synthetic	  de	  novo	  CNVs	  of	   sizes	  5,	  10,	  25,	  50,	  100,	  250,	  500	  and	  1000	  kb	  were	  generated	   by	   randomly	   sampling	   different	   numbers	   of	   probes	   from	   ten	   large	  positive	  control	  CNVs	  (eight	  deletions	  and	  two	  duplications).	  The	  performance	  of	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de	  novo	  classification	  using	  a	  posterior	  probability	  threshold	  of	  0.95	  was	  tested	  separately	   for	   deletions	   and	   duplications	   for	   regions	   containing	   from	   2	   to	   50	  SNPs,	   and	   for	   2	   different	   call	   qualities	   (wscore	   of	   0.5	   and	   0.75).	   For	   both	  deletions	   and	   duplications,	   for	   both	   wscore	   values,	   the	   de	   novo	   classification	  performance	   improved	   as	   the	   size	   and	   number	   of	   SNP	   markers	   increased.	  Overall,	   the	   algorithm	   performed	   well	   for	   de	   novo	   classification	   of	   high	  confidence	   CNV	   calls	   (as	   assessed	   by	   the	  wscore)	   for	   all	   sizes	   and	  numbers	   of	  probes	   tested,	   with	   very	   small	   numbers	   of	   false	   negative	   and	   inconclusive	  classifications	  (see	  Figure	  4-­‐4).	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CNVs	  in	  926	  controls	  using	  exon-­‐CGH	  and	  CNsolidate	  
Summary	  of	  CNV	  calls:	  	  We	   performed	   CNV	   discovery	   using	   CNsolidate	   on	   data	   generated	   from	   926	  control	  samples	  on	  the	  exon-­‐focused	  CGH	  array	  described	  above.	  We	  used	  as	  a	  reference	  a	  pooled	  DNA	  made	  up	  of	  500	  control	  individuals.	  We	  called	  a	  total	  of	  199,967	   autosomal	   CNVs	   with	   a	   median	   of	   215	   per	   sample.	   	   As	   expected	   we	  detected	   slightly	   more	   losses	   (58%)	   than	   gains,	   it	   has	   been	   well	   established	  [208]	   that	   gains	  are	  more	  difficult	   to	  detect	   than	   losses	  due	   to	  a	   lowered	  dose	  response	  particularly	  in	  commonly	  variable,	  complex	  regions	  of	  the	  genome.	  We	  defined	   35,571/	   199,967	   autosomal	   CNVRs	   as	   rare	   by	   classifying	   events	   with	  greater	  than	  80%	  overlap	  with	  a	  CNV	  of	  the	  same	  type	  (loss	  or	  gain),	  observed	  at	  greater	   than	  1%	  population	   frequency	   (see	  Methods)	   as	   being	   common	  CNVs.	  This	  resulted	  in	  classifying	  17.8%	  (17,839	  	   losses	  and	  17,732	  	  gains)	  of	  all	  CNV	  calls	   as	   being	   rare,	   indicating	   that	   our	   capacity	   for	   calling	   rare	   CNVs	   using	  CNsolidate	  was	  nearly	  equivalent	  for	  losses	  and	  gains.	  The	  number	  of	  autosomal	  CNV	   calls	   detected	   per	   sample	  was	   very	   consistent,	  with	   a	  mean	   of	   215	   and	   a	  95%	   probability	   of	   being	   in	   the	   interval	   between	   165	   and	   289	   across	   all	   926	  exon-­‐CGH	  datasets	  (see	  Figure	  4-­‐5).	  	  	  
	  Figure	   4-­‐5	   Histogram	   showing	   the	   number	   of	   autosomal	   CNV	   calls	   made	   by	  CNsolidate	  per	  sample	  across	  926	  exon-­‐CGH	  data	  sets.	  The	  green	  line	  shows	  the	  median	   number	   of	   CNV	   calls	   and	   the	   red	   lines	   show	   the	  median	  ±	  the	  median	  absolute	  deviation	  of	  the	  number	  of	  CNV	  calls	  per	  sample.	  The	   largest	   CNV	   detected	   was	   8.5	   Mb	   in	   length	   and	   was	   observed	   in	   two	  independent	   samples,	   one	   deletion	   and	   one	   duplication	   sharing	   precisely	   the	  same	  break	  points.	  These	  large	  CNVs	  spanned	  the	  entire	  pericentromeric	  region	  on	   the	  p	  arm	  of	   chromosome	  9,	   a	   region	  well	  known	   to	  contain	   large	  common	  variants	  [211,	  212].	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We	  defined	  87,634	   (44%)	  CNVs	   as	   single	   gene	   events	   by	   comparison	  with	   the	  GENCODE	  gene	  set	  (version	  17).	  Of	  all	  single	  gene	  CNVs	  16,695	  (19%)	  included	  only	  a	  single	  exon	  with	  the	  majority	  (37%)	  being	  intragenic.	  For	  all	  exonic	  single	  gene	  CNVs	  there	  was	  a	  minimum	  of	  1,	  median	  of	  3	  and	  maximum	  of	  407	  exons	  per	  CNV.	  Additionally	  we	  found	  4,386	  single	  exon	  CNVs	  that	  were	  overlapped	  by	  multiple	   genes,	   with	   73%,	   26%,	   0.8%	   and	   0.02	   %	   of	   these	   CNVs	   being	  overlapped	   by	   2,	   3,	   4	   and	   5	   genes	   respectively.	   Overall,	  we	   detected	   a	   total	   of	  21081	   single	   exon	   CNVs	   (10%	   of	   all	   detected	   CNVs),	   split	   relatively	   evenly	  between	   losses	   and	   gains	   (11,393	   and	   9,688	   respectively).	   We	   defined	   3,748	  (18%)	  of	  all	  single	  exon	  CNVs	  as	  rare,	  a	  similar	  rate	  compared	  to	  all	  CNVs,	  and	  defined	  1,722	  discrete	  rare	  single	  exon	  CNV	  loci	  by	  collapsing	  all	  rare	  CNV	  calls	  using	  an	   iterative	  50%	  reciprocal	  overlap	  rule.	  To	  evaluate	   the	  proportion	  that	  had	   been	   described	   previously	   elsewhere	   we	   compared	   the	   1,722	   rare	   single	  exon	   CNV	   loci	   against	   the	   database	   of	   genomic	   variation	   (DGV)	   [168]	   using	   a	  50%	  reciprocal	  overlap	  rule.	  We	  found	  that	  only	  14%	  were	  contained	  inside	  the	  DGV	   and	   add	   an	   additional	   1,472	   discrete	   rare	   single	   exon	   CNV	   loci	   to	   the	  literature.	  	  
Inheritance	  classification	  of	  CNV	  Calls	  in	  Generation	  Scotland	  trios	  Using	  VICAR,	  we	   inferred	   the	   inheritance	   status	   for	  CNVs	  detected	  using	  exon-­‐CGH	  in	  420	  offspring,	  using	  SNP-­‐genotyping	  data	   from	  the	  Generation	  Scotland	  trios.	  To	  ensure	  all	  inheritance	  classifications	  were	  high	  confidence,	  we	  choose	  to	  apply	  a	   strict	   cut-­‐off	   equal	   to	  one	  on	   the	  posterior	  probability	  of	   the	   identified	  inheritance	  model	   estimated	  by	  VICAR.	  Furthermore	  we	  only	   considered	  CNVs	  with	   at	   least	   5	   SNP	   markers	   to	   be	   eligible	   for	   inheritance	   classification;	   we	  estimated	  by	  simulation	  that	  at	  least	  five	  SNP	  markers	  were	  necessary	  to	  avoid	  large	   numbers	   of	   false	   negative	   or	   inconclusive	   classifications	   (see	   Figure	   4).	  Overall	  assigned	  an	  informative	  inheritance	  classification	  to	  2,792	  CNVs	  ranging	  in	  size	  from	  991	  bp	  to	  4.8	  Mb.	  	  We	   identified	   1,218	   paternally	   inherited,	   1,242	   maternally	   inherited,	   125	  biparental	   inherited	   and	   177	   potential	   de	   novo	   CNVs.	   There	   were	   three	   clear	  failure	  modes	  for	  de	  novo	  classifications	  from	  VICAR	  including	  poor	  quality	  SNP	  genotyping	  data,	  uneven	  SNP	  probe	  coverage	  and	  the	  absence	  of	  a	  characteristic	  BAF	   split	   for	   duplications	   due	   to	   a	   lack	   of	   heterozygous	   sites	   within	   the	  duplicated	   segment.	  After	  manual	   review	  of	   the	  177	  de	  novo	  classifications,	   24	  were	  reclassified	  as	  paternal,	  32	  maternal,	  15	  biparental	  and	  17	  as	  unclear.	  To	  further	   increase	   the	   stringency	   for	   de	   novo	   classifications	   and	   avoid	   potential	  false	   positives	  we	   removed	   all	   CNV	   regions	   observed	   to	   be	  multi-­‐allelic	   across	  the	  926	  exon-­‐CGH	  datasets,	  leaving	  16	  high	  confidence	  de	  novo	  events	  ranging	  in	  size	  from	  4.9	  Kb	  to	  4.8	  Mb.	  	  For	  paternal	   and	  maternal	   classifications	  we	  observed	  a	   significant	   increase	   in	  the	   number	   of	   informative	   classifications	   made	   for	   losses	   compared	   to	   gains	  overall	   (P=6.26E-­‐09,	   7.25E-­‐05	   respectively),	   consistent	   with	   the	   lowered	   dose	  response	  available	  for	  gains	  when	  using	  SNP	  genotyping	  arrays	  [213].	  For	  the	  16	  high	  confidence	  de	  novo	  CNVs	  we	  observed	  no	  significant	  difference	  between	  the	  numbers	   of	   informative	   classifications	  made	   for	   losses	   compared	   to	   gains	   and	  there	   was	   no	   observable	   size	   dependent	   bias	   with	   approximately	   the	   same	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number	  of	  classified	  de	  novo	  losses	  and	  gains	  across	  the	  genomic	  size	  range	  (see	  
Figure	  4-­‐6).	  	  
	  Figure	   4-­‐6	   The	   frequency	   of	   de	   novo	   CNVs	   against	   size	   across	   840	   parent-­‐offspring	  transmissions.	  The	  black,	  red	  and	  blue	  lines	  show	  the	  overall,	  deletion	  and	  duplication	  frequency	  of	  de	  novo	  CNV	  events	  respectively.	  Using	  a	  similar	  approach	  to	  [207]	  we	  determined	  the	  parent-­‐of-­‐origin	  for	  15	  of	  16	   high	   confidence	   de	   novo	   CNVs	   (see	   Methods).	   We	   observed	   a	   two-­‐fold	  enrichment	  for	  de	  novo	  CNVs	  present	  on	  the	  paternally	  inherited	  allele,	  with	  10	  paternal	  and	  five	  maternal	  de	  novo	  events	  identified	  (median	  sizes	  of	  153	  kb	  and	  194	  kb	  respectively).	  Although	  the	  sample	  size	  was	  small	  (N=15)	  and	  there	  was	  not	  sufficient	  statistical	  evidence	  for	  a	  parent-­‐of-­‐origin	  effect	  overall	  (P	  =	  0.35),	  the	  proportion	  of	  paternal	  de	  novo	  CNVs	  increased	  as	  the	  size	  of	  CNVs	  decreased	  (see	  Table	  4-­‐1)	  with	  100%	  of	  CNVs	  less	  than	  50	  kb	  in	  size	  (N=4)	  being	  present	  on	  only	  the	  paternally	  inherited	  allele.	  	  Table	  4-­‐1	  Table	  showing	  the	  proportion	  of	  de	  novo	  CNVs	  present	  of	  the	  paternal	  allele	  versus	  the	  CNV	  size	  in	  kilobases.	  The	  total	  number	  of	  observations	  with	  a	  CNV	  size	  less	  than	  each	  size	  bin	  is	  given	  as	  N.	  
	  
CNV Size (kb) Sample Size (N) Paternal Proportion 
50 4 100% 
100 6 83% 
250 9 67% 
500 11 63% 
1000 12 67% 
5000 15 67% 
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  We	  determined	  that	  all	  of	  the	  de	  novo	  CNVs	  originating	  from	  the	  maternal	  allele	  (N=5)	   had	   a	   least	   one	   flanking	   transposable	   element	   within	   a	   1	   kb	   window	  around	   both	   CNV	   breakpoint	   (start	   and	   end)	   positions.	   CNVs	   formed	   by	   non-­‐allelic	   homologous	   recombination	   (NAHR)	  during	  meiosis	   are	   often	   flanked	  by	  low	   copy	   repeats	   (LCR)	   and	   transposable	   elements	   (TE)	   [214-­‐216].	   Of	   the	   de	  
novo	  CNVs	  originating	  from	  the	  paternal	  allele	  (N=10)	  sixty	  percent	  (N=6)	  were	  not	  flanked	  by	  LCR	  or	  TE	  supporting	  the	  hypothesis	  [217]	  that	  it	  may	  be	  possible	  to	   explain	   the	   paternal	   bias	   for	   CNV	   generation	   by	   an	   increase	   of	   replication	  based	  CNV	  formation	  mechanisms	  such	  as	  non-­‐homologous	  end	   joining	  (NHEJ)	  or	   microhomology	   mediated	   break	   induced	   repair	   (MMBIR)	   in	   the	   male	  compared	  to	  the	  female	  germline.	  We	  did	  not	  observe	  a	  significant	  difference	  in	  the	   paternal	   age	   at	   conception	   for	   samples	   containing	   a	   de	   novo	   CNV	   on	   the	  paternally	  inherited	  allele,	  with	  a	  median	  paternal	  age	  of	  32	  and	  30	  for	  samples	  with	   paternal	   de	   novo	   CNVs	   flanked	   and	   not	   flanked	   by	   a	   TE	   respectively	  compared	  to	  a	  median	  paternal	  age	  of	  29	  across	  all	  samples.	  	  	  	  	  	   	  
	   149	  
4.5	   DISCUSSION	  	  We	  have	  developed	  a	  novel	  CNV	  discovery	  algorithm,	  CNsolidate,	  that	  integrates	  and	   weights	   CNVs	   called	   by	   up	   to	   12	   component	   algorithms,	   and	   we	   have	  demonstrated	  that	  it	  has	  improved	  performance	  over	  single	  algorithms.	  	  We	   used	   CNsolidate	   to	   discover	   CNVs	   in	   exon-­‐CGH	   data	   from	   926	   apparently	  healthy	   controls.	   CNV	   detection,	   using	   a	   default	   0.5	   wscore	   cut-­‐off	   value,	   was	  consistent	   across	   926	   normal	   controls	   and	   achieved	   an	   estimated	   mean	  sensitivity	  of	  greater	  than	  0.82	  with	  a	  mean	  1-­‐specificity	  of	  0.052.	  We	  found	  that	  the	   confidence	   metric	   (wscore)	   generated	   by	   CNsolidate	   was	   better	   for	  predicting	  call	  quality	  compared	  to	  any	  other	  call	  quality	  measure	  assessed.	  The	  estimates	   for	   the	   call	   quality	   predictors,	   absolute	   mean	   ratio	   and	   number	   of	  probes	   may	   have	   been	   slightly	   lowered	   due	   to	   conditioning	   that	   greater	   than	  80%	  of	  replicates	  must	  be	  in	  agreement	  for	  a	  CNV	  call	  to	  be	  included	  in	  the	  truth	  set.	   For	   example,	   it	  may	   have	   been	   possible	   to	   detect	   additional	   true	   CNVs	   in	  higher	  quality	  datasets	  that	  could	  be	  distinguished	  from	  the	  background	  noise	  in	  lower	   quality	   datasets,	   or	   that	   false	   low-­‐level	   CNV	   calls	   including	  many	   array-­‐CGH	   probes	   may	   have	   been	   made	   in	   low	   quality	   datasets.	   Nevertheless,	   the	  approach	   used	   clearly	   shows	   an	   accurate	   comparison	   between	   different	   call	  quality	   measures	   in	   providing	   consistent	   CNV	   calls	   across	   datasets	   of	   varying	  quality,	  an	  important	  aspect	  of	  any	  large-­‐scale	  CNV	  study	  [104].	  In	  terms	  of	  the	  power	   to	  detect	  genic	  CNVs	   that	  have	  a	  higher	  probability	  of	  being	  biologically	  meaningful,	  we	  observed	  a	  clear	  difference	  in	  the	  number	  of	  intronic	  and	  exonic	  CNVs	  detected	  per	  sample	  when	  compared	  to	  a	  higher	  resolution	  CNV	  discovery	  study	   [50].	  We	   detected	   on	   average	   40	   and	   119	   intronic	   and	   exonic	   CNVs	   per	  sample	  compared	  to	  269	  and	  38	   from	  the	  higher	  resolution	  study	  respectively,	  reflecting	   the	   difference	   between	   an	   exon	   focused	   array	   design	   (exon-­‐CGH)	  compared	  to	  a	  genome	  wide	  discovery	  design	  [50].	  	  	  We	   performed	   a	   CNV	   validation	   experiment	   using	   9008	   CNVRs	   showing	   that	  greater	   than	   80%	   of	   CNVs	   above	   the	   default	   wscore	   cut-­‐off	   could	   be	  experimentally	  validated.	  It	  should	  be	  noted	  that	  by	  using	  the	  validation	  data	  as	  the	   gold	   standard	   we	   confound	   both	   the	   false	   positive	   detections	   from	   the	  discovery	   array	   with	   the	   false	   negative	   detections	   from	   the	   validation	   array.	  Overall,	   we	   consider	   an	   80%	   agreement	   between	   results	   observed	   from	   two	  independent	   array	   platforms	   across	   26	   samples	   to	   be	   high,	   [202]	   showed	   that	  reproducibility	   in	   replicate	   experiments	   on	   the	   same	   array	   was	   typically	   less	  than	   70%	   for	   most	   platforms.	   Although	   array-­‐CGH	   is	   a	   relatively	   mature	  technology	  and	  has	  been	  applied	   to	  studies	  of	  CNV	   for	  over	  a	  decade	   [11],	   it	   is	  still	  possible	  to	  make	  marked	  advances	  in	  the	  analytical	  algorithms	  for	  both	  CNV	  detection	  and	  interpretation.	  As	  the	  application	  of	  new	  technologies	  such	  as	  next	  generation	  sequencing	  (NGS)	  becomes	  more	  wide	  spread	  in	  studies	  of	  CNV	  it	  is	  important	   to	   carefully	   consider	   the	   performance	   of	   any	   available	   analytical	  software	  to	  ensure	  high	  quality	  CNV	  discovery.	  	  	  We	   also	   developed	   a	   Bayesian	   approach,	   VICAR,	   to	   determine	   the	   inheritance	  status	  of	  a	  previously	  discovered	  CNVs	  using	  SNP	  genotyping	  chip	  data	  from	  the	  children	  and	   their	  parents.	  Using	   synthetic	  CNVs	  of	   varying	   sizes	  derived	   from	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empirical	  data,	  we	  evaluated	  the	  capacity	  of	  VICAR	  to	  infer	  the	  inheritance	  state	  of	  CNVs	  detected	  from	  exon-­‐CGH.	  We	  found	  that	  the	  most	  important	  parameter	  affecting	  classifier	  performance	  was	  the	  number	  of	  SNP	  markers	  present	  on	  the	  genotyping	  platform	  within	  the	  CNV	  region.	  As	  expected	  we	  observed	  decreased	  classification	  performance	  for	  gains	  compared	  to	  losses,	  likely	  due	  to	  a	  decreased	  response	   of	   probe	   intensity	   for	   gains	   compared	   to	   losses	   on	   array	   based	  platforms	  [218].	  	  	  CNsolidate	  is	  available	  as	  a	  software	  package	  with	  no	  external	  dependencies	  and	  can	   be	   applied	   to	   any	   array-­‐CGH	   dataset	   to	   search	   for	   data	   segments	   (change	  point	   intervals)	   that	   are	   potentially	   significantly	   different	   to	   the	   background	  noise.	  Although	  CNsolidate	  has	  been	  primarily	  developed	   for	  use	  on	  array-­‐CGH	  data	  it	  can	  be	  applied	  to	  any	  time-­‐series	  like	  data	  types,	  for	  example	  read	  depth	  data	  derived	  from	  sequence	  based	  datasets	  [219].	  The	  key	  to	  maintaining	  its	  high	  performance	   is	   the	   accurate	   assessment	   of	   individual	   algorithm	   performances	  and	   the	   creation	   of	   reliable	   algorithm	   weighting	   functions.	   Critical	   to	   this	  approach	  is	  ensuring	  that	  the	  predictive	  variables	  used	  to	  assess	  individual	  caller	  performance	  are	  sufficiently	  descriptive	  such	  that	  all	  or	  most	  differences	  in	  data	  characteristics	   effecting	   detection	   performance	   are	   measured.	   We	   expect	  CNsolidate	   to	   achieve	   high	   performance	   using	   its	   pre-­‐generated	   algorithm	  weighting	   functions	  however,	   to	  achieve	  optimal	  performance	  when	  applied	   to	  different	  data	  types,	  the	  number,	  type	  and	  ranges	  of	  predictive	  call	  performance	  measures	  need	  to	  be	  carefully	  considered.	  	  VICAR	  provides	  a	  novel	  model	  for	  incorporating	  additional	  information	  into	  the	  classification	   of	   inheritance	   states	   from	   parent-­‐offspring	   data.	   To	   apply	   the	  model	  to	  different	  data	  types	  estimates	  of	   the	  change	  point	  call	  quality,	  variant	  mutation	  rate,	  variant	  size	  and	  population	  frequency	  needs	  to	  be	  defined	  for	  the	  chosen	   platform.	   The	   main	   limitation	   for	   classifying	   inheritance	   states	   during	  this	   study	   was	   a	   difference	   in	   genomic	   resolution	   between	   the	   parent	   (SNP	  genotyping)	  and	  offspring	  (array-­‐CGH)	  data,	  which	  had	  a	  negative	  impact	  on	  the	  number	  of	  CNVs	  that	  could	  be	  classified	  with	  an	  informative	  inheritance	  state.	  	  We	  have	  shown	  an	  improvement	  in	  detection	  performance	  when	  using	  multiple	  algorithms	   to	   call	   CNVs	   from	   array-­‐CGH	   data	   and	   demonstrated	   a	   novel	  approach	   to	   weighting	   individual	   algorithm	   given	   certain	   predictive	   variables	  (see	  Methods).	  As	  the	  number	  and	  performance	  of	  analytical	  software	  available	  for	  calling	  variants	  from	  sequence	  based	  data	  increases	  [37,	  38,	  40,	  220,	  221],	  it	  may	   be	   worthwhile	   considering	   using	   similar	   approaches	   to	   combining	  information	   across	   multiple	   callers,	   improving	   the	   detection	   performance	  overall.	  Across	   926	   normal	   control	   samples,	   CNsolidate	   detected	   a	   total	   of	   199,967	  autosomal	  calls	  ranging	  in	  size	  from	  44	  bp	  to	  8.5	  Mb	  and	  covering	  14.5%	  of	  the	  genome	   (420	   Mb).	   Using	   CNsolidate	   on	   exon-­‐CGH	   we	   were	   able	   to	   detect	  relatively	  large	  numbers	  of	  single	  exon	  CNVs,	  with	  10%	  of	  all	  CNV	  calls	  affecting	  only	  a	   single	  exon	   from	   the	  GENCODE	  gene	  set	   (version	  17).	   Single	  exon	  CNVs	  have	   been	   shown	   to	   contribute	   to	   a	   number	   of	   phenotypes	   including	   severe	  intellectual	  disability	  [222],	  furthermore	  the	  rate	  at	  which	  single	  exon	  CNVs	  are	  found	  in	  normal	  controls	  has	  yet	  to	  be	  fully	  assessed	  due	  to	  either	  limited	  sample	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sizes	  [50],	  suboptimal	  genomic	  resolution	  [13,	  104]	  or	  algorithmic	  complications	  when	  detecting	  single	  exon	  CNVs	  [223].	  Here	  we	  applied	  high	  performance	  CNV	  detection	  using	  CNsolidate	  to	  almost	  one	  thousand	  healthy	  control	  samples	  using	  exon	   resolution	   array-­‐CGH,	   defining	   1,722	   discrete	   rare	   single	   exon	   CNV	   loci	  (14%	  of	  which	  are	  not	   found	   in	   the	  DGV)	  and	  add	  an	  additional	  1,472	  discrete	  rare	  single	  exon	  CNV	  loci	  to	  current	  literature.	  Using	  SNP	  genotyping	  data	  in	  420	  parent-­‐offspring	   trios	  we	  obtained	  an	   informative	   inheritance	   classification	   for	  2,792	  CNVs	  ranging	  in	  size	  from	  991	  bp	  to	  4.8	  Mb.	  There	  was	  no	  observable	  bias	  between	  the	  numbers	  of	  paternally	  and	  maternally	  inherited	  CNVs	  we	  were	  able	  to	  classify	  overall.	  A	  decrease	  in	  power	  for	  classifying	  gains	  was	  evident	  and	  we	  observed	   a	   significant	   enrichment	   in	   the	   number	   of	   losses	   fro	  which	  we	   could	  classify	  an	  informative	  inheritance	  state.	  Using	  highly	  stringent	  filtering	  criteria	  we	   defined	   16	   high	   confidence	   de	   novo	   CNVs	   and	   conservatively	   estimate	   the	  CNV	  mutation	  rate	  at	  1.9  ×  10!!	  (16	  in	  840	  transmissions)	  at	  a	  median	  detection	  resolution	  of	  15.2	  kb.	  	  We	   estimate	   a	   marked	   increase	   in	   the	   CNV	   mutation	   rate	   compared	   to	   a	  previously	  published	  genome-­‐wide	  study	  focusing	  on	  the	   identification	  of	   large	  CNVs	   (>100	  kb)	   across	  386	  parent?offspring	   trios	   [207].	  The	   authors	   estimate	  the	  CNV	  mutation	  rate	  at	  1.2  ×  10!!	  at	  a	  described	  resolution	  of	  approximately	  30	  kb	  which	  is	  smaller	  than	  our	  estimate	  of	  1.9  ×  10!!	  at	  a	  median	  resolution	  of	  15.2	  kb.	  Furthermore,	  44%	  (7/16)	  of	   the	  de	  novo	  CNVs	  we	   identified	  were	   less	  than	  100	  kb	  in	  size	  (see	  Figure	  4-­‐6)	  compared	  to	  22%	  (2/9)	  from	  [207]	  and	  for	  CNVs	  larger	  than	  500	  kb	  we	  observed	  comparable	  results	  with	  a	  mutation	  rate	  of	  5  ×  10!!	  compared	   to	  6.5  ×  10!!	  [207].	   Using	   exon	   focused	   array-­‐CGH	   (exon-­‐CGH)	   and	   SNP	   genotyping	   data	   in	   420	   parent-­‐offspring	   trios	   we	   were	   able	   to	  classify	   16	   high	   confidence	   de	   novo	   CNVs	   at	   a	   median	   resolution	   of	   15.2	   kb,	  suggesting	   that	   the	   CNV	  mutation	   rate	   is	   likely	   to	   be	   significantly	   higher	   than	  current	  estimates	  [224]	  once	  the	  contribution	  of	  smaller	  CNVs	  is	  fully	  assessed.	  Furthermore,	   we	   observed	   a	   two-­‐fold	   enrichment	   for	   rare	   de	   novo	   CNVs	  identified	   on	   the	   paternally	   inherited	   allele,	   consistent	   with	   the	   paternal	   bias	  previously	  observed	   for	  point	  mutations	   [225]	  and	  noted	   that	  as	   the	  size	  of	  de	  
novo	   CNVs	   decreased	   the	   proportion	   of	   paternal	   de	   novo	   CNVs	   increased	   (see	  
Table	   4-­‐1).	  We	   determined	   that	   100%	   (N=5)	   of	  maternal	   de	  novo	  CNVs	  were	  flanked	  by	  at	   least	  one	  TE	  within	  a	  1	  kb	  window	  around	  both	  CNV	  breakpoint	  positions	  compared	  to	  only	  40%	  (4/10)	  of	  paternal	  de	  novo	  CNVs.	  The	  difference	  in	  CNV	  mutation	  rates	  between	  the	  paternally	  and	  maternally	  inherited	  alleles	  is	  likely	   due	   to	   a	   higher	  mutation	   rate	   from	   CNV	   formation	  mechanisms	   such	   as	  NHEJ	   and	   MMBIR	   compared	   to	   NAHR,	   reflecting	   the	   relative	   difference	   in	  mutation	  rates	  for	  replication-­‐based,	  compared	  to	  meiotic-­‐based	  CNV	  formation	  mechanisms	   [226],	   in	   the	  male	  opposed	   to	   the	   female	  germline	   [207].	  The	  size	  distribution	  of	  paternal	  de	  novo	  CNVs	  with	  and	  without	   flanking	  TE’s	  showed	  a	  marked	  difference	  with	  median	  sizes	  of	  1	  Mb	  and	  53	  kb	  respectively,	  suggesting	  that	  the	  CNV	  formation	  mechanisms	  of	  non-­‐recurrent	  (rare)	  de	  novo	  CNV	  events	  may	  show	  a	  bias	  across	  the	  size	  range,	  with	  smaller	  events	  being	  preferentially	  driven	  by	  NHEJ	  and	  MMBIR	  compared	  to	  NAHR.	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5 |	   Potentially	   Clinically	   Relevant	   Copy	  Number	   Variation	   in	  
1,012	   Normal	   Control	   Samples	   from	   the	   Deciphering	  




5.1	   OVERVIEW	  	  Copy	   number	   variation	   (CNV)	   has	   been	   a	  major	   component	   of	   routine	   clinical	  medical	   genetics	   screening	   for	   over	   a	   decade.	   However,	   the	   interpretation	   of	  individual	  CNV	  events	  remains	  challenging	  with	  most	  clinical	  testing	  laboratories	  finding	   potentially	   pathogenic	   CNVs	   in	   between	   10-­‐20%	   of	   patients	   with	  intellectual	   disability,	   autism	   spectrum	   disorders,	   and/or	   multiple	   congenital	  anomalies	   Furthermore	   a	   relatively	   high	   proportion	   of	   CNVs	   are	   normally	  classified	   as	   variants	   of	   uncertain	   significance	   (VOUS)	   and	   laboratories	   often	  differ	   in	   their	   classification	  criteria.	  These	  VOUS	  are	  generally	   large,	   rare	  CNVs	  not	   found	   in	   apparently	   healthy	   controls	   however,	   the	   selection	   and	   reliable	  usage	  of	  a	  standard	  common	  CNV	  reference	  set	  is	  yet	  to	  be	  established.	  Applying	  a	  rule	  based	  approach	  to	  CNV	  filtering	  in	  1012	  apparently	  healthy	  controls	  from	  the	   Deciphering	   Developmental	   Disorders	   (DDD)	   project	   we	   found	   CNVs	   of	  potential	   clinical	   significance	   in	   7.9%	   and	   rare	   de	   novo	   CNVs	   in	   2.8%	   of	  individuals.	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5.2	   INTRODUCTION	  
	  Clinical	  microarrays	  and	  the	  analysis	  of	  CNVs	  are	  well	  established	  as	  a	  front-­‐line	  diagnostic	   test	   for	   individuals	   referred	   to	   clinical	   genetic	   service	   laboratories	  [227].	   The	   field	   of	   medical	   genetics	   has	   had	   major	   success	   and	   seen	   vast	  improvements	   in	   diagnostic	   rates	   due	   to	   CNV	   analysis,	   linking	   clinically	  significant	  variants	  in	  disease	  causing	  genes	  to	  patient	  phenotypes	  across	  a	  large	  number	  of	  genomic	  disorders	  [228-­‐234].	  However,	   it	  still	  remains	  the	  minority	  of	   patients	  who	   receive	   a	   potential	   diagnosis,	   which	   is	   of	   great	   importance	   to	  patients	   and	   families,	   often	   influencing	   clinical	   treatment,	   prenatal	   decision	  making	   and	   genetic	   counseling	   [235-­‐237].	   During	   routine	   CNV	   analysis	   in	   a	  clinical	  diagnostic	  setting	  only	  a	  small	  proportion	  of	  patients	  (normally	  less	  than	  20%)	   receive	   a	   definitive	   or	   even	   suggestive	   genetic	   diagnosis	   using	   clinical	  microarrays	   [169].	   Furthermore	   CNVs	   are	   often	   identified	   which	   have	   either	  unknown	   clinical	   significance	   (variants	   of	   uncertain	   significance)	   or	   are	   in	  association	   with	   a	   trait	   completely	   unrelated	   to	   the	   investigation	   (incidental	  finding).	   This	   potential	   for	   unintended	   and	   unexpected	   findings	   from	   clinical	  microarray	   data	   highlights	   the	   importance	   of	   informed	   consent	   and	   genetic	  counseling	   when	   performing	   clinical	   CNV	   analysis	   [238].	   Large-­‐scale	   studies	  such	   as	   the	   International	   Standards	   for	   Cytogenomic	   Arrays	   Consortium	   [239]	  and	   the	   Deciphering	   Developmental	   Disorders	   Project	   [29]	   are	   developing	  general	   frameworks	  and	  guidelines	  for	  the	  clinical	   interpretation	  of	  microarray	  and	   next	   generation	   sequence	   data	   for	   patients	   effected	   by	   disorders	   with	   a	  presumed	  genetic	  causation	  [147].	  	  It	   is	   likely	   that	   the	   phenotypes	   displayed	   for	   an	   appreciable	   number	   of	   the	  patients	  remaining	  without	  a	  clear	  diagnosis	  after	  clinical	  microarray	  screening	  are	  due	  to	  other	  types	  of	  genetic	  variation	  [240-­‐242].	  Recent	  studies	  using	  next	  generation	   sequence	   data	   have	   found	   relatively	   large	   numbers	   of	   undiagnosed	  patients	  with	  de	  novo	   single	   nucleotide	   polymorphisms	   or	   insertion	   /	   deletion	  variants	  in	  either	  known	  or	  suggestive	  genomic	  disorder	  genes	  [243,	  244].	  Even	  so,	  due	  to	  the	  difficulty	  of	  CNV	  interpretation	  and	  the	  relatively	  large	  number	  of	  approaches	   taken	   to	   CNV	   analysis,	   it	   is	   likely	   that	   a	   significant	   fraction	   of	  undiagnosed	   patients	   are	   due	   to	   either	   poorly	   understood	   or	   poorly	   captured	  CNVs.	   Although	   the	   role	   of	   de	   novo	   CNVs	   in	   genomic	   disorders	   is	   well	  characterised,	   other	   type	   of	   genetic	   models	   such	   as	   X-­‐linked,	   recessive,	  mosaicism,	   imprinting,	   digenic	   or	   even	   non-­‐coding	   CNVs	   are	   still	   to	   be	   fully	  explored.	   Furthermore,	   has	   been	   observed	   that	   the	   overall	   burden	   of	   CNVs	   is	  higher	   in	   specific	   patients	   groups	   compared	   to	   controls	   [245,	   246]	   indicating	  potential	   combinatorial	   CNVs	   effects	   [247].	   Additionally,	   is	   conceivable	   that	  specific	   combinations	  of	  CNVs,	   that	  when	  observed	   in	   isolation	  would	  often	  be	  ignored,	  may,	  by	  acting	  in	  concert,	  cause	  extreme	  phenotypes	  due	  to	  factors	  such	  as	   dosage	   compensation,	   incomplete	   penetrance	   and	   polygenic	   effects	   [151,	  248].	  It	  is	  clear	  from	  initial	  findings	  [200,	  249]	  that	  the	  sample	  sizes	  required	  to	  search	   for	   such	   CNVs	  with	   small	   effect	   sizes	  will	   be	   larger	   than	   any	   currently	  existing	  datasets.	  Most	  studies	   to	  date	  have	  used	  previously	  generated	  genome	  wide	   association	   study	   (GWAS)	   data	   however	   a	   major	   limitation	   yet	   to	   be	  addressed	   is	   the	  availability	  a	  normal	  CNV	  control	  data	  set	  with	  both	  adequate	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sample	   size	   and	   effective	   genomic	   resolution.	  With	   the	   advance	   of	   large-­‐scale	  genomic	   initiatives	  such	  as	  the	  UK10K	  and	  GEL	  projects,	  as	   the	  amount	  of	  next	  generation	  sequence	  (NGS)	  data	   increases	  and	  the	  analytical	  methods	  available	  to	  perform	  CNV	  analysis	   from	  NGS	  data	   improve	   it	   is	   likely	   that	   these	   types	  of	  CNV	  effects	  will	  become	  more	  attainable.	  The	   Deciphering	   Developmental	   Disorders	   (DDD)	   project	   is	   a	   UK	   wide	  collaboration	  based	  at	  the	  Wellcome	  Trust	  Sanger	  Institute	  involving	  the	  24	  UK	  and	   Ireland	   regional	   genetics	   services	   [29].	   We	   use	   two	   different	   presumed	  healthy	  normal	  control	  cohorts	  in	  the	  DDD	  project,	  585	  individuals	  from	  the	  UK	  blood	  donor	   service	   (UKBS)	   and	  430	   trios	   from	   the	  Generation	   Scotland	   study	  [250].	  To	  highlight	  the	  difficulties	  in	  interpreting	  patient	  CNV	  data	  in	  isolation	  of	  detailed	  patiemt	  phenotypes	  we	  applied	  an	  automated	  rule	  based	  CNV	  filtering	  system	  to	  the	  DDD	  control	  samples	  with	  the	  goal	  of	  finding	  potentially	  clinically	  relevant	  CNVs	  in	  apparently	  healthy	  individuals.	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5.3	   METHODS	  
Overview	  We	  have	  developed	  a	  CNV	  ranking	  and	  prioritisation	  system	  in	  the	  DDD	  project	  for	   flagging	   CNVs	   of	   potential	   clinical	   relevance.	   CNVs	  meeting	   certain	   criteria	  relating	  to	  potential	  clinical	  interest	  are	  flagged	  prior	  to	  being	  reviewed	  in	  detail	  during	  weekly	  multidisciplinary	  reporting	  meetings.	  	  	  
CNV	  Consensus	  Reference	  Set	  To	   define	   CNVs	   as	   rare	   we	   use	   a	   common	   CNV	   reference	   set	   incorporating	   a	  number	  of	  high	  quality	  studies	  that	  we	  term	  the	  CNV	  Consensus.	  The	  reference	  sets	  that	  are	  included	  in	  the	  CNV	  consensus	  are;	  5919	  controls	  on	  an	  Affy6	  array	  from	  the	  WTCCC	  [104],	  1892	  controls	  from	  the	  1000	  Genomes	  Project	  [36],	  845	  controls	   on	   a	   2	   Million	   probe	   Agilent	   array	   from	   the	   DDD	   Project	   [29],	   450	  controls	   from	  a	  XX	  prohe	  Agilent?	  Array	  and	  40	  controls	  on	  a	  42	  Million	  probe	  NimbleGen	   array	   from	   the	   CNV	   Project	   [50].	   This	   combined	   reference	   set	  achieves	   high	   resolution	   and	   adequate	   sample	   size,	   enabling	   an	   accurate	  population	  frequency	  estimate	  for	  copy	  number	  variable	  events	  (CNVEs)	  across	  the	  genomic	   size	   range	   (see	  Figure	   2-­‐27).	  We	  define	   common	  CNVEs	  as	   those	  observed	  at	  greater	  than	  1%	  population	  frequency	  distinguishing	  between	  CNVE	  type	   states,	  CNV	   loci	  observed	  as	  exclusively	   loss,	   exclusively	  gain	  or	  both	   loss	  and	   gain	   across	   samples.	   Patient	   CNVs	   sharing	   greater	   than	   80%	   of	   their	  boundaries	   with	   a	   common	   CNVE	   including	   the	   same	   CNV	   type	   state	   are	  classified	  as	  common.	  	  
DD	  Gene	  to	  Phenotype	  Database	  The	  CNV	  filtering	  pipeline	  makes	  use	  of	  a	  manually	  curated	  resource	  called	  the	  DDG2P	   (dd	   gene	   to	   phenotype)	   gene	   list	   that	   can	   be	   downloaded	   from	   the	  DECIPHER	   database.	   The	   DDG2P	   is	   a	   database	   of	   gene	   to	   phenotype	  relationships	   containing	   genes	   with	   some	   evidence	   of	   an	   association	   to	   a	  developmental	   disorder.	   The	   database	   contains	   gene	   names,	   genetic	  mechanisms,	  mutation	  consequences	  and	  linked	  phenotype	  terms.	  Each	  DDG2P	  entry	   is	   placed	   into	   one	   of	   four	   possible	   categories	   based	   on	   the	   amount	   of	  evidence	   available	   for	   the	   described	   association.	   Each	   gene	   is	   associated	   with	  specific	   developmental	   phenotypes	   or	   syndromes	   via	   genetic	  mechanisms	   and	  mutation	   consequences	   of	   the	   gene	   product.	   Using	   DDG2P	   enables	   any	   rare	  variant	   in	  known	  DD	  genes	  with	  a	  predictable	  effect	  on	  the	  gene	  product	   to	  be	  flagged	  on	  the	  basis	  of	  inheritance,	  genotype	  and	  likely	  mutational	  consequence.	  	  
Flagging	  CNVs	  for	  Clinical	  Review	  We	  use	  three	  different	  approaches	  for	  flagging	  CNVs	  of	  potential	  clinical	  interest.	  First	  we	  flag	  CNVs	  based	  on	  size	  and	  rarity	  alone	  (VOUS)	  using	  a	  set	  of	  fixed	  CNV	  size	  cut-­‐offs	  dependent	  on	  the	  CNV	  inheritance	  and	  parent	  affected	  state.	  Second	  we	  use	   the	  DDG2P	  gene	   list	   to	   search	   for	  CNVs	   in	   genes	  previously	   associated	  with	  genomic	  disorders	  given	   the	  patient	  gender	  and	  parent	  affected	  state,	   the	  mode	   and	   mechanism	   of	   each	   DD	   gene	   and	   the	   copy	   number	   state,	   genomic	  location	  and	  inheritance	  classification	  of	  each	  patient	  CNV.	  Finally	  we	  search	  for	  CNVs	  with	  a	  greater	  than	  50%	  reciprocal	  overlap	  with	  a	  CNV	  syndrome	  region	  of	  the	  same	  CNV	  type	  (losses	  and	  gains)	  contained	  in	  the	  DECIPHER	  database.	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Variants	  of	  Uncertain	  Significance	  (VOUS)	  The	   class	   of	   CNVs	   flagged	  using	   these	   rules	   are	   sufficiently	   rare	   in	   the	   general	  population	  such	  that	  they	  are	  normally	  of	  general	  clinical	   interest	  even	  if	   there	  contribution	  to	  patient	  phenotypes	   is	  poorly	  understood.	  To	   flag	  these	  types	  of	  variants	   we	   use	   a	   number	   of	   fixed	   cut-­‐offs	   on	   rarity	   and	   size	   given	   the	  inheritance	  classification	  for	  each	  detected	  CNV	  (see	  Table	  2-­‐2).	  CNVs	  where	  the	  inheritance	  classification	  is	  unknown	  we	  use	  a	  fixed	  500kb	  cut-­‐off,	   flagging	  any	  rare	  CNV	  (loss	  or	  gain)	  greater	  than	  500kb	  in	  length	  for	  clinical	  review.	  For	  CNVs	  where	  we	  where	   able	   to	  make	   an	   informative	   inheritance	   classification,	   if	   the	  inheritance	   is	   ‘de	  novo’	   or	  biparental	   the	   fixed	  size	   cut-­‐off	  used	   for	  deletions	   is	  100kb	  whereas	  for	  duplications	  it	  is	  250kb.	  Inherited	  CNVs	  classified	  as	  paternal	  or	   maternal	   can	   be	   flagged	   so	   long	   as	   the	   father	   or	   the	   mother	   are	   affected	  respectively.	   Additionally	   male	   patients	   CNVs	   on	   chromosome	   X	   classified	   as	  maternal	  are	  flagged	  irrespective	  of	  the	  mothers	  affected	  status.	  
Developmental	  Disorder	  Genes	  (DDG2P)	  The	  current	  version	  of	  DDG2P	  includes	  1,850	  entries	  (1,336	  unique	  genes)	  and	  there	   are	   a	  number	  of	   rules	  needed	   for	   flagging	  CNVs	  based	  overlaps	  with	   the	  DDG2P	   including,	   sample	  gender,	   copy	  number	   state	  of	   the	  CNV	  and	   the	  mode	  and	  mechanism	  of	  the	  DD	  gene	  (see	  Table	  2-­‐1).	  DD	   genes	  with	   a	   biallelic	  mechanism	   on	   any	   chromosomes,	   in	   both	  males	   and	  females	  with	  either	  uncertain,	  loss	  of	  function	  or	  dominant	  negative	  mutational	  consequences	   are	   always	   flagged	   if	   the	   estimated	   copy	   number	   state	   is	   zero.	  Exactly	   the	   same	   rules	   are	   used	   for	  monoallelic	   and	   X-­‐linked	  DD	   genes	   except	  that	   single	   copy	   losses	   (heteroygous	   deletions)	   are	   also	   flagged.	   Additionally,	  gains	   (copy	   number	   greater	   than	   2)	   in	  monoallelic	   DD	   or	   X-­‐linked	   genes	  with	  either	  a	  uncertain	  or	  increased	  gene	  dosage	  mutational	  consequence	  are	  flagged	  if	  they	  encompass	  the	  entire	  gene	  transcript.	  CNVs	  in	  hemizygous	  DD	  genes	  with	  either	  a	  uncertain,	  loss	  of	  function	  or	  dominant	  negative	  mutational	  consequence	  are	   flagged	   if	   the	   sample	   is	  male	   and	   the	   copy	   number	   state	   is	   less	   than	   two.	  Gains	  in	  hemizygous	  DD	  genes	  CNVs	  are	  flagged	  in	  both	  male	  and	  female	  samples	  if	   the	   copy	   number	   state	   is	   greater	   than	   two,	   the	   DD	   gene	   mutational	  consequence	   is	  either	  uncertain	  or	   increased	  gene	  dosage	  and	   they	  encompass	  the	  entire	  gene	  transcript.	  
Syndrome	  Regions	  (DECIPHER)	  To	  search	  for	  events	  in	  known	  disease	  associated	  genomic	  regions	  we	  compare	  rare	   patients	   CNVs	   against	   a	   list	   of	   known	   syndromic	   regions	   from	   the	  DECIPHER	  database.	  The	  DECIPHER	  syndrome	  list	  contains	  70	  genomic	  loci,	  we	  compared	   patient	   losses	   against	   regions	   annotated	   to	   be	   associated	   to	   a	  syndrome	   when	   the	   copy	   number	   is	   less	   than	   two	   and	   patient	   gains	   against	  regions	   annotated	   to	   be	   associated	   to	   a	   syndrome	   when	   the	   copy	   number	   is	  greater	   than	   two.	   Patient	   CNVs	  we	   a	   greater	   than	  50%	   reciprocal	   overlap	   to	   a	  DECIPHER	  syndrome	  region	  of	  the	  correct	  CNV	  type	  (loss	  or	  gain)	  were	  flagged	  for	  clinical	  review.	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5.4	   RESULTS	  
Variants	  of	  potential	  clinical	  significance	  	  We	   previously	   reported	   a	   framework	   and	   ranking	   system	   for	   determining	  variants	  of	  potential	   clinical	   significance	   (Wright CF – manuscript under review).	  There	   we	   described	   a	   rule-­‐based	   approach	   to	   prioritising	   CNVs	   and	   here	   we	  applied	  exactly	  the	  same	  parameters	  to	  the	  control	  samples.	  Overall	  67	  CNVs	  in	  64/926	  samples	  were	  flagged	  for	  clinical	  review	  ranging	  in	  size	  from	  223	  bp	  to	  8.5	  Mb.	  The	  majority	  (78%)	  were	  flagged	  based	  on	  size	  and	  rarity	  alone	  with	  the	  remainder	  (22%)	  being	   flagged	  because	   they	  were	  rare	  and	  overlapped	  a	  gene	  previously	  associated	  with	  a	  known	  developmental	  disorder	  (DD).	  	  Of	   the	   52	   CNVs	   flagged	   based	   on	   rarity	   and	   size,	   39	  were	   duplications	   and	   13	  were	  deletions	   suggesting	   that	  duplications	  are	  better	   tolerated	   in	   the	  genome	  than	   deletions.	   The	   Untied	   Kingdom	   blood	   donor	   service	   (UKBS)	   samples,	   for	  which	   SNP	   genotyping	   data	   and	   consequently	   inheritance	   classifications	   were	  not	   available,	   accounted	   for	   75%	   of	   these	   flagged	   CNVs	   highlighting	   the	  importance	   of	   inheritance	   information	   when	   interpreting	   large	   CNVs	   of	  uncertain	  clinical	  significance.	  Of	   the	  remaining	  25%,	  detected	   from	  generation	  scotland	   (trio)	   samples,	   nine	   were	   classified	   as	   de	   novo	   by	   VICAR,	   one	   was	  classified	   as	   inconclusive	   due	   to	   poor	   quality	   SNP	   genotyping	   data	   and	   three	  were	  unclassified	  due	  to	  being	  on	  chromosome	  X	  (see	  Methods).	  	  The	  15	  CNVs	  flagged	  due	  to	  overlapping	  a	  DDG2P	  entry	  contained	  a	  total	  of	  12	  unique	   DD	   genes.	   The	   8	   deletions	   were	   all	   single	   copy	   losses	   and	   included	   6	  monoallelic	  DD	  genes	   (4	   loss	  of	   function	  and	  2	  dominant	  negative).	  Two	  genes	  (SETBP1	   &	   NRXN1)	   were	   observed	   in	   two	   independent	   samples	   whereas	   the	  remaining	   four	   (COL9A1,	   GJB6,	   AUTS2	   &	   FBN2)	   were	   only	   observed	   in	   single	  samples.	   The	   seven	   duplications	   included	   six	   unique	   DD	   genes,	   three	   with	   an	  uncertain	  mode	  of	  action,	  one	  hemizygous	  loss	  of	  function	  gene	  and	  two	  in	  genes	  associated	  with	  both	  developmental	  disorders	  and	  incidental	  findings.	  One	  gene	  (KCNE1)	  was	  observed	  in	  two	  independent	  samples	  whereas	  the	  remaining	  five	  genes	  (ACADS,	  GK,	  MAF,	  PTCH1	  &	  TP63)	  were	  only	  observed	  in	  single	  samples.	  	  	  Next	  we	  determined	  that	  six	  rare	  CNVs	  (three	  duplications	  and	  three	  deletions)	  overlapped	  three	  known	  syndromic	  regions	  from	  the	  DECIPHER	  database	  using	  a	   greater	   than	   0.5	   reciprocal	   overlap	   rule.	   The	   tree	   duplications	   were	   all	  classified	  as	  inherited.	  One	  paternally	  inherited	  duplication	  shared	  over	  95%	  of	  its	   boundaries	   with	   the	   1q21.1	   recurrent	   microduplication	   region,	   a	   possible	  susceptibility	  locus	  for	  neurodevelopmental	  disorders	  such	  as	  autism	  [251].	  The	  remaining	  two	  duplications,	  one	  paternally	  and	  one	  maternally	  inherited,	  shared	  over	   78%	   of	   their	   boundaries	   with	   the	   16p13.11	   recurrent	   microduplication	  region,	   another	   neurocognitive	   disorder	   susceptibility	   locus	   reported	   to	   be	  associated	  with	   schizophrenia	   [252].	  The	  3	  deletions	   shared	  over	  90%	  of	   their	  boundaries	   with	   the	   steroid	   sulphatase	   deficiency	   (STS)	   syndrome	   region	   on	  chromosome	   X.	   Two	   of	   the	   control	   samples	  were	   female,	   and	   both	   had	   single	  copy	  (heterozygous)	  deletions	  encompassing	  all	  of	  the	  STS	  syndrome	  region.	  The	  one	  remaining	  deletion	  was	  homozygous	  and	  observed	  in	  a	  male	  sample,	  sharing	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greater	   than	   99.9%	   of	   its	   boundaries	   with	   the	   STS	   syndrome	   region	   and	  including	  the	  HDHD1,MIR4767,VCX,PNPLA4,MIR651	  genes.	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5.5	   DISCUSSION	  	  We	   determined	   the	   number	   and	   type	   of	   potentially	   clinically	   relevant	   CNVs	  detected	   using	   exon-­‐CGH	   in	   1,012	   control	   samples	   by	   applying	   a	   rule-­‐based	  approach	  to	  clinical	  variant	  ranking	  [147].	  The	  majority,	  52	  CNVs	  (13	  deletions	  and	   39	   duplications)	   were	   flagged	   based	   on	   rarity	   and	   size	   alone	   and	   could	  collectively	   be	   termed	   variants	   of	   uncertain	   significance	   (VOUS).	   However,	   15	  CNVs	   (eight	   deletions	   and	   seven	   duplications)	   were	   flagged	   due	   to	   rarity	   and	  because	   they	   overlapped	   a	   known	   DD	   gene	   with	   the	   relevant	   mode	   and	  mechanism.	  These	  15	  CNVs	  contained	  a	  total	  of	  12	  unique	  DD	  genes,	  three	  were	  observed	   in	  more	   than	   one	   individual	  whereas	   nine	  were	   only	   observed	   once	  across	  1,012	  controls.	  Furthermore,	  we	  observed	  six	  CNVs	  sharing	  greater	  than	  50%	  positional	  similarity	  to	  a	  total	  of	  four	  unique	  previously	  defined	  syndrome	  regions.	  Of	  the	  recurrently	  mutated	  DD	  genes,	  two	  were	  heterozygous	  deletions	  of	  exon	  3	  in	   the	   SETBP1	   gene,	   a	   gene	   associated	   with	   Schinzel-­‐Giedion	   syndrome	   and	  Myeloid	   Leukemia.	   	   A	   previous	   study	   [253]	   described	   point	   mutations	   in	   13	  individuals	   with	   Schinzel-­‐Giedion	   syndrome	   and	   found	   all	   mutations	   to	   be	  clustered	   to	   a	   highly	   conserved	   11-­‐bp	   region	   on	   exon	   4.	   Furthermore	   [254]	  determined	   that	   amino	   acids	   182	   to	   223	   of	   the	   Myeloid	   Leukemia-­‐Associated	  SET	  gene,	   interacted	  with	  amino	  acids	  1238	  to	  1434	  of	  SETBP1.	  Both	  CNVs	  we	  observe	  in	  SETBP1	  have	  not	  been	  described	  in	  association	  with	  DD,	  delete	  exon	  3,	  including	  amino	  acids	  163	  to	  181,	  suggesting	  to	  us	  that	  exon	  3	  of	  SETBP1	  may	  be	  non-­‐essential	  for	  gene	  function.	  	  We	  observed	  two	  independent	  heterozygous	  deletions	   of	   the	   NRXN1	   gene,	   a	   monoallelic	   Schizophrenia	   susceptibility	   locus	  [255]	   and	   a	   biallelic	   Pitt-­‐Hopkins-­‐like	   syndrome-­‐2	   (PTHSL2)	   locus	   [256].	  Thereby	   we	   report	   a	   0.2%	   prevalence	   of	   Schizophrenia	   susceptibility	   due	   to	  heterozygous	  deletions	  of	  the	  NRXN1	  gene	  in	  normal	  control	  individuals.	  Finally	  we	   observed	   two	   independent	   duplications	   of	   the	   KCNE1	   gene,	   both	  encompassed	  the	  entire	  gene	  and	  were	  not	  predicted	  to	  perturb	  gene	   function.	  The	   two	   duplications	   were	   flagged	   due	   to	   KCNE1	   being	   an	   incidental	   finding	  gene.	  KCNE1	  is	  associated	  with	  Jervell	  and	  Lange-­‐Nielsen	  syndrome	  type	  2	  [257]	  with	   a	   biallelic	   	   mode	   of	   action	   and	   with	   Long	   QT	   syndrome-­‐5	   [258]	   with	   a	  monoallelic	  mode	   of	   action.	   Thus	   the	   increased	   gene	   dosage	   conferred	   by	   the	  duplications	   we	   observed	   at	   KCNE1	   was	   not	   predicted	   to	   predispose	   the	  individuals	   to	   sudden	   death	   from	   cardiac	   arrhythmias	   (severe	   Long	   QT	  syndrome)	   or	   cause	   the	   phenotypes	   associated	  with	   Jervell	   and	   Lange-­‐Nielsen	  syndrome	  type	  2.	  	  	  Furthermore	  six	  CNVs	  with	  sufficient	  positional	  similarity	  to	  previously	  defined	  syndrome	  regions	  were	  flagged.	  We	  observed	  three	  inherited	  microduplications	  at	  a	  frequency	  of	  one	  and	  two	  in	  1,852	  transmissions	  for	  the	  1q21.1	  and	  16p11.2	  syndrome	  regions	  respectively.	  A	  recent	  study	  into	  the	  expression	  of	  the	  1q21.1	  microduplication	   in	   adults	   suggested	   that	   anticipatory	   care	   should	   include	  attention	   to	   later-­‐onset	   conditions	   such	   as	   schizophrenia	   [259]. The	   16p11.2	  region	   has	   been	   shown	   by	   a	   number	   of	   studies	   to	   be	   associated	   with	  schizophrenia	  [252,	  260,	  261].	  	  We	  observed	  three	  microdeletions	  at	  a	  frequency	  of	   three	   in	  1,852	   transmissions	   at	   the	   STS	   syndrome	   region	  on chromosome X.	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Ichthyosis	  X-­‐linked	  (XLI)	   is	  a	  relatively	  common	  rare	  disorder	  [262],	  estimated	  to	   occur	   as	   often	   as	   once	   in	   2000	  male	   births	   [263],	  we	   screened	   926	   normal	  controls	  and	  observed	  a	  single	  homozygous	  deletion	  of	  the	  STS	  syndrome	  region	  in	  a	  male	   individual.	  XLI	  results	   from	  steroid	  sulfatase	  deficiency	  and	  generally	  only	  occurs	  in	  boys	  with	  90%	  of	  patients	  have	  deletions	  of	  the	  STS	  gene.	  Girls	  can	  be	  carriers	  but	  symptoms	  are	  usually	  mild	  or	  normal	  [264,	  265].	  Most	  deletions	  of	  the	  STS	  gene	  in	  boys	  result	  in	  the	  XLI	  skin	  disorder	  and	  although	  rare	  cases	  of	  homozygous	   females	   from	  cosanguineous	  marriages	  have	  been	  reported	   [266],	  we	   assume	   both	   female	   samples	   here	   to	   be	   phenotypically	   normal	   with	   XLI	  carrier	  status.	  However	  we	  do	  predict	  the	  homozygous	  deletion	  observed	  in	  the	  male	  sample	  to	  cause	  the	  relatively	  common	  [263]	  XLI	  skin	  disorder.	  	  Here	  we	   report	   a	  potential	   diagnostic	   feedback	   rate	  of	   7.9%	   in	  normal	   control	  samples,	  71%	  of	  which	  were	  rare	  VOUS,	  21%	  were	  rare	  and	  overlapped	  a	  known	  DD	   gene	   and	   8%	   were	   in	   defined	   syndromic	   regions.	   Although	   it	   might	   be	  appropriate,	   for	  most	  CNVs	  observed	  in	  a	  known	  DD	  gene	  or	  syndromic	  region	  for	   a	   patient	   with	   a	   clearly	   associated	   phenotype(s)	   to	   conclude	   that	   the	  observed	  phenotype(s)	  are	  caused	  by	  the	  specific	  CNV,	  it	  is	  not	  necessarily	  true	  that	  the	  CNVs	  observed	  in	  the	  known	  DD	  gene	  or	  syndromic	  region	  is	  sufficient	  to	   cause	   the	   associated	   phenotype(s).	   There	   are	   a	   number	   of	   more	   complex	  situations	   that	   can	   occur	   and	   mask	   the	   appearance	   of	   a	   phenotype	   given	   the	  genotype	   previously	   associated	   with	   DD,	   such	   as	   dosage	   compensation	   [149],	  partial	   penetrance	   [150]	   and	   polygenic	   effects	   [151].	   The	   findings	   presented	  here	   add	   weight	   to	   the	   general	   guidelines	   that	   genomic	   findings	   must	   be	  interpreted	  with	  a	  degree	  of	  caution	  and	  reviewed	  carefully	  by	  clinical	  experts	  in	  relation	  to	  patient	  phenotypes	  before	  any	  solid	  conclusions	  should	  be	  made.	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6 |	  Discussion	  &	  Future	  Direction	  
6.1	   Discussion	  During	   this	   research	   thesis	  various	  analytical	  methodology	  and	  software	   to	  aid	  the	   detection	   and	   interpretation	   of	   copy	   number	   variants	   (CNVs)	   from	   data	  generated	  using	  high-­‐resolution	  array-­‐CGH	  has	  been	  developed	  (see	  Chapter	  2).	  A	   large-­‐scale	   automated	   and	   tightly	   versioned	   analytical	   pipeline	   for	   standard	  use	   in	   the	   Deciphering	   Developmental	   Disorders	   (DDD)	   project	   has	   been	  implemented	   (see	   Chapter	   3).	   By	   applying	   the	   methods	   across	   over	   1,000	  apparently	  healthy	  control	  datasets,	   two	  specific	   studies	  were	  performed;	  a)	  A	  study	   describing	   the	   detection	   performance	   achieved	   by	   CNsolidate	   and	   the	  overall	   characteristics	   of	   CNVs	   found	   using	   the	   DDD	   array-­‐CGH	   platform	   (see	  
Chapter	  4);	  b)	  A	  study	  presenting	  the	  number	  and	  type	  of	  potentially	  clinically	  relevant	  CNVs	  found	  across	  two	  different	  control	  cohorts	  (see	  Chapter	  5).	  
CNsolidate	  CNsolidate	  is	  currently	  in	  use	  as	  the	  main	  CNV	  discovery	  method	  for	  patient	  data	  generated	  as	  part	  of	  a	  cutting	  edge	  translational	  project	  based	  at	  the	  Wellcome	  Trust	  Sanger	  Institute	  (WTSI).	  This	  project,	  the	  DDD,	  is	  a	  collaboration	  between	  the	   WTSI	   and	   the	   National	   Health	   Service	   (NHS),	   involving	   the	   24	   regional	  genetic	   services	   across	   the	  UK	   and	   Ireland.	  The	  high	  performance	   achieved	  by	  CNsolidate	  for	  CNV	  detection	  (see	  Chapter	  2),	  allowing	  increased	  detection	  rates	  and	   the	   accurate	   ranking	   of	   detection	   quality	   scores	   (wscore)	   has	   a	   positive	  impact	  on	  the	  DDD	  projects	  ability	  to	  feedback	  meaningful	  CNVs	  to	  the	  regional	  NHS	   genetic	   services.	   The	   methods	   developed	   (CNsolidate)	   to	   control	   the	  balance	   between	   the	   Type	   I	   and	   Type	   II	   error	   rates	   across	  multiple	   data	   sets	  allows	  a	  variety	  of	  approaches	   for	  genomic	  variation	  feedback	  to	  be	  taken.	  The	  precise	  definition	  of	  high	  quality	  (QC	  passed)	  CNV	  calls	  can	  be	  adjusted	  using	  a	  single	   threshold	   on	   the	   detection	   quality	   measure	   generated	   by	   CNsolidate	  (wscore)	  across	  multiple	  data	  sets.	  This	  allows	  the	  DDD	  array-­‐CGH	  CNV	  data	  to	  be	  mined	   in	   an	   iterative	  manner.	   Initially,	   following	   the	   normal	   guidelines	   for	  diagnostic	   testing,	   the	   error	   rates	   were	   tuned	   to	   achieve	   high	   specificity	   (low	  Type	  I	  error)	  for	  an	  acceptable	   level	  of	  sensitivity	  (Type	  II	  error).	  Although	  the	  DDD	  project	  advices	  that	  all	  genetic	  variation	  it	  feeds	  back	  should	  be	  validated	  in	  an	   accredited	   laboratory	   (the	   regional	   genetic	   services),	   it	   is	   important	   to	  minimise	   the	   reporting	   of	   erroneous	   CNV	   calls,	   potentially	   wasting	   important	  resources	  that	  could	  be	  put	  to	  better	  use.	  For	  example,	  time	  and	  money	  may	  be	  better	   used	   for	   additional	   or	   complementary	   assays	   to	   aid	   the	   search	   for	   any	  underlying	  genetic	  causation	  to	  specific	  patient	  symptoms.	  In	  any	  analysis	  within	  a	   diagnostic	   setting	   there	   is	   always	   a	   careful	   balance	   to	   be	   made	   between	  minimising	   the	   chance	   of	   reporting	   an	   incorrect	   result	   (false	   positive)	   and	  maximising	  the	  chance	  of	   finding	  the	  cause	  of	  specific	  patients	  symptoms	  (true	  positive	   or	   diagnosis).	   CNsolidate	   allows	   this	   balance	   to	   be	   modified	   in	   a	  relatively	  easy	  and	  reliable	  way	  by	  simply	  adjusting	  the	  cut-­‐off	  used	  on	  the	  call	  quality	   wscore	   values,	   thereby	   changing	   the	   Type	   I	   and	   Type	   II	   errors	   rate	  balance	  consistently	  across	  large	  numbers	  of	  samples	  (see	  Chapter	  2).	  	  The	  number	  of	  proband	   (patient)	   samples	   expected	   to	  have	  data	   generated	  by	  the	  DDD	  array-­‐CGH	  platform	  is	  in	  excess	  of	  8,000	  individuals.	  It	  will	  undoubtedly	  be	  the	  case	  that	  a	  proportion	  of	  individuals	  will	  receive	  a	  potential	  (suggestive	  or	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compelling)	   diagnosis	   based	   on	   specific	   CNVs	   observed	   in	   their	   genome	   alone,	  however	   unfortunately	   this	  will	   leave	   a	   proportion	   of	   individuals	  without	   any	  CNV	   based	   diagnosis.	   The	   expectation	   is	   that	   a	   number	   of	   these	   ‘missed’	  diagnosis	  will	   be	   due	   to	   CNVs	   that	  where	   either	   not	   detectable	   using	   the	  DDD	  array-­‐CGH	  platform	  or	  whose	  CNVs	  may	  have	  been	  filtered	  out	  due	  to	  selecting	  relatively	   stringent	   quality	   criteria	   for	   passing	   CNVs	   during	   clinical	   reporting.	  When	   further	   mining	   the	   DDD	   patient	   array-­‐CGH	   CNV	   data	   for	   potential	  diagnosis,	   the	  wscore	   (adjusted	   and	  non-­‐adjusted)	  will	   prove	   extremely	   useful	  for	  maintaining	  consistent	  error	  rates	  within	  and	  across	  samples.	  The	  DDD	  is	  a	  research	  project,	  geared	  towards	   furthering	  the	  understanding	  of	  rare	  genomic	  variation	   and	   the	   discovery	   of	   novel	   genetic	   changes	   that	   could	   potentially	   be	  driving	   certain	   developmental	   disorders.	   Again	   the	  mentioned	  methods	   inside	  CNsolidate	   will	   allow	   the	   search	   space	   for	   potentially	   pathogenic	   CNVs	   to	   be	  increased	  across	  DDD	  samples	  with	  relative	  ease,	  while	  importantly	  maintaining	  a	  consistent	  false	  positive	  rate.	  CNsolidate	   is	   not	   only	   in	   use	   for	   the	  DDD	  project,	   it	   is	   also	   being	   trialled	   by	   a	  number	  of	  other	  projects	  based	  at	  the	  WTSI	  and	  elsewhere.	  The	  data	  sets	  in	  use	  for	   these	  different	  projects	   are	   rather	  different	   to	   those	  within	   the	  DDD,	   some	  being	   generated	   using	   different	   array	   platforms	   and	   others	   being	   generated	  using	   completely	   different	   sample	   types,	   for	   example	   aneuploidy	   (cancer)	  samples.	  CNsolidate	  has	  been	  provided	  to	  these	  projects	  as	  a	  standalone	  piece	  of	  detection	   software	   and	   has	   various	   predefined	   default	   parameter	   values.	  CNsolidate	   is	   expected	   to	   deliver	   high	   detection	   performance	   using	   its	   default	  settings	  but	  if	  performance	  is	  found	  to	  be	  lower	  than	  desired	  specific	  weighting	  functions	   and	   parameter	   settings	   can	   be	   tuned	   using	   a	   number	   of	   semi-­‐automated	   simulation	   based	   methods	   within	   CNsolidate.	   The	   performance	   of	  CNsolidate	   for	   the	   detection	   of	   CNVs	   from	   these	   different	   projects	   is	   yet	   to	   be	  fully	  assessed	  but	  the	  early	  indications	  have	  all	  been	  positive.	  	  Additionally	   a	   CNV	   validation	   experiment	   using	   a	   custom	   Agilent	   array	   was	  designed.	  This	  array,	  the	  validation	  array,	  comprises	  of	  six	  8	  x	  60k	  Agilent	  arrays	  and	   the	   probe	   content	   has	   been	   spend	   on	   tiling	   CNV	   detections	   made	   with	  CNsolidate	   across	   a	   number	   of	   samples	   (see	  Appendix).	   These	   detections	   are	  randomly	   selected	   across	   the	   detection	   quality	   score	   (wscore)	   range.	   This	  allowed	   a	   real	   false	   positive	   rate	   estimate	   to	   be	   derived	   across	   the	   range	   of	  detection	  quality	  scores	  produced	  by	  CNsolidate	  (see	  Chapter	  4).	  	  The	  main	  message	   and	   finding	  made	   during	   the	   development	   of	   CNsolidate	   is	  that	  by	  using	  a	  combination	  of	  change	  point	  detection	  algorithms	  it	  was	  possible	  to	   increase	   detection	   performance	   compared	   to	   individual	   algorithms.	  Furthermore,	   by	   incorporating	   some	   prior	   knowledge	   on	   the	   performance	   of	  individual	   algorithms	   given	   measurable	   characteristics	   from	   the	   input	   data,	   it	  was	  possible	  to	  improve	  the	  ranking	  of	  detected	  segments	  compared	  to	  using	  a	  simple	  consensus	  based	  approach.	  Moreover,	  by	  estimating	  the	  performance	  of	  detection	   quality	   ranking	   between	   datasets	   of	   differing	   qualities	   detection	  ranking	   measures	   could	   be	   adjusted	   to	   achieve	   a	   consistent	   error	   rate	   across	  large	  numbers	  of	  datasets.	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Copy	  Number	  Tagging	  SNPs	  A	  novel	  methodology	  for	  the	  tracking	  of	  array-­‐CGH	  data	  using	  CNV	  tagging	  SNPs	  has	  been	  developed	  during	  this	  thesis	  and	  implemented	  for	  the	  DDD	  project.	  This	  provides	   some	   additional	   confidence	   that	   the	   linked	   dataset	   and	   CNVs	  potentially	   fed	   back	   to	   the	   regional	   genetic	   services	   were	   detected	   from	   the	  correct	  sample.	  Data	  tracking	  in	  the	  DDD	  project	  is	  extremely	  important	  and	  we	  have	   shown	   that	   it	   is	   possible	   to	   use	   CNV	   tagging	   SNPs	   to	   detect	   sample	  mismatches	   between	   a	   genotyping	   assay	   (Sequenom)	   and	   an	   array-­‐CGH	  experiment.	  This	  approach	  is	  both	  considerably	  more	  complex	  and	  less	  accurate	  than	   the	   tracking	   systems	   used	   for	   the	   sequencing	   and	   genotyping	   analytical	  pipelines	   at	   the	   WTSI.	   	   There	   are	   a	   number	   of	   areas	   that	   could	   improve	   the	  discriminatory	  power	  of	   the	  CNV	   tagging	  SNPs	  data	   sample	   tracking	  approach.	  One	   obvious	   improvement	  would	   be	   to	   increase	   the	   number	   of	  markers	   (CNV	  tagging	  SNPs)	  from	  which	  to	  base	  the	  probabilities	  of	  the	  model	  on.	  Furthermore	  as	  the	  amount	  of	  data	  generated	  increases	  the	  estimates	  of	  the	  model	  parameters	  and	   the	  definition	  of	   copy	  number	  state	  boundaries	  are	   likely	   to	   improve.	  This	  could	  potentially	   improve	   the	  discriminatory	  power	  of	   the	   tracking	  values	   and	  lend	  to	  a	  more	  reliable	  data	  tracking	  system	  overall.	  	  For	   the	  DDD	  project,	   due	   the	   sensitive	  nature	  of	   the	  data	  under	   consideration,	  the	  data	  tracking	  method	  is	  not	  used	  to	  resolve	  any	  sample	  swaps,	  rather	  only	  to	  fail	  sample	  mismatches	  and	  request	  a	  new	  sample.	  However,	  we	  have	  shown	  that	  the	  approach	  could	  potentially	  be	  used	  to	  resolve	  such	  situations	  (see	  Chapter	  
2).	  For	  example,	  if	  by	  reordering	  the	  given	  sample	  IDs	  in	  the	  appropriate	  manner	  the	  proportion	  of	  sample	  matches	  for	  an	  entire	  plate	  where	  to	  increase	  above	  a	  certain	   level	   it	  may	   be	   considered	   as	   enough	   evidence	   to	   reassign	   all	   samples	  across	   the	   plate.	   Overall	   the	   approach	   developed	   using	   CNV	   tagging	   SNPs	   for	  tracking	  array-­‐CGH	  dataset	  acts	  as	  a	  good	  proof	  of	  principal	  for	  array-­‐CGH	  data	  tracking	  as	  a	  whole.	  
CNV	  Consensus	  Reference	  Set	  The	  CNV	  consensus	  reference	  set	  developed	  during	  this	  thesis	  is	  currently	  used	  in	  the	  DDD	  project,	  among	  others,	  to	  allow	  the	  accurate	  filtering	  of	  CNVs	  based	  on	   population	   frequency	   estimates.	   It	   provides	   positional,	   frequency	   and	   type	  state	   information	   for	   common	   CNVEs	   across	   a	   wide	   genomic	   size	   range	   (see	  
Chapter	  2).	  The	  accurate	  estimation	  of	  population	  frequency	  of	  common	  CNV	  is	  important	   to	  variant	   filtering	  and	  allows	  variants	   to	  be	   classified	   into	  different	  groups	  based	  on	   frequency	  estimate	  bins.	  This	   is	  particularly	   important	   to	  any	  clinical	   feedback	   of	   genomic	   variation,	   where	   it	   is	   generally	   believed	   that	   any	  variant	   observed	   above	   a	   certain	   frequency	   within	   the	   general	   population	   is	  unlikely	  to	  be	  pathogenic.	  Furthermore,	  this	  is	  an	  important	  element	  for	  various	  research	   based	   questions	   of	   potential	   interest.	   	   For	   example,	   it	   may	   transpire	  that	   rare	  CNVs	   (those	  observed	  with	   low	   frequency	   in	   the	   general	   population)	  could	  still	   contribute	   to	  extreme	  phenotypes.	   	   It	   is	  not	  unreasonable	   to	  predict	  that	  certain	  rare	  genomic	  syndromes	  may	  be	  caused	  not	  by	  a	  single	  CNV	  rather	  a	  specific	  combination	  of	  CNVs.	  Again,	  it	  is	  a	  reasonable	  hypothesis	  that	  CNVs	  seen	  at	  lower	  frequency	  within	  the	  general	  population	  have	  a	  greater	  potential	  to	  be	  damaging	   (or	   contribute	   to	   damage)	   than	   those	   seen	   at	   the	   higher	   end	   of	   the	  frequency	  spectrum.	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The	   CNV	   consensus	   reference	   set	   is	   provided	   inside	   CNsolidate	   along	   with	   a	  number	  of	  useful	  comparison	  and	  filtering	  approaches	  to	  allow	  the	  accurate	  and	  efficient	   classification	   of	   CNVs	   based	   on	   positional,	   type	   state	   and	   population	  frequency	   estimates.	   By	   including	   only	   studies	   believed	   to	   be	   high	   quality	   and	  with	  varying	  genomic	  resolutions	  and	  samples	  sizes	  the	  CNV	  consensus	  achieves	  both	   high	   quality	   frequency	   estimates	   and	   good	   genome	   coverage.	   Overall	   the	  CNV	   consensus	   reference	   set	   will	   provide	   useful	   functionality	   to	   a	   number	   of	  studies	   into	   rare	   and	   common	  CNV.	   It	   has	   been	  made	   publically	   available	   in	   a	  variety	   of	   different	   formats	   and	   can	   be	   downloaded	   from	   databases	   such	   as	  DECIPHER.	   Furthermore,	   as	   the	   amount	   of	   genome	   data	   increases	   it	   may	   be	  worth	   considering	   adding	   additional	   datasets	   into	   the	   CNV	   consensus	   or	  generating	   additional	   CNV	   consensus	   reference	   sets.	   This	  may	   be	   of	   particular	  use	   and	   interest	   to	   studies	   into	   CNV	   using	   next	   generation	   sequencing	   (NGS)	  data	   as	   currently	   there	   are	   very	   few	   reliable	   common	   CNV	   reference	   sets	  generated	  using	  exclusively	  NGS	  data.	  
CNV	  Filtering	  	  During	   this	   thesis	   a	   filtering	   system	   for	   flagging	   CNVs	   of	   potential	   clinical	  significance	   has	   been	   developed	   and	   implemented	   for	   the	   DDD	   project.	   This	  software	   relies	   heavily	   on	   a	   manually	   curated	   list	   of	   gene	   to	   phenotype	  relationships	   (DDG2P),	   the	   CNV	   consensus	   reference	   set	   and	   the	   call	   quality	  measures	   and	   copy	   number	   estimates	   provided	   by	   CNsolidate.	   This	   filtering	  system	   is	   in	   standard	   use	   for	   the	   DDD	   project,	   facilitating	   the	   feedback	   of	  potentially	  clinically	  relevant	  CNVs	  to	  the	  clinical	  genetic	  teams.	  The	  parameters	  chosen	   for	   standard	   use	   in	   the	   DDD	   project	   are	   aimed	   at	   delivering	   only	   high	  confidence,	  likely	  causative	  CNVs	  for	  manual	  review	  prior	  to	  potential	  deposition	  in	  the	  DECIPHER	  database	  and	  subsequent	  feedback	  to	  the	  clinical	  genetic	  teams.	  The	   filtering	   pipeline	   has	   been	   developed	   in	   such	   a	   way	   to	   allow	   iterative	  reporting	  of	  CNV	  calls	  over	  time,	  meaning	  that	  as	  the	  DDD	  project	  progresses	  it	  is	  possible	  to	  change	  filtering	  parameters	  and	  flag	  additional	  CNVs	  for	  review.	  This	  functionality	   is	   important	   not	   only	   to	   allow	   the	   filtering	   parameters	   to	   be	  changed	   (e.g.	   relaxed)	  but	   also	  because	   it	   is	   likely	   that	   our	  understanding	   into	  the	  role	  that	  CNVs	  play	  in	  developmental	  disorders	  will	  increase	  over	  time.	  This	  improved	  understanding	  may	  result	  in	  new	  genes	  being	  discovered	  or	  linked	  to	  additional	   phenotypic	   characteristics	   and	   therefore	   the	   filtering	   of	   CNVs	   for	  potential	   clinical	   significance	   must	   be	   repeated	   in	   light	   of	   this	   new	  understanding.	   Furthermore,	   technical	   improvements	   to	   the	   input	   data,	  underlying	   detection	   (CNsolidate)	   or	   classification	   (CNV	   consensus)	   methods	  may	   be	  made	   and	   result	   in	   a	   requirement	   to	   re-­‐run	   clinical	   filtering	   across	   all	  samples	   within	   the	   DDD	   project.	   Such	   a	   situation	   was	   demonstrated	   (see	  
Chapter	  2)	  where	  a	  complication	  with	  the	  performance	  of	  certain	  probes	  on	  the	  DDD	  array-­‐CGH	  platform	  was	  observed	  and	  after	  the	  solution	  was	  implemented	  the	   filtering	  of	  CNVs	   for	  clinical	   interest	  needed	   to	  be	  repeated.	  This	  highlights	  the	   important	   aspect	   of	   reporting	   potentially	   relevant	   genomic	   variants	   in	  general,	  that,	  particularly	  in	  a	  diagnostic	  setting,	  over	  time	  results	  should	  always	  be	  reassessed	  by	  experts	  in	  light	  of	  any	  improved	  knowledge	  gained.	  	  
DDD	  Pipeline	  We	  have	  developed	  a	   large	  scale	  analytical	  pipeline	  which	  is	   in	  standard	  use	   in	  the	   DDD	   project	   (see	   Chapter	   3).	   This	   pipeline	   is	   fully	   versioned	   and	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documented	  allowing	  relatively	  easy	  maintenance	  and	  further	  development.	  This	  is	  a	  very	  important	  aspect	  of	  any	  software	  development	  project	  but	  particularly	  where	  analytical	  results	  may	  be	  considered	  to	  be	  of	  a	  sensitive	  nature.	  As	  well	  as	  providing	  details	  of	  software	  components	  and	  analytical	  processes,	  the	  pipeline	  documentation	   allows	   the	   pipeline	   to	   be	   executed	   at	   scale	   by	   anyone	  with	   the	  relevant	   amount	   of	   computational	   knowledge	   (e.g.	   another	   bioinformatician).	  This	   is	   important	   to	   the	   DDD	   project	   generally	   as	   maintaining	   pipeline	  throughput	   is	   important	   to	   meet	   specific	   project	   milestones	   and	   there	   should	  always	  be	   a	   certain	  degree	  of	   redundancy	  built	   into	   any	   team.	   Specifically	   it	   is	  beneficial	   that	  more	   than	  one	   individual	  within	   a	   team	  knows	  how	   to	  perform	  certain	  analysis	  such	  that	  no	  one	  individual	  becomes	  irreplaceable.	  
Drafted	  Manuscript	  1	  
Chapter	  4	  is	  made	  up	  of	  a	  drafted	  manuscript	  that	  is	  intended	  to	  be	  submitted	  to	  Genome	  Research.	  It	  describes	  two	  pieces	  of	  analytical	  software	  (CNsolidate	  and	  VICAR)	   in	   detail,	   presents	   a	   number	   of	   performance	   based	   analysis	   to	  demonstrate	   an	   improved	   performance	   compared	   to	   existing	   methods	   and	  describes	   a	   high	   resolution	   CNV	   map	   generated	   using	   almost	   one	   thousand	  healthy	  control	  samples.	  	  Receiver	   operator	   (ROC)	   analysis	   using	   73	   technical	   replicates	  was	   performed	  comparing	   the	   performance	   of	   CNsolidate	   against	   individual	   algorithms	   and	  comparing	   CNsolidates	   call	   quality	   measure	   (wscore)	   against	   a	   number	   of	  different	   call	   quality	   predictors.	   Based	   on	   the	   ROC	   analysis	   we	   show	   that	  CNsolidate	  outperforms	  all	  individual	  algorithms	  and	  that	  the	  wscore	  generated	  by	  CNsolidate	   is	  better	  at	  predicting	  call	  quality	  compared	  to	  any	  other	  quality	  measures	   assessed.	   Additionally	   a	   validation	   experiment	   is	   described	  where	   a	  custom	   validation	   array	   was	   designed	   targeting	   CNV	   calls	   across	   the	   wscore	  range	   in	   32	   selected	   validation	   samples	   (see	   Appendix).	   By	   performing	   an	  analysis	   on	   the	   correlation	   in	   log2	   ratio	   values	   between	   the	   discovery	   and	  validation	   array	   at	   9,008	   validation	   sites	   across	   26	   samples	   it	  was	   possible	   to	  demonstrate	  an	  approximately	  80%	  validation	  rate	  at	  the	  default	  wscore	  cut-­‐off	  value	   of	   0.5.	   This	   rate	   of	   validation	   could	   be	   considered	  high	  when	   comparing	  results	  across	  two	  different	  platform,	  others	  have	  observed	  that	  reproducibility	  in	   replicate	  experiments	  on	   the	  same	  array	   is	   typically	   less	   than	  70%	  for	  most	  platforms.	   Additionally	   an	   analysis	   looking	   at	   the	   sensitivity	   of	   de	   novo	  classification	   achieved	   by	   VICAR	  was	   performed	   by	   using	   subsampling	   from	   a	  number	  of	   positive	   control	   (previously	   known)	  CNVs.	  Based	  on	   this	   analysis	   it	  was	   found	   that	   the	  most	   important	   parameter	   affecting	   classifier	   performance	  was	  the	  number	  of	  SNP	  markers	  within	  the	  CNV	  region	  and	  there	  was	  a	  decrease	  in	  classification	  performance	  for	  gains	  compared	  to	  losses.	  For	  the	  high	  resolution	  CNV	  map	  firstly	  we	  describe	  the	  overall	  characteristics	  of	  CNV	  calls	  across	   the	  healthy	  control	   samples	  and	  show	  a	  consistent	  number	  of	  total	  CNV	  detections	  per	  sample.	  This	  is	  a	  relatively	  clear	  indication	  of	  high	  call	  quality	  across	  the	  sample	  cohort	  as	  large	  differences	  in	  the	  number	  of	  CNVs	  per	  genome	   in	   healthy	   individuals	   is	   biologically	   unlikely.	   Next	   we	   show	   that	   the	  number	   of	   single	   exon	   CNV	   detections	   made	   across	   the	   control	   cohort	   is	  relatively	  large	  compared	  to	  the	  number	  available	  from	  current	  literature.	  When	  comparing	   the	   single	   exon	   CNVs	   detected	   by	   CNsolidate	   against	   those	   found	  within	   the	   DGV	   we	   report	   an	   additional	   1,472	   single	   exon	   CNVs	   to	   current	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literature.	  Finally,	  by	  using	  SNP	  genotyping	  data	  in	  42-­‐	  parent-­‐offspring	  trios,	  we	  describe	  the	  characteristics	  of	  2,792	  informative	  CNV	  inheritance	  classifications	  made	   by	   VICAR.	   A	   redefinition	   and	   suggested	   increase	   in	   the	   current	   CNV	  mutation	  rate	  estimate	  is	  made	  by	  defining	  16	  high	  confidence	  de	  novo	  CNVs	  at	  a	  median	   detection	   resolution	   of	   15.2	   kb	   across	   840	   parent	   offspring	  transmissions.	   Furthermore,	   by	   performing	   a	   parent	   of	   origin	   analysis	   on	   the	  high	  confidence	  de	  novo	  CNVs	  a	  marked	  increase	  in	  the	  number	  of	  de	  novo	  CNVs	  present	   on	   the	   paternally	   inherited	   allele	   as	   the	   size	   of	   CNV	   decreases	   was	  evident.	   This	   observation	   reflects	   the	   relative	   difference	   in	  mutation	   rates	   for	  replication-­‐based,	  compared	  to	  meiotic-­‐based	  CNV	  formation	  mechanisms	  in	  the	  male	  opposed	  to	  the	  female	  germline.	  Additionally	  by	  assessing	  the	  number	  of	  de	  
novo	   CNVs	   flanked	   by	   transposable	   elements	   we	   suggest	   that	   CNV	   formation	  mechanisms	  of	  non-­‐recurrent	  (rare)	  de	  novo	  CNV	  events	  may	  show	  a	  bias	  across	  the	   size	   range,	   with	   smaller	   events	   being	   preferentially	   driven	   by	   NHEJ	   and	  MMBIR	  compared	  to	  NAHR.	  
Drafted	  Manuscript	  2	  
Chapter	  5	  is	  made	  up	  of	  a	  drafted	  manuscript	  that	  is	  intended	  to	  be	  submitted	  to	  Genome	   Research.	   The	   manuscript	   is	   focused	   on	   highlighting	   some	   of	   the	  challenges	  faced	  when	  interpreting	  genomic	  data	  within	  a	  clinical	  setting.	  Using	  the	  CNV	  clinical	   filtering	  pipeline	  developed	   in	  Chapter	   2	  we	  apply	   filtering	   to	  over	   one	   thousand	   healthy	   control	   samples	   to	   search	   for	   potentially	   clinically	  relevant	  CNVs.	  	  Overall	   a	   surprisingly	   high	   7.9%	  potential	   feedback	   rate	   of	   predicted	   clinically	  relevant	  CNVs	  in	  healthy	  controls	  is	  reported.	  Breaking	  these	  flagged	  CNVs	  down	  by	  type	  it	  is	  clear	  that	  the	  majority	  (78%)	  were	  flagged	  based	  on	  size	  and	  rarity	  alone	  and	  could	  collectively	  be	  termed	  variants	  of	  uncertain	  significance	  (VOUS).	  We	  indicate	  that	  75%	  of	  the	  flagged	  VOUS	  CNVs	  were	  detected	  in	  one	  of	  the	  two	  healthy	   control	   sample	   cohorts	   used	   (the	   UKBS	   blood	   donor	   cohort).	   This	  highlights	   the	   importance	   of	   having	   parental	   data	   available	   when	   interpreting	  CNVs	   within	   a	   clinical	   setting.	   The	   UKBS	   cohort	   did	   not	   have	   parental	   data	  available	   and	   were	   therefore	   enriched	   for	   large	   rare	   CNV	   compared	   to	   the	  Generation	   Scotland	   cohort.	   The	   filtering	   pipeline	   excludes	   CNVs	   that	   are	  classified	  as	  inherited	  from	  an	  unaffected	  parent	  and	  as	  the	  Generation	  Scotland	  cohort	   had	   CNV	   inheritance	   classifications	   a	   proportion	   of	   large	   rare	   CNVs	   in	  child	   samples	   would	   have	   been	   filtered	   out	   due	   to	   an	   informative	   parental	  inheritance	  classification.	  For	   the	   remaining	   flagged	  CNVs,	   15	  were	   flagged	  due	   to	   overlapping	   a	  DDG2P	  entry	  with	  the	  relevant	  mode	  and	  mechanism.	  Overall,	  within	  this	  class	  of	  flagged	  CNV,	  there	  is	  a	  relatively	  low	  recurrence	  rate	  with	  only	  3/15	  DDG2P	  genes	  being	  observed	   in	   multiple	   samples.	   Looking	   in	   detail	   at	   the	   characteristics	   of	   the	  recurrently	   mutated	   DDG2P	   genes	   containing	   a	   flagged	   CNV,	   for	   the	   SETBP1	  gene	  the	  position	  of	  both	  CNVs	  is	  not	  within	  the	  highly	  conserved	  11-­‐bp	  region	  on	   exon	   4	   or	   contained	   within	   the	   amino	   acid	   sequence	   predicted	   to	   interact	  with	  the	  Myeloid	  Leukemia-­‐Associated	  SET	  gene.	  Therefore	  we	  suggest	  that	  the	  two	  CNVs	   affecting	   exon	  3	  of	   SETBP1	  observed	   in	  healthy	   controls	  during	   this	  analysis	  may	   be	   non-­‐essential	   for	   gene	   function.	   Furthermore	  we	   suggest	   that	  the	   two	   flagged	   duplications	   found	   within	   the	   KCNE1	   gene	   are	   unlikely	   to	  predispose	   the	   individuals	   to	   sudden	   death	   from	   cardiac	   arrhythmias	   (severe	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Long	  QT	  syndrome)	  or	  cause	  the	  phenotypes	  associated	  with	  Jervell	  and	  Lange-­‐Nielsen	  syndrome	  type	  2.	  A	  gain	  in	  copy	  number	  (duplication)	  of	  the	  KCNE1	  gene	  has	   not	   been	   previously	   associated	  with	   either	   phenotype	   and	   the	   reason	   the	  two	  duplication	  CNVs	  were	  flagged	  by	  the	  filtering	  pipeline	  is	  because	  KCNE1	  is	  annotated	  as	  both	  a	  DD	  and	  IF	  gene	  within	  the	  DDG2P	  database.	  However,	  we	  do	  report	   a	   0.2%	   prevalence	   of	   Schizophrenia	   susceptibility	   due	   to	   heterozygous	  deletions	  of	  the	  NRXN1	  gene	  across	  the	  healthy	  control	  cohort.	  Schizophrenia	  is	  a	   complex	   genomic	   disorder	   and	   we	   hypothesise	   that	   Schizophrenia	   like	  phenotypes	  are	  potentially	  relatively	  under	  diagnosed	  in	  the	  general	  population	  (healthy	  controls).	  Finally	  we	  describe	  6	  CNVs	  that	  were	  flagged	  due	  to	  having	  sufficient	  positional	  similarity	   with	   a	   previously	   defined	   syndromic	   region.	   Three	   of	   these	   CNVs	  overlapped	   with	   the	   1q21.1	   and	   16p11.2	   microduplication	   regions,	   both	   of	  which	   have	   been	   previously	   associated	   with	   schizophrenia.	   These	   three	  additional	   CNVs	   strengthen	   the	   hypothesis	   that	   complex	   phenotype	  characteristics,	  particularly	  those	  affecting	  mental	  health	  such	  as	  Schizophrenia,	  may	   be	   present	   in	   healthy	   control	   cohorts	   due	   to	   poor	   recognition	   /	   under	  diagnosis	  within	  the	  general	  population.	  The	  3	  remaining	  flagged	  CNVs	  are	  found	  at	  the	  Ichthyosis	  skin	  phenotype	  linked	  STS	  microdeletion	  syndromic	  region	  on	  chromosome	  X.	   Ichthyosis	   X-­‐linked	   (XLI)	   is	   a	   relatively	   common	   rare	   disorder	  estimated	  to	  occur	  as	  often	  as	  once	  in	  2000	  male	  births.	  Two	  of	  the	  three	  flagged	  CNVs	  were	  observed	  in	  female	  controls	  and	  are	  therefore	  predicted	  to	  have	  XLI	  carrier	  status.	  The	  single	  CNV	  at	  the	  STS	  microdeletion	  region	  observed	  in	  a	  male	  sample	  is	  predicted	  to	  cause	  the	  relatively	  common	  XLI	  skin	  disorder.	  Overall	   the	   findings	   presented	   in	   Chapter	   5	   are	   aimed	   at	   strengthening	   the	  general	  guidelines	  that	  interpreting	  genomic	  data	  in	  a	  clinical	  setting	  should	  be	  done	  with	  a	  degree	  of	  caution.	  To	  avoid	  the	  incorrect	  assignment	  of	  variants	  to	  phenotypic	   effects	   in	   patient	   data	   it	   is	   important	   that	   clinical,	   genetic	   and	  technical	   experts	   work	   closely	   together	   to	   interpret	   any	   biological	   affect	  predicted	  from	  the	  analysis	  of	  genomic	  data.	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6.2	   Future	  Direction	  Moving	   forward	   the	  methods	  described	  here	  are	  currently	  being	  used	   in	   large-­‐scale	   projects	   such	   as	   the	  DDD.	  Generally,	   the	   overall	   performance	  of	   all	   these	  methods	   across	   a	   large-­‐scale	   study,	   such	   as	   the	   DDD,	   acts	   as	   a	   good	   proof	   of	  method	   robustness.	   Over	   the	   course	   of	   the	   DDD	   project,	   the	   performance	   of	  CNsolidate	  will	  be	  under	  constant	  assessment	  and	  improvements	  are	  likely	  to	  be	  made	  to	  a	  number	  of	  the	  underlying	  models.	  Furthermore,	  I	  would	  like	  to	  create	  a	  lightweight	  version	  of	  CNsolidate	  (CNsolidateLite	  or	  similar)	  for	  general	  use	  by	  groups	  interested	  in	  change	  point	  detection	  problems.	  For	  CNV	   interpretation,	   firstly	   I	  would	   like	   to	   add	   some	  new	  data	   sources	   into	  the	   CNV	   consensus	   reference	   set.	   As	   the	   amount	   of	   high	   quality	   data	   sources	  available	  for	  common	  CNV	  increases	  I	  plan	  to	  assess	  potential	  data	  sources	  and	  incorporate	  them	  where	  appropriate.	   I	  also	  believe	  there	  are	  some	  areas	  of	  the	  current	  CNV	  filtering	  approach	  that	  could	  be	  improved:	  	  
1)	  Currently	   there	   is	  no	  definition	  of	  how	  gains	   in	  copy	  number	   (duplications)	  affect	  the	  surrounding	  genomic	  landscape.	  Not	  all	  gains	  in	  copy	  number	  result	  in	  an	   increase	   in	   dosage	   of	   a	   gene	   (or	   genic	   element),	   rather	   events	   I	   term	  “disruptive	   duplications”	   can	   interrupt	   gene	   transcripts	   (or	   genic	   elements)	  potentially	  truncating	  or	  destroying	  any	  gene	  product.	  It	   is	  a	  difficult	  to	  predict	  the	   effect	   these	   CNV	   types	   might	   have	   in	   terms	   of	   any	   individual	   genome.	  However,	   I	   expect	   that	   the	   most	   likely	   effect	   of	   disruptive	   duplications	   is	   to	  destroy	  the	  function	  of	  a	  single	  gene	  copy	  resulting	  in	  a	  similar	  consequence	  as	  for	   single	   copy	   number	   losses	   (heterozygous	   deletions).	   It	   is	   likely	   that	   in	  subsequent	  versions	  of	  the	  CNV	  filtering	  system	  I	  will	  apply	  a	  modification	  to	  the	  logic,	   where	   I	   will	   define	   disruptive	   duplications	   based	   on	   their	   overlap	  characteristics	  compared	  to	  gene	  transcripts	  and	  treat	  them	  in	  a	  similar	  way	  to	  single	  copy	  losses.	  	  
2)	  Not	  all	  genomic	  disorders	  are	  linked	  to	  specific	  genes;	  rather	  some	  are	  linked	  to	  genomic	   ranges	   termed	  syndromic	   regions.	  These	  syndromic	   regions	  can	  be	  linked	  to	  copy	  number	  gains	  or	  losses	  or	  both	  and	  have	  normally	  been	  linked	  to	  specific	   phenotypic	   traits	   (or	   syndromes).	   The	   DECIPHER	   database	   contains	  seventy	   defined	   syndromic	   regions	   and	   in	   subsequent	   versions	   of	   the	   CNV	  filtering	  system	  I	  plan	  to	  add	  these	  regions	  as	  an	  additional	  filtering	  route.	  	  
3)	   Not	   all	   phenotypic	   traits	   are	   caused	   by	   a	   single	   specific	   CNV;	   rather	   some	  require	   two	   or	   more	   events	   in	   combination	   due	   to	   effects	   such	   as	   dosage	  compensation.	   Although	   currently	   relatively	   poorly	   understood,	   I	   expect	   the	  number	   of	   known	   “multiple	   hit”	   linked	   loci	   to	   see	   a	   marked	   increase	   in	   the	  future.	   Some	   of	   these	   improvements	   are	   likely	   to	   be	   due	   to	   specific	   areas	   of	  research	   within	   the	   DDD	   project	   and	   other	   large	   scale	   studies	   into	  developmental	  disorders.	  I	  would	  like	  to	  build	  this	  functionality	  into	  subsequent	  versions	   of	   the	   CNV	   filtering	   system	   in	   anticipation	   of	   these	   new	   exciting	  research	  findings.	  	  Finally,	  although	  CNVs	  have	  been	  linked	  to	  a	  large	  number	  of	  genomic	  disorders	  and	  has	  historically	  been	  the	  main	  focus	  of	  diagnostic	  assays,	  with	  the	  increased	  usage	  of	  NGS	  data,	   the	  number	  of	   SNP	  and	   INDEL	  variants	   linked	  with	  patient	  phenotypes	   is	   sure	   to	   continue	   increasing.	   I	   see	   a	   need	   to	   develop	   a	   general	  filtering	   pipeline	   for	   genomic	   variation	   of	   all	   kinds	   and	   to	   integrate	   this	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information	   as	   much	   as	   possible.	   For	   example	   a	   compound	   heterozygous	  mutation,	   resulting	   in	   no	   functional	   copy	   of	   a	   gene,	   could	   result	   from	   a	   single	  copy	   loss	   (CNV)	   on	   one	   allele	   and	   a	   damaging	   SNP	   on	   the	   other.	   This	   is	   an	  important	  complication	  to	  resolve	  and	  needs	  to	  be	  accounted	  for	  to	  help	  further	  the	  understanding	  of	  genomic	  variation	  as	  a	  whole	  and	  its	  potential	  effect	  on	  the	  health	  of	  an	  individual.	  	  One	  major	  research	  question	   that	   interest	  me	  and	  that	   I	  aim	  to	   focus	  on	   in	   the	  future	   is	   to	   what	   extent	   common	   variants	   (those	   observed	   in	   the	   general	  population)	  contribute	  individually	  or	  in	  combination	  to	  extreme	  phenotypes.	  To	  this	   goal	   I	   plan	   to	   carryout	   a	   large	   scale	   analysis	   of	   CNVs	   detected	   across	   the	  entire	   DDD	   cohort	   (approximately	   8,000	   patient	   datasets)	   once	   the	   data	  generation	  phase	  of	  the	  DDD	  array-­‐CGH	  laboratory	  has	  completed.	  I	  believe	  that	  the	  wscore	  will	  be	  especially	  useful	  during	  two	  main	  analysis	  using	  the	   DDD	   array-­‐CGH	   CNV	   data	   1)	   To	   empower	   a	   thorough	   and	   detailed	  assessment	   of	   every	   individual	   patient	   in	   terms	   of	   the	   CNVs	   detected	   in	   their	  genome	  using	  the	  DDD	  array-­‐CGH	  platform.	  Particularly	  useful	   for	  this	  analysis	  will	   be	   the	  non-­‐adjusted	  wscore	   as	   in	   its	   raw	   form	   (non-­‐adjusted),	   the	  wscore	  provides	  an	  accurate	  ranking	  of	  CNV	  calls	  in	  terms	  of	  quality	  across	  an	  individual	  dataset.	   This	   is	   important	   as	   the	   thorough	   assessment	   of	   all	   CNV	   calls	   in	   any	  individual	   genome	   is	   a	   time	  consuming	   task	   requiring	  a	  high	   level	  of	   expertise	  and	  as	  such	  it	   is	   important	  to	  aid	  CNV	  interpretation,	  decreasing	  the	  amount	  of	  time	  an	  analyst	  needs	  to	  spend	  on	  interpreting	  individual	  genomes.	  2)	  To	  allow	  different	  error	  rates	  to	  be	  explored	  across	  datasets	  in	  a	  consistent	  way	  using	  the	  adjusted	  wscore	  when	  mining	  the	  CNV	  data	   for	  novel	  disease	  associations.	  The	  patients	  recruited	   into	   the	  DDD	  study	  and	  who	  have	  array-­‐CGH	  CNV	  calls	  have	  also	   usefully	   be	   accurately	   and	   consistently	   phenotyped	   using	   the	   Human	  Phenotype	  Ontology	  (HPO).	  This	  will	  potentially	  allow	  groups	  of	  patients	  or	  even	  specific	   patient	   phenotypes	   to	   be	   associated	   with	   specific	   genetic	   variants.	   I	  expect	   it	   will	   be	   possible	   to	   discover	   novel	   CNV	   changes	   observed	   in	   specific	  groups	   of	   patients	   sharing	   particular	   HPO	   terms	   that	   are	   not	   observed	   (or	   at	  lower	   frequency)	   across	   all	   other	   patient	   or	   control	   individuals.	   Key	   to	   these	  types	  of	  analysis	   is	  maintaining	  consistent	  detection	  error	  rates	  across	  samples	  as	  either	  high	  false	  positive	  rates	  or	  low	  true	  positive	  rates	  in	  even	  a	  few	  samples	  within	   the	  dataset	   population	   can	   easily	   lend	   to	   false	   associations	   and	  destroy	  the	  power	  of	  any	  association	  test.	  Finally,	  with	  the	  vast	  amount	  of	  NGS	  data	  being	  produced	  by	  projects	  such	  as	  the	  DDD	   and	   Genomics	   England	   (GEL),	   I	   would	   like	   to	   test	   the	   utility	   of	   using	  CNsolidate,	  or	  methods	  derived	  from	  elements	  of	  CNsolidate,	  for	  the	  discovery	  of	  CNVs	  using	  NGS	  data.	   Specifically	   I	   plan	   to	   explore	   the	  performance	  of	  using	   a	  CNsolidate	   like	   approach	   for	   change	   detection	   using	   the	   relative	   difference	   in	  read	  depth	  across	  samples	  as	  the	  measure	  of	  copy	  number	  state.	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7 |	  Appendix	  
7.1	   CNsolidate	  Parameters	  
7.1.1	   Simulation	  Methods	  In	  CNsolidate	  there	  are	  a	  number	  of	  simulation-­‐based	  methods	  that	  can	  help	  to	  optimize	   certain	   necessary	   parameters	   for	   data	   of	   different	   types.	   These	  methods	  are	  capable	  of	   learning	  certain	  characteristics	  of	   the	   input	  data	  under	  consideration.	  Given	   a	   series	   of	   training	   data	   sets	   the	   simulation	   methods	   will	   calculate	   the	  central	   and	   difference	   based	   noise	  measures	   as	   well	   as	   the	   overall	   range	   and	  scale	  of	  the	  data	  values.	  These	  measures	  are	  saved	  as	  R	  objects	  and	  used	  during	  the	   generation	  of	   synthetic	   data	   sets.	  Additionally	   a	   custom	  wavelet	   transform	  algorithm	   is	   used	   to	   extract	   a	   number	   of	   different	   frequency	   components	  (’octaves’)	  from	  the	  training	  data	  sets.	  These	  are	  again	  saved	  as	  objects	  and	  used	  to	   add	   varying	   degrees	   of	   auto-­‐correlation	   (’wave’)	   effects	   to	   the	   synthetically	  generated	   data	   sets.	   Furthermore,	   a	   method	   that	   adds	   a	   given	   number	   of	  randomly	  dispersed	  single	  outlier	  data	  points	  across	  the	  range	  is	  included.	  This	  is	   aimed	   at	   making	   the	   generated	   synthetic	   data	   characteristic	   more	   realistic.	  The	   range	   of	   the	   number	   of	   single	   outlier	   data	   points	   to	   be	   added	   is	   again	  estimated	  from	  the	  input	  training	  datasets.	  
	  Figure	  7-­‐7-­‐1	  Example	  of	  a	  synthetically	  generated	  array-­‐CGH	  data	  set	  Above	  (see	  Figure	  7-­‐1)	  is	  an	  example	  of	  a	  synthetically	  generated	  data	  set	  from	  the	   synthetic	   test	   set.	   The	   parameter	   ranges	   used	   were	   estimated	   using	   a	  training	   set	   made	   up	   of	   close	   to	   300	   individual	   real	   array-­‐CGH	   data	   sets.	   To	  create	   the	   set	   of	   synthetic	   test	   data	   sets,	   the	   mentioned	   parameters	   were	  randomized	  1	  million	  times,	  generating	  a	  unique	  synthetic	  data	  set	  for	  each	  set	  of	  parameters.	  Each	  data	  set	  is	  made	  up	  of	  24	  subsets	  (relating	  to	  the	  chromosomes	  of	  the	  input	  training	  data	  arrays),	  each	  of	  the	  subsets	  contains	  10000	  data	  points,	  giving	  a	  total	  of	  240000	  data	  point	  per	  synthetic	  data	  set.	  The	  above	  plot	  shows	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’chromosome1’	  from	  a	  particular	  synthetic	  data	  set,	  which	  displays	  relatively	  low	  noise	   values	   for	   the	   three	   data	   estimators,	   rp68,	   dLRs	   and	  ws.	   	   The	   1	  million	  synthetic	  test	  data	  sets	  contain	  a	  large	  number	  of	  different	  combinations	  of	  noise	  characteristics.	   Below	   is	   an	   example	   showing	   the	   effect	   of	   adding	   a	   relatively	  high	  amplitude	  wave	  component	   from	  the	   frequency	  component	  bank	  (derived	  from	  the	  training	  data	  sets).	  
	  Figure	  7-­‐7-­‐2	  Example	  of	  adding	  a	  wave	  component	  On	  the	  top	  panel	  (see	  Figure	  7-­‐2)	  chromosome1	  from	  the	  original	  synthetic	  data	  set	   and	   on	   the	   lower	   panel	   chromosome1	   after	   adding	   a	   training	   data	   derived	  wave	  component	  is	  shown.	  The	  ws	  value	  in	  the	  top	  panel	  is	  0.678,	  whereas	  in	  the	  bottom	  panel,	  after	  adding	  the	  wave	  component,	  the	  ws	  has	  increase	  to	  a	  value	  of	  2.38.	  The	  rp68	  value	  for	  the	  top	  panel	  is	  0.136	  whereas,	  for	  the	  bottom	  panel	  it	  is	  0.212.	  The	  dLRs	  value	  for	  the	  top	  panel	  is	  0.11458	  whereas,	  for	  the	  bottom	  panel	  it	  is	  0.11450	  (slightly	  decreased).	  This	  provides	  a	  reasonable	  illustration	  for	  the	  difference	  between	  the	  three	  included	  noise	  estimators	  and	  why	  it	  is	  important	  to	  use	  multiple	  estimates	  of	  data	  noise	  characteristics.	  The	   rp68,	   being	   a	   measure	   of	   the	   scale	   of	   noise	   within	   the	   centralized	   value	  region,	   provides	   a	   measure	   of	   the	   normally	   distributed	   noise	   within	   the	   68th	  percentile	  of	  the	  median	  normalized	  value	  distribution.	  The	  dLRs,	  being	  based	  on	  the	   IQR	  between	   the	  differences	  between	   consecutive	  data	  points,	   provides	   an	  approximation	  of	  the	  difference	  between	  consecutive	  values	  needed	  to	  define	  an	  outlier,	  assuming	  that	  the	  data	  is	  normally	  distributed.	  The	  ws,	  being	  designed	  to	  search	   for	   auto-­‐correlation	   across	   a	   time-­‐series,	   provides	   a	   reasonable	  approximation	   of	   the	   level	   at	  which	   the	   data	   is	   actually	   ’normally’	   distributed,	  assuming	  auto-­‐correlation	  is	  the	  only	  difference	  to	  normality.	  	  	  The	  main	  benefit	  of	  using	  simulation	  to	  estimate	  algorithm	  performance	  is	  that	  it	  is	  possible	  to	  obtain	  a	  reliable	  measure	  of	  the	  false	  and	  true	  positive	  rates.	  The	  reason	   for	   this	   is	   that	   during	   the	   data	   simulation	   synthetic	   CNV	   events	   are	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inserted	   and	   their	   location	   and	   characteristics	   are	   recorded.	   Therefore	   by	  comparing	  change	  point	  detection	  results	  against	  the	  pre-­‐known	  CNV	  locations	  it	  is	  possible	  to	  assess	  how	  successful	  individual	  algorithm	  were	  at	  1)	  detecting	  the	  inserted	  change	  point	  interval	  (CNVs)	  –	  the	  TP	  rate	  and	  2)	  How	  many	  erroneous	  detections	  (those	  not	  pre	  known)	  were	  made	  –	  the	  FP	  rate.	  On	   top	   of	   being	   able	   to	   generate	   reliable	   TP	   and	   FP	   rates	   for	   individual	  algorithms	   overall,	   by	   using	   this	   type	   of	   simulation	   approach	   it	   is	   possible	   to	  generate	   different	   rates	   given	   various	   predictive	   variables	   and	   scales.	   As	  mentioned	   above	   three	   different	   data	   noise	   measures	   were	   varied	   across	   the	  simulations	   allowing	   data	   type	   and	   level	   specific	   FP	   and	   TP	   rate	   estimations.	  Furthermore,	  during	  the	  insertion	  of	  synthetic	  CNV	  events	  it	  was	  possible	  to	  vary	  some	  additional	  parameters	  relating	  to	  specific	  characteristics	  of	  the	  CNV	  events	  themselves.	   For	   this	   the	   mean	   log2	   ratio,	   the	   number	   of	   data	   points	   and	   the	  variance	  across	  data	  points	  within	  a	  synthetic	  CNV	  were	  used	  as	  the	  predictive	  variables.	  It	  was	  then	  possible	  to	  estimate	  the	  effect	  that	  differences	  in	  the	  values	  of	   these	  3	  variables	  had	  on	  the	  FP	  and	  TP	  rates	  overall	   (the	   feature	  dependant	  weighting	  functions).	  
6.1.2	   Optimized	  Algorithm	  Parameters	  One	  complication	  with	  using	  such	  a	  large	  number	  of	  algorithms	  in	  combination	  is	  that	   each	   algorithm	   has	   a	   number	   of	   different	   parameters	   that	   need	   to	   be	  optimized.	   This	   can	   be	   a	   time	   consuming	   and	   complex	   task	   even	   for	   a	   single	  algorithm.	   However,	   when	   considering	   multiple	   algorithms,	   the	   number	   of	  possible	   combinations	   for	   parameter	   definitions	   quickly	   becomes	   large.	   	   The	  simulation-­‐based	  methods	  included	  in	  CNsolidate	  allow	  this	  process	  to	  be	  semi-­‐automated.	   They	   do	   not	   only	   work	   in	   the	   context	   of	   single	   algorithms,	   the	  optimization	   of	   parameters	   can	   be	   assessed	   in	   the	   context	   of	   the	   combined	  performance	  of	   all	   algorithms.	  This	  means	   that	   the	  optimized	  set	  of	  parameter	  definitions	   are	   estimated	   based	   upon	   on	   the	   performance	   of	   all	   algorithms	   in	  concert.	  During	  this	  parameter	  optimization	  process,	  all	  algorithms	  are	  assumed	  to	  contribute	  equal	  weight	  to	  individual	  change	  point	  detections.	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6.1.3	   Approximating	  Weighting	  Functions	  Individual	  algorithm	  performances	  vary	  given	  differing	  data	  characteristics.	  We	  approximate	   this	   behaviour	   by	   deriving	   specific	   weighting	   functions	   for	   each	  algorithm	  given	  certain	  data	  characteristics.	  	  
	  Figure	   7-­‐7-­‐3	   Example	   of	   deriving	   weighting	   functions	   based	   on	   estimated	  individual	  algorithm	  performances	  Above	  (see	  Figure	  7-­‐3)	  is	  an	  example	  of	  the	  results	  of	  assessing	  the	  performance	  of	   individual	   algorithms	   using	   data	   simulation	   in	   terms	   of	   the	   estimated	   false	  positive	  (FP)	  and	  true	  positive	  (TP)	  rates	  given	  the	  noise	  type	  and	  range	  of	  the	  synthetic	  data	  sets.	  The	  9	  panels	  displayed	  show	  both	  the	  FP	  (red)	  and	  TP	  (blue)	  rates	   against	   a	   measure	   of	   noise	   across	   over	   1	   million	   data	   simulations.	   The	  shade	  of	  the	  data	  points	  on	  the	  plots	  relate	  to	  the	  different	  noise	  predictors	  used.	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6.2	  Implementation	  All	  detection	  and	  combination	  methods	  described	  above	  are	  contained	   inside	  a	  single	   R	   package	   with	   no	   external	   dependencies.	   It	   is	   completely	   platform	  independent	  and	  can	  be	  installed	  on	  any	  machine	  with	  a	  valid	  R	  installation.	  	  The	  package	   also	   contains	   some	  normalization	  methods	   appropriate	   for	   array-­‐CGH	  data.	   There	   are	   splines	   and	   lowess	   based	   dye-­‐bias	   normalization	   methods,	   a	  general	   regression	   based	  method	   and	   a	   custom	  wavelet	   transform.	   	   The	   code	  base	  contains	  approximately,	  138	  R	  scripts,	  16	  Java	  classes,	  16	  C	  classes,	  4	  C++	  classes	  and	  a	  few	  Fortran	  methods	  (see	  package	  documentation	  for	  full	  function	  definition	  and	  usage).	  All	  parameter	  and	  weighting	  function	  definitions	  have	  some	  default	  options	  that	  can	  be	  used	  and	  should	  perform	  well	  across	  a	  range	  of	  data	  types.	  However	  there	  are	   also	   some	   simulation	   based	   methods	   included	   which	   allow	   the	   semi-­‐automated	   definition	   of	   individual	   algorithm	   parameters	   and	   weighting	  functions.	  These	  simulation-­‐based	  methods	  are	  capable	  of	   learning	  certain	  characteristics	  of	   the	   input	   data	   type.	   The	   methods	   can	   perform	   large	   (or	   small)	   scale	  simulations	  to	  allow	  some	  necessary	  parameters	  to	  be	  accurately	  estimated	  for	  the	  specific	  data	  type.	  The	  results	  of	  these	  simulation	  methods	  are	  R	  objects	  that	  can	  be	  saved	  and	  referenced	  during	  subsequent	  analysis.	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6.2	   DDD	  Validation	  Array	  Design	  
 
6.2.1	   Objective	  The	  primary	   aim	  of	   this	   experiment	   is	   to	   select	   a	   set	   of	   CNVs	   for	   validation	   to	  permit	  estimation	  of	  the	  false	  discovery	  rate	  for	  the	  DDD	  CNV	  discovery	  pipeline,	  and	   fine-­‐tuning	   of	   the	   algorithms	   used	   to	   detect	   CNVs.	   This	   experiment	   is	   not	  designed	  to	  evaluate	  estimation	  of	  de	  novo	  CNV	  status,	  so	  only	  proband	  samples	  will	  be	  included	  on	  the	  array,	  but	  these	  will	  be	  selected	  from	  complete	  trios.	  
 
6.2.2	   Sample	  Selection	  There	  is	  a	  trade-­‐off	  between	  minimising	  the	  number	  of	  samples	  required	  for	  the	  validation	  experiment,	  and	  making	  sure	  enough	  sample	  DNA	  remain	  for	  the	  DDD	  pipelines	  and	  other	  future	  experiments.	  As	  the	  aim	  is	  to	  validate	  both	  the	  array-­‐CGH	  and	  Exome	  CNV	  calling	  algorithms,	  samples	  will	  be	  selected	  from	  the	  pilot	  trios.	  	  	  Forty	  trios	  meeting	  the	  following	  criteria	  were	  identified:	  
 1. The	   proband	   has	   at	   least	   one	   high-­‐quality	   set	   of	   array-­‐CGH	   and	   Exome	  calls	  2. There	  is	  sufficient	  (>	  1	  ug)	  DNA	  for	  all	  members	  of	  the	  trio	  
 A	  number	  of	  the	  probands	  have	  two	  sets	  of	  array-­‐CGH	  data,	  one	  from	  blood	  DNA	  and	  another	  from	  salivary	  DNA.	  	  In	  each	  instance	  the	  sample	  that	  generated	  the	  highest	  quality	  call-­‐set	  will	  be	  used	  for	  the	  validation	  experiment.	  	  Where	  there	  is	  no	  difference	  in	  call	  quality,	  the	  sample	  with	  the	  largest	  amount	  of	  DNA	  available	  will	  be	  used.	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6.2.4	   CNV	  selection	  strategy	  This	   validation	   design	   will	   try	   to	   validate	   calls	   from	   both	   the	   array-­‐CGH	   and	  Exome	  platform	  so	  CNVs	  that	  are	  called	   in	  only	  one	  dataset,	  and	  those	  that	  are	  called	  in	  both	  need	  to	  be	  considered.	  CNVs	  will	  be	  selected	  from	  the	  set	  of	  pilot	  patients	  with	  high-­‐quality	  data	  from	  both	  sources.	  	   1. High	  quality	  call	  sets	  for	  the	  32	  samples	  are	  generated	  for	  both	  array-­‐CGH	  and	  Exome	  platforms	  2. Each	   of	   these	   is	   split	   into	   common	   and	   rare	   categories	   using	   the	   CNV	  consensus	  v2.1	  as	  the	  reference	  set	  3. To	  define	  common,	  a	  >	  0.8	   forward	  overlap	  and	  >	  0.5	  backward	  overlap	  for	   array-­‐CGH	  and	  >	  0.8	   forward	  overlap	   and	  >	  0	  backward	  overlap	   for	  Exome,	  from	  CNVs	  with	  a	  1%	  or	  greater	  population	  frequency.	  4. The	  proportion	  of	  common	  to	  rare	  CNVs	  to	  select	  is	  set	  at	  25%	  and	  75%	  respectively.	  
 Using	  the	  CGH	  8	  x	  60	  format	  select	  36	  CNV	  regions	  per	  sample	  (9	  common	  and	  27	  rare).	  This	  strategy	  is	   independent	  of	  detection	  quality	  scores	   in	  both	  cases,	  however	   the	   call	   lists	   used	   for	   selection	   are	   'pre-­‐filtered'	   based	   on	   detection	  quality	  scores.	  The	  goal	  is	  to	  include	  a	  relatively	  small	  number	  of	  edge	  cases	  near	  the	  currently	  defined	  quality	  score	  cut-­‐offs.	  	  After	   selection	   it	   is	   acceptable	   to	   generate	   some	   summary	   statistics	   about	   the	  distribution	   of	   various	   characteristics	   of	   the	   selected	   CNV	   regions,	   combined	  with	   the	  visual	   inspection	  of	  a	  number	  of	  events.	  This	  should	  be	  used	   to	  check	  that	  the	  selected	  CNV	  set	  is	  generally	  sensible	  but	  not	  used	  to	  exclude	  individual	  CNV	   regions.	   If	   the	   final	   selected	   CNV	   validation	   set	   displays	   general	   poor	  characteristics	  the	  random	  selection	  procedure	  must	  to	  performed	  again.	  
 
6.2.5	   Analysis	  Visual	   inspection	   can	   be	   used	   to	   confirm	   or	   investigate	   findings,	   but	   it	   is	   not	  feasible	  to	  do	  this	  for	  all	  CNVs	  included	  in	  the	  experiment.	  Statistical	  analysis	  of	  the	  data	  could	  take	  a	  variety	  of	  approaches.	  Individual	  summary	  statistics	  for	  the	  intensity	  at	  CNV	  can	  be	  compared	  either	  to	  all	  other	  regions	  within	  an	  individual,	  or	  across	  all	  other	  samples	  at	   the	  same	  region.	   	  The	   intensity	  of	  probes	  within	  the	  CNV	  break	  points	  can	  be	  compared	  to	   those	  outside	  (within	  an	   individual),	  although	  this	  assumes	  that	  the	  break	  points	  have	  been	  accurately	  captured	  in	  the	  original	  experiment.	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6.2.6	   Timeline 
 Table	  7-­‐1	  Validation	  array	  processing	  timeline	  Step	   Time	   Details	  Array	  design	   3	  weeks	   Out-­‐sourced	  to	  Agilent	  Array	  production	   6	  weeks	   Upper	  limit	  of	  estimated	  delivery	  time	  Scale-­‐down	  of	  array	  processing	   2	  weeks	   Partial	  overlap	  with	  production	  time	  Array	  processing	   2	  weeks	   Can	  process	  100	  slides	  per	  fortnight	  Analysis	   3	  weeks	   	  Total	   16	  weeks	   	  
 
6.2.7	   Data	  Quality	  Measures	  –	  array-­‐CGH	  and	  Exome	  The	   32	   samples	   are	   selected	   based	   on	   data	   quality	   measures	   from	   both	   the	  array-­‐CGH	  and	  Exome	  platforms.	  For	   the	  array-­‐CGH	  quality	  measure	   the	  mean	  dLRs	  (derivative	  log2	  ratio	  spread)	  between	  both	  arrays	  (arrayA	  and	  arrayB)	  is	  used,	  whereas	  for	  the	  Exome	  platform	  use	  the	  MAD	  (median	  absolute	  deviation)	  of	  the	  log2	  ratio	  values	  is	  used	  (see	  Figure	  7-­‐4).	  
Figure	  7-­‐7-­‐4	  Noise	  measures	   in	   array-­‐CGH	  against	  Exome	  across	  32	   validation	  samples	  	  Above	   (see	  Figure	   7-­‐4)	   is	   a	   plot	   of	   the	   quality	  measures	   from	   array-­‐CGH	   and	  Exome	   platforms	   for	   each	   of	   the	   32	   selected	   samples.	   Overall	   the	   data	   quality	  measures	   are	   relatively	   low,	   denoting	   high	   quality	   data	   from	   both	   platforms.	  Furthermore,	  the	  data	  quality	  from	  both	  platform	  displays	  a	  reasonable	  range	  of	  values	  across	  the	  high	  quality	  band	  (0.05	  -­‐	  0.2	  Exome	  and	  0.1	  -­‐	  0.2	  array-­‐CGH).	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6.2.8	   Data	  Quality	  Measures	  –	  array-­‐CGH	  Additionally,	   for	   the	   array-­‐CGH	   platform,	   we	   look	   at	   the	   agreement	   of	   three	  different	   QC	   measures	   between	   the	   two	   arrays	   for	   each	   sample	   (arrayA	   and	  arrayB). 
	  Figure	   7-­‐7-­‐5	   Noise	   measure	   between	   arrayA	   and	   arrayB	   from	   the	   array-­‐CGH	  platform	  across	  32	  validation	  samples	  Left	  -­‐	  dLRs,	  Middle	  -­‐	  wave	  score	  and	  Right	  -­‐	  tracking	  posterior	  	  Above	  (see	  Figure	  7-­‐5)	  are	  three	  plots	  showing	  the	  agreement,	  for	  each	  sample,	  between	  arrayA	  and	  arrayB	  on	  the	  array-­‐CGH	  platform.	  Generally,	  the	  agreement	  is	  reasonable	  for	  each	  validation	  sample	  across	  all	  QC	  values.	  
6.2.9	   Array	  Design	  The	   8	   x	   60	  Agilent	   format	   is	  most	   sensible	   for	   this	   validation	   experiment	   (see	  
Table	  7-­‐1).	  This	  format,	  using	  32	  samples,	  can	  yield	  a	  total	  of	  2304	  CNVs	  regions	  (72	   per	   sample)	   for	   validation.	   This	   has	   to	   be	   split	   across	   the	   two	   platforms,	  meaning	   that	   36	   CNV	   regions	   can	   be	   selected	   from	   each	   sample	   for	   both	   the	  array-­‐CGH	  and	  Exome	  platforms.	  	  Additional	  probes	  -­‐	  Control	  Probes:	  	   1. 10000	  random	  probes	  selected	  from	  the	  DDD	  array-­‐CGH	  design	  that	  are	  not	   called	   in	   any	   of	   the	   32	   individuals	   -­‐	   evenly	   spread	   between	   the	   22	  autosomes	  2. 300	  CNV	  tracking	  probes	  -­‐	  same	  as	  on	  the	  DDD	  array-­‐CGH	  design.	  3. 30	  gender	  markers	  -­‐	  same	  as	  on	  the	  DDD	  array-­‐CGH	  design.	  	  After	  the	  inclusion	  of	  the	  additional	  probes	  there	  are	  a	  total	  of	  48760	  probes	  for	  CNV	   region	  validation.	  Therefore,	   for	   each	  CNV	  region,	   for	  validation	   there	  are	  approximately	  21	  probes	  available	  (48760/2304	  =	  21.16).	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6.2.10	   CNV	  Region	  Selection	  -­‐	  Call	  Sets	  High	  quality	   calls	   sets	   from	  both	   array-­‐CGH	  and	  Exome	  detection	  methods	   are	  supplied	  for	  the	  32	  samples.	  CNsolidate	  with	  default	  parameters	  is	  used	  for	  CNV	  detection	   from	   the	  array-­‐CGH	  data.	  Detection	  quality	  measures	   'wscore'	   and	   'p	  value'	  are	  used	  to	  pre-­‐filter	  the	  detections,	  with	  a	  cut-­‐off	  of	  >=	  0.5	  and	  	  <=	  0.001	  respectively.	   CoNVeX	   using	   t=5	   and	   p=2	   is	   used	   for	   CNV	   detection	   from	   the	  Exome	  data,	  the	  'CoNVex	  score'	  is	  used	  to	  prefilter	  the	  detections	  using	  a	  cut-­‐off	  of	  5	  (t=5).	  
	  Figure	   7-­‐7-­‐6	   Detection	   quality	   scores	   for	   the	   selectable	   CNVs	   across	   the	   32	  samples	  for	  array-­‐CGH	  (left)	  and	  Exome	  (right)	  The	  two	  distributions	  above	  (see	  Figure	  7-­‐6)	  are	  somewhat	  similar	  however	  the	  log	  of	   the	   'convexscore'	   is	  more	   truncated	  and	  has	  a	   larger	  range.	  Whereas	   the	  'wscore'	   has	   a	   range	   between	   0	   -­‐	   1	   and	   seems	   to	   displays	   a	   slightly	   greater	  proportion	  of	  quality	  scores	  towards	  the	  higher	  end. Table	  7-­‐2	  Summary	  of	   the	  overall	  number	  of	  CNV	  detections	  made	   from	  array-­‐CGH	  and	  Exome	  across	  the	  32	  validation	  samples	  	  	   Array-­‐CGH	   Exome	  Min	   146	   99	  1st	  Qu.	   197	   207	  Median	   220	   230	  Mean	   216	   241	  3rd	  Qu.	   232	   261	  Max	   290	   444	  	  The	  overall	  number	  of	  detections	  for	  the	  32	  samples	  is	  6929	  and	  7733	  for	  array-­‐CGH	   and	   Exome	   respectively	   (see	   Table	   7-­‐3).	   Above	   is	   a	   table	   showing	   a	  summary	   of	   the	   number	   of	   detections	   for	   each	   sample	   from	   array-­‐CGH	   and	  Exome	   respectively.	   All	   of	   these	   CNV	   calls	   are	   available	   for	   the	   selection	  procedure.	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6.2.11	   array-­‐CGH	  and	  Exome	  CNV	  Selection	  The	  high	  quality	  detection	  lists	  for	  the	  32	  samples	  are	  used	  to	  select	  CNV	  regions	  for	  validation	  using	  the	  previously	  described	  approach.	  
 
 
Figure	  7-­‐7	  The	  overlap	  with	  the	  CNV	  Consensus2.1	  of	  the	  selected	  validation	  CNVs	  (left)	  and	  the	  number	  of	  rare	  and	  common	  selected	  validation	  CNVs	  per	  sample	  (right)	  from	  the	  array-­‐CGH	  platform 
 
Figure	  7-­‐8	  The	  overlap	  with	  the	  CNV	  Consensus2.1	  of	  the	  selected	  validation	  CNVs	  (left)	  and	  the	  number	  of	  rare	  and	  common	  selected	  validation	  CNVs	  per	  sample	  (right)	  from	  the	  Exome	  platform 
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Above	  is	  a	  plot	  of	  overlap	  against	  the	  CNV	  consensus2.1	  and	  the	  total	  number	  of	  selected	  CNV	  region	  in	  the	  common	  and	  rare	  categories	  per	  sample	  (see	  Figure	  
7-­‐7	   &	   Figure	   7-­‐8).	   This	   is	   reassuring	   since	   1)	   the	   classification	   of	   rare	   and	  common	   is	   accurate	   given	   the	   defined	   parameters	   and	  2)	   the	   total	   number	   of	  selected	  CNVs	   in	  each	   category	  per	   sample	   is	   close	   to	   that	  defined	   (9	   common	  and	  27	  rare	  per	  sample).	  
	  Figure	   7-­‐7-­‐9	   Detection	   quality	   scores	   for	   the	   selected	   CNVs	   across	   the	   32	  samples	  for	  array-­‐CGH	  (left)	  and	  Exome	  (right)	  Above	  (see	  Figure	  7-­‐9)	  are	  histograms	  of	  the	  detection	  quality	  measures	  for	  the	  selected	  CNV	  regions.	  In	  both	  cases	  this	  is	  a	  fair	  reflection	  of	  the	  distribution	  of	  detection	  quality	  measures	  of	  the	  'selectable'	  CNV	  calls	  sets	  (see	  Figure	  7-­‐6).	  The	   selection	   procedure	   is	   totally	   random	   within	   the	   rare	   and	   common	  categories.	   Below	   is	   a	   summary	   of	   the	   numbers	   of	   rare	   and	   common	   variants	  selected	  for	  the	  array-­‐CGH	  and	  Exome	  platforms.	  Table	  7-­‐3	  Numbers	  and	  types	  of	  selected	  validation	  CNVs	  
 Total Rare Common p.common p.nonredundant 
Array-CGH 1152 864 288 0.26 0.87 
Exome 1152 860 292 0.25 0.84 
 The	  number	   of	   redundant	   CNV	   regions	   selected	   (exactly	   the	   same	  break	   point	  positions)	  is	  13%	  and	  16%	  for	  array-­‐CGH	  and	  Exome	  respectively	  (see	  Table	  7-­‐
4).	  Furthermore,	  there	  are	  574/1152	  (49%)	  and	  683/1152	  (59%)	  selected	  CNV	  regions	  that	  display	  an	  overlap	  (any	  overlap)	  with	  at	  least	  1	  other	  selected	  CNV	  region,	  for	  array-­‐CGH	  and	  Exome	  data	  respectively.	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  Figure	   7-­‐7-­‐10	   Overlapping	   CNVRs	   from	   the	   selected	   validation	   CNVs	   in	   array-­‐CGH	  (left)	  and	  Exome	  (right)	  Above	   (see	   Figure	   7-­‐10),	   for	   each	   of	   the	   selected	   CNV	   regions,	   for	   each	   set	  individually	  (array-­‐CGH	  and	  Exome),	  the	  number	  of	  other	  CNV	  regions,	  from	  the	  set,	  that	  show	  an	  overlap	  (any	  overlap)	  with	  the	  selected	  region	  is	  shown.	  Most	  of	  the	  selected	  regions	  are	  unique	  to	  that	  set,	  87%	  and	  84%	  for	  array-­‐CGH	  and	  Exome	  respectively.	  Those	  remaining	  display	  exactly	  the	  same	  break	  points	  and	   cannot	  be	   considered	   as	   specific	   events.	   The	   larger	  number	  of	   overlaps	   in	  the	   exome	   data	   is	   likely	   due	   to	   smaller	   (exon)	   level	   events	   detected	   within	   a	  larger	  called	  region.	  These	  are	  highly	   interesting	   for	   inclusion	  and	  may	  help	   to	  optimise	   any	   merging	   issues.	   These	   comparisons	   are	   using	   the	   selected	   CNV	  regions,	  not	  the	  full	  calls	  lists.	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6.2.12	   array-­‐CGH	  Selected	  vs.	  Exome	  Selected	  CNV	  Regions	  The	  previous	  section	  compares	  each	  set	   individually;	  here	  each	  set	   (array-­‐CGH	  and	   Exome)	   is	   compared	   against	   one	   another.	   Overall,	   there	   are	   225/1152	  (19.5%)	  and	  280/1152	  (24.3%)	  CNV	  regions	   that	  display	  any	  overlap	  with	   the	  other	  set,	  for	  the	  array-­‐CGH	  and	  Exome	  sets	  respectively.	  
	  Figure	   7-­‐7-­‐11	   Overlapping	   CNVRs	   from	   the	   selected	   validation	   CNVs	   between	  array-­‐CGH	  (left)	  and	  Exome	  (right)	  Above	  (see	  Figure	  7-­‐11)	  are	  some	  plots	  to	  display	  the	  overall	  distribution	  of	  the	  overlaps	   between	   sets.	   Per	   sample,	   for	   any	   overlap	   of	   selected	   CNV	   regions	  between	   the	   sets	   (array-­‐CGH	  and	  Exome)	   the	   total	   number	   is	   52/1152	   (4.5%)	  and	  the	  median	  is	  1.5	  per	  sample.	  
	  Figure	   7-­‐7-­‐12	   Overlapping	   CNVRs	   CNVRs	   from	   the	   selected	   validation	   CNVs	  between	  array-­‐CGH	  (left)	  and	  Exome	  (right)	  per	  sample There	  are	  7	  samples	  that	  have	  no	  selected	  CNV	  region	  that	  overlaps	  between	  the	  sets	  (see	  Figure	  7-­‐12).	  However,	  the	  number	  of	  overlapping	  regions	  per	  sample	  is	  not	  dominated	  by	  samples	  showing	  high	  numbers	  of	  overlaps	  (which	  could	  be	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due	   e.g.	   an	   over-­‐segmentation	   of	   calls).	   The	   majority	   of	   samples	   (25)	   show	   a	  small	   number	   (1-­‐4)	   of	   selected	   CNV	   regions	   that	   are	   shared	   between	   sets	   per	  sample.	  
6.2.13	   Summary	  Overall	  the	  current	  selected	  CNV	  calls	  are	  a	  reasonable	  representation	  of	  the	  all	  CNV	   calls	  made	   across	   the	   32	   samples.	   The	   selection	  method	   is	   available	   as	   a	  single	  R	  script	  with	  a	  dependency	  for	  an	  R	  package.	  The	  selection	  can	  be	  re-­‐run	  from	   start	   the	   finish	   very	   easily	   and	   the	   various	   parameters	   can	   be	   modified	  using	   the	   'selection.R'	   script.	   See	   the	   README	   file	   for	   instructions.	   This	   will	  result	  in	  a	  number	  of	  plots,	  summaries	  and	  output	  files.	  
6.2.14	   Validation	  -­‐	  Data	  QC	  Array	   results	   (validation	   array)	   were	   obtained	   for	   the	   32	   samples	   run	   on	   the	  105K	  custom	  Agilent	  array	  from	  the	  DDD	  high-­‐throughput	  array-­‐CGH	  laboratory.	  The	  8	  x	  105K	  slides	  were	  scanned	  using	  an	  Agilent	  scanner	  with	  default	  settings	  and	  the	  linear	  dye	  bias	  normalisation	  option.	  After	  normalisation	   the	  32	  data	  sets	  were	   interrogated	   for	  data	  quality	  using	  a	  custom	   data	   tracking	   measure.	   This	   measure	   is	   based	   on	   the	   concordance	  between	   approx.	   30	   CNV	   tagging	   SNPs	   typed	   on	   a	   Sequenom	   assay	   and	   the	  estimated	  copy	  number	  states	  at	  the	  associated	  CNVR	  (see	  Chapter	  2).	  
	  Figure	  7-­‐7-­‐13	  Data	  Tracking	  QC	  for	  the	  validation	  array,	  Left	  -­‐	  the	  data	  tracking	  posterior	  vs.	  a	  noise	  measure	  (dLRs)	  for	  the	  32	  validation	  data	  sets,	  Right	  -­‐	  the	  estimated	  gender	  of	  the	  32	  samples	  type	  on	  the	  discovery	  array	  (array-­‐CGH)	  vs.	  the	  gender	  type	  on	  the	  validation	  array	  As	  shown	  on	  the	  left	  panel	  of	  the	  above	  plot	  (see	  Figure	  7-­‐13),	  a	  greater	  than	  0.6	  cut-­‐off	   on	   the	   tracking	   posterior	   is	   used	   to	   define	   samples	   that	   pass	   data	   QC.	  Using	  this	  cut-­‐off	  resulted	  in	  failing	  6	  /	  32	  samples.	  All	  passed	  data	  sets	  display	  a	  dLRs	   of	   less	   than	   0.2	   and	   there	   were	   no	   gender	   mismatches	   between	   the	  discovery	  and	  validation	  array	  overall	  as	  indicated	  in	  the	  right	  panel	  (see	  Figure	  
7-­‐13).	   By	  using	   the	   custom	  data	   tracking	  approach	   the	  DNA	  samples	   typed	  on	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the	  validation	  array	  are	  predicted	  to	  be	  the	  same	  as	  those	  typed	  on	  the	  discovery	  array.	  
6.2.15	   Validation	  -­‐	  Array	  Design	  QC	  To	  check	  the	  accuracy	  of	  probe	  placement	  of	  the	  validation	  array	  two	  statistics,	  'Edge',	  and	  'Spread'	  were	  used.	   'Edge'	  is	  the	  proportion	  of	  probes	  in	  a	  CNV	  that	  are	  within	   the	   first	   and	   last	   10%	  of	   the	  CNV.	   'Spread'	   is	   the	  distance	   from	   the	  start	  of	   the	   first	  probe	   to	   the	  end	  of	   the	   last	  probe	  within	  a	  CNV,	   scaled	   to	   the	  length	  of	  the	  CNV	  (i.e.	  the	  maximum	  spread	  is	  1).	  
	  Figure	  7-­‐7-­‐14	  Two	  statistics	   summarizing	  probe	  placement	  within	   the	  selected	  validation	   CNVs,	   Left	   -­‐	   the	   'Edge’,	   or	   proportion	   of	   probes	   in	   the	   first	   and	   last	  10%	  of	   the	  CNV,	  Right	   -­‐	   'Spread'	   the	  distance	  between	   the	   first	   and	   last	  probe	  within	  the	  CNV,	  scaled	  by	  the	  length	  of	  the	  CNV.	  	  The	   two	  plots	   above	   (see	  Figure	   7-­‐14)	   show	   that	   the	  probe	  placement	  within	  the	   targeted	   CNVR	   is	   reasonable.	   Observe	   that,	   indicated	   by	   the	   'Spread'	  measure;	   the	   majority	   of	   CNVRs	   are	   fully	   covered	   ('Spread'	   value	   tending	  towards	  1).	  Additionally,	  the	  'Edge'	  measure	  shows	  that	  very	  few	  CNVRs	  have	  no	  probes	   in	   the	   first	   and	   last	   10%	   of	   the	   CNVR	   ('Edge'	   ==	   0).	   Furthermore	   the	  majority	  of	  'Edge'	  values	  are	  between	  a	  value	  of	  0-­‐1	  and	  approximately	  centred	  between	  0.2-­‐0.3,	  meaning	  that	  the	  probe	  placement	  in	  the	  majority	  of	  CNVRs	  in	  even	  across	  the	  region.	  	  
